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Abstract 
The thesis makes three contributions to the evidence base for outcome measurement 
in Ankylosing Spondylitis (AS). First, a systematic review and evaluation of the 
entire range of patient-based and anthropornetric measures of outcome applied in 
published studies of AS represents the first detailed and explicit synthesis of evidence 
relating to the development, measurement properties, acceptability and feasibility of 
outcome measures applied in current practice in AS. Secondly, the development of 
the first AS-specific individualised measure of disease-related quality of life, the 
Patient Generated Index for AS (PGI-AS). Thirdly, the first comparative evaluation 
of the PGI-AS and an evidence-based selection of disease-specific, anthropometric 
and generic measures of outcome in patients with AS. This study is the largest clinic- 
based and one of the largest multi-centre postal evaluations of outcome measures in 
AS within the United Kingdom. The study also describes the most rigorous process 
of instrument testing reported in AS. 
The systematic review describes the wide diversity of outcome measures applied in 
the evaluation of AS. The first standardised and evidence-based package of 
instruments to fulfil domains considered important in the evaluation of AS is 
described. However, the evaluation of these instruments indicated that no instrument 
adequately fulfilled the required measurement properties and practical criteria 
considered necessary for use in individual evaluation, and no clear recommendation 
for the disease-specific evaluation of health-related quality of life, disease activity, 
functional disability or spinal mobility could be made. Several instruments can be 
recommended for use in group analysis and in clinical trials. Gaps in the availability 
of evaluative instruments for specific domains of health and the need for 
modifications and further research to evaluate measurement properties of new, 
modified and widely used instruments are described. Initial evidence suggests 
satisfactory measurement properties for the PGI-AS and further evaluation of the role 
of individualised measures in routine practice, research, clinical decision making and 
directing patient-centred management is required. 
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Chapter 1 The Measurement of Health Outcome and Ankylosing Spondylitis 
1.1 Introduction 
This chapter provides an overview of the measurement of health outcome in general 
and an introduction to Ankylosing Spondylitis, and places the work that follows in 
context. Section 1.2 describes the status of outcome measurement in general and the 
role of patient-based evaluation. Ankylosing Spondylitis (AS), its impact and 
management, and the present status of outcome measurement in AS are discussed in 
sections 1.3 and 1.4 respectively. Section 1.5 describes the foundation for the 
empirical work that follows. 
1.2. The measurement of health outcome 
Historically the outcome of health care was based on the biomedical model reflecting 
a disease-based view of outcome that considered ill-health to be an objective, 
measurable concept (Jones, 1992; Jenkinson, 1994). At an individual level this model 
focussed on the presence or absence of disease. The belief was that a quantitative 
relationship between organ impairment, ill-health and well-being existed and 
correction of disease at the organ level would positively influence wider issues of ill- 
health (Jones, 1992). History of the disease process and laboratory and radiographic 
based assessments were the mainstay of a cliniciarfs evaluative repertoire. At a 
population level indicators of disease consisted of morbidity rates, disease incidence 
and prevalence, and most commonly mortality rates (McDowell and Newell, 1996). 
Where initially medical intervention was accepted for the ability to prolong life, with 
advancing medical technologies acute, life-threatening illnesses no longer dominated 
the medical picture (McDowell and Newell, 1996). Long term, chronic illness 
associated with increased survivorship became the prime focus of health care, 
demanding increasing health care resources and a change in emphasis in management 
and evaluation (Fitzpatrick et al, 1998a). Where mortality is no-longer the main 
concern of outcome evaluation there is increased relevance of the World Health 
Organisations (WHO) broad definition of health as: 
'physical, mental and social well-being, not merely the absence of disease and infmnity' 
(VvrHO, 1947) 
When it was first proposed the definition was considered immeasurable (McDowell 
and Newell, 1996), but advances in measurement techniques have operationalised 
concepts proposed in the definition and improved acceptance over recent years. 
Within this definition the impact of disease may be considered in terms of the 
impairment, disability and handicap associated with ill-health (Caff, 1996). 
Impairment represents disease impact at the anatomical, physiological or 
psychological level and disability relates to the disadvantage experienced by an 
individual when performing an activity as a result of the impairment. Handicap 
considers the broader impact of ill-health as the role and social disadvantage 
experienced by an individual. Although traditional measures of impairment, for 
example, laboratory based assessments, are informative to clinicians the simple 
dichotomy of health and illness presented by the biomedical model was no longer 
considered an adequate representation of disease (van der Linden and van der Heijde, 
1995; Fitzpatrick et al, 1998a). Health is a complex and abstract concept that requires 
indicators that focus attention on the quality of survival and wider issues of relevance 
to patients, health care professionals and health care providers (McDowell and 
Newell, 1996; Ware, 1998). 
Associated with the acknowledged inadequacy of the biomedical assessment was 
increasing evidence that a patienfs subjective perception of health, the psychosocial. 
impact of disease and treatment were important to the evaluation of outcome and 
allocation of health care (Barlow et al, 1992; Jenkinson, 1994). This information was 
considered complimentary to traditional assessments by demonstrating the broad 
impact of health care and was supported by evidence that the patient is the best judge 
of disease impact (Albrecht, 1994). The importance of the patient in this evaluative 
role is highlighted by the following definition of medical outcome as: 
'the extent to which a change in a patients behavioural. functioning or well-being 
mccts the patients needs or expectations' (Ware, 1997) 
The measurement of a patient's subjective perception of health-related quality of life 
(HRQL) is now recommended as a core component in the assessment of health 
outcome (Albrecht, 1994; Fitzpatrick et al, 1998a), and treatment that improves only 
traditional biomedical features without benefiting HRQL may be considered to have 
only limited medical success. 
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Despite the lack of consensus definition of HRQL the construct develops on the WHO 
definition of health through the inclusion of health status and social well-being 
(Guyatt et al, 1993; Albrecht, 1994). Most authors agree that HRQL is a multi- 
dimensional concept, with patient-reported symptoms of physical and mental health 
major components (Fitzpatrick, 1993a; Ward, 1998; Ware, 1998). Questionnaires 
which attempt to place the patient at the centre of the evaluative process have been 
developed for a wide range of health problems and have invariably been referred to as 
measures of quality of life or HRQL, often without further definition of the concept 
addressed by the instrument. The evaluation of quality of life should, in theory, 
consider a very broad concept of life that does not focus simply on the impact of ill- 
health (Wolfe, 1995). The focus of HRQL evaluation is towards aspects of life that 
might in principle be influenced by health and health care (Patrick and Erickson 1993; 
Ware, 1997; Jenkinson et al, 1998a). However, despite the apparent congruency 
between the concepts of impairment, disability, handicap and HRQL this relationship 
is not hierarchical and evaluation should consider all elements to provide a complete 
representation of disease impact (Caff and Thompson, 1994; Caff, 1996). 
The goals of management of chronic and often incurable conditions focus on 
symptom amelioration, the restoration and preservation of function and well-being 
and enhancement of a patients HRQL (Barlow and Barefoot, 1996). Multi- 
disciplinary health care teams are generally involved in the management process with 
patients playing a central role. Traditional biomedical assessments provide an 
incomplete picture of the wide impact of various therapeutic interventions on health 
(Streiner and Norman, 1995). Therefore, methods of evaluation that provide 
appropriate feedback on the relative success of interventions associated with the goals 
of management are required. Asking patients their own views about ill-health and 
health care retains their position in the multi-disciplinary team throughout the cyclical 
process of treatment planning, implementation and evaluation whilst providing a 
broad representation of health. Where relative and informative evidence is gained 
from evaluation this may influence the effectiveness and quality of care and empower 
patients to undertake or maintain an active role in management. Health care reforms 
have focussed attention towards the evaluation of medical outcomes, especially 
towards those reflecting consumer or patient subjective perceptions and preferences 
(Albrecht, 1994; Ware, 1998). Evidence based practice with a foundation based on a 
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combination of traditional objective measurement and patient-based measures of 
outcome may be more informed and responsive to the challenges and demands of ill- 
health for which health care aims to provide. 
1.2.1 Taxonomy of measures of health-related quality of life 
Two broad approaches to measuring patient perceptions of HRQL can be described: 
generic instruments that provide a broad summary of HRQL, and specific instruments 
that focus on issues of relevance to a specific disease or patient group. Generic 
instruments are not age, disease or treatment specific and contain multiple HRQL 
concepts of relevance to patients and the general population, supporting application in 
both populations (Guyatt et al, 1989a; Ware, 1997). Population-based normal values 
can be calculated, which supports data interpretation from disease-specific groups 
(Ware, 1997). i 
Two classes of generic instrument can be described: health profiles and utility 
measures. Scores on different domains of HRQL covered by a single health profile 
are presented separately to support data interpretation, therefore reflecting a clinical 
perspective (McDowell and Newell, 1996). Sometimes a single or summary score 
may be generated, but proponents argue that measurement is most meaningful within 
separate domains. The Short Form 36-item Health Survey Questionnaire (SF-36) is a 
widely used example of a generic health profile (Ware, 1997). The items cover eight 
domains of HRQL including physical and social functioning and mental health. 
Responses to each item are summed (0-100), where 0 is the worst possible HRQL, 
and 100 the best. Mental and physical component summary scales may also be 
generated. Population norms have been calculated in several countries (Ware, 1997). 
The values and preferences for outcome generated by the patient (direct weighting) or 
the general population (indirect weighting) provide external weightings for utility 
measurement (Garratt et al, 2000). Although utility measures can cover several 
domains of HRQL, the weighting generates a single index that relates HRQL to death 
(0) or perfect health (1)(Guyatt et al, 1993). The EuroQoI (EQ-5D)(EuroQol Group, 
1990) is an example of a utility measure that incorporates indirect valuations of health 
states (Kind et al, 1998). A benefit of utility measures is the recommendation for use 
in cost-utility economic analysis, but a disadvantage is that the single score limits data 
interpretation (Guyatt et al, 1993). 
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Specific instruments may be specific to a particular disease (e. g. AS), to a patient 
population (e. g. child health), to a specific problem (e. g. pain, limited range of 
movement), or to a described function (e. g. functional ability) (Guyatt et al, 1993). 
For example, the Revised Leeds Disability Index (RLDQ) is an AS-specific measure 
of functional disability (Abbott et al, 1994). Responses to each item are summed (0- 
48), where 0 is the best possible functional ability. 
The broad content of generic instruments supports identification of co-morbid features 
and treatment side-effects that may not be captured by specific instruments, but this 
may reduce instrument responsiveness to small and important disease-specific 
changes. Disease-specific instruments, may have greater clinical appeal due to the 
specificity of content, and an associated increased responsiveness to specific change 
in condition (Guyatt et al, 1993; Garratt, 1997). Their combined use is therefore 
recommended in the evaluation of health outcome (Guyatt et al, 1993; McDowell and 
Newell, 1996). 
1.2.2 Application of measures of health outcome 
To be suitable for use in an evaluative role, instruments should be acceptable and 
feasible for the required application, and possess certain measurement properties: 
reliability, validity and responsiveness to change (Fitzpatrick et al, 1998a). These 
properties are addressed in detail in the ensuing chapters. 
Patient-based measures of health outcome are intended to provide supplementary 
information to traditional biomedical assessments and several forum for their 
application have been described, including clinical research, routine clinical practice 
and health policy (Guyatt et al, 1993; Ware, 1997). By far the greatest evidence is 
available to support application in clinical research, where the results may, for 
example, support evaluation of comparative management strategies in a controlled 
trial. A measure of patient perceived physical fitness (Astrand Fitness Index)(Astrand 
and Rodahl, 1977) and the Health Assessment Questionnaire for the 
Spondyloarthropathies (HAQ-S)(Daltroy et al, 1990), a disease-specific measure of 
functional ability, suggested improved levels of physical fitness and function in AS 
patients randomly assigned to receive supervised group exercise therapy over a nine- 
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month period, versus those pursuing a home exercise programme only (Hidding et al, 
1994a). 
Potential benefits from the application of patient-based instruments in clinical practice 
include: improved patient-clinician communication (Jenkinson et al, 1996), the 
identification of functional and psychosocial problems that may have previously been 
missed (Greenhalgh and Meadows, 1999), and regular standardised patient 
monitoring where the information may assist in clinical decision making at the 
individual patient level (Ware, 1997). However, evidence suggests that there has 
been a limited adoption of these instruments, in routine practice (Bellamy et al, 1998, 
1999; Greenhalgh and Meadows, 1999). Attitudinal, practical and methodological 
barriers have been cited as reasons for their limited uptake (Bellamy et al, 1999). A 
review of the effectiveness of including patient-based instruments in routine clinical 
practice reported that there was limited evidence to support the proposed benefits 
(Greenhalgh and Meadows, 1999). In addition, there was little evidence to indicate 
that their use substantially influenced patient management or improved outcome. 
At a managerial and policy level, measures of HRQL support the comparison of costs 
and benefits of competing health care programmes, where managers will seek to 
provide the best health care for the best price (Ware, 1997). Rationing of health care 
is the inevitable consequence of limited resources, and the use of reliable, valid and 
responsive measures of HRQL may provide beneficial information to support the 
distribution of resources for health care (Ware, 1997; Garratt, 1997). Guyatt et al 
(1993) suggest that generic instruments are of greatest interest to the policy maker or 
manager because they consider consumer needs and preferences, whilst facilitating 
comparison of HRQL and economic evaluation across populations and conditions. 
Alternatively, disease-specif ic measures of HRQL, due to the significance of item 
content, are of greatest relevance to patients and health professionals. However, the 
limitations of data from patient-based instruments and its interpretation when 
supporting important clinical decisions at both individual and policy level should be 
recognised (Bindman et al, 1990; Jenkinson, 1995). 
1.3 Ankylosing Spondylitis 
The focus of the empirical work that follows in subsequent chapters is the evaluation 
of approaches to measuring health outcome in Ankylosing Spondylitis (AS). 
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AS is a chronic systemic, often progressive, inflammatory disorder, primarily 
affecting the sacro-iliac joints of the pelvis, the axial skeleton and the thoracic cage 
(Russell, 1998). Peripheral joints, entheses, and extra-articular sites may also be 
affected (Dawes et al, 1988). The subsequent impact of AS on a patient's health- 
related quality of life encompasses broad multi-dimensional issues including social 
interactions, role and physical functioning, psychological well-being, impact of 
treatment, and the actual disease symptoms. 
1.3.1 Epidemiology and aetiology 
The true prevalence of AS is unknown but in virtually any racial group it is reported 
to reflect the prevalence of a genetic marker, the Human Leucocyte Antigen (HLA) 
B27 (Rigby, 1991; van der Linden and van der Heijde, 1995). However, HLA B27 
lacks specificity for AS, and where in the healthy caucasian population HLA B27 may 
have a prevalence of between 7-12%, the prevalence of AS has been estimated as 
between 0.1-0.4% (Rigby, 199 1; Johnsen et al, 1992), and as high as 1-2% of the 
caucasian population in certain circumstances (Pal, 1987; Johnsen et al, 1992). In 
caucasian patients with AS, 90-95% are HLA B27 positive (Albert and Scholz, 1987; 
van der Linden and van der Heijde, 1995). These results suggest that there may be 
60-70,000 clinically diagnosed cases of AS in the United Kingdom (UK)(Barlow et 
al, 1993a). However, where results are based on hospital records, and possibly biased 
towards the more severe cases, the true prevalence of AS may be underestimated- It 
is suggested that 750,000 individuals may have AS, if sub-clinical or very mild forms 
of the disease are taken into account (Barlow et al, 1993a). 
The aetiology of AS is unknown. It is hypothesised that environmental factors, for 
example infection, may act as a trigger in genetically predisposed individuals (Calin, 
1985; Carbone et al, 1992). The role of genetics in causation is strengthened by the 
accumulated evidence of a familial link, and the inherited susceptibility marked by 
HLA B27 (Carbone et al, 1992; van der Linden and van der Heijde, 1996). However, 
the relative importance of these factors, and the mechanism by which AS and HLA 
B27 are related is unknown and remains under investigation. 
AS was traditionally described as a disease of young men. However, recognition of 
the disease in females has improved and male to female ratios of between 2-5: 1 have 
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been variously reported (Calin, 1985; Gran and Husby, 1998). The peak incidence of 
disease onset is between 25-34 years of age, and onset after 55 years of age is unusual 
(Carbone et al, 1992). However, evidence suggests that the disease does not 'bum 
ouf, and most patients remain symptomatic throughout most of their life, with pain a 
dominant feature (Thompson and Chalmers, 1993). Although AS is considered 
generally not to be life threatening, there are few studies of AS mortality, and no 
studies prior to the treatment of AS with radiotherapy in the 1940's and 1950's 
(Symmons, 1996). Patients with most severe disease often received radiotherapy 
during this period, and excess mortality related to leukaemia and malignancy has been 
reported (Ramos-Remus and Russell, 1992; Symmons, 1996), thereby confounding 
subsequent studies of mortality. However, deaths attributable to AS generally occur 
in patients with longer-standing disease, of more than 20 years duration, and a 
population based study reported an 88% relative survival rate when compared to a sex 
and age matched group (Carbone et al, 1992). Cardiovascular abnormalities or 
'violent death! are often the cause of death (Symmons, 1996). For example, fracture 
of the immobile and osteoporotic vertebrae following a fall or even minor trauma. 
However, outcome is notoriously difficult to predict and disease progress varies 
widely between patients (Calin, 1985; Goodacre et al, 1991). 
1.3.2 Pathophysiology 
The primary pathological site of AS is the enthesis (Calin, 1985). That is, the 
insertion of ligament, tendon orjoint capsule into bone. Entheses are found in 
synovial and cartilagenous joints and at extra-articular sites. For example, the 
insertion of intercostal ligaments at the stemocostal margins. Although not specific to 
AS, the ensuing enthesopathy is a hallmark of the disease (Haslock, 1993; van der 
Linden and van der Heijde, 1996). The major feature of the pathological -process 
involves inflammation which affects the synovium, articular capsules, 
fibrocartilagenous joints and entheses (Freemont, 1987). Inflammation is followed by 
a healing process typified by calcification and bony ankylosis (Haslock, 1993). At the 
discovertebral. junction calcification leads to the development of slender outgrowths 
from the vertebral margin, referred to as syndesmophytes or enthesophytes (Dziedzic, 
1998; Haslock, 1993). With continuing inflammation and repair these may grow and 
eventually bridge the gap between vertebra, resulting in the bony ankylosis 
characteristic of AS. Fusion of syndesmophytes, and capsular and ligamentous 
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ossification leads to the characteristic, progressive spinal rigidity, and the 'bamboo 
spine'of advanced disease. 
Spinal involvement varies between patients, as does the speed of disease progression. 
In some patients the disease may be relatively benign with pathology limited to the 
pelvis (Carette et al, 1983). Alternatively, the disease may follow a rapidly 
progressive course with involvement of the whole spine, thoracic cage, peripheral 
joints and extra-articular features (Calin, 1985). Reduced joint mobility, particularly 
limited spinal mobility and chest expansion, feature strongly in the diagnostic criteria 
for AS (Modified New York Criteria - van der Linden et al, 1984), and have 
influenced assessment in AS for many years. However, diagnosis of AS is difficult 
and consideration of all presenting features is important in clinical practice (Dziedzic, 
1998). A delay in diagnosis of up to six years in men, and nine years in females has 
been reported (Calin et a], 1988), but this has reduced with improved recognition of 
the female presentation of the disease (Dalyan et a], 1999). 
Multiple entheses may be involved in the disease process, but the tarsal region, 
including the insertion of the Achilles tendon and the plantar fascia, has been reported 
to account for between 26.743.5% of all enthesitis in adult onset AS (Burgos-Vargas, 
1990). Patients may experience pain following palpation at the site of entheses 
actively involved in the disease process, and two clinical measures have been 
developed in an attempt to quantify enthesitis as a reflection of disease activity 
(Dawes et a], 1987; Mander et al, 1987). Peripheral joint involvement has been 
reported in between 20-30% of adults with AS, primarily involving the gleno-humeral 
or hip joints (Dalyan et al, 1999). The incidence of peripheral joint involvement in 
patients with disease onset before 20 years of age is almost double that seen in 
patients with a disease onset after this age (40% versus 22%), and involvement of the 
hip is reported to be most likely in the first ten years of symptoms (Carrette et al, 
1983). Extra-articular features have been reported in 5-25% of patients and include 
uveitis, cardiovascular and gastrointestinal complications, respiratory embarrassment, 
and renal disease (Dziedzic, 1998). 
1.3.3 Impact of AS on health-related quality of life 
The following domains will be adopted to summarise evidence relating to the disease 
impact on a patients HRQL: 
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" symptoms 
" physical function 
" role function 
" social interaction 
" emotional well-being 
symptona 
Symptoms have been defined as a patienfs subjective perception of an abnormal 
physical, emotional or cognitive state (Anderson and Burckhardt, 1999). Pain and 
stiffness are the most frequently mentioned symptoms of patients with AS (Dziedzic, 
1998), closely followed by reports of fatigue and sleep disturbance (Ward, 1998). 
The cause of pain in AS is multi-faceted and may be contributed to by the 
pathophysiological disease-process, the biomechanical impact, AS-related systemic 
illness, and depression. An early study of AS reported that pain and/or stiffness in the 
lumbar spine or buttocks were the presenting symptoms in 73.4% of patients, whereas 
24% indicated that the initial symptoms involved peripheral joints (Dudley Hart, 
1955). Evidence suggests that pain fluctuates throughout the course of the disease 
(Thompson and Chalmers, 1993; Ward, 1998). A longitudinal cohort evaluation of 
151 male Anny veterans with AS reported the most severe pain experience in the first 
10 years after diagnosis (Carrette et al, 1983). At re-examination (average disease' 
duration 38 years) 68% reported pain as a predominant feature of the disease, and in 
30% of these it was considered moderate or severe. 30% of patients reported no pain 
at re-examination (Carette et al, 1983). However, these results may be influenced by 
the dominance of male patients, and the loss to follow-up (n--5 1). A hospital based 
postal survey of 1492 AS patients reported pain and disease activity to be equivalently 
high in patients with a disease duration of less than 10 years or of more than 30 years, 
when assessed by an AS-specific instrument (Bath Disease Activity Index)(Kennedy 
et al, 1993). 
Stiffness is an important clinical feature in AS and is included in the diagnostic 
criteria. Worse on awakening (Jamieson et al, 1995), or after prolonged periods of 
immobility, it often lasts for more than two hours (Garrett et al, 1994) but generally 
eases with movement. Stiffness is a complex symptom and although differentiation 
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from limited mobility or pain is difficult, patients are often able to distinguish 
between symptoms (Dziedzic, 1998). Although a strong association between stiffness 
severity and duration has been reported (Garrett et al, 1994), the assessment of 
severity is more informative than duration in inflammatory conditions (Hazes et al, 
1993). A high correlation between stiffness and pain (Garrett et al, 1994) and 
stiffness and change in global health following group exercise therapy has been 
reported (Hidding and van der Linden, 1995). 
Fatigue has been recognised as an important complaint by up to 65% of patients with 
AS (Garrett et al, 1994; Ward, 1998), and up to 11% of patients report major 
difficulties with sleep or rest (Bakker et al, 1995; Jamieson et al, 1995). Fatigue has 
been reported to correlate highly -with increased pain, stiffness and functional 
disability (Jones et al, 1996b), and discomfort in bed, a frequent complaint of patients 
with AS, often leads to disturbed sleep which may result in complaints of tiredness 
and fatigue. This pattern may also be associated with adverse mental health (Walker 
et al, 1993). Effective analgesic control may facilitate improved sleep, but evidence 
suggests that better sleep is associated with increased stiffness on awakening 
(Jamieson et al, 1995). 
There is no gold standard measure of sYmptomology or disease activity in AS, and the 
unique disease profile seen in many patients may complicate assessment (Goodacre et 
al, 1991; Dalyan et al, 1999). Therefore, a combination of measurements including 
pain, stiffness, articular and enthesitis indices, laboratory-based assessment, analgesic 
consumption and the presence of extra-articular features are traditionally adopted 
parameters. Patient reported change in pain and stiffness have been recorded in 
routine practice and clinical research for many years. Often measurement involves 
the representation of severity on single item visual analogue (VAS) or likert-type 
scales and the multi-dimensional nature of pain or stiffness is infrequently addressed 
(Dziedzic, 1998). Fatigue and sleep disturbance are less frequently recorded. 
However, recent developments in patient-based evaluation have produced the Bath 
AS Disease Activity Index (BASDAI), an AS-specific measure of disease activity 
containing items addressing pain, stiffness and fatigue (Garrett et al, 1994), and the 
Body Chart, a global representation of bodily pain in AS (Dziedzic, 1997). These 
instruments are considered further in Chapters 2 and 4 respectively. 
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Physicalfunction 
Functional disability is one of the most important complaints in AS following pain 
and stiffness (Dougadas et al, 1988), and refers to limitation in activities of daily 
living, mobility and self-care. The impact of pain, stiffness and altered biornechanics 
on axial and peripheral joints, and the limited mobility of advancing AS, may limit 
physical functioning witha resulting loss of independence in certain activities. 
However, many patients may underestimate and under-report functional difficulties 
(Hidding et al, 1992). This may reflect patients adjusting to functional difficulties 
over the years of often relentless disease progression, and thus failing to report 
difficulties. Patients may adopt unusual movements or gadgets to assist in the 
performance of activities (Abbott et a], 1994), and no longer consider the activity 
impossible or difficult to perform. Alternatively, patients may learn to accept the 
reality of the disease, and adjust their functional expectation accordingly. A survey of 
129 AS out-patients reported physical difficulties with routine daily activities as a 
consequence of AS (53%), the majority indicating greater problems with general 
mobility (47%), as opposed to self-care (6%)(Bakker et al, 1995). A further survey of 
members of an American AS self-help group rated difficulty with physical 
functioning highly, and four areas were described (Nemes, 199 1): firstly, limited neck 
mobility restricting activities such as sleeping prone, driving, reaching and hugging. 
Secondly, sexual function was affected. This may relate to the pain and/or stiffness 
and immobility associated with AS. Alternatively, a spouse or partner may avoid 
sexual contact for fear of causing pain. Pain associated with rest was a third factor, 
and was closely associated with sleep disturbance, tiredness or fatigue. Finally, axial 
dysfunction and difficulty with activities requiring degrees of spinal mobility was 
reported. For example, bending to put on socks, or getting into/out of the bath. 
Following a review of available evidence, Ward (1998) suggests that sexual 
functioning may be a 'substantial problem' for patients, especially females, with more 
than 30% of patients experiencing moderate or severe pain. In a subsequent study, 
mild sexual difficulties were reported in 25% of patients (n= 44 out-patients), leading 
the investigators to include items relating to sexual function in a modified AS-specific 
disability index (Dalyan et al, 1999). 
Several risk factors for increased functional disability have been described, and 
include younger age at onset, neck, hip and/or gleno-humeral joint involvement, 
increased disease activity and depression (Ward, 1998). A survey of relatively young 
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AS patients (mean age 36 years), with severe disease (n--- 17) (Brown et al, 1987) 
rated their top four most important problems as stiffness (82%), inability to do 
everyday tasks (82%), sexual problems (71%) and pain (65%). 50% of these patients 
had undergone hip replacement surgery, and 35% were unable to work due to the 
extensive AS-associated deformities and related fatigue and dernotivation. However, 
accumulated evidence suggests that most patients remain functionally independent, 
despite often chronic discomfort (Calin, 1985; Dalyan et al, 1999). 
There is no gold standard for the evaluation of functional disability in AS, and many 
investigators adopt patient-based questionnaires originally developed for patients with 
Rheumatoid Arthritis (RA). For example, the Health Assessment Questionnaire 
(HAQ) (Fries, 1980). However, these instruments focus on peripheral joint 
impairment and difficulty with prehensile activities. Therefore, item content has little 
relevance to patients with a predominantly axial disease. The functional assessment 
of AS has lagged behind that of other rheumatic diseases, such as RA, but with the 
increasing realisation that rheumatic disease has an important impact on both 
functional and psychosocial. issues, instruments to evaluate these domains have been 
developed, and are evaluated in Chapter 2. 
The axial and thoracic dysfunction of AS is a dominant feature of the disease. 
Although reflecting a very limited aspect of disease impact, measurement of the 
limitation in spinal mobility and chest expansion have dominated the evaluation of 
outcome in AS for many years. Proponents suggest that rigorous and regular 
anthropometric assessment is essential to describe the clinical outcome in AS and to 
support clinical decision making (Lubrano and Helliwell, 1999). Serial measurement 
may also provide an insight into the natural history of disease progression reflecting 
either structural, irreversible change in axial status (Kennedy et al, 1995) or reversible 
change in mobility (Roberts et al, 1988), and identify sub-groups of patients in 
relation to disease severity (Dawes, 1999; van der Heijde and Spoorenberg, 1999). 
Numerous anthropometric; measurement techniques can be described, and are 
evaluated in Chapter 2. 
Rolefunction 
Role performance describes the ability of a patient to continue with daily life-style 
obligations, such as employment and household chores (Jenkinson et al, 1998a). The 
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early onset of AS, striking at the prime of life, suggests that the impact on paid 
employment could be considerable. Up to one third of patients experience at least one 
prolonged period of sick leave from work (Worsdworth and Mowat, 1986), this rate 
increasing for patients involved in manually demanding jobs (Guillemin et al, 1990). 
Many patients report changes in employment to less physically demanding roles, but 
accumulated evidence suggests that 60-85% of patients with a disease duration of 14 
years or more remain in paid employment (Ward, 1998; Dalyan et al, 1999). 
Social interaction 
There has been little specific research on the impact of AS on social function and 
interaction (Ward, 1998). When the impact of AS on daily routine problems was 
considered (n7- 129), few reported diff iculties with social function (Bakker et al, 
1995): 6% indicated that leisure activities were limited, 3% were limited in role 
activities, 2% with communication, and only 10!, ýo reported difficulties with social 
interaction. However, 41% of patients with severe disease (mean age 36 years; n-- 17) 
described depression, loneliness and boredom as important features (Brown et al, 
1987). Dalyan et al (1999) indicated that few patients reported marital strain, or 
marriage avoidance due to AS. 
Emotional well-being 
A patient with AS may experience involvement of the 'whole system' in the disease 
process and attention to the locomotor system alone may detract from possible extra- 
articular manifestations and symptoms (Dziedzic, 1998; Reynolds et al, 1999). 
Almost 25% of patients reported emotional well-being as an important area of routine 
daily life affected by AS (n7- 129)(Bakker et al, 1995). 20% of patients related this 
impact to their emotional health, and a further 4% demonstrated concern over their 
physical appearance. One third of patients with AS, and a significantly higher 
proportion of females than males, may experience clinical depression (Barlow et al 
1993b). A strong association with pain, particularly in females, and a weaker 
association with functional disability, was indicated. A strong association between 
depression and poor physical function, social inadequacy and low self-esteem has also 
been reported (Barlow et al, 1992; Hidding et al, 1994b; Ward, 1998). The AS 
pathological process leading to the adoption of an altered posture, may have a multi- 
faceted impact on the well-being of a patient, being associated with pain and reduced 
function, thereby strengthening the possible association with depression. It has been 
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suggested that the rarity of psychological problems in patients with AS is associated 
with the ability of the patient to accommodate to the gradual physical and 
psychological demands of the disease (Dalyan et al, 1999). Alternatively, this may 
reflect the infrequency with which psychosocial aspects of AS have been addressed in 
research and routine practice. Patients with detected depressive problems may have a 
better outcome than patients where symptoms are not identified, and evaluation of this 
important symptom in AS is recommended (Barlow and Barefoot, 1996). 
1.3.4 Management 
AS is incurable, progressive and unpredictable in its progress. Therefore, long-term 
management centering around the control of pain and improvement of function is 
indicated, with the responsibility for daily management lying primarily with the 
individual patient (Barlow and Barefoot, 1996). This is a significant undertaking and 
requires notable physical and psychological adjustment (Barlow et al, 1993a). 
There are two main facets to management in AS: drug therapy and physiotherapy. 
Drug therapy may involve three categories of therapy: 1) disease-controlling anti- 
rheumatic therapy (DC-ART), such as sulphasalazine, which influence the disease 
process; 2) symptom-modifying anti-rheumatic drugs (SMARD), such as non- 
steroidal anti-inflammatory drugs (NSAID), which'suppress inflammation without 
influencing the disease process; and finally, 3) analgesics and muscle relaxants for 
pain relief. Drug management is decided on an individual basis, and many patients 
chose not to take medication due to the potential side effects. However, the benefits 
of pain-free movement and reduced stiffness, with the ensuing ability to continue with 
normal activities of daily life afforded by selective medication may outweigh any 
possible side effects (Dziedzic, 1998). 
Physiotherapy, including daily exercise therapy and education is recognised as an 
essential part of any management programme in AS (Viitenan and Suni, 1995). The 
classical image of a patient with advanced AS, is that of a'question-mark' posture 
(Hyde, 1980). That is, flattening of the lumbar spine with associated hip flexion, 
increased thoracic kyphosis, and protraction of the upper cervical spine to facilitate a 
forward looking gaze. It is suggested that the change of posture is initially adopted as 
a pain relieving response to inflammation of the spinal zygoapophyseal joints 
(Dziedzic, 1998), but subsequent ankylosis and soft tissue shortening may result in a 
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fixed posture, with its resulting adverse impact on functional ability and emotional 
well-being. Management aims to maintain or improve mobility, posture and general 
fitness, and thus enhance the quality and expectations of a young life. Education 
plays an important role in this process and patients should be empowered to 
incorporate such a routine into their everyday life. Although physical exercise has 
been demonstrated to improve functional outcome, patient education may have a 
greater impact on psychological well-being, for example, feelings of depression and 
patient self-efficacy with disease management requirements (Barlow and Barefoot, 
1996). However, these issues are rarely evaluated in AS. 
Various surgical procedures may be indicated in patents with severe AS, and range 
from total hip joint replacement to spinal wedge osteotomies or stabilisation to reduce 
pain and improve posture and functional outcome (Dziedzic, 1998). 
1.4 Measurement of outcome in AS 
Mortality is not such an important outcome measure in a chronic, incurable disease 
such as AS, where accumulated evidence suggests that life expectancy is not 
significantly reduced, but the impact of disease on HRQL is great. Patients and health 
professionals require more relevant information about the impact of disease and 
disease management than is provided by the traditional biomedical assessments 
frequently encountered in AS. However, little attention has been paid to the 
evaluation of HRQL in AS. A review of outcome measures applied in published 
studies of AS showed that physician assessed measures of impairment or disability 
prevailed in 79% of studies, the majority recording spinal mobility, pain at sites of 
entheses or joints, and laboratory based assessment (Bakker et al, 1993b). Some 
studies included a physician generated global assessment of patient health on a single 
visual analogue scale (VAS). 67% of studies included patient-based evaluation, but in 
65% of cases this included only the assessment of pain or stiffness on single item 
VAS or Likert-type scales. 
Measures of health outcome which adequately fulfil the measurement and practical 
properties deemed necessary for evaluative purposes (Kirshner and Guyatt, 1985; 
Fitzpatrick et al, 1998a) provide the evidence upon which evidence-based clinical 
decision-making in routine practice, research, medical audit and health policy is based 
(Ruta et al, 1998b; Bowker, 1998). However, despite the wide acceptance of many 
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anthropometric measures, and to a lesser extent patient-based instruments, in routine 
practice and research, few measures of outcome have adequate evidence of their 
measurement properties, acceptability or feasibility to support their adoption in the 
evaluation of AS (Laurent et a], 1991; Bellamy et al, 1991 a). There is no 
standardisation of measurement practice in AS, a feature common with many other 
chronic disorders, and it remains unclear how patient-based and anthropornetric 
measures relate to each other and how best to incorporate these instruments in 
evaluation. These are important and unresolved issues. There has been no systematic 
review of the wide range of available instruments in AS or an explicit appraisal of 
instrument development and application to describe the best available instruments. 
Also, no empirical evaluation of the comparative role of the many available patient- 
based and anthropometric measures has been described. 
Awareness of the need to standardise and reduce the number of instruments frequently 
applied in the evaluation of AS has resulted in the recent recommendations by the 
Assessment in Ankylosing Spondylitis group (ASAS) (van der Heijde et al, 1997; 
1999a, b, c)(table 2.65). Recommendations were based on expert opinion and followed 
the identification of several domains considered important in AS evaluation and the 
subsequent fulfillment of these domains by AS-specific measures of outcome. 
Recommendations are heavily biased towards the measurement of impairment and are 
considered further in Chapter 2. 
1.5 The current research 
The apparent knowledge gap in how best to evaluate outcorne in AS provides a strong 
case for further methodological research, and is addressed in the current research. 
The following chapters describe three stages in this process. 
Firstly, the entire range of patient-based and anthropometric measures of outcome 
applied in published studies of AS were identified and assessed as a reflection of 
current evaluative practice. Evidence for the acceptability, feasibility and 
measurement properties was systematically reviewed and appraised to produce the 
first explicit evaluation of all instruments. Any gaps in evaluation were identified. 
Historically the selection of instruments for inclusion in research or routine practice 
has been based upon 'usual' practice, historical precedence (Jenkinson et al, 1994a), or 
on expert opinion (van der Heijde et al, 1997), and consequently has resulted in a lack 
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of standardisation. This review has described the f irst evidence-based selection of 
patient-based and anthropornetric measures of health outcome to reflect the different 
domains of HRQL considered important in the evaluation of AS. Secondly, the f irst 
individualised measure of AS-related quality of life, the Patient Generated Index for 
AS (PGI-AS) was developed and tested for the first time. 
Thirdly, the study describes the first empirical comparison of the selected instruments, 
the PGI-AS and two generic measures of HRQL in a large population of AS patients. 
The study describes one of the largest clinic-based and multi-centre postal surveys of 
outcome measures in AS in the United Kingdon (UK). The detailed assessment of 
data quality, scaling assumptions and measurement properties for such a broad 
selection of measures of outcome has not previously been undertaken in AS. The 
concurrent evaluation supports instrument comparison and final recommendations are 
based on accumulated evidence of instrument acceptability, feasibility and 
measurement properties (McHomey and Tarlov, 1995). 
The first standardised and evidence-based package of patient-based and 
anthropornetric measures of outcome for application in AS clinical practice and 
research that fulfills the domains considered important in the evaluation of AS will be 
described. The study will also support the reduction in multiple measures of 
impairment and disability traditionally adopted in AS evaluation, and provide 
guidance for the role of disease-specific and generic measures of HRQL in AS 
alongside the more traditional measures of impairment. The role of individualised 
patient assessment of disease-related quality of life in AS will be introduced to the 
evaluation of AS for the first time. 
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Chapter 2 Systematic review of patient-based and anthropometric measures 
of outcome in AS 
2.1 Introduction 
This chapter presents a systematic review of patient-based and anthropometric 
measures of outcome applied in published studies of AS between 1990 and May 2000. 
The status of outcome measurement in AS is described in section 2.2 and the role of 
systematic reviews is discussed in section 2.3. The methods for performing a 
systematic review and explicit evaluation of outcome measures are described in 
section 2.4. The results of the literature review, identification of articles and measures 
of outcome are described in section 2.5. Section 2.6 describes the data evaluation and 
selection of instruments. The chapter closes with a discussion. 
2.2 AS and measures of outcome 
There is no current consensus on the best approach to take in the evaluation of a 
disease with such a wide clinical spectrum as AS (van der Heijde et al, 1997). 
Diverse issues from observable clinical manifestations to the impact on HRQL may 
be considered, and a multitude of instruments are often applied in published studies 
and in clinical practice (Laurent et al, 1991; Jenkinson et al, 1994a). However, AS 
evaluation has largely focussed on clinical measures of impairment, disease process 
and the presence of subjective symptoms of disease activity such as pain and stiffness 
(Laurent et al, 199 1; Bakker et al, 1993b). A recent survey of routine practice 
revealed that two anthropometric measures from the AS diagnostic criteria (lumbar 
anterior flexion and chest expansion) were usually or always included in AS 
longitudinal evaluation by more than 70% of clinicians, but less than 50% included 
patient-based instruments (Bellamy et al, 1998; 1999). A lack of familiarity with 
patient-based instruments, logistic restraints and a lack of emphasis on formalised 
measurement of outcome were offered as suggestions for the described measurement 
practice (Bellamy et al, 1998; 1999). 
There is a need for the standardisation of approaches used in the evaluation of AS to 
foster comparison of results across studies and to reduce the unnecessary burden to 
both patient and clinician of completing a large number of potentially inappropriate 
instruments. The result will be a package of outcome measures that are of relevance 
to both patient and clinician. In recognition of the difficulties in selecting appropriate 
evaluative instruments the Assessment in Ankylosing Spondylitis (ASAS) group was 
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formed in 1995 as a sub-committee to the larger Outcome Measurement in 
Rheumatology (ONIERACT) initiative (van der Heijde et al, 1997; 1999a, b, c). ASAS 
is an'invited'international working group consisting of clinical experts in AS, clinical 
epidemiologists, patient representatives and delegates from the pharmaceutical 
industry. 
The ASAS group first described three different settings in which therapy could occur: 
firstly, disease-controlling anti-rheumatic therapy (DC-ART); secondly, symptom 
modifying anti-rheumatic drugs (SMARD) and physical therapy; thirdly, clinical 
record keeping and clinical practice (van der Heijde et al, 1997). Following a 
Medline (index medicus on-line: 1986-1995) database search, further supported by a 
hand-search of the bibliographies of selected articles, 110 instruments applied in AS 
during this period were identified. This total included both single component 
measures and composite indices (van der Heijde et a], 1997). 
Members chose those instruments they felt should be included in a core set for each 
setting, spending points to indicate the relative importance of each instrument. 
Instruments were subsequently ranked and the domains described to produce a core 
set of domains for each setting (table 2.1). 
DC-ART SMARD / Physical therapy Clinical record keeping 
Common to all settings 
Physical function 
Pain 
Spinal mobility 
Spinal stifffiess 
Patient global assessment 
Pe? IpheralJoints / entheses Peripheraljoints / entheses 
Acute phase reactants 
Spine radiograph 
Hip radiographs 
Fatigue- 
___ ___ 
Acute phase reactants 
Table 2.1 Preliminary core sets of domains for the evaluation of patients with AS 
identified by the ASAS working group (van der Heijde et al, 1997). 
Domains in italic print are not definitely included, but are on the ASAS research agenda. 
OMERACT and ASAS have proposed a filter to support instrument selection that 
relies upon evidence of truth, discrimination and feasibility (Bellamy, 1999). Truth 
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considers validity and discrimination the reliability and responsiveness of an 
instrument as a collective attribute. Feasibility addresses instrument brevity, 
simplicity and scoring when applied in routine practice or research. Subsequent to 
domain identification instrument selection was initially based upon evidence of 
feasibility and relevance, as determined by expert opinion and group consensus only 
(van der Heijde and van der Linden, 1998; van der Heijde et al, 1999ab, c). This 
process did not appraise evidence to support instrument development or measurement 
properties. ASAS acknowledges that further appraisal of instrument measurement 
properties is required and indicate that any necessary amendments to 
recommendations following this process will be made (van der Heijde et a], 
1999a, b, c). 
The ASAS instrument selection fulfilling the core set of proposed domains was 
published subsequent to the initial systematic review described in section 2.4. The 
selection will be discussed in relation to the instruments selected as a result of the 
systematic review in section 2.7. 
2.3 Systematic reviews of scientific evidence 
A systematic review has been defined as: 
vidence from 'the process of systematically locating, appraising and synthesising e 
scientific studies in order to obtain a reliable overview. ' 
(Centre for Reviews and Dissemination (CRD) Report 4,1996) 
Available literature on the methodology for performing systematic reviews 
concentrates predominantly on the critical appraisal of randomised controlled trials 
(RCTs)(CRD Report 4,1996). This study differs from standard reviews because the 
majority of the studies included in the evaluation are not RCTs, and the main focus of 
the study is to determine the quality of patient-based and anthropometric measures of 
outcome. 
Several structured surveys and more practical approaches to evaluating the 
developmental and measurement properties of patient-based measures of outcome to 
support making recommendations for the adoption of certain instruments have been 
described. For example, Beurskens; et al (1995) critically appraised the evidence in 
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support of four widely used functional measures of low back pain, and McDowell and 
Newell (1996) and Bowling (1996) have produced texts which describe and appraise 
various outcome measures and rating scales. Also, standards for instrument 
development, testing and appraisal have been described by several authors (Streiner 
and Norman, 1995; McDowell and Jenkinson, 1996; Fitzpatrick et al, 1998a). 
The review of outcome measures described by ASAS, although extensive, was not 
systematic. The review design and inclusion criteria by which instruments were 
identified were not defined, the search was not exhaustive and article retrieval not 
systematic. Assessment and instrument selection was dictated by expert opinion and 
group consensus and not by an explicit appraisal of available evidence. Also, 
although experts offer extensive knowledge in relation to AS, 'content experts' may 
lack the objectivity desirable in critical appraisal (Oxman, 1995). 
The first article to describe a systematic literature review of two specific patient-based 
outcome measures was published subsequent to the initial review (section 2.4) (Ruof 
and Stucki, 1999a). The investigators compared the properties and performance of 
the Dougadas Functional Index (DFI)(Dougadas et al, 1988) and the Bath Ankylosing 
Spondylitis Functional Index (BASFI)(Calin et al, 1994). Article retrieval followed a 
database search of Medline (index medicus online), scanning reference lists and 
contact with the instrument developers. Evidence was appraised in accordance with 
the OMERACT filter (Boers et al, 1999) modified to consider instrument 
development. Contact with the instrument developers was made to improve 
identification of all relevant published data. However, permission to use either 
instrument is not required and contact with the developers assumes an awareness of 
all studies applying each instrument. A more exhaustive search of the major 
electronic databases and hand-searching of relevant j ournals would improve the 
systematic nature of the search and improve study replication (Jadad et al, 1998). 
When designing a systematic review structured, thorough and replicable methods of 
data collection are essential to ensure the identification and retrieval of all, or nearly 
all, relevant studies (Dickersin et al, 1995; Jadad et al, 1998). Data collection should 
clarify methods adopted to identify data, study inclusion criteria and a structured data 
extraction to support analysis. The adoption of explicit methodology improves the 
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validity of results, allows study replication and supports appreciation of why results 
and conclusions of similar reviews may differ (Mulrow, 1995). 
The review described in this chapter has adapted the guidelines for performing a 
systematic review of RCTs proposed by the CRD in York (CRD Report 4,1996) and 
available evidence to support the requirements of evaluative instruments to develop a 
systematic review and explicit evaluation outcome measures. Due to the large 
number of outcome measures included in AS evaluation and the limited study 
resources, the review has focussed on the identification of patient-based and 
anthropometric measures of outcome and available publications to support the 
development and testing of these instruments. 
Patient-based measures reflect a relatively new approach to the evaluation of patient 
outcome reflected by the growth in availability of instruments in rheumatology and 
other specialities (McDowell and Newell, 1996; Bowling, 1996). Broadly defined, 
patient-based measures of outcome record a patients perspective about various 
domains of health, illness and the effects of health care (Fitzpatrick et at, 1998a; 
Greenhalgh and Meadows, 1999). 
Anthropometric measurement has clinical relevance to both AS research and clinical 
practice (Lubrano et al, 1998). Despite a lack of standardisation and paucity of data 
supporting the measurement properties (Laurent et al, 1991; Bakker et al, 1993b), 
clinicians routinely include these measures in the longitudinal evaluation of patients 
(Lubrano et al, 1998; Bellamy et al, 1998,1999). 
Although playing an important role in diagnosis and as a long-term end-point in 
assessment, radiographic evaluation is not well established as an evaluative procedure 
in AS (Dawes, 1999; van der Heijde and Spoorenberg, 1999) and has been excluded 
fromthereview. Laboratory based measures are considered 'unhelpful' in the 
evaluation of AS (Calin, 1995a) and evidence of a relationship between laboratory 
based measures of disease activity and axial disease is weak (Ruof and Stucki, 1999b; 
Dawes, 1999). These measures have also been excluded. 
A'triple research questiorf (CRD Report 4,1996), modified to suit to focus of the 
review, was proposed: 
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1) Instruments: What patient-based and anthropometric measures of 
outcome are used in the evaluation of patients with the adult expression of 
AS? 
2) Measurement properties: What is the available published evidence 
supporting the development, testing and application of these instruments? 
3) Success of instrument: Do these instruments successfully fulfil the 
necessary attributes required of an evaluative instrument to support 
recommendation for use in clinical practice and research? (Fitzpatrick et 
al, 1998a). 
The primary aim of the review is two-fold: first, to provide the first comprehensive 
report of the entire range of patient-based and anthropometric measures of outcome 
applied in published studies of patients with AS between 1990 - 2000; and secondly, 
to synthesise the evidence base in support of the development and subsequent testing 
of identified instruments. 
A secondary aim is to make recommendations in support of the first evidence-based 
selection of instruments for use in research and clinical practice which fulfil the 
domains considered important in the evaluation of AS. These instruments will be 
adopted in a comparative study (Chapter 4) where measurement and practical 
properties will be further evaluated before a final recommendation is made. 
2.4 Methodology for a systematic review and evaluation of patient-based and 
anthropometric measures of outcome in AS 
A systematic review and evaluation of patient-based and anthropometric measures of 
outcome requires selection criteria for the identification of articles and measures of 
outcome. Search strategies for a systematic and exhaustive literature search are 
described. Data extraction from selected articles and the explicit evaluation of 
instruments then follows a systematic format. A grading scheme to provide a quality 
assessment and quantiative, summary of the evidence for instrument measurement 
properties is also described. 
The initial literature search covered the years 1990 - April 1998. The start date of 
1990 was chosen because very little work on patient-based measures of outcome had 
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taken place in AS before this time. Although anthropometric measures had been in 
use prior to 1990, the review was to be a reflection of current practice, therefore 
representing those approaches accepted into routine practice or research. Little 
evidence for the measurement properties of anthropometric measurement existed 
before this time (Laurent et al, 1991; Bellamy et al, 1991a). The search was 
subsequently extended to May 2000 to identify further published evidence and 
progress in the field of outcome measurement in AS. This will inform the discussion 
in subsequent chapters following instrument selection for the empirical evaluation. 
2.4.1 Inclusion criteria 
All articles and measures of outcome were required to satisfy certain criteria of 
relevance to the study question, patient population, type of outcome and language. 
Article inclusion criteria is shown in table 2.2. 
Articles 
Inclusion Exclusion 
Published articles (1990-2000) focussing on i. Not specific to evaluation of adult form of AS 
evaluation of adult form ofAS and containing ii. Non-English language identifiable patient-based or anthropometric 
measures of outcome iii. Development testing or use of laboratory, 
Published articles referring to development / testing 
of patient-based or anthropometric measures of 
outcome applied in studies of AS between 1990- 
2000 
radiographic or imaging techniques 
iv. Do not describe instrurnents in sufficient detail to 
allow identification 
V. Non-published data 
vi. Narrative reviews 
Table 2.2 Article inclusion and exclusion criteria. 
A measure of outcome was selected if it was patient-based or anthropornetric and 
applied in the evaluation of adults with AS between 1990-2000, as shown in table 2.3. 
Measures of Outcome 
Inclusion Exclusion 
Applied in evaluation of adult AS patients (1990 - i. Only used in relation to other conditions, or in 
May 2000): childhood forms of AS 
Published (Anglicised) patient-based 
measures of outcome 
Examination-based anthropometric measures 
(spinal and thoracic) 
ii. Anthropometric peripheral joint assessment 
iii. Laboratory, radiographic and imaging techniques 
iv. Single item measures 
V. Instruments not clearly identified in published text 
vi. Non-Anglicised instruments 
vii. Insuvrnents for which only stage III information 
can be obtained ' 
Table 2.3 Patient-based and anthropometric measures of outcome inclusion and exclusion 
criteria. 'stage lH refers to article type in which instrument was identified (defined in s(clion 2.4.2) 
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AS predominantly affects the axial skeleton (van der Heijde and van der Linden, 
1998). Although peripheral joints, in particular the large axial joints, maybe involved 
in the disease process, this is less common and with a tendency to be episodic and 
therefore difficult to assess (Kidd et al, 1988). Assessment of peripheral joints has 
therefore been excluded and anthropornetric evaluation restricted to the assessment of 
spinal and thoracic mobility. 
A preliminary review of selected articles identified a wide range of single item 
measures adop ted for the evaluation of features ranging from pain or stiffness to 
global health. Given the large variation in the number of items identified and the 
frequent lack of methodological detail these instruments were excluded from the 
review. 
Although limiting the extent and generalisability of the review, due to limited 
resources only English language articles and Anglicised instruments were included. 
Where instruments have been translated into other languages this has been referred to. 
Where articles describe the application of instruments that have not been translated 
into English these articles and instruments have been excluded from the review. 
Where communication with experts identified the development of new instruments 
this has been acknowledged. However, resource constraints meant that only 
published instruments and published evidence in support of development and testing 
have been included. 
2.4.2 Review search strategies 
The strategy adopted for obtaining articles and the identification of instruments is 
outlined in figure 2.1. Three stages can be described: 1) identifying articles; 2) 
identifying measures of outcome; 3) assessment of articles and instrument relevance. 
1) Identifying articles 
The strategy adopted in developing the literature search for articles used the following 
four steps: i) developing search terms; ii) electronic database searches; iii) hand 
searching keyjoumals; and iv) scanning reference lists (Jadad et al, 1998). 
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Reject words with 
Wgh recall or low 
precision 
Identify key words 
for search strategies 
Systematic literature 
search 
Reject article 
Use inclusion and 
exclusion criteria to select 
I 
abstract / article 
I 
Can patient-based 
measures of outcome be 
identified in the article? 
No 
Yes 
Has instrument already 
been identified? 
No 
List instruments and classify 
domains addressed 
Self-completed, / interview-administered I examination-based 
AS-specific II Arthritis specific II Domain specific II Generic 
No 
Reject afticl 
Is evidence supporting 
instrument development 
testing provided by the article? 
Yes 
Stage 1: Initial development Stage H: Further testing by original 
authors or other investigators 
Make recormnendation for application of 
instrument based on synthesis of gathered 
evidence 
Yes 
Anthropometfic 
Stage IH: Wider application 
Figure 2.1 Strategy for obtaining relevant articles, identification and evaluation of measures of outcome 
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i. Developing search terms 
Contacts with experts in rheumatology and outcome measurement 
Consultation was made in order to gain a wide-ranging perspective of cuffent issues 
in the measurement of outcome and AS and to call upon expert knowledge of relevant 
literature and ongoing research. Individuals were identified due to exceptional 
publications in AS and from identification in the British Society for Rheumatology 
Handbook (1995-1996)(table 2.4). Information regarding the use of and knowledge 
of the development and testing of patient-based measures of outcome, evaluation 
guidelines and recommendations for monitoring in AS was requested. 
Health professionals United Kingdom Health professionals International 
Dr. Julie Barlow Coventry University Dr. Maarten Boers Netherlands 
Dr Robin Butler Shropshire Professor Peter Brooks Australia 
Dr. Andre Calin Bath Dr. Maxime Dougadas France 
Dr. Martin Davis Cornwall Dr. Desiree van der Heijde Netherlands (Chair of ASAS) 
Dr. Chris Eastmond Scotland Dr. M. A. Khan USA 
Profe-or Ian Haslock Cleveland Professor S. Van der Linden Netherlands 
Dr. Philip Helliwell Leeds 
Dr. Nigel Hurst Edinburgh 
Dr. Dcreck Jacoby South Devon 
Dr. Andrew Keat London 
Dr. Gabrielle Kingsley London 
Associations 
American College of Rheumatology (ACR) America 
Arthritis Rheumatism Council (ARC) England 
Dr. David Perry London 
Professor Roger Sturrock Scotland National Ankylosing Spondylitis Society England 
Dr. Paul Wordsworth Oxford 
Table 2.4 Contact with health professionals and rheumatology associations 
Retrospective searching 
Articles and text-books were identified that provide overviews of the development, 
evaluation and application of patient-based measures of outcome. Articles providing 
a more general overview of the application of patient-based and anthropometric 
measures of outcome in AS, rheurnatology and other disorders were also identified. 
Searching these items provided references to relevant publications and provided an 
indication of the state of outcome measurement within AS and rheumatology. 
These two steps provided a basis from which to develop search terms to be used in 
electronic database searches. Key words that regularly appeared in the title or text of 
publications already identified and associated with outcome measurement and / or AS 
were used to develop the search strategies. 
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ii. Electronic database searches 
The selection of instruments for inclusion in the review was based on a search of the 
literature covering the years 1990-April 1998. The extension of the search to May 
2000 made little difference to the availability of evidence in support of instrument 
selection. Therefore, the combined search results (1990-May 2000) are presented. 
A comprehensive search of the literature used the most important electronic 
databases: Medline (index medicus on line), EMBASE (excerpta medica online), 
CINAHL (cumulative index of nursing and allied health online), PsycLIT 
(psychological abstracts online), AMED (allied and alternative medicine online), 
Cochrane Library (Cochrane database of systematic reviews (CDSR), Database of 
abstracts of reviews of effectiveness (DARE), Cochrane Controlled Trials Register 
(CCTR)), Centre for Reviews and Dissemination Reviews Database (CRD)) and 
ASSIA (applied social sciences online). 
The comprehensiveness of an electronic database search depends on the search 
strategy adopted (Brettle et al, 1998). Test searches were run on each database to 
establish the recall and precision of various search terms. Terms that failed to retrieve 
any articles or retrieved a large number of inappropriate articles were omitted from 
the final search strategy. However, the heterogeneity of terms used in the field of 
outcome measurement has been commented on by other authors (Fitzpatrick et al, 
1998a) and an extensive list of search terms was required to make the search as 
sensitive as possible. All searches specified'Ankylosing Spondylitis', 'Spondylitis 
Ankylosing', or an alternative (Bechterews or Marie-Strumpell Disease) as the main 
focus. All additional terms were required to be associated with these key terms. 
Individual terms varied for each database searched. The Medline (Silverplatter 
software) search strategy is shown in figure 2.2. This was modified to suit the 
specific requirements of the other databases. 
All abstracts were searched and articles retrieved following the application of the 
inclusion criteria (Cook et al, 1997). It was not always possible to be certain of the 
relevance of the article based purely upon the search results. Articles of definite and 
possible relevance were retrieved in full and the inclusion criteria re-applied. 
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#1 (Spondylitis-Ankylosing). sh. 
#2 Ankylosing Spondylitis. tw. 
#3 #1 or #2 
#4 Bechterews Disease 
#5 #3 or #4 
#6 Health status. tw. 
#7 (ilealth-status). sh. 
#8 (Ifealth-status-indicators). sh. 
#9 (outcome-and-process-assessment-(health care)). sh. 
#10 (outcorne-assessment-(health care)). sh. 
#11 (process-assessment-(health care)). sh. 
#12 outcome$ or proces$. tw. 
#13 outcome measureSAw. 
#14 (treatment-outcome). sh. 
#15 assess or assessing or assessment$. tw. 
#16 (quality-of-life). sh. 
#17 health-related quality of life or health related quality of life. tw. 
#18 (severity-of-illness-index). sh. 
#19 severity of disease. tw. 
#20 disease activity. tw. 
#21 index or in(hcc$. tw. 
#22 (self-assessment-(psychology)). sh. 
423 self-assess or self assess or self-assessment or self assessmentAw. 
424 end point$ or end-point$ or endpomLtw. 
#25 measure$ or measuring or measurementS. tw. 
#26 (physical-examination). sh. 
#27 (range-of-motion-articular). sh. 
#28 metrology. tw. 
#29 functiod or functional. tw. 
#30 finictional, impairment or functionally impairedtw. 
#31 functional disabilit$ or functionally disabledtw. 
#32 finictional. abilit$ or hinctionally able. tw. 
#33 functional activitS. tw. 
#34 (activities-of-daily4iving). sh. 
#35 physical therapy. tw. 
#36 health status. tw. 
#37 mental status. tw. 
#39 handicap-tw. 
#39 (disability-evaluation). sh. 
#40 disabilit$. tw. 
#41 (evaluation-studies). sh. 
#42 (clinical-trials). sh. 
#43 (pain-measurement). sh. 
#44 (questionnaires). sh. 
#45 flexion or extension or rotationtw. 
#46 chest expansion-tw. 
#47 physical mobility. tw. 
#48 score$ or scoringAw. 
#49 monitor$ or monitoringtw. 
#50 (reproducibility-of-results). sh. 
#51 reliable or reliability. tw. 
#52 valid or validity or validate. tw. 
#53 responsive or responsiveness. tw. 
#54 6 or 7o r8 or 9 or 10 or II or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 
26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 
45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 
#55 #5 and #54 
#56 PY > 1989 
#57 IA = English 
Figure 2.2 Medline (index medicus online) database search strategy (1990-2000) 
Notation: sh. - MeSh heading (medical subject heading); tw. - word in any of the text; S- truncation symbol. 
iii. Hand searching keyjournals 
It is possible that articles are indexed inaccurately in the online sources or are 
overlooked in the search process (CRD Report 4,1996). Hand searching may also 
identify articles yet to be registered with online sources (Jadad et al, 1998). The 
following journals were considered most relevant to the topic and were hand 
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searched: Rheumatology (formerly the British Journal of Rheumatology), Journal of 
Rheumatology, Current Opinion in Rheumatology, Annals of Rheumatic Diseases, 
Arthritis and Rheumatism, Arthritis Care and Research, Seminars in Rheumatology, 
Clinical and Experimental Rheumatology, Spine, Quality of Life Research. 
iv. Scanning reference lists 
Scanning the reference lists of retrieved articles identified further articles for 
consideration. Specifically, this search supported the acquisition of articles published 
pre-1990 that may report the development and testing of instruments. 
Z Identifying measures of outcome 
Following application of the inclusion criteria all patient-based and anthropometric 
measures of outcome listed in the article were identified- If instruments fulfilling the 
inclusion criteria could not be identified the article was rejected. Instruments were 
then listed according to their completion format. That is, patient self-completed, 
interview-administered or examination-based / anthropometric. Finally, the disease 
specificity or domain addressed was indicated. Instruments may be broadly classified 
as either specific or generic (Guyatt et al, 1993). Further divisions within this simple 
dichotomy provide a more detailed analysis of the potential instrument properties. 
Within this review instruments were classified as: AS-specific, arthritis-specific, 
domain-specific, generic or anthropometric. 
Where an inadequate description of the instrument, the methodology adopted or an 
inadequate reference to support the approach was found the instnunent was excluded. 
3. Assessment of relevance 
The final stage in the search strategy was to assess the identified articles and measures 
of outcome for their relevance to the research question (figure 2.1). 
Application of the review inclusion criteria ensured that patient-based and 
anthropometric measures of outcome applied in AS evaluation were identified. 
Evidence describing the development and / or subsequent testing of instruments was 
required from the published articles. Articles could be classified into three different 
stages of instrument development reflecting the original development, testing and 
subsequent application of an instrument (table 2.5)(figure 2.1). 
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Stage of development Properties of article 
I Original development and testing 
Further development and testing 
Performed by original authors or other investigators. Studies have a specific 
aim to evaluate the instruments measurement properties 
Wider testing and use of the measure in AS-specific clinical practice, 
research, and audit, etc. 
Table 2.5 Stage of instrument development described by article 
A hierarchy of instrument development has been described to support the degree to 
which evidence from the review could be incorporated in the data evaluation (section 
2.4.4). Studies from the developers of each instrument were described as Stage I 
articles and were sought for each instrument. These articles should describe 
instrument purpose and conceptual base, clarify the intended population and provide 
evidence in support of the development and initial testing. Stage II articles provide 
further evidence of instrument application and build upon evidence in support of the 
measurement properties. These investigations may be performed by the original 
developers or by subsequent investigators. In stage III, the wider application of the 
instrument in clinical research and routine practice is sought. These articles may 
provide further evidence in support of instrument reliability, validity and 
responsiveness. Evidence of the generalisability of the results in terms of AS, and the 
feasibility and acceptability of instruments beyond application by the original 
developers is sought. Selected articles were listed under each registered instrument 
and the stage of instrument development reflected by an article indicated. Where 
published evidence in support of stages I and II could not be identified instruments 
were excluded from the review. 
2.4.3 Data extraction 
Using criteria considered important in the evaluation of patient-based measures of 
outcome (Streiner and Norman, 1995; McDowell and Newell, 1996) a data extraction 
sheet was developed to retrieve data reflecting the development, testing and 
evaluation of instruments from selected articles (Appendix 1). Tabulated evidence in 
support of the identified instruments was created that follows the structure of the data 
extraction sheet. 
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Data extraction was performed by the lead investigator only (KLH), and all articles 
and data-extraction sheets were double-checked by the same investigator for 
consistency and accuracy of content. Appraisal by a second reviewer to check for 
human error and reduce any potential of bias in data extraction was not possible 
within the given resources. 
2.4.4 Data evaluation 
The data evaluation of all selected instruments was performed by the lead investigator 
(KLH) and is based on published evidence from retrieved articles (Cook et al, 1997). 
Using widely cited criteria adapted from several publications a structured and explicit 
qualitative framework was applied (Streiner and Norman, 1995; Beurskens et al, 1995; 
McDowell and Newell, 1996). The framework allows for appraisal of each 
instrument in terms of the areas summarised in table 2.6. 
Review criteria Key questions 
Title Title provided by the original author and any subsequent revisions 
Author Lead author in original development 
Year Year of first publication and the year of any major revision 
Purpose What is the purpose of the instrument? 
What does it aim to evaluate? 
Conceptual base Do the authors provide a conceptual definition of what they aim to 
measure? What is the rational behind the design and development? 
What is the focus and relevance of the instrument? 
Is there justification for the items included? 
Does the rational relate to the 'purpose'? 
Population On which populations has the instrument been developed and 
tested? 
General description, item What method of item development is used? 
development and scale structure Are all participants involved in this process identified? 
What domain(s) are covered by the items? 
What method of item scaling is used and why? 
Time specificity? 
Performance or capacity based? 
Are developers active in developing / modifying the instrument? 
Measurement properties Published evidence of - reliability, validity and responsiveness; 
population investigated and study design (developers and 
subsequent investigators) 
Acceptability Is the instrument acceptable to patients? 
Feasibility and application Is the instrument practical and acceptable to all users? 
Has respondent/clinician burden been considered in administration 
and scoring? Is there a 'users manual'? 
Has the instrument been applied by investigators other than the 
original developers? 
Commentary Synthesis of evidence 
Table 2.6 Summary of data evaluation. 
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Following the guidelines proposed by McDowell and Newell (1996), the appraisal of 
each instrument was based upon published information together with an 
accompanying users manual if available. As a minimum, published information 
relating to an instruments development should consider the purpose and conceptual 
base, development and subsequent testing of measurement properties, the 
standardisation of application and scoring procedures, and identify the definitive 
version (McDowell and Newell, 1996). 
In addition to the retrieval of descriptive data and statistical results, a grading scheme 
to provide a quantitative summary of the quality of evidence supporting the reliability, 
validity and responsiveness of identified instruments has been developed based on 
previous work (McDowell and Newell, 1996)(tablc 2.7) 
Thoroughness of testing Results of testing 
0 No reported evidence 0 No numerical results reported 
+ Basic information only + Weak evidence only 
++ Several types of test, or several studies ++ Moderate levels of evidence 
reporting evidence 
+++ All major forms of validity / reliability Strong evidence to support 
responsiveness reported. Several good 
quality trials reporting evidence 
Table 2.7 Grading scale summary of the reliability, validity and responsiveness of 
identified instruments - (adapted from McDowell and Newell, 1996) 
Test-retest reliability describes the stability of scores over time and is most often 
assessed by the calculation of the correlation coefficient. 'Internal consistency 
reliability may be assessed by calculating Cronbach's alpha coefficient which 
evaluates the homogeneity of items in a multi-item instrument based on classical test 
construction theory. Validity examines if the instrument measures what it purports to 
measure, and both qualitative (face and content) and quantitative (construct) 
assessments of validity are described. Responsiveness describes the ability of the 
instrument to detect clinically important change over time. The concepts of 
reliability, validity and responsiveness are addressed in detail in Chapters 5,6 and 7 
respectively. The quality of evidence considers both the thoroughness and the results 
of testing the measurement properties considered important for evaluative instruments 
(Kirshner and Guyatt, 1985). The grading scheme summarises evidence in terms of 
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ordered categories and consists of a four-point scale: a score of V indicates 'no 
support' for the underlying criteria, whereas a score of '+++' indicates a strong level 
of published evidence (table 2.7). 
2.5 Results of review 
The results of the review will be considered in three stages: 1) identification of 
articles; 2) identification of measures of outcome; 3) the data evaluation (section 2.6). 
2.5.1 Identification of articles 
For each electronic database searched a total number of abstracts were identified, as 
shown in table 2.8. 
Electronic database No. of abstracts 
No. of abstracts / 
articles reviewed No. of articles included 
No. of articles 
(additional to Medline) 
Medline 499 129 80 90 
EMBASE 589 123 83 21 
CINAIIL 135 20 16 3 
AMED 45 24 21 0 
ASSIA (until 1997) 2 2 2 0 
Cochrane - CTR 210 65 32 0 
Cochrane - DARE 3 1 0 0 
Cochrane - SR 9 9 0 0 
PsychLIT 15 7 3 0 
Database total - - - 104 
I landsearching and 54 
citation searching 
TOTAL 158 
Table 2.8 Results of systematic literature review (1990-2000) 
Following application of the inclusion criteria the nurnber of articles selected for the 
review was 104. The hand and citation search produced an additional 54 articles, 
making a total of 158 articles, 
2.5.2 Identification of measures of outcome 
A total of 33 self-completed and one interview-administered patient-based measures 
of outcome (table 2.9), and 46 examination based / anthropometric measures (table 
2.10) were identifie4. 
The patient-completed instruments included six generic measures of HRQL, six AS- 
specific measures of functional disability (including the interview-administered 
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MACTAS/PET), two AS-specific measures of disease activity, and a further two AS- 
specific measures of global health or HRQL (BAS-G; AS-AIMS2)(table 2.9). 
The Bath AS-Global Score (BAS-G) quantifies the impact of AS on well-being (Jones 
et al, 1996a). It consists of two 10cm horizontal VAS: one records the impact of AS 
over the last week and the second the impact over the previous six months. However, 
the results of the VAS are not combined and are not routinely applied together. The 
BAS-G should be considered a single item measure and was excluded from the data 
evaluation. Only the AS-AIMS2 (Guillemin et al, 1999) was published subsequent to 
the initial review and was not available for consideration for inclusion in the 
comparative study (Chapter 4). 
Category Original reference Instrument 
Generic 
Healthprofile Bergner et al (1976) Sickness Impact Profile. 
Hunt et al (1989) Nottingham Health Profile. 
Ware (1997) Short Form 36-item Health Survey. 
Utility measure Torrence (1976) Standard Gamble. 
Torrence (1976) Rating Scale. 
Bennett et al (199 1) McMaster Utility Measurement Questionnaire. 
AS-specifx 
Functional disability Nemeth et al (1987) Ankylosing Spondylitis Assessment Scale. 
Dougadas et al (1988) Dougadas / Spondylitis Functional Index. 
Daltroy et al (1990) 1 lealth Assessment Questionnaire - Spondyloarthropathics 
Abbott et al (1994) Leeds (Revised Leeds) Disability Questionnaire. 
Calin et al (1994) Bath AS Functional Index. 
Bakker et al (1995) McMaster Toronto AS Patient Preference Disability 
Questionnaire / Patient Elicitation Technique 
Disease activity Kennedy et al (1993) Bath Disease Activity Index. 
Garrett et al (1994) Bath Ankylosing Spondylitis Disease Activity Index. 
AS IIRQL / 
global health Jones et al (I 996a) Bath Ankylosing Spondylitis Global Score. 
Guillemin et al (1999) AS Arthritis Impact Measurement Scales 2. 
Arthritis-speciflw 
Functional disability Fries et al (1980) Health Assessment Questionnaire. 
Meenan et al (1980) Arthritis Impact Measurement Questionnaire. 
I lelewa et al (1982) Toronto Activities of Daily Living Questionnaire. 
Kirwan & Reeback (1983) Modified - HAQ. 
Sel&efficacy Nicassio et al (1985) Arthritis Helplessness Index. 
Barlow et al (1996) Generalised Self-Efficacy Scale. 
Sexualfunctioning Blake et al (1987) Sexual Activity and Satisfaction Questionnaire. 
Doinain specific 
Perceivedfuness Astrand & Rodahl (1977) Astrand Fitness Index 
Borg (1978) Borg Scale - subjective effort / physical performance 
Socialfunction Carlson & Levy (1968) Carlson Adjective Checklist - Social Personal Orientation 
Mari et al (1985) Self-Report Questionnaire 20. 
Funch(1986) Social Support Scale. 
De Witte (1991) Self-Assessed Function Questionnaire. 
Pain Melzack R (1975) McGill Pain Questionnaire. 
Melzack R (1975) Pain Rating Index (Rank). 
Depression Radloff DP (1977) Centre for Epidemiological Studies Depression Scale. 
Wallston et al (1978) Multi-dimensional Health Locus of Control. 
de JonE-Gierveld & KaMpobuis (19851 Loneliness Scale. 
Table 2.9 Self-completed patient-based measures of outcome. 6 requires interview completion 
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Category Original reference Instrutnent 
AS4pecifsc 
Disease-mlMty Mander et al (1987) Newcastle Enthesitis Inde)L 
Dawes et al (1987) Stoke Enthesitis Index. 
Dougadas et al (1988) Dougadas / Spondylitis Articular Index. 
Creemers et al (1996) Ankylosing Spondylitis Disease Activity Scale. 
Anthropometric Jenkinson et al (1994a) Bath Ankylosing Spondylitis Metrology Indey- 
Arthrilis-sperific 
Disease-wfivity Steinbrocker et al (1949) Steinbrocker Functional Criteria (for RA). 
Ritchie et al (1968) Ritchie Articular Indey- 
Generic anthropometric 
Cervical rotation Cheshire (1957) Cervical rotation -'Large protractor'. 
AAOS (1965) Universal goniometer. 
OThiscoll (1978) Simple or Spirit inclinometer. 
Viitanen (1992) Myrin inclinometer. 
Viitam (1998) Tape measure. 
Cervicalflexion / extension AAOS (1965) Universal goniometer. 
ODriscoll (1978) Simple inclinometer. 
Calcraft (1974) Tape measure: occiput to C7; Chin to chest 
Cervical lateraljkxion AAOS (1965) Universal goniometer. 
AAOS (1965) Tape measure: tragus to acrornioclavicular joint. 
013riscoll (1978) Simple inclinometer. 
Chest expansion Ilast et al (1963) Nipple level. 
Moll & Wright (1972) 4th intercostal space; hands on head. 
Tomlinson (1986) Mphistemum; hands on bead / by side. 
Thoracolumbar, flexion AAOS (1965) C7 - iliac crest. 
Calcraft (1974) C7 - 10cm proximal to L5/S I junction. 
Hyde(1980) C7 - sacrococcygeal point 
Armstrong (1984) C7 - posterior superior iliac spines. 
Viitanen (1992) C7 - SI. 
Avems (1996) C7 - L5. 
77ioracic rotation Viitanen (1993) Thoracolumbar rotation frame. 
Viitanen (1999) Pavlaka method. 
Fingertip tofloor distance 
(anteriorflexion) Miller (1994) Tape measure; patient stands on floor. 
Tomlinson (1986) Vertical mounted ruler; patient stands on floor. 
Kippers & Parker (1987) Ruler / tape; patient stands on raised stool. 
Stokes (1988) ! Portable spinal mobility scale (PSMS). 
Lumbarflexion Von Schober (1937) Schober'l0cm` index. 
Macrae & Wright (1969) Modified Schober Index (I 5cm) (lumbar flexion). 
Adrichern & van der Korst Lumbar Flexion Index. 
(1973) 
Lumbar extension Dunham (1949) Dunham Spondylometer (flexion I extension). 
Moll (1972b) ? Iumb-line'extensiorL 
Miller (1984) Smythe technique (flexion / extension). 
Lumbar lateralflexion Moll (1972a) Skin distraction technique (ipsi/contralateral). 
DomJan (1990) Fingertip markings, lateral thigh (ipsilateral). 
Pile (1991) Fingertip to floor - vertical mounted ruler (ipsilateral). 
Little (1986) Fingertip to fibula (ipsilateral). 
Spinalposture Ton-lison (1986) Tragus to wall distance - Y-square. 
Stokes (1988) Occiput to wall distance - PSMS. 
ARA (1984) Occiput to wall distance - tape measure. 
Table 2.10 Anthropometric / examination-based instruments 
Footnote: AAOS-American Academy of Orthopedic Surgeons, ARA- American Rheurnatology Association. 
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The examination based measures include four AS-specific measures of disease 
activity and one AS-specific battery of anthropornetric measures (Bath Ankylosing 
Spondylitis Metrology Index, BASMI)(Jenkinson et al, 1994a). However, the 
Ankylosing Spondylitis Disease Activity Scale (AS-DAS)(Creemers et al, 1996) 
represents a battery of several AS-specific instruments including laboratory-based 
measures and has been excluded from the evaluation. A total of 39 generic 
anthropornetric measures were identified and are listed under the evaluation of 
cervical, thoracic or lumbar mobility, or spinal posture (table 2.10). 
2.6 Results of data evaluation 
The data evaluation has been restricted to the AS-specific measures of. 1) functional 
disability, 2) disease activity and 3) all anthropometric measures. The domains were 
selected in light of the core domains identified by the ASAS working group (table 
2.1). 
2.6.1 AS-specific functional disability 
This section presents the evaluation of the six AS-specific measures of functional 
disability (table 2.9). A general description and the scale structure is summarised in 
table 2.11, and table 2.12 details the item content. 
Purpose and conceptual base 
The Ankylosing Spondylitis Assessment Questionnaire (ASAQ)(Nemeth et al, 1987) 
is proposed as a simple self-administered measure of spinal mobility or disability in 
AS. The purpose is not defined further and the conceptual base is not described. 
The Dougadas Functional Index (DFI)(Dougadas et al, 1988) is the first AS-specific 
measure of functional disability. It is an evaluative instrument defining functional 
ability as an appreciation of how a patient functions within their own environment. 
The initial choice of items was based on the expert opinion of three rheurnatologists 
familiar with AS and not in relation to any stated theory of functional disability. 
The Health Assessment Questionnaire for the Spondyloarthropathies (HAQ-S) 
(Daltroy et al, 1990) describes difficulties with functional activities of daily life as a 
result of an inflammatory spondyloarthropathy. The foundation for the instrument is 
the Health Assessment Questionnaire (HAQ)(Fries, 1980) which focuses on the 
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disability and discomfort associated with peripheral arthritis. The HAQ-S represents 
the impact of a disease characterised by axial involvement and oligoarthritis. 
The Leeds Disability Questionnaire (LDQ)(Abbott et al, 1994) and the revised 
instrument, the Revised LDQ (RLDQ), evaluate AS-specific functional disability. 
Items were identified to fulfil the multi-dimensional nature of functional disability 
(Dougadas et a], 1986) and to describe functional groupings described by Badley et al 
(1984) (table 2.12). 
The Bath Ankylosing Spondylitis Functional Index (BASFI)(Calin et al, 1994) is 
proposed as an evaluative measure to assist in the definition and monitoring of 
functional ability in AS. However, functional ability is not defined and item content 
is not related to any stated theory (table 2.12). 
The MacMaster Toronto Ankylosing Spondylitis patient priority questionnaire / 
Patient Elicitation Technique (MACTAS/PET)(Bakker et al, 1995) provides a patient 
elicited AS-specific evaluation of functional disability and social dysfunction. 
Patients identify their own preference for improvement in patient-derived areas of 
functional handicap (Tugwell et al, 1987), an approach which is intended to assist in 
clinical decision-making. Following a broad definition of function capturing AS- 
specific difficulties with both physical and social function, nine functional disability 
groups act as prompts for item generation (table 2.12). 
Studypopulation 
All developers indicate that the instruments are specific to AS evaluation, although 
the developers of the HAQ-S suggest application in patients with inflammatory 
spondyloarthropathy. However, patient populations involved in instrument 
development are often not clarified. The developers of the ASAQ provide no 
information about the patient population involved in instrument development. Only 
the developers of the HAQ-S described the sampling frame from which patients were 
selected and patient inclusion criteria, but method of patient selection was not 
indicated. No other developers clearly define the study sample frame, beyond the 
distinction of in-patient or out-patient status. All instruments, except for the 
MACTAS/PET, have been applied in both in-patient and out-patient populations but 
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the method of patient selection or inclusion criteria is largely unclear, with many 
reporting the participation of consecutive patients. 
General description and scale structure 
The ASAQ was proposed as a measure of pain and spinal immobility, but the pain 
item was deleted from the final instrument. Two items describing gross spinal 
movements of the lumbar and cervical spine were retained. The process of item 
development is not described. The response to both items is combined but there is 
little detail about the response scale. Score interpretation is not described. 
The DFI was developed for interview-administration to be completed by a clinician 
following the verbal response of a patient. However, the majority of published 
studies have administered the DFI in a self-completed format. The DFI consists of 20 
items relating to functional ability and activities of daily living (table 2.12). 
Following initial item selection, further development and initial testing was 
undertaken as part of a trial of AS out-patients with active disease (Dougadas et al, 
1988). A principle component analysis (PCA) reduced the number of items from 29 
to 20 and a strong level of concurrent validity was found between the original and the 
revised indices (r-- 0.95). Each item is scored on a three-point ordinal scale of ability 
(table 2.11). Item scores are totalled (range 0-40); lower scores indicate better 
functional ability. The treatment of missing values is not described. Items are 
capacity based and readily understood by patients (Dougadas et al, 1988), although 
the time speci fi city is not indicated. Average completion time is 100 seconds (Calin 
et a], 1994). 
In developing the HAQ-S five items were added to the disability index of the HAQ 
(total 25 items) and an additional VAS (stiffness severity) added to the pain and 
discomfort dimension. A postal survey of British AS patients was reviewed as a basis 
for item development. Items, referred to as sub-scales (SPAR I and SPAR 2), ask 
about ability over the previous week and are capacity based (tables 2.11 - 2.12). 
Items in the disability index are scored on a four-point ordinal scale of ability (table 
2.11). However, the HAQ check-list for registering the use of aids or assistance, or 
the scoring procedure for the ordinal scale or VAS is not described. The HAQ totals 
the highest item score within each section (total range 0- 24) and divides by the 
number of sections (8) to produce a score between 0-3 (Fries, 1980); lower scores 
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indicate better functional ability. The treatment of missing values is not described. 
Daltroy et al (1990) refers to a 'modified HAQ' without further description or 
reference. A 'Modified HAQ' (MHAQ) has been described (Pincus et al, 1983) which 
contains only one item in each of the eight disability components and scoring includes 
all item scores. 
The LDQ is a self-administered questionnaire describing four areas of AS-specific 
functional disability: mobility, bending down, reaching up and neck movements, and 
posture (table 2.12). Items derived from external sources related to the evaluation of 
functional disability in AS and rheumatology (Badley et al, 1984; Dougadas et al, 
1986) were selected by the developers. A pre-pilot evaluation involved group 
discussion between selected AS in-patients (n-- 12). The form of the discussion is not 
described. Following item selection patients graded items within each sub-section in 
increasing order of difficulty. The methods of patient selection and their 
characteristics are not provided. Following testing items were removed from the 
LDQ, but criteria for removal are not clearly specified. The revised instrument, 
RLDQ, contains 16 items (table 2.12). Each item is scored on a four-point ordinal 
scale similar to that used in the HAQ, but to improve discrimination between options 
the third option indicates the use of 'unusual movements or gadgets' (Abbott et al, 
1994), an option that was further clarified in the RLDQ (table 2.11). The LDQ is 
scored in the same way as the HAQ: score range 0-3; lower scores indicate better 
functional ability. The treatment of missing values is not described. Scoring of the 
RLDQ has been revised to consider all items: score range 0- 48; lower scores 
indicating better functional ability. If more than 2 items in any one section are 
missing then no final score is given (Helliwell P. - personal communication, 1999). 
Although capacity-based the time specificity of the LDQ is not described, but the 
RLDQ reflects a patients ability over the past week. 
The BASFI consists of ten items that encompass functional anatomy (8 items) and the 
ability of a patient to cope with activities of everyday life (2 items)(table 2.12). 
Although a multidisciplinary development group including patients was indicated, 
further detail about members and their selection are not provided. The generation of 
items was not reported and the level of agreement between members before items 
were retained or rejected is not defined. The form of the discussion is not described. 
Each item is scored on 10cm horizontal VAS anchored by adjectival descriptors 
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d easy' and 'impossible', with no further distinguishing marks (table 2.11). The 
position marked on each VAS is recorded (0-10) and the mean value for the ten items 
gives the final BASFI score (0-10); lower scores indicating better functional ability. 
No guidance for missing values is provided. A normal score distribution covering 
95% of the BASFI scale was reported in both in-patients and out-patients, and was 
accepted as support for instrument data quality. The BASFI is capacity based, 
patients scoring their ability with each activity over the last week. It requires a 
maximum completion time of 100 seconds. 
The MACTAS/PET is a modification of the McMaster Toronto Rheumatoid Arthritis 
patient priority questionnaire (MACTAR)(Tugwell et al, 1987) and the Patient 
Elicitation Technique (PET)(Bell et al, 1990; Bakker et al, 1995). Administration 
with a trained interviewer follows a scripted format. Completion is in three stages. 
Patients identify up to 15 disease-related functional difficulties with normal activities 
of daily life over the last week, assisted by the nine functional probes generated 
following completion of a PET questionnaire in a large group of AS out-patients (n-7 
144)(Bakker et al, 1995). Patient identified problems are divided into three groups: 
mobility and role activity, social interaction and appearance. Each problem is ranked 
using seven-point Likert scaling for the relative difficulty / severity / frequency of the 
item, and an additional scale is used to assess the importance of each problem (0-7). 
To score the MACTAS/PET, for each problem the importance score (0-7) is 
multiplied against the relative difficulty / severity / frequency score (0-7). Results are 
totalled and divided by the number of problems identified (range 0- 15) producing a 
possible range of 049; higher scores represent greater patient-perceived disability. 
Completion time is approximately 10- 15 minutes on the first administration and 5- 10 
at subsequent completions. At follow-up patients are allowed to view the baseline 
questionnaire but are not allowed to alter the areas identified which are reassessed for 
difficulty/ severity/ frequency and importance, and a revised MACTAS/PET score 
calculated. 
Reliability 
Evidence of the reliability of all instruments is shown in table 2.13. Only a six week 
test-retest reliability assessment of the ASAQ has been performed and good levels of 
reliability calculated (r> 0.78). 
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Test-retest reliability of the DFI has been assessed in both in-patient and out-patient 
populations and over one-week and one-day retest periods, and high levels of 
reliability have been calculated (ICC > 0.86). Condition stability in the original study 
was based upon the clinical opinion of the investigating physician (Dougadas et al, 
1988). High inter-observer reliability has also been calculated (ICC 0.99). Internal 
consistency reliability of the DFI has not been evaluated. 
Test-retest reliability of the LDQ has been assessed in both in-patient and out-patient 
populations and over one-day and five-day retest periods respectively. High levels of 
test-retest reliability have been calculated (ICC 0.93 - 0.98). A high level of internal 
consistency reliability was calculated for the total LDQ (a= 0.93) and for each 
instrument section. There is no published evidence of the reliability of the RLDQ. 
High levels of one-day test-retest reliability of the BASFI in an in-patient population 
has been reported (r-- 0.89). Internal consistency reliability has only been reported in 
a published letter reflecting a retrospective analysis of patients. A high level of alpha 
was calculated (a-- 0.94). 
There was no assessment of condition stability in the assessment of test-retest 
reliability for the ASAQ, LDQ and BASE, and hence some patients may have 
changed thereby weakening the results. There is no published evidence of the test- 
retest reliability or the internal consistency reliability of the HAQ-S or the 
MACTAS/PET. 
Validity 
Evidence of the validity of all instruments is shown in table 2.14. Issues of face and 
content validity were not specifically addressed by any development authors. No 
investigators have established a priori hypothesised relationships between variables in 
the assessment of construct validity. 
Evidence of the construct validity of the ASAQ is limited. The result of the 
comparison between the HAQ and the ASAQ was not reported and it was impossible 
to verify the nature of other outcome measures against which validity was assessed. 
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The evaluation of construct validity of the DFI is limited (table 2.14). Small to 
moderate correlation between the DFI and several poorly established clinical 
instruments and measures of disease activity and a high correlation with another AS- 
specific measure of functional ability (r-- 0.89) has provided evidence for the validity 
of the DFI. 
There is moderate evidence in support of the validity of the HAQ-S, as a measure of 
functional disability (Daltroy et al, 1990; Hidding et a], 1994b). A strong level of 
concurrent validity with the HAQ was reported, and moderate to strong levels of 
correlation with an established generic measure (Sickness Impact Profile - SIP, 
Bergner et al, 1976) and an arthritis-specific measure of HRQL (Arthritis Impact 
Measurement Scale 2- AIMS2, Meenan et a], 1992) were found (table 2.14). Small 
to moderate correlation with anthropometric measures were found. 
The evaluation of construct validity for the LDQ has been limited to comparison with 
anthropometric measures and disease characteristics, and moderate to strong 
correlations were calculated (table 2.14). The concurrent validity of the RLDQ and 
the LDQ was not calculated and there is no evidence for the validity of the RLDQ. 
The evaluation of construct validity of the BASH is limited. Small to moderate 
correlation with several poorly established clinical variables and a high correlation 
with another AS-specific measure of functional ability (r-- 0.89) was reported (table 
2.14). 
The evaluation of the construct validity of the MACTAS/PET is limited and relies on 
the results of one published study. However, a wide range of instruments were 
applied (table 2.14). Moderate correlation with generic (SIP) and arthritis-specific 
(AIMS2) measures of HRQL and small correlation with other AS-specific measures 
of functional ability (DFI, HAQ-S) were reported. 
Responsiveness 
Evidence of the responsiveness of all instnunents is shown in tables 2.15 and 2.16. 
There is no evidence of the responsiveness of the ASAQ or the RLDQ. 
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The strongest evidence of the responsiveness of the DFI has been reported in drug 
therapy trials which suggest statistically significant change in functional ability 
following active treatment. The observed change in the DFI was often closely 
associated with change in other clinical variables (tables 2.15-2.16). However, weak, 
evidence of responsiveness following physiotherapy intervention has been reported. 
Accumulated evidence suggests that the HAQ-S is not responsive to clinically 
important change in functional ability in AS (Hidding et al, 1993a; Bakker et al, 
1995), although it may be able to detect differences in functional ability between 
groups of patients (Hidding et al, 1993a). Comparison of change in score of the 
HAQ-S with change in score of various other measures of health and functional status 
strengthen the evidence of poor responsiveness (table 2.16). 
Limited evidence of LDQ responsiveness suggests that it is responsive to clinically 
important change in AS out-patients receiving physical therapy, a treatment of known 
efficacy, over the short term (6-weeks)(table 2.15). 
Evidence suggests that the BASFI is capable of detecting statistically significant 
change in functional ability over the short-term following physical therapy, but not 
following evaluations of drug therapy. Comparison with an established generic 
measure of HRQL, the SF-36, following a short-term evaluation of in-patient 
physiotherapy failed to provide strong evidence of responsiveness for either 
instrument (table 2.15). 
Several different evaluations on the same data-set provide good evidence in support of 
the responsiveness of the MACTAS/PET following physical therapy intervention in a 
large and heterogeneous group of patients. The instrument compared favourably to 
other instruments demonstrating evidence of responsiveness (tables 2.15-2.16). 
Acceptability 
All developers have reported good levels of acceptability by patients, although no 
developer indicates how the level of acceptability was derived or defined. 
Completion rates following in-patient or postal completion have not been reported. 
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Feasibility and application 
The DFI and BASH have become the most widely applied AS-specific measures of 
functional disability, although the majority of articles using the BASH have been 
published by members of the development team (n-- 12/14 articles). The DFI has 
been most widely accepted by investigators outside of the development team (n-- 
13/19 articles). The original DFI was developed in the French language, but 
procedures for translation into English have not been described. Both the DFI and 
BASH have been translated into other languages (Dutch Functional Index - Creemers 
et al, 1994; Turkish Functional Index - Dalyan et al, 1999; French BASFI - 
Claudepierre et al, 1997; Swedish BASH - Cronstedt et al, 1999). 
The HAQ-S has been widely used by other investigators, but seven articles refer to 
different stages in the same randomised trial of physical therapy. There is only one 
published article describing the development and initial testing of the LDQ, which 
proposed adoption of the revised instrument, the RLDQ (Abbott et al, 1994). 
Commentary 
The purpose of the six instruments is similar - to evaluate AS-specific functional 
disability. Table 2.17 provides a summary of the data synthesis. All instruments lack 
sufficient information about intended purpose and conceptual base. The DFI and 
LDQ provide the most detailed attempt at a definition of purpose. The LDQ has a 
similar theoretical grounding to the DFI but a stronger conceptual base due to the 
association with an arthritis disability classification (Badley et al, 1984). However, 
the theoretical approach adopted is poorly explained. 
There is a lack of information supporting the item development of all instruments. 
Although most instruments involve patients at some stage of item development there 
is limited information to indicate patient selection or characteristics, beyond the 
diagnosis of AS, and the nature of the patient role in item selection. The content of all 
instruments has been dominated by expert opinion but there is little information to 
support the experience of these experts and the criteria by which items were selected. 
Without a clear definition of instrument purpose and conceptual base an appreciation 
of item development is limited. In combination these factors also restrict an appraisal 
of content and construct validity. 
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The degree of limitation in functional disability investigated by each instrument 
varies. The ASAQ is limited as a measure of functional disability. The DFI has good 
face validity, containing items that cover a wide range of functional activities (table 
2.12). However, it does not address neck mobility. Subsequent investigators have 
described the importance of neck mobility in AS-specific functional disability 
(Daltroy et al, 1990; Nemes, 199 1) and items to address neck mobility are 
recommended in a modification of the DFI. 
The version of the HAQ adopted for the HAQ-S is not clear. Clarification is needed 
to support standardisation of application. There is evidence that the HAQ-S fails to 
focus sufficiently on spondyloarthropathy related disability and that HAQ items with 
a focus on peripheraljoint arthritis are of limited relevance to AS patients. A ceiling 
effect in 25% of AS out-patients completing the HAQ-S suggested that their 
functional ability could not get any better (n-- 144)(Hidding et al, 1993a). Low mean 
values and inadequate score coverage further supports the inadequacy of the HAQ-S 
as a measure of functional disability in AS (Hidding et al, 1993a; 1994b). A revision 
of item content is required. 
The LDQ does not include more strenuous functional activities such as running or 
housework, activities included in both the DFI and BASFI. The lack of more arduous 
activities may be a reflection of the patient population included in instrument 
development. In-patients may reflect the more severe spectrum of disease (Kennedy 
et al, 1995) and patients with long-standing disease often report adaptation in 
functional activities and changed priorities. As a result, the more basic requirements 
of functional ability may appear to be paramount. The inclusion of more difficult 
functional activities should improve instrument content validity. 
The BASE covers a wide spectrum of functional disability sharing a similarity of 
item content with other instruments (table 2.12). Although it does not include items 
reflecting easier functional activities, score distribution suggests that it captures the 
extremes of functional disability when completed by patients representing a broad 
spectrum of disease (Calin et al, 1994). 
54 
The functional probes included in the MACTASTET and the results of validity 
testing suggest that it may represent a broad reflection of HRQL, as opposed to 
functional disability. 
In light of criticisms of insensitivity the response scale of the DFI has recently been 
modified to a five-point adjectival scale (Spoorenberg et al, 1999a). The involvement 
of the original developers (Dougadas) should help to distinguish the official modified 
version from other 'modifications' referred to in published articles. However, the 
modification is inadequately described by Spoorenberg et al (1999a). 
The HAQ-S and the LDQ adopt the same four-point ordinal response scale as the 
HAQ, despite critisism for its relative insensitivity to change (Liang et al, 1985; 
McDowell & Newell, 1996). Results from completion of the HAQ-S would suggest 
that it suffers similar problems of insensitivity. However, this may be related to both 
an inadequacy of item content and of the response scale. Although offering more 
response options than the original DFI, there is limited evidence of the responsiveness 
of the LDQ (RLDQ), and the five-point adjectival response scale of the modified DFI 
(Spoorenberg et al, 1999a) may improve the sensitivity of the DFI beyond that offered 
by the RLDQ. 
The BASFI includes ten VAS. The acceptance of VAS by clinicians and patients is 
not clear, and reservations about the feasibility of, and understanding associated with, 
these scales have been expressed (Streiner & Norman, 1995; Fitzpatrick et al, 1998a). 
A recent survey suggests that Likert type response scales are more readily accepted 
than VAS by clinicians in routine evaluation (Bellamy et al, 1998; 1999). 
Notwithstanding the wide range of retest intervals and the lack of consideration for 
disease stability shown by many authors, evidence of the test-retest reliability of the 
ASAQ, DFI, LDQ and BASE seems satisfactory and supports application of each 
instrument in group evaluation (> 0.70). The reliability of the DFI and the LDQ 
supports application in individual evaluation (> 0.90). Improved evidence of test- 
retest reliability with appropriate retest periods and the external evaluation of 
condition stability is required, particularly for the ASAQ, HAQ-S, RLDQ, BASH and 
MACTAS/PET. The assessment of internal consistency reliability is required for all 
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instruments, except for the MACTAS/PET for which the calculation is not 
appropriate. 
There is limited evidence to support the validity of all instruments. All investigators 
fail to hypothesise expected relationships between various constructs a priori to the 
analysis and the results are therefore logically weak (McDowell and Jenkinson, 1996). 
Comparison of the DFI, LDQ/RLDQ and BASFI with other more established 
measures of functional ability or HRQL, either generic or disease-specific, has not 
been undertaken and are recommended with a priori hypothesised relationships stated 
to provide a wider appreciation of the constructs addressed. 
All instruments, apart from the ASAQ and the RLDQ, have been applied in trials of 
known efficacy and several strategies for assessing responsiveness have been applied 
to the DFI, HAQ-S, BASH and MACTAS/PET. There is strong evidence to support 
the responsiveness of the DFI following drug therapy intervention and increasing 
evidence for the BASE following short-term rehabilitation programmes. There is 
limited evidence for the responsiveness of the LDQ and the MACTAS/PET following 
trials of physical therapy. Accumulated evidence suggests that the HAQ-S is not 
responsive to change following physical therapy. 
All instruments are easy to understand although the lack of detail relating to the 
ASAQ makes interpretation difficult. All instruments, apart from the MACTAS/PET 
which requires interview-administration, are quick to administer (2-8 minutes) and are 
self-completed. The DFI, LDQ and BASFI have all been administered in both in- 
patient, out-patient and postal evaluations. 
Conclusion 
All instruments have been developed integrating clinical expertise with a theoretical 
appreciation of functional ability in AS. Based upon the limited data available 
following the initial literature search (April 1998), three of the six AS-specific 
measures of functional disability have acceptable evidence in support of their 
development and measurement properties and appear to be acceptable to patients in a 
self-completed format: DFI, LDQ/RLDQ and BASFI. 
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The ASAQ and HAQ-S are not recommended for application in AS. These 
inadequacies relate to the lack of clarity in instrument purpose, development and 
structure, irrelevance of certain items, inadequacy of response scale and lack of 
standardisation in instrument administration. However, the HAQ-S highlighted the 
relevance of neck mobility in the assessment of AS-specific functional disability. 
The MACTAS/PET pro-6des a wider view of the impact of AS than a simple 
reflection of functional disability. Although providing a novel approach to evaluation 
it has not been widely accepted into research or routine practice. Methods of dealing 
%%ith patients unable to identify problem areas, and further evidence of the 
acceptability, reliability and responsiveness is necessary. 
'Me final selection was made bct, %vccn the DFI, LDQ/RLDQ and BASH. All 
instruments had positive and negative points with important gaps relating to 
development and performance (table 2.18), making selection of one instnunent 
difficult. 
All instnuncrits DFI LDQ/RLDQ BASH 
Data quality and "ins Item con= modifica6cin Itcm content modification Tcst-rctcst rcliabifity - 
assufflIptions - items relating to neck - more arduous functional longer retest period and 
mobility activities external evaluation of 
change 
Response Kale Testing of revised Further testing of revised 
comparison - Ukcrt, VAS response scale instrumcrit - RLDQ 
am numerical rating 
WAICS 
Explicit rules for missing Time specificity Further evaluation of responsiveness - drug trials and 
data longer term follow-up 
Internal consistency Compare intcn iew AM 
rchability ScIf-compIctod f0muts 
Validity testing against Formal cross-cultural 
esubls%W instrumcrits - adaptation into English 
h)pothctical constructs 
prcT*" a pn(wi 
Table 2.19 Gaps in the c%idcncc base of three AS-spccific measures of functional 
disability. 
The original DFI has more published evidence in support of its development and 
testing. The application and testing of the BASFI has not been widely described 
outsidc the development base. The LDQIRLDQ remains at the very early stages of 
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development, and only one published article has been identified (Abbott et al, 1994), 
which recommends adoption of the revised instrument (RLDQ). ' 
There is greater clarity of instrument purpose and conceptual base for the LDQ than 
seen for both the DFI and BASH, and an attempt by developers to include items in 
response to a definition of functional disability. All instruments involved clinical 
experts in item development and the LDQ and BASE included patients. All 
instruments have a similarity of item content, although the DFI lacks items addressing 
neck mobility, and the LDQ lacks the more arduous activities included in the DFI and 
BASFI. 
There is greater evidence in support of both the test-rctest and internal consistency 
reliability of the LDQ than for the DFI and BASE, but evidence for validity is limited 
for all instruments. There is limited evidence in support of the responsiveness of all 
instruments, %Nith the strongest evidence for the DFI following placebo-controlled 
drug trials. 
In rccommcnding both the DFI and the BASH in the evaluation of AS functional 
abi I ity (van der Ilcijdc et al, 1999ab, c; Ruof & Stucki, 1999a), the ASAS make no 
rcfcrcncc to the LDQ and no reference to the modified DFI. This is a serious 
omission by the ASAS group in making recommendations for a standardiscd set of 
instrumcnts; and the modificd DFI should be spccified. It also suggests that the extent 
of the instrument review %%2s limited. 
In light of the proposed revision to the DFI response scale (Spoorcnbcrg et al, 1999a), 
the support for the DFI may increase. However, this modification was reported aflcr 
instrument selection for the comparative study (Chapter 4). The conceptual base, 
dcvclopmcnt methodology and early evidence of measurement properties suggests 
that the RLDQ is worthy of further testing, and was selected for the proposed study. 
2.6.2 AS-specific discase activity 
Ilis section describes the evaluation of the five AS-spcciric mcasurcs of disease 
activity (tables 2.9 and 2.10). A general description and the scale structure is 
summarised in table 2.19. The NET, SEI and DAT require clinician completion and 
the Bath DAI and BASDAT arc paticnt-compicted. 
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Purpose and conceptual base 
The Newcastle Enthesitis Index (NEIXMander et al, 1987) and the Stoke Enthesitis 
Index (SEI)(Da%ves et a], 1987) were the first non-invasive clinical methods to 
evaluate disease activity in AS as a reflection of the extent and severity of enthesitis. 
The assessment of disease activity had previously relied upon laboratory-based 
assessment, or the evaluation of pain and stiffness. 
The Dougadas Articular Index (DAI)(Dougadas et a], 1988) was the first published 
AS-specific instrument to scorejoint tenderness. The initial choice ofjoint sites was 
based on the expert opinion of three rheumatologists familiar with the pathological 
process of AS. 
The Bath Disease Activity Index (Bath-DAIXKennedy ct al, 1993) was the first self- 
administered AS-specific measure of disease activity focussing on a patient's 
perception of symptoms, disease progression and global well-being. The developers 
thcorised that a patients perception of disease activity could be described by pain, 
stiffness and the need for persistent medication, providing a more relevant assessment 
of disease activity than laboratory-based assessment and radiographic analysis, but 
provide no further support for this theory. 
71c Bath Ankylosing Spondylitis Disease Activity Index (BASDAIXGarrett ct al, 
1994) was proposed as a simple self-administered measure in response to the need to 
provide a comprehensive measure of AS-specific disease activity (Garrett et al, 1994). 
Although the dcvclopers do not dcfinc discasc activity, the nccd to distinguish 
bctwccn discasc activity and scvcrity is highlightcd. 
Sludypopulation 
All developers indicate that the instruments are specific to the evaluation of patients 
vAth AS. However, there is a lack of clarity about the patient populations involved in 
the development of most instruments. No developers clearly describe the population 
sampling frame beyond the distinction of in-patient or out-patient status, and method 
of patient selection was generally unclear. Many investigators do not detail patient 
variables or disease characteristics. All instruments, except for the SEI have been 
applied in both in-patient and out-patient populations. Only the BASDAT has been 
applied in a postal survey (Jones et al, 1996b). 
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General description and scale structure 
The NEI consists of 15 items reflecting sites of entheses involved in the pathological 
process of AS. Items (entheses) were generated by the clinical opinion of the 
development team. However, the number and experience of participants was not 
described and the extent of the literature search was not detailed. Patient-reported 
discomfort following palpation of chosen sites by a trained clinician is recorded. 
Following testing (n-- 6 AS out-patients xvith active disease) non-responsive items 
were removed from the draft instrument; that is, no change in entheses activity over a 
one-week period. Each item is scored on a four-point ordinal scale of discomfort 
(table 2.19), and although patient input was not described, a standard palpation in an 
area devoid of enthesis (clavicle) is recommended before each evaluation to foster 
patient discrimination between pain and palpatory pressure. Item scores are totalled 
(range 045); a lower score indicating less disease activity. The treatment of missing 
values is not described. All items are performance based and completion time is 
approximately three minutes. 
71c SEI consists of 22 items rcflccting 13 cnthesis zones involved in the AS 
pathological process. Ile level of patient reported discomfort is recorded following 
palpation of chosen sites by a trained clinician. There is a similarity of item content 
to the NEI (table 2.20), but no detail about item development for the SEL 
Spine Pelvis Lower limb 
Cervical. tlKwwic and lumber spin" Anterior superior iliac spines Femoral greater trochanters (bilateral) 
promwo -I group (NFI) (bilaterawl) 
Anterior superior border of iliac crests Achilles tendon insertion (bilateral) 
(%cpsrate) Vertebral processes at (SEI): 
(bilatcralXSEI) 
Cl /2 Ischial tubmwitics (bilateral) Plantar fascia insertion (bilateral) 
C7/Tl 
T12/Ll 
LS /Si 
Table 2.20 Similarity of item content between the NEI and SEI 
Dawes ct a] (1987) indicate that the index is scored in a similar way to the NEI, and 
describe a four-point ordinal scale of patient discomfort in response to firm palpation 
over the crithesis site. Item scores are totalled (range 0-66); a lower score indicating 
less disease activity. The treatment of missing values is not described. All items are 
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performance based4 but completion time is not calculated. No attempt to standardise 
palpation or to improve patient discrimination is described. 
Following the initial selection of items for the DAI by three rheumatologists, further 
development and initial testingwas undertaken as part of a trial of AS out-patients 
with active disease (n= 88)(Dougadas et al, 1988). A principle component analysis 
(PCA) reduced the number of items to 10 (table 2.19) and a strong level of concurrent 
validity %vas found bet-ween the original and revised indices (r-- 0.84). The 
homogeneity of itemswas further supported in a subsequent, larger study (Dougadas 
ct al, 1990). Completion requires a trained clinician. A patient response is recorded 
follo%vingjoint movement or firm digital pressure to a designated site. Each item is 
scored on a four-point ordinal scale of discomfort (range: 'no tenderness' (0) to 
6patient said that itmas painful, winced and withdrew the limb'(3)). Item scores are 
totalled (range 0-30); a lower score indicates less disease activity. The treatment of 
missing values is not described. 
The Bath-DAI contains four items with a focus on pain, disease activity and well- 
being 'selected' from the AIMS, an arthritis-specific measure of HRQL (Meenan et 
al, 1980), The criteria for item selection or item development is not provided. Two 
items (pain severity, and frequency of severe pain) are scored on vertical six-point 
Likcrt scales (nonc'/'nevce (1) tovery scvere'Palways'(6) respectively). A third 
item, paticnt-asscssed disease activity, is scored on a four-point scale ('not at all 
active'(1) to'very activc'(4)). The fourth item, AS-related well-being, is scored on a 
horizontal I Ocm VAS with adjectival (very well, well, fair, poor and very poor) and 
numerical (0,2.5,5.0,7.5 and 10) descriptors. Item scores are totalled (range 3-26); a 
lower score indicates a lower patient perceived disease activity. Each response is 
considered over the previous month. The treatment of missing values is not 
described. 
The BASDAI is sclf-completed containing six items representative of AS disease 
activity (table 2.19). Item development was based upon the clinical experience of a 
multi-d iscipl i nary group including patients, but the number of participants and the 
form of discussion is not described. Item generation and selection was not reported. 
Patient selection, disease characteristics and level of input is not clarified. The item 
relating to fatigue was included due to recent research from the development group. 
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Following testing, the quality of morning stiffness was added and item wording 
modified. Each item is scored on aI Ocrn horizontal VAS anchored by adjectival 
descriptors 'none' and 'very severe' (items 1-5). Item 6 (duration of morning 
stiffness) is anchored by a time scale (V to '2-hours') with marks every quarter of an 
hour, and further adjectival support at half-hour intervals. The two hour period was 
selected follo%%ing a retrospective analysis of patient questionnaires (unpublished 
dataXGarrctt et al, 1994). Tle VAS scoring procedure is not described. It is assumed 
that the position marked on each VAS is recorded (0-10). The mean of the two 
morning stiffness items (items 5 and 6) is calculated to ensure equal weighting of 
symptoms. All items are totalled (range 0-50) and the total score converted to a 0-10 
scale; a lower score indicates less disease activity. No guidance for missing values is 
provided. Ile BASDAI is capacity based, considers symptoms over the previous 
wcek, and has an average completion time of 67 seconds (range 30 seconds to 2 
minutes). 
Reliability 
Evidence of the reliability of all instruments is shown in table 2.21. Low levels of 
test-rctest reliability (ICC 0.52) and significant inter-observer variability has been 
reported for the NEI, prompting the developers to suggest that the same observer 
should be employed during clinical trials. A higher level of reliability was reported 
by Crccmcrs ct al (1996) but the methodology is unclear. 
Tcst-rctcst reliability of the DAI has been assessed following one-week and 48-hour 
rctcst pcriods in out-paticnt populations and moderate to high reliability reported (ICC 
0.59toO. 83). High inter-observer reliability has been calculated (ICC > 0.90). 
High onc-day tcst-rctcst reliability of the Bath-DAI and BASDAI has been reported in 
the same in-paticnt population supporting their application in individual assessment (r 
> 0.93). A high level of internal consistency reliability has been reported for the 
BASDAI in a published letter reflecting a retrospective analysis of patients (Jones ct 
al, 1996c), and more recently following a drug therapy trial (Calin et al, 1999a)(cE 
0.84). 
There is no published evidence for reliability of the SEI, and internal consistency 
reliability has not been evaluated for the NEI, SEI, DAI or the Bath-DAI. 
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Validity 
Evidence of the validity of all instruments is shown in table 2.22. Issues of face and 
content validity have only been specifically addressed for the Bath-DAL No 
investigators have established a priori hypothesised relationships between variables in 
the assessment of construct validity. 
Although limited, the assessment of construct validity of the NEI has been more 
extensive than that of the SEL Both instruments have been assessed for their 
relationship with traditional clinical measures of disease activity. Similar moderate 
levels of correlation were reported with pain (VAS), but a stronger correlation 
between the SEI and stiffness (VAS). Generally, low and non-significant correlation 
between both indices and laboratory based measures of disease activity and 
anthropometric measures have been reported. A limited range of scores was observed 
when the NEI was completed in an in-patient population (approximately 50% of 
available range). This was in contrast to the 95% coverage of score range observed in 
the BASDAI and the Bath-DAI in the same patient population, prompting the 
investigators to suggest that the NEI had a limited ability to represent disease activity 
in patients with a wide spectrum of disease (Garrett et al, 1994). 
The DAI was compared to traditional measures of outcome employed in clinical 
practice and research. Dougadas et al (1988) wished to determine if the new index 
measured 'something other than (or the same thing as)'these instruments, but a priori 
hypothesised relationships were not stated. Low to moderate correlations were 
calculated with all clinical instruments (table 2.22). Low correlations were also 
calculated with the DFI, a measure of AS-specific functional disability, and with 
change in patient-assessed global health following physical therapy (r-- 0.18)(table 
2.22). 
The face and content validity of the Bath-DAI was critisised by the original 
development team for its focus on pain and well-being and the failure to address 
important issues of AS disease activity, such as fatigue, and Garrett et al (1994) 
subsequently recommended the BASDAL Evidence of the construct validity of the 
Bath-DAI is limited but a strong correlation with the BASDAI and with the DFI 
(functional disability) has been found (r> 0.75)(table 2.22). The Bath-DAI was also 
able to discriminate between an in-patient and an out-patient population (p< 0.00 1). 
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Evidence for the construct validity of the BASDAI is limited. Strong correlation with 
the Bath-DAI and the BAS-G, an AS-specificý measure of global health, and moderate 
to strong correlation with AS-specific measures of functional activity have been 
reported. Direct correlation with more traditional measures of disease activity, for 
example, patient reported pain or stiffness, or laboratory based assessment has 
recently been assessed and very low correlation with Erythrocyte Sedimentation Rates 
(ESR)(r-- 0.06 - 0.19) and C-Reactive Protein (CRP)(r-- 0.06 - 0.23) have been 
reported in patients with active disease (Spoorenberg et al, 1999b). The investigators 
suggest that the result supports the inability of the laboratory based measures (acute 
phase reactants) to reflect disease activity in AS. However, a strong correlation of 
change in BASDAI score with change in ESR has been reported following a drug trial 
of known efficacy (Maksymowych et al, 1998)(table 2.24). 
Responsiveness 
Evidence of the responsiveness of all instruments is shown in tables 2.23 and 2.24. 
Evidence suggests that the NEI is not responsive to change following physical therapy 
intervention. However, following a drug trial of known efficacy evidence suggests 
that the NEI and the assessment of pain severity (VAS) are both capable of 
discriminating between patients receiving the active drug or placebo (Mander et al, 
1987). There is no evidence for the responsiveness of the SEL 
The strongest evidence of the responsiveness of the DAI has been reported in drug 
therapy trials, with evidence to suggest that the DAI is capable of detecting 
statistically significant change in disease activity following active treatment. The 
observed change in the DAI was often closely associated with change in other clinical 
variables (tables 2.23-2.24). There is little evidence to support the responsiveness of 
the DAI following physical therapy intervention. 
There is limited evidence of the responsiveness of the Bath-DAI following 
physiotherapy intervention, but greater score improvement was calculated for the 
Bath-DAI (22.8%) than for the BASDAI (16.4%). The BASDAI has been assessed 
following both physiotherapy and drug therapy trials of known efficacy (tables 2.23- 
2.24). Although the evaluations of physiotherapy had limited follow-up periods, 
significant improvement in BASDAI score for active treatment groups for both 
treatment modalities have been recorded. 
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Acceptability 
All developers have reported good levels of acceptability of respective instruments by 
patients, although no developer defines acceptability or indicates how the level of 
acceptability was derived. Completion rates have not been reported. 
Feasibility and application 
The NEI and DAI have become the most widely applied clinician completed AS- 
specific measures of disease activity. However, few published articles have referred 
to the use of the NEI and DAI since 1998. The BASDAI is the only recommended 
patient-completed instrument and recent years have seen a rapid increase in published 
articles referring to its use, although the majority of articles have been published by 
members of the development team (n7- 10/13 articles). The original DAI was 
developed in the French language but procedures for translation in to English have not 
been described. The BASDAI has been translated into French (Claudepierre et al, 
1997) and Swedish (Waldner et al, 1999). 
Commentary 
Although all five instruments purport to measure AS-specific disease activity, the 
nature of disease activity and the approach adopted by each instrument differs. The 
NEI, SEI and DAI all require clinician administration and record a patient response to 
movement or palpation of specific sites. However, the NEI and SEI describe the 
pathological involvement of entheses and the DAI records the involvement of 
articular sites in the disease process. The Bath-DAI and BASDAI adopt a very 
different approach, requiring a patient-completed evaluation of symptoms associated 
with AS disease activity. Table 2.25 provides a summary of the data synthesis. The 
purpose and conceptual base of all instruments has practical appeal and clinical 
relevance. However, no instrument provides a clear definition of disease activity and 
inferences from results rely heavily on the definition used (Spoorenberg et al, 1999b). 
The NEI is described as both a measure of disease activity and disease severity. 
These terms communicate different aspects of disease status and are not 
interchangeable (Symmons, 1995). Inflammation is a key feature of AS and the 
measurement of disease activity aims to quantify the inflammatory process at one 
point in time whilst reflecting the extent of associated reversibility. For example, the 
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evaluation of pain, stiffness or fatigue. The measurement of disease severity has a 
more prognostic role and may describe the structural and irreversible change that 
occurs as a result of disease process (Symmons, 1995). 
Although a pragmatic approach to instrument development was adopted by all 
authors, there is a lack of detail supporting item development. Without a clear 
definition of instrument purpose and conceptual base an appreciation of item 
development and instrument validity is limited. Knowledge of the pathoanatorny of 
AS was required to support item generation for the NEI, SEI and DAI, but item 
development for all instruments has been dominated by experts in clinical 
rheumatology, with little information to support their experience with AS or the 
criteria by which items were selected. Despite the requirement for a patient response 
to a clinicians palpation, there is no indication of patient involvement in developing 
the NEI, SEI or DAL Only the developers of the BASDAI indicate that patients were 
involved in the development process but do not detail patient selection, characteristics 
and input. 
The developers of the BASDAI (Garrett et al, 1994) critisised the NEI and the Bath- 
DAI for their failure to adequately represent the wide spectrum of AS disease activity. 
Although the BASDAI contains a range of items relating to pai n (spinal and 
peripheral joints), fatigue and tiredness, bodily discomfort (representative of 
enthesitis) and morning stiffness (severity and duration), there remains a focus on 
pain. Although the items have good face validity, due to the failure to define disease 
activity, a lack of conceptual base and a paucity of detail about item development, an 
appraisal of content validity is limited. Appraisal of content validity is similarly 
limited for other study instruments. However, when comparing the NEI and SEI, 
greater detail about item development and selection for the NEI is provided, and 
although containing fewer items the entheses cover a wider range of sites, thus 
benefiting from greater face validity. 
Notwithstanding the wide range of retest intervals and the lack of consideration for 
disease stability shown by many authors, evidence of the test-retest reliability of the 
DAT, Bath-DAI and BASDAI seems satisfactory and supports application in group 
evaluation (> 0.70). However, the DAI does not clarify ifjoint movements are active, 
active-assisted or passive. This is an important methodological issue when evaluating 
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the impact of pain onjoint movement and requires standardisation to support 
consistent administration. The reliability of the Bath-DAI and BASDAI supports 
application in individual evaluation (> 0.90). Despite the attempt to standardise 
administration the test-retest and inter-observer reliability of the NEI is low, 
suggesting significant error in repeat administrations. There is no evidence for the 
reliability of the SEL The BASDAI is the only instrument with evidence of both test- 
retest and internal consistency reliability. Greater evidence of test-retest reliability, 
with appropriate retest periods and the external evaluation of condition stability is 
required for all instruments. The assessment of internal consistency reliability is also 
required. 
There is limited evidence to support the validity of all instruments. Results are weak 
due to the failure of all investigators to hypothesise expected relationships between 
constructs a priori (McDowell and Jenkinson, 1996). Agold standard measure of 
disease activity in AS is lacking (Symmons, 1995; Spoorenberg et al, 1999b), and the 
quantification of disease activity has traditionally relied upon the measurement of 
subjective domains such as pain or stiffness, or on laboratory based assessment. The 
direct relationship between these traditional measures and all instruments, except for 
the Bath-DAI and the BASDAI, have been reported. Generally, moderate 
relationships with subjective measures, but small correlation with laboratory based 
measures were found, providing support for some authors to suggest that the ESR is a 
poor reflection of AS disease activity (Mander et al, 1987; Symmons, 1995). 
However, a strong correlation between change in BASDAI score and change in ESR 
following a drug therapy trial has been reported (Maksymowych et al, 1998). 
A direct comparison between two AS-specific measures of disease activity has only 
been reported between the BASDAI and Bath-DAI (strong relationship). The NEI 
has been applied in the same study as the Bath-DAI and the BASDAI and scores were 
converted to 0-10 to help comparisons. The NEI was critisised for the low mean 
value (1.96) and for coveringjust over 50% of the available score range in 
comparison to wider range covered by the Bath-DAI and BASDAI (both 
95%)(Garrett et al, 1994). However, the correlation relationship between instruments 
was not reported. Comparison of all instruments with other measures of disease 
activity and with more established generic measures of HRQL have not been 
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undertaken, and are recommended with a priori hypothesised relationships stated to 
provide a wider appreciation of the constructs addressed. 
All instruments, apart from the SEI, have some evidence of responsiveness, but 
accumulated evidence suggests that the NEI is not responsive to change. There is 
good evidence for the responsiveness of the DAI following drug therapy and limited 
evidence for the responsiveness of the Bath-DAI following trials of physical therapy. 
There is increasing evidence for the responsiveness of the BASDAI following drug 
therapy and physical therapy. A greater percentage improvement in Bath-DAI score 
(22.8%) than calculated for the BASDAI (16.4%) was reported following an 
evaluation of physical therapy (Garrett et al, 1994). The authors suggest that items 
relating to pain are very responsive to intensive physiotherapy but not to change in 
disease activity as a whole. Consequently the responsiveness of the Bath-DAI reflects 
the greater focus on pain and patient's well-being (Garrett et al, 1994). However, 
three of the six items of the BASDAI also address pain and discomfort. 
All developers have reported good levels of acceptability, but completion rates have 
not been reported. All instruments are easy to understand, although the lack of detail 
relating to the SO makes interpretation difficult. The patient-completed instruments 
are quick to complete (1-2 minutes). The cliniCian-completed instruments require 
longer for administration, all taking a similar time to complete (3-5 minutes), but none 
require special equipment. All instruments have been administered in both in-patient 
and out-patient populations, and the BASDAI has also been administered in a postal 
survey (Jones et al, 1996b). 
Conclusion 
All instruments have been developed integrating clinical expertise with a theoretical 
appreciation of disease activity in AS. Based on the limited published evidence at the 
time of instrument selection there was acceptable evidence in support of the 
development and measurement properties of the DAI, Bath-DAI and the BASDAL 
However, the developers of the Bath-DAI recommend adoption of the BASDAI 
(Garrett et al, 1994). The comparative study (Chapter 4) required a patient-completed 
instrument and so the BASDAI was the only available option. 
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There is inadequate published evidence to support the development and measurement 
properties of the NEI and SEI and they are not recommended as disease-specific 
measures of disease activity. These inadequacies relate to the lack of clarity in 
instrument development (SEI) and, where reported, the poor levels of reliability and 
responsiveness. 
2.6.3 Anthropometric measures 
This section describes the evaluation of the anthropometric measures listed in table 
2.10. The measures will be considered in terms of the evaluation of cervical mobility, 
chest expansion, thoracolumbar mobility, fingertip to floor distance, lumbar mobility 
and spinal posture. One composite index, the Bath Ankylosing Spondylitis Metrology 
Index (BASMI; Jenkinson et al, 1994a) is also evaluated. 
Purpose and conceptual base ofanthropometric measurement 
The identified anthropometric measures represent the available range of movement, or 
postural status, at a specific area of the axial skeleton. Limitation in spinal mobility is 
an objective feature of the pathological process of AS, and in 1968 recommendation 
was made for spinal movement in AS to be assessed in'three planes of movement' 
(Bennett and Wood, 1968 cited by Moll et al, 1971). 
Studypopulation 
There is a lack of clarity about the patient population involved in most studies. Many 
investigators do not clearly describe the population sampling frame from which 
patients were selected beyond the distinction of in-patient or out-patient status and the 
method of patient selection was generally unclear. Many investigators do not 
adequately describe patient variables and disease characteristics. Also, the training or 
experience of observers recording the measurements is often inadequately detailed, an 
important consideration when assessing the feasibility and reliability of measurement. 
Cervical mobility 
General description 
Thirteen approaches for the assessment of cervical mobility have been identified: five 
rotation, four lateral flexion and four flexion / extension. A general description, and 
methodology is summarised in table 2.26. All approaches require special equipment 
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and goniometers, inclinometers and tape measures have been adopted by different 
authors for the evaluation of each range of movement. 
Certain methodologies describe a composite movement. For example, combined left 
and right rotation is described for the protractor (Calcraft et al, 1974), the goniometer 
(American Academy of Orthopaedic Surgeons (AAOS, 1965) and the inclinometer 
(O'Driscoll et al, 1978; Viitanen et al, 1992). However, the separate movements of 
right and left rotation are described by the tape measure methodology (Viitenan et al, 
1998)(table 2.26. ) Difficulty in finding the neutral starting position is often cited in 
support for composite measurement, but the inability to determine if a problem exists 
with left or right movement is support for separate analysis of each movement. 
Reliability 
Evidence of the reliability of all measures of cervical mobility is shown in table 2.27. 
High levels of inter and intra-observer reliability have been reported for all 
approaches for the measurement of cervical rotation (inter-observer r> 0.84, ICC 
0.89)(intra-observer r> 0.96, ICC> 0.89), although inter-observer reliability has not 
been calculated for measurement with a goniometer. 
More moderate levels of inter-observer reliability was reported for the assessment of 
cervical lateral flexion using a goniometer or tape measure (r< 0.76). High levels of 
inter-observer reliability were reported by Viitenan et al (1998) for a selection of 
anthropornetric measurements including cervical lateral flexion (tape measure: 
AAOS, 1965), but the specific result was not reported. Evidence for the reliability of 
the simple inclinometer in patients with AS is limited. Pile et al (1991) report that 
90% of measurements of cervical lateral flexion repeated by one or more trained 
observer will vary by up to 10 degrees when measured with a goniometer, and by up 
to 2.5cm. when measured with a tape measure, and that changes of less than this could 
be attributed to methodological variation and not due to true change in cervical 
mobility. 
Low levels of inter-observer reliability were calculated for the assessment of cervical 
flexion and extension with a goniometer (AAOS, 1965; Pile et al, 1991), but several 
studies report moderate to high levels following assessment with a tape measure 
(Calcraft et a], 1974; Bellamy et al, 1991a; Viitenan et al, 1995ab). There is no 
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evidence of reliability for the measurement of flexion or extension with an 
inclinometer in patients with AS. 
Validity 
Limited evidence of the validity of all measures of cervical mobility is shown in table 
2.28. There is no evidence in support of the validity of cervical lateral flexion 
measured with a goniometer or hydrogoniometer, or for flexion / extension measured 
with a goniometer or a tape measure (occiput to C7 distance). Most frequently, the 
relationship between measurement techniques and spinal radiographic change have 
been assessed, with small to moderate relationships reported. The strongest 
relationships were with cervical rotation (spirit inclinometer)(r-- 0.59)(Kennedy et al, 
1995) and cervical lateral flexion (tape measure)(r-- 0.58)(Viitenan et al, 1998). The 
lowest correlation was between cervical rotation (Myrin inclinometer) and cervical 
spine age-adjusted radiographic change (Viitenan et al, 1995a). Small correlation 
between cervical lateral flexion measured with a tape measure (AAOS, 1965) or with 
a Myrin inclinometer and radiographic change in the thoracic and lumbar spine, and 
in the sacroiliac joints have also been reported (Viitenan et al, 1998). 
Moderate correlation between cervical rotation (protractor) and the HAQ-S 
(functional disability) (Daltroy et al, 1990), and between rotation (simple 
inclinometer) and sub-sections of the LDQ (functional disability) (Abbott et al, 1994) 
have been reported. A small to moderate correlation between flexion / extension 
(simple inclinometer) and sub-sections of the LDQ have also been reported, the 
strongest relationship with the sub-section addressing neck mobility. Moderate to 
strong correlation between the protractor assessment of rotation and other 
anthropornetric assessments have also been reported. No other investigators have 
reported the relationship between cervical mobility and other anthropometric 
assessments. 
Responsiveness 
Limited evidence of the responsiveness of all measures of cervical mobility is shown 
in table 2.29. Evidence suggests that cervical rotation measured with a goniometer or 
either form of inclinometer may be responsive to change following physical therapy. 
There is no evidence of responsiveness for rotation measured with a protractor or tape 
measure. Evidence suggests that cervical lateral flexion, flexion or extension are not 
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responsive following physical therapy. There is limited data suggesting a lack of 
responsiveness for cervical mobility assessment following drug therapy. 
Acceptability 
Acceptability to patients has not been reported. 
Feasibility and application 
Cervical rotation is the most frequently measured range of cervical mobility assessed 
in patients with AS identified in the review. All items of equipment have the benefit 
of being applicable to the measurement of any range of cervical mobility, but only the 
tape measure and universal goniometer can be used for other anthropometric 
assessments, improving the acceptance in clinical practice. They are also the cheapest 
and most portable items. 
Chest expansion 
General description 
Three approaches for the assessment of chest expa nsion have been clearly described 
in the literature, all using a tape measure but adopting different patient starting 
positions and body land-markings. All land marks are easily identified and a general 
description and methodology is summarised in table 2.30. 
Reliability 
Evidence of the reliability of chest expansion is shown in table 2.31. Lowlevelsof 
inter-observer (r< 0.53), and high levels of intra. -observer reliability (r> 0.91) have 
been reported for chest expansion measured at both the 4th intercostal space and at the 
xiphisternum. A high level of inter-observer reliability, improving following 
standardisation of technique, has been reported for measurement at nipple level 
(Bellamy et al, 199 1 a). 
Validity 
Evidence of the validity of chest expansion is shown in table 2.32. There is no 
evidence of the validity of measurement at nipple level (Hart et al, 1963). Small to 
moderate correlation between chest expansion (4th intercostal space) and other 
anthropometric measures have been reported by several investigators. Very small 
levels of correlation were reported with age, disease duration, laboratory based 
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measures of disease activity and radiographic change in the lumbar spine. The 
strongest correlation was reported with the measurement of vital capacity, a reflection 
of lung function (Franssen et al, 1986). Small to moderate levels of association 
between measurement at the xiphisternurn level and the HAQ-S (Daltroy et al, 1990), 
sub-sections of the LDQ (Abbott et al, 1994), and correlation of change score with 
patient reported change in global health following physical therapy (Hidding and van 
der Linden, 1995) (table 2.33) have been reported. 
Responsiveness 
Evidence of the responsiveness of chest expansion is shown in table 2.33. There is no 
evidence of the responsiveness of measurement at nipple level (Hart et al, 1963). 
Evidence following three-week rehabilitation programmes suggests that chest 
expansion (4th intercostal space and xiphisternum) may be responsive to short term 
change, but that improvement is not retained at a longer term follow-up. However, 
evidence following a six-week study of physiotherapy suggests a non-significant 
improvement (Hidding et al, 1993b). Evidence following drug therapy trials suggests 
that chest expansion is not a responsive measurement. 
Acceptability 
Acceptability to patients has not been reported. 
Feasibility and application 
Chest expansion is widely measured in clinical trials and in clinical practice (Bellamy 
et al, 1998; 1999). However, further evidence in support of clear methodologies is 
limited due to inadequate descriptions and referencing by investigators. 
Thoracolumbar Nxion 
General descriplion 
Six methods for the assessment of thoracolumbar flexion have been described. All 
use a tape measure, but identify different bony landmarks. A general description and 
methodology is summarised in table 2.34. 
Reliability 
Evidence of the reliability of thoracolumar flexion is shown in table 2.35. There is no 
evidence for two approaches (Hyde, 1980; Averns et al, 1996a), but high levels of 
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inter-observer reliability are reported for the remaining methods. The highest 
reliability is for the measurement C7 to 1 Ocrn proximal to the lumbo-sacral junction, 
reflecting thoracic flexion (Calcraft et al, 1974). High levels of intra-observer 
reliability have been reported for C7 to iliac crest (AAOS, 1965) and C7 to SI 
(Viitenan et al, 1992). 
Validity 
Evidence of the validity of thoracolumar flexion is shown in table 2.36. Validity 
testing has only been reported for the measurement C7 to the sacrococcygeal junction 
(Hyde, 1980), and C7 to L5 (Averns et al, 1996a). Moderate to high correlation with 
radiographic evaluation of the spine and moderate correlation between C7 to 
sacrococcygeal junction and other anthropometric measures was reported (Taylor et 
al, 1991 a). 
Responsiveness 
Limited evidence of responsiveness for thoracolumar flexion is shown in table 2.37. 
Accumulated evidence following physiotherapy suggests poor responsiveness over 
the active treatment period (three-weeks), and no improvement over the longer term 
follow-up (Viitenan et al, 1992,1995ab). Further evidence suggests that 
thoracolumbar flexion is not responsive following drug therapy and does not 
discriminate between patients receiving active or placebo treatment (Taylor et al, 
199 1 C). 
Acceptability 
Acceptability to patients has not been reported. 
Feasibility and application 
Thoracolumbar flexion is often referred to in published articles. However, the 
methodology for five of the six techniques is very similar and standardisation of 
technique is recommended to allow data to be combined to further support evaluation. 
Thoracic rotation 
General description 
Two approaches for the assessment of thoracic rotation have been described, both 
developed by the same autbor (table 2.34). The first requires a 43cm long indicator 
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needle to be strapped to the patients chest, who sits behind a large semi-circular 
degree scale (Viitenan, 1993). The second, the Pavlaka method (Viitenan et al, 1999) 
requires only a tape measure, and is the only new anthropornetric measure to be 
identified following extension of the initial review period. A general description and 
methodology is summarised in table 2.34. 
Reliability 
Evidence of the reliability of thoracolumbar rotation is shown in table 2.35 and 
suggests good intra and inter-observer reliability for both methodologies. However, 
the correlation coefficient is not reported for the Pavlaka methodý the developers 
reporting only the 95% limits of agreement (Bland and Altman, 1986). The limits of 
agreement describe a statistical range of error that may relate to clinical acceptability 
(Bruton et al, 2000), but the developers do not discuss the implications of the result. 
Validity 
Evidence of validity of thoracolumbar rotation is shown in table 2.36. Small to 
moderate correlation between thoracolumbar rotation and radiographic evaluation of 
the spine have been reported, the strongest relationship with AS-specific change in the 
lumbar spine. A stronger, but still moderate relationship between the Pavlaka method 
and AS-specific spinal change in the same patient group has been reported (Viitenan 
et al, 1999). 
Responsiveness 
Evidence of the responsiveness of thoracolumbar rotation is shown in table 2.37. 
Two studies suggest that the measurement is responsive over the short term following 
intensive physiotherapy, although the improvement was not maintained over the long 
term follow-up (Viitenan et al, 1995ab). 
Acceptability 
Acceptability to patients has not been reported. 
Feasibility and application 
Use of the rotation frame in the assessment of AS has only been published by the 
instrument developers. The frame may not be readily accepted in clinical practice or 
91 
research. The same development team have recently proposed the Pavlaka method 
which only requires a tape measure and may prove to be more feasible. 
Fingertip to floor distance 
General description 
Four approaches for measuring fingertip to floor distance (FFD) following anterior 
spinal flexion have been described. All require special equipment ranging from a tape 
measure (Miller et al, 1984) to a Portable Spinal Mobility Scale (PSMS)(Stokes et al, 
1988). A general description and methodology is summarised in table 2.38. 
Reliability 
Evidence of the reliability of FFD is shown in table 2.39. High levels of inter and 
intra-observer reliability were reported for all approaches (inter-observer r> 0.94, ICC 
> 0.98; intra-observer r> 0.98, ICC > 0.97), except for the PSMS where a significant 
difference between observers was reported (p= 0.04)(Stokes et al, 1988). Inter- 
observer reliability of FFD following the technique described by Kippers and Parker 
(1987) has not been calculated in AS patients. 
Validity 
Evidence of the validity of FFD is shown in table 2.40. Moderate correlation between 
FFD (mounted ruler) and sub-sections of the LDQ (Abbott et al, 1994), and a small 
correlation between FFD (patient on a stool; Kippers and Parker, 1987) and the HAQ_ 
S (Daltroy et a], 1990) have been reported. Small correlation between the 
measurement of FFD with a mounted ruler (Tomlinson et al, 1986) or tape measure 
(Miller et al, 1984) and radiographic change in the lumbar spine have been reported 
(Averns et al, 1996a; Viitenan et al, 1995a). A significant difference between the 
measurement of FFD using a tape measure or the PSMS (Stokes et al, 1988) has been 
reported. 
Responsiveness 
Evidence of the responsiveness of FFD is shown in table 2.41. Evidence is not 
available for the approach described by Kippers and Parker (1987). The measurement 
of FFD with a mounted ruler (Tomlinson et al, 1986) or a tape measure (Miller et al, 
1984) have both been used in the longitudinal evaluation of physiotherapy in AS, with 
evidence to suggest a statistically significant change over both short and long term 
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follow up. However, Roberts et al (1989) suggest that the long term change in range 
may not have clinical significance (mean change 2.89cm). Limited evidence suggests 
that FFD is not responsive following a placebo-controlled dug trial (Clegg et al, 
1996). There is also limited evidence to support the responsiveness of the PSMS 
following physical therapy, and to suggest that the measurement can distinguish 
between patients receiving more active physiotherapy (Kragg et al, 1990). 
Acceptability 
I 
When comparing acceptance of several mobility measures patients (n-- 3) indicated 
that FFD (tape measure) was the most convenient, followed by the Modified Schober 
Index (Macrae and Wright, 1969), the Smythe technique (Miller et al, 1984) and 
finally goniometer assessment (Miller et al, 1984). In addition, many patients with 
AS cite fear of falling as a concern (Chapter 3) and it is unlikely that they would 
accept a methodology requiring them to bend forward whilst standing on a stool 
(Kippers and Parker, 1987; PSMS - Stokes et al, 1988), challenging their ability to 
remain balanced as opposed to reflecting trunk mobility. 
Feasibility and application 
Fingertip to floor distance is widely referred to in published articles and more than 
50% of clinicians usually or always measure it during routine clinical evaluation 
(Bellamy et al, 1998,1999). The most frequently cited methodologies use a tape 
measure or mounted ruler with the patient standing on the floor. 
Lumbar mobility 
Ten methods for the assessment of lumbar mobility have been identified: three 
flexion, one extension, two flexion and / or extension, and four lateral flexion. All 
approaches require special equipment, but tape measures have been adopted for the 
evaluation of most movements (Macrae and Wright 1969; Miller et al, 1984; Moll et 
al, 197 1). A general description and methodology is summarised in table 2.42. 
a Lumbarflexion 
General description 
Two methodologies adopt a tape measure: the Schober Index (von Schober, 1937) and 
the Modified Schober Index (MSI)(Macrae and Wright, 1969). The third, the Lumbar 
Flexion Index (LFI) requires a flexible rule (Adrichern and van der Korst, 1973). 
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Reliability 
Evidence of the reliability of lumbar flexion is shown in table 2.43, and high levels of 
inter and intra-observer reliability have been reported. The greatest amount of 
evidence is in support of the MSI with the highest levels of reliability generally 
reported. However, Pile et al (1991) reported a lower level of inter-observer 
reliability (r-- 0.78) in a population of 10 AS out-patients, and indicated that there was 
a significant probability that underlying observer mean values were different (p= 
0.007). 
Validity 
Evidence of the validity of lumbar flexion is shown in table 2.44, but limited evidence 
is available for the Schober Index and the LFI. High correlation between the Schober 
Index and lumbar flexion radiographs (r-- 0.90) and a moderate to high correlation 
with age-adjusted radiological change in the lumbar spine (r-- -0.66) have been 
reported. Moderate correlation between the LFI and the measurement of chest 
expansion and vital capacity, and small correlation with thoracic pain, disease 
duration and laboratory based measures of disease activity have been reported 
(Fransen et a], 1986). Several studies report moderate to high correlation between the 
MSI and lumbar spine radiographic change (Kennedy et al, 1995; Averns et al, 1996a; 
Viitenan et al, 1999), and additional radiographic analysis strengthens the role of the 
MSI as a measure of lumbar spine movement (r-- 0.97) devoid of hip involvement 
(Macrae and Wright, 1969). Moderate to strong correlation with anthropometric 
assessment of axial status and chest expansion have been reported, but low to 
moderate levels of correlation with AS-specific measures of functional disability 
(Dougadas et a], 1988; Abbott et al, 1994). A small correlation with age, and a 
moderate correlation with disease duration has also been reported for the MSI. 
Responsiveness 
Evidence of responsiveness of lumbar flexion is shown in tables 2.45. Evidence from 
two longitudinal evaluations of physiotherapy with short term follow-up suggest that 
the Schober Index is not responsive. The MSI has been applied in several 
longitudinal evaluations of physiotherapy and placebo-controlled drug therapy trials. 
Accumulated evidence suggests that it is not responsive over the short or longer term, 
and is unable to discriminate between patients receiving active or placebo drugs. The 
LFI has only been applied in a single trial of two active drugs in patients with active 
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disease and a significant improvement in range was reported for both short and long- 
term follow-up (Fransen et al, 1986). 
b. Lumbar extension 
General description 
One approach to specifically assess thoracolumbar extension has been described 
which requires a plumb-line and tape measure (Moll et al, 1972b). Two additional 
approaches measure both flexion and / or extension of the lumbar, thoracic or total 
spine: Dunham spondylometer (Dunham, 1949) and the Smythe Technique (Miller et 
al, 1984). The Smythe technique requires a tape measure and a treatment couch. A 
general description and methodology for these techniques is summarised in table 2.42. 
Several authors have referred to the use of the MSI in the assessment of lumbar 
extension but without further methodological detail. Macrae and Wright (1969) do 
not describe the measurement of lumbar extension with the MSI and this methodology 
has not been included in the review. 
Reliability 
Evidence of the reliability of lumbar extension is shown in table 2.43. Good levels of 
inter-observer reliability are reported for the spondylometer assessment of both 
flexion and extension, although low inter-observer reliability pre-standardisation of 
flexion methodology was reported (Bellamy et al, 1991 a). There is limited evidence 
of intra-observer reliability of the spondylometer in patients with AS. A good level of 
inter-observer reliability for the plumb-line extension technique (Moll et al, 1972b) 
has been reported by several studies, but intra-observer reliability has only been 
reported in healthy subjects (Moll et al, 1972b; Reynolds, 1975). Evidence of 
reliability for the Smythe technique suggests good inter and intra-observer reliability 
for the sum assessment (sum-S) and individual segmental assessment (lower-L, 
middle-M, upper-U). However, evidence for the Smythe technique is limited due to 
poor clarification for the segmental assessment recorded. 
Validity 
Evidence of the validity of lumbar extension is shown in table 2.44. High levels of 
correlation between the spondylometer and the MSI have been reported, and agood' 
level of correlation with spinal radiographic change (Dunham, 1949). A significant 
102 
difference in range of movement between AS patients with vertebral fracture and 
those without was also reported (Ralston et al, 1990). However, investigators do not 
always clarify if movement refers to spinal flexion, extension or both. A strong 
relationship between plumb-line extension and radiographic evaluation of spinal 
extension (r-- 0.75)(Moll et al, 1972b), and moderate to strong relationships with other 
measures of spinal range of movement have been reported. A low relationship with 
age and disease duration was also reported. Strong correlation between the Smythe 
(sum) and other assessments of total spinal mobility and with FFD have been 
reported. Small correlation with several assessments of disability have been reported 
suggesting a small relationship with functional disability and patient-assessed health. 
Responsiveness 
Limited evidence of the responsiveness of lumbar extension is shown in table 2.45. A 
single, small sample study suggests that plumb-line extension may be responsive to 
change following active drug therapy combined with physiotherapy. However, the 
spondylometer and the Smythe technique appear not to be responsive following drug 
therapy and physiotherapy respectively. 
c. Lumbar lateralflexion 
General description 
Four approaches for the assessment of lumbar lateral flexion (LLF) have been 
described. Three methodologies require only a tape measure, and the fourth requires 
a vertically mounted ruler with a horizontal slide. A general description and 
methodology is shown in table 2.42. 
Reliability 
Evidence of the reliability of LLF is shown in table 2.46. There is no consensus on 
the level of inter-observer reliability of the skin distraction technique (Moll et al, 
1972a) and a range of values have been reported, ranging from small to good (r-- 0.31 
to 0.97), and Pile et al (1991) report a significant probability that the observer means 
are different (p< 0.02). A moderate level of inter-observer reliability was reported for 
the measurement of fingertip to fibula distance (r-- 0.79), a value that deteriorated 
post-standardisation of procedure (r-- 0.77)(Bellamy et al, 199 1 a). There is limited 
evidence of the reliability of the methodology described by Domj an et al (1990) in 
patients with AS. Creemers et al (1996) report a good level of intra-observer 
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reliability (r-- 0.88), but do not describe the number of observers or retest period. The 
strongest support is for fingertip to floor distance following LLF (Pile et al, 199 1), 
with good inter (r-- 0.79 to 0.84) and intra-observer (r-- 0.99) reliability reported by 
different investigators. Evidence for the intra-observer reliability of other 
methodologies in AS is limited. 
Validity 
Evidence of the validity of LLF is shown in table 2.47. There is no evidence of the 
validity of fingertip to fibula distance (Little, 1986) and the method described by 
Donijan et al (1990) in AS. Most evidence supports the skin distraction technique, 
and a strong relationship with radiographic evaluation of LLF was reported (r-- 
0.79)(Moll et al, 1972a). Moderate correlation with a sub-section of the LDQ (Abbott 
et al, 1994), and moderate to strong correlation with various anthropometric spinal 
measures. Low to moderate correlation with age and disease duration was also 
reported (Moll et al, 1973). A moderate relationship between LLF (mounted ruler) 
and lumbar radiographic change (r-- 0.59)(Kennedy et al, 1995) was reported. 
Responsiveness 
Limited evidence of the responsiveness of LLF is shown in table 2.48, and suggests 
that LLF measured by skin distraction is unable to distinguish between patients 
receiving active drug or placebo in a controlled trial (Calcraft et al, 1974). There is no 
evidence for other methodologies. 
Acceptability ofmeasures oflumbar mobility 
The skin distraction techniques were designed to reduce the potential danger or 
inconvenience to patients observed in other measurement approaches (Macrae and 
Wright, 1969; Moll et al, 1972a; Moll and Wright, 1973). Patients described the MSI 
as the most convenient assessment of lumbar mobility (Miller et al, 1984). 
Feasibility and application ofteasures oflumbar mobility 
The measurement of lurnbar flexion with the MSI is one of the most frequently cited 
measurements in published articles, and in routine clinical practice (Bellamy et al, 
1998; 1999). The Spondylometer has not been widely applied over the review period. 
The need for costly equipment that may not be readily portable may have supported 
the decline in use. 
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Posture 
General description 
Three methodologies for the assessment of upper cervical or spinal posture have been 
identified. One approach measures tragus to wall distance (TYM) Y'rith a perspex t- 
square (Tomlinson et al, 1986). The remaining two methods measure occiput to wall 
distance (OWD), one approach using a tape measure (Americam Rheumatology 
Association - ARA, 1984) and the second a PSMS (Stokes et al, 1988). A general 
description and methodology is summarised in table 2.49. 
Reliability 
Evidence of the reliability of the measurement of spinal posture is shown in table 
2.50. High levels of inter and intra-observer reliability have been reported for all 
measurement techniques, but evidence for the PSMS is limited to a single study from 
the developers. Several studies report high levels of reliability for OWD with a tape 
measure (inter-observer ICC> 0.92, intra-observer ICC> 0.99), and TWD with a t- 
square (inter-observer r> 0.97, intra-observer r> 0.99). 
Validity 
Limited evidence of the validity of the measurement of spinal posture is shown in 
table2.51. Small to moderate correlation between OWD (tape measure) and lumbar 
spine age-adjusted radiological change (r-- 0.49)(Viitenan et al, 1995a), and with AS- 
specific radiographic change in the cervical and lumbar spine (range r-- 0.37 to 0.38) 
have been reported (Taylor et al, 199 1 a). A strong correlation between TWD (t- 
square) and cervical spine radiographic assessment was reported (r-- 0.6 1)(Kennedy et 
al, 1995). Moderate to high correlation between OWD (tape measure) and other 
anthropometric assessments was reported, but a small correlation between OWD and 
FFD both measured with the PSMS (Stokes et al, 1988). 
Responsiveness 
Evidence of the responsiveness of the measurement of spinal posture is shown in table 
2.52. There is limited evidence for all methodologies and no consensus can be clearly 
drawn. Evidence suggests that the PSMS is not responsive, but that OWD (tape 
measure) and TWD (t-square) may demonstrate low levels of responsiveness 
following physiotherapy. 
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Acceptability ofmeasures ofspinal / upper cervicalposture 
Acceptability to patients has not been reported. 
Feasibility and application ofineasures ofspinal / upper cervical posture 
There has been wide application of the measurement of both OWD and TWD in 
published studies, but the PSMS has only been referred to in two studies beyond the 
developers. Bellamy et al (1998,1999), report that the measurement of OWD is 
routinely applied in clinical practice by more than 50% of clinicians, but the 
methodology is not defined. 
BASMI 
Purpose and conceptual base 
Jenkinson et al (1994a) determined the need to identify the minimum number of 
clinically appropriate measures to accurately assess axial status in AS. Axial status 
was described by mobility of the cervical, thoracic and lumbar spine, hips and pelvic 
region. 
General description 
The BASMI consists of five items, as shown in table 2.53: cervical rotation (simple 
inclinometer - Klaber-Moffett et al, 1989), TWD (t-square - Tomlinson et al, 1986), 
LLF (mounted ruler - Pile et al, 1991), lumbar flexion (MSI - Macrae and Wright, 
1969) and hip mobility (intermalleolar distance - Calin, 1985). Items were selected 
from an initial pool of 20 measures, supported by a literature search, clinical opinion 
and an assessment of all measures in a sample of in-patients (n-- 43). The extent of 
the literature search, item selection criteria (beyond the reflection of axial status), and 
the patient assessment was not detailed. A high level of concurrent validity between 
the five selected measures and the original 20 measures was reported (r-- 0.94). The 
original three-point response scale, determined by the specific range of movement 
available for each measure, was replace by an II -point response scale due to poor 
sensitivity (Jones et al, 1995). An open-ended range of possible movement values for 
each measure is divided into II equal sections (0- 10), determined by expert opinion. 
Each item response is totalled (0-50), and the mean value reflects the BASMI score 
(0-10); a lower score indicating less restricted axial mobility. 
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Reliability 
As shown in table 2.54 high levels of inter (r> 0.94) and intra-observer (r> 0.98) 
reliability of the individual measurements included in the BASMI have been reported, 
but the test-retest reliability of the index has not been reported. 
Validity 
Moderate to strong levels of correlation between the total BASMI index (r-- 0.74) and 
most individual items (range LLF r-- 0.56 to MSI r-- 0.69) in the index with 
radiographic analysis of related spinal areas were reported and accepted as evidence 
for the validity of the index as a reflection of axial status, as shown in table 2.55. The 
lowest correlation was between intermalleolar distance and a hip radiograph (r-- 0.27). 
A moderate correlation between the index and disease duration was reported (r--0.44). 
The developers suggest that the BASMI should be considered the new'gold standard' 
for the evaluation of mobility, replacing radiographic evaluation (Jenkinson et al, 
1994a; Kennedy et al, 1995). 
Responsiveness 
Limited evidence of responsiveness suggests that the BASMI is responsive to change 
following a short period of intensive physiotherapy (p< 0.001)(Band et al, 1997). 
Significant score improvement following a longitudinal drug study is limited to the 
evaluation of only 8 patients (Maksymowych et al, 1998)(table 2.56). 
Acceptability 
Acceptability to patients has not been reported. 
Feasibility and application 
The BASMI takes 7-minutes to administer but several items of equipment are 
required: inclinometer, t-square, mounted ruler, tape measure and a treatment couch. 
Clinical feasibility has not been reported. The BASMI has been identified in 5 
published articles and 1 letter, all by members of the development team. 
Normal values 
No identified anthropometric measure is purely AS-specific, and the impact of normal 
aging or pathological insult should be considered as independent facets when 
assessing mobility (Viitenan et al, 1995a). Normal movement covers a wide range of 
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values that may overlap with ranges observed in specific pathologies, thereby 
supporting the assessment of mobility against a range of values instead of a single 
average value (Moll et al, 1972b; Moll and Wright, 1973). There is no consensus on 
the clinical significance associated with change in most anthropometric assessments. 
In the evaluation of FFD, Roberts et al (1989) reported a statistically significant mean 
change of 2.86cm following the long term follow-up of physiotherapy but suggested 
that this was not clinically significant. However, Kragg et al (1990,1994) suggest 
that a change of 3.0cm. is clinically significant. 
Only the BASMI provides a battery of measurements that, when combined, provide a 
score specific to the evaluation of AS. The response scale for each section of the 
instrument was based on clinical knowledge of AS and not on published evidence of 
normal values. 
Commentary 
Traditionally, evaluation of axial movement was based on visual estimation (AAOS, 
1965). However, the lack of reliable and valid data led to the development of more 
objective means for anthropometric assessment. The purpose and conceptual base of 
all reviewed anthropometric measures has practical appeal and clinical relevance 
related to the impact of AS on the axial skeleton. All measurements have been 
developed through clinical knowledge and experience with AS, often following a 
pragmatic approach to measurement. The majority of anthropometric measures 
assessed purport to measure axial mobility. Tragus or occiput to wall distance 
provides a representation of spinal posture, as opposed to spinal movement. All 
methodologies are examination-based and place different demands on patient and 
clinician in terms of time and ease of administration, convenience and need for special 
equipment. Tables 2.57 to 2.63 provide a summary of the data synthesis. 
A full description or reference to support the methodology adopted is essential to 
allow data to be combined. It was often difficult to identify articles describing the 
original development of a methodology (level I articles) and the evidence for several 
anthropometric measures commence with the first clear description of application in 
AS (level II articles). In addition, where articles reflecting initial development of a 
methodology were identified detail was often limited. Difficulties in clearly 
identifying methodological approaches was a common problem in the review. Many 
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investigators simply indicate that, for example, lumbar flexion was assessed. The 
review has illustrated that many similar methodologies exist for measuring the same 
movement. However, reliability and standardisation effects are not the same for 
closely related techniques and the'most appropriate technique from competing 
alternatives' (Bellamy et al, 1991a) should be identified. Also, although 
methodologies may not differ substantially, standardisation is essential to support 
comparison of results (Viitenan et al, 1995a) and to support the synthesis of evidence. 
The acceptability, feasibility and measurement properties of an anthropometric 
measure can only be inferred for the protocol described, and therefore, despite the 
large number of articles indicating the use of anthropometric measurements the 
availability of data has been limited. 
Many investigators do not indicate the time of day the measurements were taken. 
Morning stiffness is a significant feature of AS (Dziedzic, 1998), and due to stiffness 
resolution measurements taken in the morning may differ to those taken later in the 
day. This could influence estimates of instrument reliability, validity and 
responsiveness. Mobility may also be influenced by the level of exercise pre- 
measurement and standardisation. of warm-up or exercise is recommended (Roberts et 
al, 1988) but not often reported by investigators. 
The relative experience or training and number of observers was often not detailed. 
Application of clear methodology and the need to identify specific bony landmarks 
for certain measurements implicates the need for training and, or standardisation of 
approach between observers. Bellamy et al (1991a) highlight the influence of 
methodology standardisation on several anthropometric measurements, generally 
resulting in an improvement in inter-observer reliability. 
Notwithstanding these issues, together with a range of test-retest intervals and the lack 
of consideration for disease-stability shown by many investigators, evidence of the 
inter and intra-observer reliability for many frequently adopted measures seems 
satisfactory and supports the application of most methods in group evaluation. Many 
methods achieve higher levels of reliability and are suitable for individual evaluation, 
for example, MSI and TWD. However, there is a lack of evidence, for the reliability 
of several measures, for example, inclinometer assessment of cervical flexion and 
extension. These measures are not recommended for use without some evidence in 
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support of their reliability in AS. Greater evidence of reliability with clearly defined 
and appropriate retest periods, clarification of the number and experience of 
observers, defined patient populations, and external evaluation of condition stability is 
required for all measurements. 
There is limited evidence to support the validity of most anthropometric measures, 
and all investigators have failed to state a priori hypothesised relationships between 
variables, therefore logically weakening the results (McDowell and Jenkinson, 1996). 
A'gold standard' evaluation of spinal movement is not available for routine use, 
although radiographic evaluation may provide a valid representation of vertebral joint 
movement (Kennedy et al, 1995). The relationship between several anthropometric 
measures and radiographic evaluation of regional joint movement or of AS-specif 1c 
change has been reported. A strong relationship between certain measures, for 
example, between the MSI and the lumbar spine, and between TWD and the cervical 
spine, have been accepted as evidence of the validity of the anthropometric measure 
as a reflection of spinal mobility or disease progression. 
Direct comparison between anthropometric measures presenting different approaches 
to measuring the same range of movement have been reported for measurements of 
lumbar and total spinal flexion, and strong correlation reported. For example, 
between the MSI, spondylometer and goniometer. Evidence of the acceptance, 
feasibility and reliability of methods with evidence to suggest that they measure a 
similar movement may further assist in the selection of a specific methodology. Few 
studies of direct comparison between the many available methods for measuring 
different ranges of cervical mobility, or the different ranges of lumbar mobility, for 
example, rotation versus flexion, have been identified and may further assist 
appreciation of the inter-relationship between movements. For example, it may not be 
necessary to include measurements of lumbar flexion and lateral flexion in an 
evaluation if a strong relationship between the two measurements exists. 
Although small to strong levels of correlation have been reported between selected 
anthropometric measures and AS-specific measures of functional disability, 
comparison with more established measures of HRQL have not been undertaken and 
are recommended with a priori hypotheses stated. This may provide a wider 
appreciation of the role of anthropometric assessment in patient evaluation. 
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Many anthropometric measures do not have evidence of responsiveness. 
Accumulated evidence suggests that cervical rotation and fingertip to floor distance 
(anterior flexion) (FFD) are responsive to change in mobility following 
physiotherapy, but not following drug therapy. Chest expansion may be responsive to 
change in thoracic mobility following physiotherapy, but the extent of change may 
not be clinically significant (Moll and Wright, 1973). Evidence suggests that lumbar 
flexion and lateral lumbar flexion are not responsive to change in mobility following 
physiotherapy or drug therapy over the short terrn. However, radiographic evaluation 
of AS-specific change in the lumbar spine is strongly correlated with the MSL 
Radiographic change is often used as a long term end-point in the evaluation of AS 
(Dawes, 1999), and the MSI may therefore play an important role in the long-term 
evaluation of AS, reflecting structural change in axial status. 
Few authors report on the acceptability of measures. However, the frequent 
application of certain measures in research and in routine practice suggests high 
feasibility. The anthropometric measures used by more than 70% of clinicians in 
routine longitudinal evaluation require only a tape measure, and are quick and easy to 
perform (MSI, TWD, FFD and chest expansion) (Bellamy et al, 1998,1999). In 
addition, cervical rotation is the most frequently measured cervical movement in 
published articles, and several authors have indicated that cervical rotation and lateral 
flexion are both clinically useful measures of cervical mobility (Pile et al, 199 1; 
Jenkinson et al, 1994a). 
Cervical mobility 
Irrespective of methodology, evidence suggests that the assessment of cervical 
rotation is more reliable and responsive than the measurement of cervical lateral 
flexion, flexion or extension, as shown in table 2.57, and is the measurement selected 
for inclusion in the longitudinal study. However, selection of a specific methodology 
was not self-evident. 
Although universal goniometers are readily accessible in most clinics, the protractor 
(Calcraft et a], 1974; Roberts et al, 1988) is bulky and less available, and evidence of 
poor reliability suggests that neither methodology should be adopted in AS 
evaluation. There was often a lack of clarity for the type of inclinometer adopted by 
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investigators and although all operate on a similar principle, different types may 
possess different levels of reliability and clarity is needed (Mellin et al, 1994). 
However, although inclinometers are expensive and not widely accessible, good 
levels of reliability and evidence of validity have been reported. Good evidence of 
reliability and validity also exists for the evaluation of cervical rotation with a tape 
measure: a cheap, quick, portable and widely accepted item of equipment. Due to the 
difficulty in selecting between these two methodologies the evaluation of cervical 
rotation with a tape measure and with a simple inclinometer were both selected for 
inclusion in a pre-pilot evaluation (Chapter 4), to support selection for the 
comparative study. Difficulty in selecting between available methodologies for the 
assessment of cervical mobility due to inadequate methodological detail and poor 
study design has been reported by other investigators (Jordan, 2000), and 
recommendation to adopt the tape measure as a feasible, cheap and acceptable 
methodology for cervical assessment was made. 
Chest expansion 
Limitation in chest expansion, relative to normal values and adjusted for age and sex, 
is included in the diagnostic criteria for AS (van der Linden et al, 1984), and it is a 
widely adopted measurement in routine practice (Bellamy et al, 1998,1999). 
However, evidence suggests poor standardisation of methodology, poor inter-rater 
reliability and a level of responsiveness following physiotherapy that may not be 
clinically significant (Moll and Wright, 1973)(table 2.58). Therefore, although 
important diagnostically, the measurement is not recommended for the longitudinal 
evaluation of AS. 
Thoracolumbarflaxion 
Although evidence for reliability is good, there is poor standardisation of 
methodology, validity is limited and accumulated evidence suggests poor 
responsiveness (table 2.59). Therefore, the measurement is not recommended for 
evaluative purposes in AS. 
Thoracic rotation 
The original methodology requires a large and cumbersome frame, which is not easily 
portable and limits the feasibility of application in research or clinical practice. 
Despite promising evidence of measurement properties, the approach has not been 
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adopted by investigators outside the development team and was not recommended for 
inclusion in the longitudinal study (table 2.59). Limited evidence suggests that the 
Pavlaka method (Viitenan et al, 1999) has good reliability and validity, and improved 
feasibility. 
Fingertip tofloor distance 
The popularity of the measurement of FFD (anterior flexion) is demonstrated by the 
large number of published studies including it in evaluation (table 2.60), and the 
report that more than 60% of clinicians usually or always include it in the longitudinal 
evaluation of AS patients (Bellamy et al, 1998,1999). Although originally 
recommended as a measure of thoracolumbar vertebral flexion (AAOS, 1965), 
validity is disputed. Many investigators indicate that it does not reflect pure spinal 
movement due to the influence of soft tissues and hip mobility and is therefore 
'clinically unhelpful'in assessment (Pile et al, 1991). However, proponents suggest 
that it is a useful measure of trunk mobility, and analysis in healthy adults, further 
supported by radiographic analysis in AS patients (Viitenan et al, 1995a; Avems et al, 
1996a) has reported a strong association with'trunk! and hip flexion, and a low 
association with vertebral flexion (Kippers and Parker, 1987). 
The highest levels of reliability are reported for the simplest methodologies requiring 
only a tape measure or ruler with the patient standing on the floor (table 2.60). 
Although only a low to moderate association with AS-specific measures of functional 
disability have been reported, Kragg et al (1990,1994) reported that FFD and 
functional ability were the only two measures to demonstrate significant improvement 
during a four-month follow-up of physical therapy in AS, and accumulated evidence 
suggests that it is responsive to change following intensive physiotherapy, but not 
following drug therapy. The evaluation of FFD with a tape measure and with a 
vertically mounted ruler were both selected for inclusion in a pre-pilot evaluation 
(Chapter 4) to support selection for the comparative study. 
Lumbarfle-xion 
Limitation in anterior flexion of the lumbar spine, relative to normal values and 
adjusted for age and sex, is included in the AS diagnostic criteria (van der Linden et 
al, 1984), and the Modified (15cm) Schober Index (MSI)(Macrae and Wright, 1969) 
is the preferred approach. Measurement of lumbar flexion with the MSI is the most 
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frequently applied measurement in published articles, and in routine clinical practice 
(Bellamy et al, 1998,1999). Accumulated evidence suggests that it is a reliable and 
valid measure of lumbar spine flexion, but it is not responsive to change over the short 
term following either physiotherapy or drug intervention (table 2.61). The MSI was 
selected for inclusion in the longitudinal study as a reflection of lumbar spine mobility 
and long term AS-specific change in the lumbar spine (Chapter 4). 
Lumbar extension 
Although evidence for the reliability and validity of lumbar extension measured with 
the skin distraction technique (Moll et al, 1972b) is good, the developers indicate that 
lumbar flexion (MSI) is a more sensitive index of AS (Moll et al, 1972b), and the 
method has not been widely applied in the published literature or clinical practice 
(Bellamy et al, 1998,1999)(table 2.6 1). The Dunham spondylometer and Smythe 
technique have not been widely applied and evidence of measurement properties and 
feasibility is varied, although a strong association with the MSI has been reported. 
The evaluation of spinal extension is not recommended as part of routine clinical 
evaluation and has not been included in the longitudinal study. 
Lateral lumbarflexion 
Although evidence of reliability is limited, LLF (skin distraction)(Moll et al, 1972a) is 
widely applied in the published literature. Evidence suggests that the most reliable 
method is LLF measured with a mounted ruler (Pile et al, 199 1)(table 2.6 1). 
Radiographic evaluation of the lumbar spine correlates strongly with both techniques, 
supporting the validity of the methodologies as measurements of LLF. Based on 
published evidence alone it was difficult to select between these methodologies, and 
both were selected for inclusion in a pre-pilot evaluation (Chapter 4). 
Posture 
Occiput (OWD) or tragus to wall distance (TWD) are frequently assessed measures of 
spinal posture in published studies and in clinical practice, with more than 40% of 
clinicians usually or always recording the value in routine practice (Bellamy et al, 
1998,1999). Evidence suggests good reliability, and radiographic assessment of the 
cervical spine demonstrated a moderate correlation of OWD and strong correlation 
with TWD. Evidence of responsiveness is not conclusive and suggests a low 
responsiveness following physiotherapy. Measurement of TWD with a t-square was 
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selected for inclusion in the comparative study (table 2.62) (Chapter 4). 
BASM 
Items included in the BASMI were selected as a result of expert opinion and a 
literature review of evidence. However, this process was very limited, and the 
developers do not detail selection methdology. Based on the limited published 
evidence at the time of instrument selection for the comparative study, there was 
acceptable evidence of the reliability, validity and responsiveness of the BASMI. 
However, the responsiveness of an index score that includes both measures of 
reversible and irreversible change in axial status should be addressed, and would be 
unlikely to be high. In addition, evidence of the acceptability and feasibility of the 
approach was lacking and several specialised items of equipment are required for 
administration (table 2.63). Therefore, the BASMI was not selected. 
Conclusion 
There is no strong recommendation for any anthropometric measure identified and 
evidence is limited for most methodologies. Many anthropometric measures have 
limited evidence for reliability, validity and, or responsiveness. Most vary in the'need 
for special equipment and the time and inconvenience for the investigator, clinician or 
patient. The clinical feasibility and level of acceptability to the patient are important 
features for all methodologies but are rarely reported by investigators. In addition, 
there is no consensus on the value of measuring axial status in the longitudinal 
evaluation of patients with AS (Pile et al, 1991). Four of the nine measures selected 
for inclusion in a pre-pilot evaluation miffor those included in the BASMI. However, 
the feasibility, acceptability and reliability of the different approaches for measuring 
the selected ranges of movement will be assessed (Chapter 4) before a final selection 
for the comparative study is made. 
2.7 Discussion 
This review has followed the guidelines for performing a systematic review of 
randomised controlled trials and the effectiveness of interventions described by the 
Centre for Reviews and Dissemination (CRD Report 4,1996) to provide as systematic 
a review of patient-based and anthropometric measures of outcome as possible. 
Although structured reviews of outcome measures have been identified, reviews with 
a similar systematic format to that described in this chapter had not been identified at 
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the time of the initial search. In 1999 a report, described as a systematic literature 
review, was detailed by Ruof and Stucki (1999a). Although limited in the extent of 
the literature search and assessing only two AS-specific measures of functional 
disability, the method of data extraction would appear to be systematic and the quality 
of both instruments was assessed in terms of evidence for instrument development 
and measurement properties. However, detail in the published article is lacking, no 
reference to standard texts for performing systematic reviews of evidence is made, 
and there is no attempt to explicitly appraise instrument quality. 
In conducting a systematic review of outcome measures it is important that all, or 
nearly all articles, and all outcome measures of relevance to the focus of the review 
are identified to limit a biased assessment (Greenhalgh and Meadows, 1999). The 
review has produced the first comprehensive list of patient-based and anthropometric 
measures of outcome applied in published studies of AS. The reviews described by 
Bakker et al (1993b) and extended by van der Heijde et al (1997) focussed only on 
AS-specific measures of outcome and included single-item measures. The described 
search was as comprehensive as possible and it is highly unlikely that any major 
patient-based or anthropometric outcome measures have not been identified. The 
search was limited by the exclusion of non-English articles and non-Anglicised 
patient-based measures of outcome, a necessary limitation within the study resources, 
but one that limits the generalisability of the review. Several English-language 
articles describe instruments developed in a different language. For example, the 
Dougadas Functional Index (Dougadas et al, 1988). These instruments have 
subsequently been applied in English-speaking populations without indication of 
translation and re-testing of measurement properties. Likewise, other investigators 
apply English-developed instruments in non-English speaking populations (Hidding et 
al, 1993ab; Bakker et al, 1995) without further indication of translation or 
consideration of cross-cultural differences in item content (Anderson et al, 1995). 
Where referral was made to the original English-based article describing instrument 
development, these articles have been included in the review of evidence. However, 
this highlights the need for investigators to clarify the version of an instrument 
adopted and any translation and subsequent re-testing of the instrument performed. 
Translation and cross-cultural differences may result in different measurement 
properties and requires careful attention when instruments are applied across cultures 
and languages (Anderson et al, 1995). 
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Peripheraljoint assessment was also excluded from the review. Evidence of the role 
of peripheral joint assessment in AS evaluation is required, particularly for the hip 
joint. Several investigators have described the importance of hipjoint pathology in 
advancing AS and its relationship with functional disability and future disease 
prognosis (Braun et al, 1998 ; Dalyan et al, 1999), and is recommended for inclusion 
in a further review of anthropometric measurement in AS. 
Although anthropometric measurement has been referred to in published articles for 
many years and recommendation to include lumbar mobility in AS assessment was 
made in 1968 (Bennett and Wood, 1968), the first application of most measures 
identified in the review is supported by articles from the late 1980's. This reference 
indicates the first article where a clear methodological approach could be described, 
and not the first time that a measurement was referred to in a published article. 
Evidence supporting the measurement properties of anthropometric measures has 
been limited by the inadequate or incorrect indexing of measures. Without 
methodological clarity, evidence supporting application or measurement properties 
could not be included in the review and has been restricted to that obtained from 
articles with clear methodological description or reference. The lack of 
standardisation of anthropometric measurement in AS was first highlighted in 1991 
(Laurent et al, 199 1), and the review has indicated that this remains a problem. A 
further recommendation for standardisation of technique and methodological clarity 
or referencing of anthropometric measurement is made. 
Evidence in support of anthropometric measurement could have been enhanced by a 
structured literature search of electronic databases pre-1990. However, in light of the 
paucity of referencing or methodological description in both pre and post-1990 
literature this would be unlikely to result in a large number of additional articles 
supporting defined anthropometric measures. This extended search is not necessary 
for the patient-based measures of outcome because the first AS-specific measure was 
published in 1987 and all published references have been obtained. Alternatively, the 
investigators for each article could be contacted to clarify the measurement 
approaches adopted. This would greatly enhance the availability of data for each 
anthropometric assessment described and would clarify the version of patient-based 
measures adopted, but was not feasible within the study resources. Instrument 
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developers could also be contacted to request information about the application of the 
respective instrument. However, use of the AS-specific patient-based measures of 
outcome and all anthropometric measures identified does not require the permission 
of instrument developers and this approach is unlikely to identify further references 
beyond the exhaustive literature search described. 
Searching the grey literature could have identified a wider range of publications and 
outcome measures, but the focus of the review was to identify patient-based and 
anthropometric measures of outcome used in the published literature. However, 
communication with experts identified several newly developed measures, yet to be 
published: the Body Chart (Dziedzic K. - personal communication, 1997) provides a 
disease-specific measure of bodily pain, and the AS Quality of Life questionnaire 
(ASQoL), an AS-specific measure of HRQL (Doward L. (Galen Research) and 
Helliwell P. - personal communication, 1998). Both instruments are considered 
further in Chapter 4. 
Following data evaluation no strong recommendation for any patient-based or 
anthropornetric measure of outcome could be made. Evidence of instrument 
development, measurement properties and levels of acceptability and feasibility of 
adopting the instruments in clinic based or postal evaluation was limited for most 
instruments (Haywood et al, 1998). However, instrument selection was based on a 
systematic, rigorous and explicit methodological approach (Mulrow, 1995; Sutton et 
al, 1999) and results and conclusions may differ from other reviews of outcome 
measures due to differences in methodological and selection criteria (Pile et al, 199 1; 
Jenkinson et al, 1994a; van der Heijde et al, 1999a, b, c). 
An important step in synthesising the evidence of systematic reviews of randomised 
clinical trials (RCT) is to assess the quality of each trial (Jadad et al, 1998). This 
process requires a definition of the quality construct and the adoption of an 
assessment tool. However, these are controversial issues (Moher et al, 1995; Jadad et 
al, 1998). The current systematic review has modified this process for the purpose of 
appraising the evidence in support of instrument quality and has focussed on 
measurement properties. That is, an evaluative instrument requires evidence in 
support of instrument reliability, validity and responsiveness (Kirshner and Guyatt, 
1985). A scale originally described by McDowell and Newell (1996) in the 
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evaluation of evidence to support the reliability and validity of reviewed instruments, 
was adopted for the current study to provide a quantitative summary of the level of 
evidence to support the thoroughness and results of testing for instrument 
measurement properties (section 2.4.4). However, in common with scales adopted in 
the quality assessment of RCTs this scale has not undergone rigorous testing and the 
summary based upon this scale should be viewed with caution (Moher et al, 1995). In 
addition, the scale has not been applied by different assessors in the current review 
and appraisal of assessor agreement was not possible (Jadad et al, 1998). The review 
has therefore, provided detailed and explicit qualitative evidence (both text and 
tabular) which may validate the quantitative assessment, whilst providing the reader 
the opportunity to assess the evidence, and possible instrument hierarchy, irrespective 
of quality score (Cook et al, 1997; Jadad et al, 1998; Sutton et al, 1999). In addition, 
the review also considered the development, acceptability and feasibility of each 
instrument in the data synthesis, an aspect not included in the quality scale 
assessment. 
A different approach to identifying and evaluating instruments for use in AS was 
adopted by the ASAS group (van der Heijde et al, 1997; 1999ab, c) and the systematic 
review. Both methodologies are summarised and compared in table 2.64. 
Recommendations made by ASAS were based on the consensus opinion of gathered 
experts who considered the relevance and feasibility of the instrument (table 2.65) 
(van der Heijde et al, 1999ab, c). Selection was not based on a systematic review and 
explicit evaluation of gathered evidence relating to instrument development, 
measurement properties, acceptability and feasibility. 
Although the systematic review described considered all measurement properties and 
practical requirements in data evaluation and therefore presents a more detailed and 
explicit instrument appraisal then the ASAS, data extraction and evaluation was 
performed by a single investigator (KLH) and may exhibit a biased result. This could 
be lessened by a second reviewer checking the extraction and evaluation of all, or a 
random sample of, articles and instruments but was not feasible within the study 
resources (Jadad et al, 1998). 
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ASAS Systematic review 
Identif ied available outcome measures in AS (1985- 1. Identified all patient-based and anthropometric measures 
1996) (Medline and citation searches only - non of outcome applied in AS (1990-2000) (exhaustive 
exhaustive search). search of major electronic databases; hand searching and 
citation searching). 
2. Identification of core domains by expert opinion - based 2. Domains addressed by identified paticrit-based and 
on domains addressed by listed outcome measures. andiropomctrio outcome measured listed. 
3. Group consensus (expert opinion) raised issues of 
domains not initially selected. 
3. Domains considered important in evaluatim of AS listed 
following literature review and expert opinion. Gaps 
identified. 
4. Selection of outcome measures based on appreciation of 
relevance and feasibility - determined by expert opinion 
and group consensus, not on review of evidence. 
5. No consideration of generic instruments or measures of 
BRQI. 
6. outcome measures recommended for use in evaluative 
studies of AS. Evidence of construct validity, reliability 
and responsiveness not considered in making 
recommendation (relevance and feasibility only). ASAS 
report that this is the next step in the selection process. 
4. Quality of disease-specific and anthropometric measures 
of outcome appraised in light of systematic evaluation 
and synthesis of published evidence of development, 
measurement properties, feasibility and acceptability. 
Instruments selected to fulfill domains considered 
important in the evaluation of AS patients. 
5. Literature search and contactwith experts identified 
additional generic and non-published disease-specific 
instruments to fulfill gaps in domains - specifically 
IIRQL 
6. Selected instruments the focus of comparative empirical 
study (Chapter 4). Primary objective to further evaluate 
the practical requirements and measurement properties of 
identified instruments. Recommendations will be made 
in supp(xt of a standardised package of evaluative 
patient-based and anthropometric measures of outcome. 
Table 2.64 Comparison of approaches adopted by ASAS group and the systematic review for 
identification of outcome measures in AS. 
The literature search conducted by ASAS was not exhaustive and may have failed to 
identify all available outcome measures applied in AS. Generic measures of ERQL 
applied in the evaluation of patients with AS have not been identified, and the 
domains assessed are biased towards the evaluation of impairment and disability. The 
ASAS included single item measures in the evaluation process and several have been 
recommended for evaluative purposes (table 2.65). The systematic review explicitly 
excluded single item measures due to the poor measurement properties inherent in 
such measures (Fitzpatrick et al, 1998a). However, single item measures are widely 
applied in both research and clinical practice and a further review to establish the 
variety of single items adopted, and the available evidence in support of measurement 
properties would be beneficial to support or reject the use of these measures. 
Instruments recommended by ASAS and following the systematic review are 
surnmarised in table 2.65. 
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ASAS (1999) Systematic review (1998) 
Domains Instrument Domains Instrument 
Function Dougadas Functional Index Clinical Revised Leeds Disability Questionnaire 
BASFI Functional status (Dougadas Function Index) 
Pain i. VAS, last week, spine, at night due to AS. Clinical i. Body Chart-global pain, now. 
ii. VAS, last week, spine, due to AS. Pain 
Spinal Chest expansion 
mobility Modified Schober (10cm) 
Occiput to wall 
Clinical Cervical rotation 
Spinal mobility Modified Schober Index (15cm) 
Tragus to wall 
Fingertip to floor distance: 
L forward flexion 
ii. lateral lumbar flexion 
Patient global VAS, last week 
Stifrness Duration morning stifThess, spine, last week 
Peripheral Number of swollen joints (44 joint count); 
joints and No preferred instrument for assessment of 
entheses entheses 
Fatigue No preferred instrument available 
Patient global 
Stiffness 
Periphcral joints 
and entheses 
Fatigue 
Clinical 
Disease activity 
Disease-specific 
HRQL psychometric 
Disease-specific 
HRQL individualised 
Generic 
Psychometric 
Addressed in PGl-AS' 
Addressed in ASQoO, BASDAlb and 
PGI-AS' 
Not assesiedL 
Review - non-conclusive evidence for 
entheses indices 
Addressed in ASQoO, BASDAI'and 
PGI-AS" 
BASDAI 
Ankylosin t Spondylitis - Quality of Life 
(AS-QoL) 
Patient Generated Index - Ankylosing 
Spondylitis: (PGI-AS)" 
SF-12* 
Generic EuroQol' 
utility 
Table 2.65 Domains and measures of outcome identified by ASAS (van der Heijde et al, 1999a) 
and the systematic review. 
Superscript: a Development of PGI-AS described in Chapter 3; 
b, c: ASQoI., Body Chart and generic instruments (EuroQoI and SF-I 2) discussed in Chapter 4. 
Conclusion 
The selection of patient-based and anthropometric measures of outcome proposed by 
the current study presents the first evidence-based selection of instruments based on a 
methodologically rigorous and explicit systematic review of the literature. 
Limitations of the review have been identified and recommendations for future 
systematic reviews of measures of outcome made. The measurement properties of the 
selected instruments will be further evaluated in the comparative study described in 
Chapter 4 before recommendations for a package of patient-based and anthropometric 
measures of outcome suitable for use in routine clinical evaluation of AS and research 
are made. 
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Chapter 3 The Development of a Patient Generated Index for AS (PGI-AS) 
3.1 Introduction 
This chapter describes the development of the first individualised measure of AS- 
related quality of life, the Patient-Generated Index for AS (PGI-AS). Section 3.2 
discusses the measurement of HRQL in AS and section 3.3 describes the stages in the 
development of the PGI-AS. The chapter closes with a discussion. 
3.2 Health-related quality of life in Ankylosing Spondylitis 
The review of outcome measures in AS (Chapter 2) has demonstrated that the most 
usual means of evaluation in published research and routine practice (Bellamy et al, 
1998,1999) remain focused towards the measurement of impairment (disease activity, 
anthropometric measurement) and disability (functional disability questionnaires). 
Although several investigators have involved patients in the development of patient- 
based measures of functional disability this involvement has been limited and 
dominated by expert opinion. Instrument content therefore remains biased towards 
the beliefs of health professionals and does not necessarily address aspects of AS 
considered important by patients. 
Although several generic measures of HRQL and domain-specific instruments that 
evaluate individual domains related to the overall concept of HRQL were identified 
(table 2.9) an AS-specific measure of HRQL was not identified in the initial review. 
The core evaluative domains recommended by the ASAS group (van der Heijde et al, 
1997,1999ab, c) were based upon knowledge of the available outcome measures and 
not surprisingly are heavily weighted towards the evaluation of impairment and 
disability. Although the group subsequently acknowledged the significance of quality 
of life in evaluation, it was not recommended as a core domain due to the'novelty' of 
the measurement in AS and 'uncertainty over the best measurement technique' (van 
der Heijde et al, 1997). The evaluation of quality of life should, in theory, consider a 
very broad concept of life that does not only focus on the impact of ill-health and 
several authors suggest that the focus of HRQL evaluation is towards aspects of life 
that might, in principle, be influenced by health and health care (Ware, 1997; 
Jenkinson et al, 1998). 
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The HRQL of a patient with a chronic, incurable disease such as AS is considered by 
many to be an important indicator of disease impact at an individual level (Guyatt et 
at, 1993; Aronson, 1997). Although many developers involve patients in item 
generation to ensure the representation of patient concerns, most instruments adopt a 
closed completion format and patients respond to all listed items. Although these 
instruments often have good measurement properties such highly standardised 
instruments may omit issues of importance to individual patients (Stratford et at, 
1995; Carr et at, 1996) Whilst containing items of little relevance to others, thus 
introducing noise to the evaluation (Tugwell et at, 1987). Items may appear detached 
from the contextual setting thus loosing the social or personal significance that may 
be afforded by a more individualised evaluation (Carr and Thompson, 1994). HRQL 
is specific to an individual, to their priorities, expectations and experience of life and 
ill-health. Therefore, many investigators suggest that evaluation should be 
individually tailored to provide a more meaningful assessment of patient-specific 
HRQL. A patient-centred evaluation fosters appreciation of the impact of ill-health 
on an individuals expectations and aspirations as well as recording the physical and 
psychosocial impact of disease (Carr, 1996). It may therefore be more sensitive to a 
patients needs, demands and change in status (Barlow et at, 1993a). 
Several instruments have been identified which attempt to provide a more patient- 
centred and individualised evaluation of HRQL. For example, the Chronic 
Respiratory Distress Questionnaire (CRD - Guyatt et al, 1987a), Disease 
Repercussion Profile (DRP - Carr and Thompson, 1994) and the Measure Yourself 
Medical Outcomes Profile (MYMOP - Paterson, 1996). The Schedule for the 
Evaluation of Individual Quality of Life (SEIQoL - O'Boyle et al, 1993) and the 
shorter SEIQoL-DW (direct weighting)(Hickey et al, 1996) provide two patient 
centred generic measures of quality of life. Patients are generally asked to 
individually nominate specific items adversely affected by ill-health or to identify 
areas of life that they consider to be important. Items are then rated to represent the 
extent of disease impact. Some instruments, such as the SEIQoL-DW, take a further 
step and ask patients to weight the relative impact or importance of each item. All of 
these instruments require interview-administration and some require a considerable 
completion time. Although representing an important development in the evaluation 
of HRQL many of these instruments have not been widely accepted into research or 
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routine practice. Many are still in development and further evidence of feasibility, 
acceptability and measurement properties are required. 
3.3 The Patient Generated Index (PGI) 
An additional patient-centred instrument, the Patient Generated Index (PGI) has also 
been described (Ruta et al, 1994a). The PGI offers a generic approach to the 
evaluation of HRQL which is made disease-specific by the inclusion of a disease- 
specific trigger list. Although a single item addresses non-health areas of life, the PGI 
is more specifically focussed towards the assessment of disease-related quality of life 
due to the instruction for patients to consider the most important areas of life affected 
by a specific disease. 
In the management and evaluation of patients medicine must not forget patient 
autonomy. The PGI supports this autonomy by providing the opportunity or freedom 
for patients to identify areas of their life that they deem to be of greatest importance 
when considering disease impact. The PGI quantifies individual disease-related 
priorities in terms of the effect of disease on a patients day-to-day life. The 
conceptual base behind the PGI defines quality of life as: 
'the extent to which our hopes and ambitions are matched and fulfiHed by experience' 
(Calman, 1984). 
If effective health care is viewed as an attempt to improve a patients HRQL, the result 
may be a reduction in the gap between a patientshopes and expectations and what 
actually happens' (Ruta et al, 1994a). This may be of particular relevance in a disease 
such as AS where a cure is not possible and management must focus on the control of 
disease activity and symptomology, and thus in reducing or minimising disease 
impact. AS can have an unpredictable progress and patients require monitoring and 
medical care for the remainder of their life span (Rigby, 199 1; Barlow et al, 1993 a). 
Patients are required to make considerable psychological, emotional and physical 
adjustments and management may be required to assist patients in a revision of life 
expectation, thus affecting a reduction in the gap between expectation and reality 
which, it would be hoped, could lead to an improvement in patient-centred HRQL. 
Successful adaptation to chronic illness has been shown to be positively influenced by 
a patient's perception of chronic disease and the impact on their life (Carr, 1996). 
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The PGI was chosen as the basis for a new AS-specific measure of disease-related 
quality of life for several reasons. Firstly, it offers a patient-centred approach to the 
evaluation of ill-health which allows issues considered important by a patient to be 
incorporated in the evaluation. Second, it can be adapted to provide an AS-specific 
evaluation of disease-related quality of life. Third, it has good evidence of 
development and measurement properties in varied patient populations (Ruta et al, 
1994a; Herd et al, 1997; Ruta et al, 1999; Jenkinson et al, 1998b) and in populations 
with similar pathologies to AS (McArthur, 1997, cited by Macduff and Russell, 
1998). Particular strengths have been reported to lie with the content validity and 
instrument responsiveness (Ruta, 1998). Finally, it has been administered in both 
self-administered (postal) and interview-based evaluations and good levels of 
feasibility and acceptability have been reported. This was an important consideration 
for the comparative study (Chapter 4). 
Since the PGI was first published in 1994 (Ruta et al, 1994a) the instrument has been 
revised to improve feasibility and patient acceptance (Cotton et al, 1993; Ruta, 1998). 
in addition, several 'hybrid' versions have been proposed. Patients with multiple 
health problems of an unrelated nature reportedly had difficulty completing the 
original PGI and a disease-specific format was proposed to allow patients to consider 
health problems not directly associated with the specific focus of the PGI (Ruta, 
1998). AS covers a wide clinical spectrum but it was considered important to allow 
patients to report the impact of non-AS related health issues and the disease-focused 
PGI was selected for the study. An additional single item in the disease-focused PGI 
allows the patient to consider the impact of health problems not related to the specific 
disease. 
Completion of the PGI is in three steps (Appendix 2- PGI-AS). The first step asks 
the patient to identify the most important areas of life that are affected by the specific 
disease, for example AS. The patient may write up to five areas in the boxes 
provided. To assist in item generation a trigger list of important areas commonly 
mentioned by other people with the specific disease is provided on an adjacent page 
for ease of reference, together with a completed example of the PGL The last two 
boxes ask the patient to consider the impact of health problems other than AS (box 6), 
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and all other non-health related areas of life (box 7). Items are not written in these 
boxes but the areas are scored in step 2. 
In the second step the patient is asked to score the areas mentioned in step 1. The 
score illustrates the impact of the identified area on the patient over the previous one 
month. A scale from 0 (the worst you could imagine') to 10 ('exactly as you would 
like to be'), with verbal descriptors for each level is provided, and each identified area 
must be scored. Should the patient not experience any other health problems (box 6) 
they may indicate 'none' in writing without a further need to score this box (as 
illustrated in the completed example). However, this box should not be left blank. 
Box 7 ('all other non-health related areas of life') must be scored by all patients. 
In the final step, step 3, the patient is asked to consider that any or all of the areas of 
their life could be improved. Points are spent to reflect the relative importance of 
each identified area with more points spent on areas where an improvement would be 
most valued. Points do not need to be spent in each listed area and all 14 points may 
be spent in one area if so desired. If no AS-specific items are identified all points 
must be spent between box 6 and / or 7. 
An index score is generated using the following equation: 
(Step 2 score x Step 3 points) 
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This is calculated for each item where points are spent. The result is then totalled (0- 
10), where a lower score represents a wider gap between expectation and reality, and 
a lower patient generated disease-related quality of life. The score relates to the 
response scale in step 2. 
3.3.1 Developing a trigger list for the PGI-AS 
The first stage in adapting the PGI for use in AS was to develop a trigger list of the 
most important areas of life affected by AS as determined by a representative 
population of AS patients. 
40 patients were randomly selected from the AS database at the Staffordshire 
Rheurnatology Centre (SRC)(33 male; mean age 46.19 years, SD 10.10; range 28- 69 
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years). Although the severity of a condition is suggested not to be synonymous with a 
patients level of quality of life (Whalley et al, 1997; Aronson, 1997) the random 
sample was intended to provide a representative sample of patients with AS. 
A letter was sent to all patients inviting them to attend the SRC for a 'chat, about the 
affect of AS on day-to-day life. The letter detailed the purpose and expected duration 
of the interviews. It was stressed that patients were under no obligation to participate 
and that the study would not impact upon normal management. Appointment times 
ranging from two to four weeks after the letter was posted were listed and patients 
asked to nominate a date and time (a tick box option) or to indicate a preferred 
appointment in writing, and to return both informed consent and appointment forms to 
the lead investigator (KLH) in the reply-paid envelope. Appointments were 
confirmed by telephone. Patients not wishing to participate were asked to return the 
pre-coded consent form. Non-responders were sent reminders and revised 
appointments at two weeks and again after four weeks. 
29 patients participated in the semi-structured qualitative interviews with the lead 
investigator (KLH)(table 3.1). 24 patients were male (82.8%)(mean age 48.41 years, 
SD 10.12, range 3 1-69 years), with a mean duration of AS diagnosis of II years (SD 
10.68, range 2-41 years), suggesting a broad spectrum of disease presentation covered 
by the population. The structure and objectives of the pilot interviews did not differ 
from the main interviews and information was incorporated in the generation of the 
trigger list. 
Pilot (n- 4) Main (n-- 36) Total (n7- 40) 
n% n % n % 
Response rate 4 100 25 69.4 29 72.5 
Refusal 0- 6 16.6 6 15.0 
Non-rcsponse 0 5 13.8 5 12.5 
Table 3.1 Response rates for qualitative interviews. 
To test for response bias patients who failed to respond or refused to participate in the 
interviews were compared with respondents by age and gender. Patients not taking 
part were significantly younger than responders (mean age non-responders 40.33 
years, SD 7.68, range 28-52 years)(t-test p= 0.02), but there was no significant 
difference in gender (Fisher's exact test, p= 0.64). 
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The aim of the interview was to elicit a patients free responses about the impact of AS 
on their everyday life and the importance of the areas affected by AS. Life priorities 
affected by AS were considered. Interviews were performed in a private room at the 
SRC and lasted between 30 minutes and one hour. The sample size was supported by 
work by other investigators (de Jong et al, 1997; Jenkinson et al, 1998a) and no new 
significant themes emerged during the last few interviews. 
With the permission of the patient interviews were audio-recorded and later 
transcribed (Whalley et al, 1997). Verbatim statements were listed that readily 
identified important and common themes related to the HRQL of patients with AS. A 
total of 99 areas of life affected by AS were identified. In the first instance the 
frequency endorsement of individual items was determined (Guyatt et al, 1987a). The 
top 22 most frequently mentioned areas are shown in table 3.2. 
Items Frequency 
endorsement 
Impact on ability to work Ability to pursue chosen hobbies or 24 
sports 
Difficulty driving 19 
Relationship with partner Worry about the future impact of AS. 17 
Feeling depressed 
Worry about deterioration in condition Difficulty walking 16 
Feeling tired / fatigued Ability to remain physically mobile 15 
Reduced spinal movement 
Constant pain Loss of independence 14 
Ability to do things /jobs around the Social life 13 
home 
Ability to do'D. I. Y' 
Disturbed sleep Ability to do housework 12 
Loss of motivation to do things 
Feelings of lethargy 
Increased dependency on partner Ability to lift heavy weights / carry 
Feeling that life is controlled by AS the shopping 
Table 3.2 Frequency endorsement of the most important areas of life affected by AS 
(maximum = 29). 
Data analysis allowed for the generation of conceptual categories (Bowling 1997). 
Related items were highlighted, grouped together and organised by category. This 
listing was discussed with a member of the research advisory group (RAG)(AG) and 
scrutinised for repetition and ambiguity. It was possible for certain items to be 
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represented in more than one category and the final decision for placement was taken 
by the lead investigator only (KLH). When related items were grouped together 16 
main categories were described (table 3.3). The hierarchy of the list is based purely 
on the frequency of endorsement for each category (range 5-66). 
Category Frequency Category Frequency 
endorsement endorsement 
Relationship with family 66 Self-esteem 44 
partner 
Pain 57 Worry about the future 43 
Functional activities 56 Tiredness / Fatigue 39 
Control over life 55 Depression / moody 33 
'Jobs' around the home 50 Leisure activities 25 
Levelofindependence 47 Driving 22 
Impact on work 45 Limited spinal movement 21 
Social life / friendships 45 Mental agility 5 
Table 3.3 Frequency endorsement of areas of life affected by AS by category. 
The final trigger list reflects these categories and contains 37 items frequently 
mentioned by patients with AS (table 3.4). The number of items was guided by the 
available space in the formatted instrument (Appendix 2) and selection was based 
upon the frequency of endorsement. Where possible the list includes verbatim 
statements made by patients. If this was not possible state m, ents closely resemble 
those made by patients. 
3.3.2 Pre-pilot study 
The pre-pilot study involved interview-administration of the index in a clinic 
environment (rr-- 10)(9 male; mean age 47.8 years, SD 8.75; range 28-58 years) and 
patient self-completion in their home in the form of a postal response (n7=10)(9 male; 
mean age 47.7 years, SD 12.9 1; range 29-69 years). Participants consisted of a 
further random sample of patients from the SRC AS database. Completion of the 
index was followed by semi-structured interviews with the lead investigator at the 
SRC to identify any ambiguities in the index, to ensure that it could be easily 
understood and completed and to invite the patients to comment on the content and 
use of the trigger list. Patients participating in the postal survey were asked to attend 
the SRC for a follow-up interview at a time convenient to them. 
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Trigger list 
Impact on work Disturbed sleep Increased time to do Walking 
Relationship with Pain 
things Difficulty sitting down 
husband / wife / partner Fre. fin(M nf Inw qf.. If. 
Control over life standing / lying down 
Ability to play with esteem Ability to plan ahead 
children / grandchildren Embarrassment Enjoyment of life 
Sex life Poor sclf body-image Worry about the future 
Family life Fatigue Pursuing chosen hobbies 
Worry over 'letting Feeling Tired Sporting activities 
people down' Loss of motivation 
L. cvelofindepcndcnce Depression 
Relationship with friends Moody 
Ability to remain 
physically active 
Fear of Falling 
Dressing 
Washing 
Ability to do jobs around 
the home 
Limited spinal movement 
Social Life 
Mental activity 
Difficulty 'getting going' 
Dfiving in the morning 
Table 3.4 PGI-AS trigger list. 
Five patients were interviewed following interview-administration of the instrument 
(mean age 43.00 years, SD 10.12; range 28-55 years) and a further six following the 
postal survey (mean age 46.00 years, SD 15.68; range 29-64 years). There was no 
significant difference in gender (Fisher's exact test, p= 0.50) or age between 
responders and non-responders for either the clinic-based (West P= 0.08) or the postal 
survey (p= 0.70). Verbatim statements were recorded. No substantial amendment to 
the PGI-AS was required in light of the evaluation and only minor modification to the 
wording in step 3. Positive feedback suggested that the trigger list was beneficial in 
assisting patients to identify the most important areas of life affected by the disease. 
3.4 Discussion 
The open and dynamic nature of the PGI-AS places the patient at the centre of the 
evaluative process and is proposed as the first individualised measure of AS-related 
quality of life. The PGI-AS was developed to provide a sufficiently short and simple 
instrument that would be feasible for application following self-completion in postal 
surveys and following interview-administration within a clinic setting. However, 
there is no clear consensus on the most appropriate format to adopt for follow-up 
completion. That is, whether patients should complete the instrument blind to areas 
identified at baseline completion (Vind'), informed of areas identified, but allowed to 
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change areas if desired (Informed and open! ) or informed of the areas, but not allowed 
to change them ('closed'). Evaluation of these different formats is essential to 
determine which approach has the greatest relevance to patients, researchers or 
clinicians (Jenkinson et al, 1998c). 
It is acknowledged that the frequency with which a concept is mentioned during semi- 
structured interviews does not necessarily equate with the social significance of the 
topic (Bowling, 1997). However, the trigger list acts only as a prompt for patients 
completing the PGI-AS. Item selection and subsequent weighting is specifically 
individualised. In addition, the content of the PGI-AS trigger list addresses a wide 
diversity of areas such as relationships with family, fear of falling, ability to plan 
ahead and the level of social embarrassment associated with poor posture and reduced 
mobility. It also captures patients concern about the future direct and indirect 
consequences of the disease. For example, the impact of disease on the ability to 
work and the resulting financial impact; plus the impact on marital and family 
relationships. Many items are distinctively associated with AS although many may 
differ over time and between patients, a feature common with other patient-centred 
measures of HRQL (Carr, 1996; Jenkinson et al, 1998a). The conceptual base of the 
PGI-AS suggests that the patient whose life is being assessed is most qualified to 
judge its quality (Ruta, 1998), and comments such as: 
'That's mel That's Spondy in a nut-sheH' 
and 
'the list made me feel that I am not alone with the AS and with the problems that I 
experience. ' 
support the content validity of the PGI-AS. In addition, this support for the trigger list 
and the individuality of instrument completion suggests that the age difference 
between responders and non-responders in developing the trigger list should not 
adversely influence instrument completion. 
Before the PGI-AS can be recommended for use in the evaluation of AS patients in 
clinical research or routine practice evidence for the measurement properties, 
acceptability and feasibility of the instrument is required. The comparative study 
described in Chapter 4 has provided the first evidence for these properties. 
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Chapter 4 Developing a package of outcome measures for use in AS 
4.1 Introduction 
This chapter describes the methodology and results of the patient recruitment and data 
collection for both clinic-based and postal surveys of the comparative study. The pre- 
pilot evaluation of the anthropometric measures identified in the systematic review is 
described in section 4.2 and the selected study instruments are summarised in section 
4.3. The aims and objectives of the comparative study are described in section 4.4 
and patient inclusion and exclusion criteria is described in section 4.5. Sections 4.6 
and 4.7 describe the survey methodology and results of the clinic-based and postal 
surveys respectively, on which the empirical work that follows is based. The chapter 
concludes with a discussion of the results. 
4.2 Pre-pilot evaluation of anthropometric measures 
Nine anthropometric measures were selected in the systematic review (Chapter 2). A 
pre-pilot evaluation of these measures assessed the clinical feasibility as determined 
by the expert opinion of three observers (two experienced physiotherapists, one 
'trained' non-physiotherapist), and the intra and inter-observer reliability. From a 
random sample of 20 AS out-patients from the SRC database, 12 agreed to participate 
in the study (n-- 12 males; mean age 48.50 years, SD 9.13; range 36-69 years; 
symptom duration 443 years, mean 21.25 years, SID 12.5 1; duration of diagnosis 3 42 
years, mean 12.9 years, SD 11.04) (Haywood et al, 1999). There was no significant 
difference in age between responders and non-responders (t-test P= 0.12), or for 
gender (Fisher's exact test, p=0.49). 
Four methodologies were excluded due to poor clinical feasibility: cervical rotation 
(inclinometer), Fingertip to floor distance (FFD)(vertically mounted ruler), Lateral 
lumbar flexion (LLF)(skin distraction) and Tragus to wall distance (TVVD)(t-square). 
The inclinometer was rejected due to the necessity for patients to lie supine, a position 
often found to be painful and difficult for patients with AS and therefore difficult to 
standardise. The vertically mounted ruler used to measure FFD (and LLF) was bulky, 
limiting movement of the most flexible patients and those of shorter stature. The 
identification and standardisation of landmarks for the LLF skin distraction technique 
was time consuming and difficult in obese patients and those with more pronounced 
spinal deformity. Measurement of FFD and LLF as fingertip to floor distance using a 
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retractable steel tape measure was more acceptable, easier and quicker. Finally, the t- 
square used to measure TWD failed to reach the tragus of the most severely affected 
patients and was replaced with a retractable steel tape measure. The measurement of 
FFD (anterior flexion), LLF (fingertip to floor distance) and TWD with a steel, 
retractable tape measure offered a compromise between the use of a tape measure, and 
the rigidity of the mounted ruler. The solid base of the steel tape measure ensured 
that the position of the ruler, perpendicular to the floor (or to the wall in measuring 
TWD) could be maintained, whilst offering a cheap, quick, readily portable and 
adaptable instrument. The tape measure assessment of cervical rotation (Viitenan et 
al, 1998) was modified, identifying the tip of the nose as a more fixed facial landmark 
than the chin. High levels of reliability were found for the selected measurements 
(ICC > 0.85) and all five were retained for the comparative study (table 4.1). 
43 Measures of health outcome 
Instruments were selected for inclusion in the Comparative study to represent a core 
set of health domains considered important in the evaluation of patients with AS. 
These domains were supported by the work of the ASAS working group (table 
2.1)(van der Heijde et al, 1997; van der Linden and van der Heijde, 1998), a further 
search of the literature relating to the measurement of health outcome (Fitzpatrick, 
1993a; Carr, 1996; Jenkinson et al, 1998a) and expert opinion (RAG). 
Disease-specific 
Two disease-specific patient-based instruments to measure functional disability and 
disease activity and five anthropometric measures of axial status were selected as a 
result of the systematic review (Chapter 2) and the pre-pilot evaluation (section 4.2) 
(table 4.1). 
Expert opinion 
The systematic review did not identify disease-specific instruments to reflect all 
important domains: that is, pain and HRQL, and communication with measurement 
experts in rheurnatology and AS identified two, as yet unpublished AS-specific 
patient-based instruments: the Body Chart and the AS Quality of Life questionnaire 
(ASQoL). The Body Chart is a measure of global bodily pain and is routinely 
administered in the clinical assessment of AS patients at the SRC (Dziedzic, 1997). 
The instrument is interview-administered and consists of a body manikin (anterior and 
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Category Instrument Description 
Clinical Revised Leeds Disability 16 items - AS-specific functional disability 
Functional status Questionnaire - RLDQ 4-point ordinal response scale - perceived activity completion 
(Abbott et al, 1994) Response 'Yes, with no difficulty' (0) to 'Unable to do' (3). Items 
totalled. Score 0-48; 0 is better functional ability 
Clinical Bath Ankylosing Spondylitis 6 items - AS disease activity. 
Disease status Disease Activity Index - Response - 6x 10cm horizontal visual analogue scale (VAS) (anchors 
BASDAT 'none' and 'very severe'). Mean of items 5 and 6, plus items 1-4; 
(Garrett et al, 1994) total divided by 5. Score 0-10; 0 is less disease activity. 
Clinical Body Chart in Ankylosing Global bodily pain. 
Pain Spondylitis Patient sketches area/areas of 'current or present paire. Each area 
(Dziedzic, 1997) scored (range 'I - mild' to '4 - very severe'). Final score is surn of 
pain intensity scores. Score 0+-, 0 is no bodily pain. 
Disease specific Ankylosing Spondylitis 18 items - AS-specific IIRQL 
Psychometric Quality of Life - ASQoL Response'Yes'or Wo'. 
(Doward et al, 1998) Score 0-18; 0 is better I IRQL 
Disease Specific Patient Generated Index - Up to 5 'most important' areas of life affected by AS identified. 
Individualised Ankylosing Spondylitis Areas scored on 10 point descriptive scale (range 0 -'the worst you PGI-AS could imagine' to 10 -'exactly as you would like to be'). 
Points spent to reflect relative importance of each problem. 
Index score calculated (0-100); 0 is a worse level of AS-related 
quality of life. 
Generic Short Form-12 Health Survey Shortened version of the SF-36.12 items with Likert type responses 
Psychometric - SF-12 - produce physical and mental component scales. 
(Ware et al, 1995) Score 0-100; 0 is worse IIRQL. 
Generic EuroQol Quality of Life Scale EQ-51): expresses HRQL in a single index score. 
Utility - EuroQol Covers 5 dimensions of health - mobility, self-care, rolelmain 
(The EuroQol Group, 1990) activity, family and leisure activities, pain and mood. 
Score -0.59-1.0; 1.0 is best HRQL 
lbermometer measure of health status separately represented on a 
vertical 20cm Viermometer' scale. 
Score 0-100; 0 worst perceived possible health state. 
Clinical Modified Schober Index Distance between two marks placed 15cm apart in standing (10cm 
Lumbar flexion (15cm) proximal and Scm distal to the PSIS) following maximal forward 
(Macrae & Wright, 1969) flexion of the spine (plastic tape measure) 
Clinical Fingertip to floor distance Distance between tip of right middle finger and the floor following 
Trunk mobility (trunk forward flexion) maximal lumbar flexior4 whilst maintaining knee extension. 
Measured with a retractable steel tape measure. 
Clinical Lumbar lateral flexion Distance between tip of ipsilateral middle finger and floor following 
Lumbar mobility maximal lateral flexion. maintaining heel contact with floor and 
without trunk rotation. Measured with a retractable steel tape 
measure. 
Clinical Tragus to wall distance Horizontal distance between right tragus and wall in standing, knees 
Upper cervical extended and chin drawn in. Measured with a retractable steel tape 
spinal posture measure. 
Clinical Cervical rotation The difference between tip of the nose and ACJ in sitting (neutral): 
Cervical mobility difference between neutral position and maximal rotation to 
ipsilateral side calculated for right/left rotation- Measured with 
plastic tape measure. 
Table 4.1 Patient-based and anthropometric study instruments. 
posterior views) onto which patients sketch or draw the area or areas of 'current or 
present'pain (Appendix 3). Each area is scored from a four-point ordinal scale 
(I=mild pain to 4= very severe pain). Areas are totalled; a lower score indicates less 
bodily pain. There is no maximum score. The Body Chart has been tested in a clinic- 
based study and preliminary evidence suggests satisfactory measurement properties, 
acceptability and feasibility (Dziedzic, 1997). Although not previously applied in a 
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self-completed format, the instrument is not complicated and it was considered 
suitable for inclusion in the postal survey. 
The ASQoL is a newly developed AS-specific measure of HRQL following a closed 
item format and needs-based model of assessment (Helliwell P. - personal 
communication, 1998; Doward L. (Galen Research) - personal communication, 
1998)(Reynolds et al, 1999). The instrument was developed following patient-based 
interviews but published detail is not yet available. It consists of 18 items with 
dichotomous response options (yes / no) (Appendix 3). Items are totalled (0-18); a 
lower score indicating a better level of AS-specific HRQL. This is the first AS- 
specific measure of HRQL to be identified and was therefore, with the permission of 
the developers (Galen Research), incorporated into the package of outcome measures. 
The PGI-AS (Chapter 3) was incorporated in the package of instruments to provide 
the first individualised measure of disease-related quality of life in AS. The choice of 
PGI-AS format for follow-up completion in the clinic or postal survey was dictated by 
the practicalities of entering baseline data into the follow-up questionnaires. The 
'closed' and 'informed and open! formats required all baseline areas (step 1) to be 
manually entered into the follow-up questionnaire. This was the responsibility of the 
lead investigator (KLH). Fewer patients participated in the clinic based test-retest 
survey; therefore, all patients completed the 'informed and open! format of the PGI- 
AS. Respondents to the two-week postal survey were randomly assigned to receive 
Vind' or 'closed' formats. Respondents to both clinic and postal surveys at six months 
completed either'blind'or'informed and open! formats. A decision not to include the 
'closed' format at six months was made to reflect the open nature of the PGI-AS and is 
discussed further in Chapter 7. 
Generic instruments 
Generic instruments have not been widely applied in AS, but six generic patient-based 
instruments including three health profiles and three utility measures were identified 
in the review (table 2.9). There is limited evidence for their measurement properties 
in AS and all instruments are very long, and therefore not acceptable for inclusion in 
the paticnt-complcted package of instruments proposed for the comparative study. 
For example, the Sickness Impact Profile (SIP)(Bergner et al, 1976) contains 136 
items and the Short-Form 36-item Health Survey (SF-36)(Ware, 1997) contains 36 
147 
items. The utility measures are specifically designed for cost-benefit studies and 
involve complex and time-consuming procedures (Carr, 1996) and are not practical 
for use in the proposed study. 
The need for a short, comprehensive instrument required a further literature search 
and the Short Form 12-item. Health Survey (SF-12)(Ware et al, 1995) and the EuroQol 
(EuroQol group, 1990) were identified. The two instruments represent quite different 
approaches to assessing overall health: the SF- 12 is a health profile and the EuroQol 
(EQ-5D) a utility measure. There is debate over which is the most appropriate in 
evaluation (Jenkinson et al, 1996) and so both were included in the study. Although 
not applied in patients with AS both instruments have good evidence of development 
and measurement properties and have been applied in the evaluation of patients with 
disease of similar nature to AS (Hurst et al, 1997,1998; Ruta et al, 1998; Coons et al, 
2000). The SF-12 is a shortened version of the SF-36, containing only 12-items with 
Likert type responses. It is based on the psychometric approach to instrument 
construction and produces two summary scales (physical and mental health) with a 
score range based on the general population (range 0-100, mean 50, standard 
deviationIO), where a higher score indicates a better HRQL. It takes approximately 
one to two minutes to complete and covers two sides of A4 paper. The EuroQol is 
based on a model including health state valuations and has greater potential for 
application in economic evaluation (Garratt, 2000). It contains two sections; the first 
(EQ-5D) has five items covering the domains of mobility, self-care, usual activity, 
pain / discomfort and anxiety / depression. Each item has a three-point response scale 
(1= no problems to 3= inability / extreme problems). In total 243 possible health 
states (35) are reflected by the EQ-513 and weighted values generated by a healthy 
population have been calculated. The index score rates HRQL on a continuum 
between -0.59 and 1.00, where 1.00 is perfect health, but a score of less than 0 is a 
state worse than death. The second section includes a vertical thermometer on which 
the patient records their overall perceived health 'today' (0 = worst imaginable to 100 
= best imaginable). The multi-dimensional generic nature of the SF-12 and EuroQoI 
cover many of the issues addressed by the several domain-specific instruments also 
listed in table 2.9, and so these instruments have not been considered further. 
The choice of generic instruments has recently been supported by a comparative 
review of evidence supporting the development and measurement properties of the 
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most widely applied generic'quality of life' instruments (Coons et al, 2000). A high 
level of evidence for the SF-36 beyond that available for other profile instruments 
such as the SIP, the Nottingham Health Profile (NHP)(Hunt et al, 19 8 1) and COOP 
charts (Nelson et al, 1987) was found, and the EuroQoI was found to be comparable 
to other utility instruments. 
The same version of each patient-based instrument was incorporated into a self- 
administered questionnaire to be completed in both clinic and postal surveys 
(Appendix 3). Demographic information relating to age, gender, AS symptom 
duration, year of AS diagnosis, employment status, extent of education, and marital 
and housing status was requested. In addition, patients were asked to report if they 
had required any assistance in completing the questionnaire. The same versions of the 
PGI-AS and Body Chart were interview-administered in the clinic survey. 
Anthropometric measures were included in the -clinic survey only. 
4.4 Aims and objectives 
The study aims to evaluate the selected patient-based and anthropometric measures of 
outcome in patients with AS to determine if each instrument fulfills its proposed role 
given the established evidence and claims of the developers. The study will also 
provide the first evidence in support of the measurement properties, acceptability and 
feasibility of the PGI-AS- 
The primary aim of the study is to provide an empirical comparison of evidence in 
support of the measurement properties, acceptability and feasibility of all selected 
instruments in the described population. The objectives are addressed in subsequent 
chapters and are as follows: 
1) To assess the data quality, scaling assumptions and reliability of the study 
instruments (Chapter 5) 
2) To assess the validity of the study instruments (Chapter 6) 
3) To assess the responsiveness of the study instruments (Chapter 7) 
A further aim of the study will be to provide additional evidence in support of a 
standardised and evidence-based package of patient-based and anthropornetric 
measures of outcome for use in AS evaluation in clinical research and routine 
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practice. Results will be considered in light of the state of health care evaluation in 
general and specifically within AS. 
4.5 Patient population 
Patients with AS are generally referred to specialist centres for diagnosis and 
management. All rheumatology centres approached for participation in the survey 
were identified as centres of excellence in the management of AS. The study 
population is expected to represent a wide disease spectrum of diagnosed disease. 
4.5.1 Inclusion and exclusion criteria 
Patients diagnosed by rheumatology specialists have a greater likelihood of 
conforming to established diagnostic criteria (Gran & Husby, 1998) and all 
rheumatologists confirmed a primary diagnosis of AS (Modified New York Criteria - 
van der Linden et al, 1984) (table 4.2). 'Probable' or'possible' AS was excluded. 
Modified New York Criteria for AS 
Clinical Criteria Grading 
Low back pain >3 Limitation of the lumbar Limitation of chest Definite -x-ray plus I 
months spine in frontal and expansion (age/sex clinical criteria 
sagittal planes related) Probable -3 clinical 
criteria 
X-Ray criteria Grading 
Sacroiliitis >/= grade 2 bilaterally or grade 34 unilaterally Definite -x-ray plus I 
clinical criteria 
Probable - x-ray criteria 
Table 4.2 Diagnostic criteria (van der Linden et al, 1984). 
Patients were also excluded if they fulfilled any of the conditions listed in table 4.3. 
Unaided questionnaire completion was required for both postal and clinic surveys, 
and an understanding of the English language was important 
Exclusion criteria Reason in support of exclusion 
'Probable' or 'possible' AS Unclear diagnosis 
Pregnancy Impact of pregnancy on HRQL 
Inability to comprehend the English language Inability to sclf-complctc questionnaire 
Lcarning difficultics 
Less than 18 years of age Juvenile expression of AS 
More than 75 years of age ? influence of co-morbidity on HRQL 
? ability to complete questionnaires unaided 
Table 4.3 Survey exclusion criteria. 
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4.6 Clinic survey 
The clinic survey comprised a six-month longitudinal study and a separate two-week 
test-retest study. The patient population is described in section 4.6.1 and section 4.6.2 
describes the process of attaining ethical approval. Section 4.6.3 describes the pilot 
study and sections 4.6.4 and 4.6.5 describe patient recruitment for the longitudinal 
clinic and test-retest survey respectively. The response rates for both surveys are 
reported in sections 4.6.6 and 4.6.7 respectively. 
4.6.1 Patient population 
100 AS patients were required for the longitudinal clinic survey and 50 additional AS 
patients for the test-retest study. The number of patients provided a figure that was 
achievable within study resources but was also comparable to, and in excess of many, 
other studies evaluating the performance of outcome measures in AS (Chapter 2). 
Resource limitations were influenced by the necessity for the lead investigator (KLH) 
to recruit all patients, perform the majority of baseline assessments and all two-week 
and six month assessments. Also, assessments were limited by the availability of 
clinic space at the SRC and the four month recruitment period (December 1998- 
March 1999). 
The SRC provided the focus for patient recruitment for all clinic-based stages of the 
study, the pilot postal survey and partial recruitment for the postal survey. The SRC 
has close ties with the community and has a large AS patient database. Permission to 
locate the study at the SRC was granted by Dr Peter Dawes, Consultant 
Rheumatologist and Clinical Director of the Locomotor Directorate (North 
Staffordshire Hospital Trust). As a check for the validity of the SRC database the 
computer-based records of all patients were checked by the lead investigator (KLH) 
for the confirmed diagnosis of AS before including patients in the sampling frame. 
4.6.2 Ethical approval 
Once permission to approach patients had been gained from all consultant 
rheurnatologists at the SRC ethical approval for the study was sought. The North 
Staffordshire local research ethics committee (LREC) was initially approached to 
grant study approval for the development and testing of the PGI-AS (Chapter 3) and 
the clinic survey. Permission was granted in April 1998 (Appendix 4). 
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4.6.3 Pilot study 
Before the main study the self-completed and interview-administered questionnaires 
were tested for ambiguity, acceptability and feasibility. The assessment was intended 
to be a reflection of normal practice and an acceptable level of respondent and 
clinician burden was sought. 
To retain the integrity of the normal clinic format patients were required to attend the 
clinic 30 minutes before their designated appointment, during which time informed 
consent was attained and the self-administered questionnaire completed (table 4.1). 
Questionnaire completion was based upon times reported by other investigators. 
Patients could request assistance from the lead investigator (KLH) and any assistance 
was noted. 
Interview-administration of the study instruments was developed to closely 
correspond with normal physiotherapy clinic practice at the SRC (Dziedzic K. - 
personal communication, 1998). During a standard 20-minute period a selection of 
patient-based and anthropometric measures are completed and other issues deemed 
necessary by the patient and therapist discussed. The research assessment was 
incorporated without detracting from information normally gained or adding to the 
time requirement. The Body Chart was already incorporated into the regular 
assessment at the SRC, further justifying its inclusion in the study. The addition of 
the PGI-AS was the only major change to the usual format and pre-pilot evaluation 
had supported the feasibility of its incorporation (Chapter 3). The five anthropometric 
measures (table 4.1) differed slightly to those routinely incorporated in the clinic 
assessment. However, available evidence and a pre-pilot evaluation of their 
feasibility supported their use in the study (section 4.2). 
Doctor and physiotherapist led clinics run in parallel during the weekly SRC 
seronegative spondyloarthropathy clinics and provided the focus for the longitudinal 
clinic survey. All patients attending the physiotherapy clinic were assessed by the 
senior physiotherapist (JW) and all patients attending the doctors clinic were assessed 
by the lead investigator (KLH) after visiting the doctor. 
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Six consecutive AS patients were identified from the computer-based list of 
appointments and asked to participate in the pilot study (mean age 42.5 yehrs, SD 
8.26; range 31-56 years). The same approach for patient recruitment was adopted in 
both the pilot and main study and is detailed in section 4.6.4. Five patients responded, 
but one patient was unable to take part due to illness unrelated to AS (n--- 4; mean age 
43.75 years, SD 10.62; range 3145 years). There was no significant difference in age 
between responders and non-responders (t-test p= 0.12). Three patients attended the 
physiotherapy clinic and one patient attended the doctors clinic. 
Following completion of the pilot study patients and the physiotherapist (JW) were 
subsequently interviewed. No problems were found and the main study followed the 
same format as that described for the pilot study. Therefore, patients were included in 
the data collection for the main clinic survey and followed-up at six months. 
4.6.4 Patient recruitment - longitudinal clinic survey 
At the SRC patients are usually followed up over a six or 12-month period, as the 
patients condition dictates (Dziedzic K. -personal communication, 1998). Therefore, 
the clinic survey involved patient assessment at baseline and six months with an 
experienced physiotherapist (Baseline JW and KLH; six-months KLH). 
Consecutive patients were identified from the computer-based list of clinic 
appointments. This list was effectively a random sample of patients registered with 
the SRC and attending the clinic during the four-month recruitment period. The 
initial approach to all patients was from a consultant rheurnatologist from the SRC 
(Dr. Peter Dawes). A patient information letter, information sheet, informed consent 
form (Appendix 5) and a reply-paid envelope was sent to patients attending the clinic 
four weeks before their appointment date. All envelopes, patient names and 
investigator signatures were individually hand-written. Non-responders were sent 
reminders after two weeks and again one week before the appointment date (McColl 
et al, 1998). Patients not wishing to participate were asked to return the pre-coded 
consent form in the reply-paid envelope. 
An additional random sample of patients was taken from the SRC database to increase 
recruitment ('research clinic'). These patients reflected those not included on the 
above clinic list and those not included in the registers of the local branch of the 
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National Ankylosing Spondylitis Society (NASS) and the weekly AS exercise group 
identified below (section 4.6.5). Appointment times ranging from two to four weeks 
after the letter was posted were listed and patients asked to nominate a date and time 
(a tick box option) or to indicate a preferred appointment in writing. Appointments 
were confirmed by telephone. Patients not wishing to participate were asked to return 
the pre-coded consent form. Non-responders were sent reminders and revised 
appointments at two weeks and again after four weeks. The lead investigator (KLH) 
performed all baseline and six-month follow-up assessments with these patients. 
For the duration of the study all patients received their usual care. Patients were 
assured that they were not obliged to participate in the study and were free to leave 
the study at any time should they choose to do so. 
Six-month follow-up appointments were designed to coincide with other clinic 
appointments. A letter was sent to all patients four weeks before the clinic 
appointment date, and at two-weeks and one-week before the appointment for non- 
responders. Where pre-arranged clinic dates were not available letters were sent four 
weeks before the six-month point, with appointments ranging from one week before 
to one week after the six-month date (tick-box format). Patients were asked to 
nominate a date and time or to indicate a preferred appointment in writing. All 
appointments were confirmed by telephone. Non-responders were sent reminders 
with revised appointments after two weeks and again after four weeks. Patients no 
longer wishing to participate in the study were asked to return the pre-coded consent 
form. 
All six-month assessments were performed by the lead investigator (KLH) following 
the same forniat as baseline assessments and were performed at a similar time of day. 
Two six-month health transition questions relating to general health and to AS- 
specific health were included in the self-administered questionnaire ('Compared to 
six-months ago how would you rate your health in general / Ankylosing Spondylitis 
now: much better, somewhat better, about the same, somewhat worse, much worse? '). 
4.6.5 Patient recruitment - test-retest survey 
To assess the two-week test-retest reliability of the study instruments in a clinic 
environment, a group of AS patients whom regularly attended the SRC was identified. 
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This sampling frame consisted of members of the Stoke-on-Trent branch of NASS 
attending weekly self-help group meetings and patients regularly attending twice- 
weekly AS exercise classes. The president of the local NASS branch (Mr. Ted 
Brown) was approached in writing to ask permission to approach members of the 
group for participation in the study and to request a copy of the branch register. All 
members were also registered with the SRC and diagnosis of AS was confirmed. This 
sampling frame represents a select group of patients with AS who were active 
participants in regular exercise and self-help groups. This was considered the most 
feasible and cost-effective approach to both patients and the study and one 
representative of normal practice. 
A simple random sample of patients was identified from the combined register and 
patients approached in writing to request their participation in the study. A choice of 
baseline and two-week appointments were listed and patients encouraged to identify 
both appointments, preferably at the same time of day. Non-respondents were sent 
reminders with revised appointment dates at two and four weeks. Patients not 
wishing to participate in the study were asked to return the blank pre-coded consent 
form. Appointments were designed to coincide with the weekly Tuesday/Thursday 
AS exercise groups and the Wednesday evening NASS group held at the SRC. To 
limit the potential interruption of the exercise classes appointments were also offered 
before and after classes. All appointments were confirmed by telephone. Patients 
were reminded of their two-week appointment at the baseline assessment. 
At the two week follow-up assessment health transition questions relating to general 
health and AS-specific health were included in the self-administered questionnaire 
('Compared to two-weeks ago how would you rate your health in general / 
Ankylosing Spondylitis now: much better, somewhat better, about the same, 
somewhat worse, much worse? '). 
4.6.6 Response rates - longitudinal clinic survey 
In total 189 patients were identified, 102 from the additional research clinic, 42 from 
the doctors clinic, 39 from the physiotherapy clinic and 6 from the pilot study (table 
4.4). Of these 36 (19.0%) failed to respond and 45 (23.8%) refused to take part. 
Thus, 108 patients agreed to take part in the baseline survey giving a final response 
rateof57.1%. The majority of patients were male (n-- 87,80.6%) with a mean age of 
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49.62 years (SD12.51, range 20 to 74 years)(table4.5). AS symptom duration ranged 
from I to 58 years (mean 20.34 years, SD 10.14) and the duration of diagnosis ranged 
from I to 49 years (mean 15.5 years, SD 11.78)(n7-- 100). 
Pilot study Doctors clinic Physiotherapist Additional Total 
clinic 'research' clinic 
n % n % n % n % n % 
Total population 6 42 39 102 189 
Non-response 1 16.6 9 21.4 4 10.2 22 21.5 36 19.0 
Refusal 1 16.6 7 9.5 10 25.6 27 26.5 45 23.8 
Patients taking 4 66.7 26 61.9 25 64.1 53 52.0 108 57.1 
part 
Table 4.4 Baseline response rate for longitudinal clinic survey 
To test for response bias, patients who failed to respond or refused to participate were 
compared with respondents in age and gender (table 4.5). 69 (85.2%) of the non- 
responders were male (Chi-square p= 0.41, non-significant difference). The mean age 
of the non-responders was 42.40 years (SD 12.44, range 20-75) and although a similar 
age range was covered a statistical difference in the ages of responders and non- 
responders was calculated (West p< 0.000 1). 
Responders (n-- 108) Non-responders (n-- 8 1) 
Gender 
male (n) 87 (80.6%) 69 (85.2%) 
female (n) 21 (19.4%) 12 (14.8%) 
Age (years) 
mean (SD) 49.62 (12.51) 42.40 (12.44) 
median 49.50 42.0 
range 20-74 20-75 
Table 4.5 Responders and non-responders to the longitudinal clinic survey at baseline. 
Almost 80% percent of the clinic population were married or co-habiting (table 4.6). 
Total 
Clinic population n% 
Married / co-habiting (n-- 77) 60 77.9 
Employed / self-employed 60 56.6 
Retired 26 24.5 
Not working due to ill-health 15 14.2 
Continued education after minimum school leaving age 48 45.3 
Degree or equivalent 25 23.6 
Table 4.6 Demographic information for longitudinal clinic survey (n-- 106), 
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56.6% of the population were in employment and 24.5% were retired, with only 
14.2% of patients unable to work due to ill-health. These figures are comparable to 
the demographic data from the larger postal survey (section 4.7.6). 
Although six-month follow-up appointments were intended to coincide with pre- 
arranged clinic dates this proved to be difficult due to the forced re-arrangement of 
many clinics and alternative research appointments to facilitate attendance were 
offered. Of the 108 patients sent an appointment 13 (12.0%) failed to respond and 7 
(6.5%) refused to take part giving a final response rate of 88 patients (81.5%)(table 
4.7). A good response was observed for all groups, with the highest response rate in 
those patients identified in the additional research clinic (86.8%). 
6-month Pilot study Doctors clinic Physiotherapist Additional Total 
Response rate clinic research clinic 
n%n%n. %n%n. % 
Total population 4 26 25 53 108 
Non-Tesponse 004 15.4 5 20.0 6 11.3 13 12.0 
Refusal 0027.7 2 8.0 1 1.9 7 6.5 
Patients taking 4 100 20 77.0 18 72.0 46 86.8 88 81.5 
part 
Table 4.7 Six-month response rate for longitudinal clinic survey. 
When compared to the baseline responders a very similar gender ratio (male n-- 71, 
80.6%) and a slightly lower mean age of 47.02 years (SD12.58; range 20 - 74) was 
observed for the six-month population. 88 of the 108 patients measured at baseline 
also participated in the six-month follow-up clinic survey. The mean age of 
responders to both baseline and six-month surveys was 49.97 years (SD 12.87; range 
20-74 years). A non-significant difference to those who only participated in the 
baseline survey was calculated (n-- 20; mean age 48.10 years, SD 10.96, West 
p--0.55). There was no significant difference in gender (Fisher exact test, p= 0.58). 
4.6.7 Response rates - test-retest survey 
In total 88 patients were identified to take part in the test-retest survey. Six patients 
were found to be participants in the larger clinic study and so were omitted from the 
test-retest sampling frame. Unfortunately one patient had died but the hospital 
records had not been updated. In addition, two patients had moved house and had no 
forwarding address and one further patient agreed to participate but was unable to 
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identify a date within the time frame of the study. A corrected total sampling frame 
of 80 with a corrected response rate of 51 (63.7%) was achieved (table 4.8). 
Response rate Baseline 2-week 
n % n % 
Total population 80 51 
Non-response 6 7.5 3 5.9 
Refusal 23 28.7 3 5.9 
Patients taking part 51 63.7 45 88.2 
Table 4.8 Response rate for test-retest clinic survey. 
45 of the 51 patients measured at baseline returned for their two-week assessment. 
Three of the six patients who failed to attend at two weeks contacted the lead 
investigator to excuse themselves due to illness. The additional three patients failed 
to contact the research team. 
The majority of patients participating in this study were male (baseline n7- 45 (90%), 
2-weeks n-- 41 (9 1 %)) and the age range covered by the baseline population was 27 to 
70 years (mean 47.7, SD 11.34). There was no significant difference between the 
mean ages of patients taking part in the baseline or two-week assessments. Patients 
reported a wide range of symptom duration (2 - 49 years; mean 21.4, SD 10.9) 
suggesting a broad spectrum of disease presentation covered by the population. 
To test for response bias, patients who failed to respond or refused to participate in the 
survey were compared with respondents in age and gender. 27 of the 29 non- 
responders were male and the mean age of non-responders was 43.6 years (SD 9.21). 
There was no significant difference between responders and non-responders in gender 
(Fisher exact test, p= 0.49) and age (West p =0.12). 
4.7 Postal survey 
Section 4.7.1 describes the postal survey patient population and the pilot study is 
described in section 4.7.2. Sections 4.7.3 and 4.7.4 describe the multi-centre nature of 
the study and acquisition of ethical approval respectively. Patient recruitment is 
described in section 4.7.5 and response rates are detailed in section 4.7.6. 
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4.7.1 Patient population 
A population of more than 400 patients were required for the postal survey. There are 
no published sample size tables for developing and testing patient outcome measures. 
I fence the planned size of this study has been based on the published work of my 
supcnisors, Dr. Andrew Garratt and Professor Ian Russell (Garratt et a], 1996a; Ruta 
ct al, 1999). In addition, the number of patients presented a figure that was achievable 
%ithin the study resources and one that %%-as comparable to, and in excess of many, 
other postal surveys of patients with AS, in particular those evaluating measures of 
outcome (Chapter 2). The numbermas also comparable to the number used in the 
PGI developmental work %%ith a population of patients with low back pain (Ruta et al, 
1994a). Resource limitationswcrc also influenced by the necessity for the lead 
investigator (KLII) to recruit all patients (February - May 1999), to send, collate and 
record all questionnaires, and to input all data. 
A multi-centrc study was rcquircd to identify sufficient patient numbers. ne main 
sampling framc is dcscribcd by a random sample of patients 'Mth diagnosed AS 
rcgistcred %%ith specialist ccntres orthcumatology in England and Scotland. Patient 
inclusion and cxclusion critcrion (section 4.5.1) %%ms confirmed by participating 
consultant thcumatologists. As a check for the validity of the patient databases, the 
records oran patients from two participating centres (Southmead Hospital, Bristol - 
Dr. Paul Crccmcr. SRC-KLI I) %%-crecvaluatcd to confirm fulfilimcnt of diagnostic 
critcria. 
4.7.2 Approach to specialist ccntrcs of rheumatology 
Seven cstablishcd thcumatology centrcs, identified due to their internationally 
rccogniscd research activity in thcumatology and AS, %vcrc targeted for participation 
in the postal survey. It %vas considered that such ccntrcs would possess accessible 
patient databases and would provide a population that was not confined to one 
particular geographical rcgion. 
Lcttcrs describing the purpose of the study and requesting the participation of the 
centrc %, crc scnt to an idcntiricd consultant thcumatologist for cach centrc. 
Consultants %%ho %%vrc %Wling to pcrmit access to their paticnt database were asked to 
complete a short questionnairc (Appcndix 6). This rcquestcd information about the 
paticnt population, the t)Toe ordatabasc used and accessibility of information. 
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Confirmation that other rhcumatologists %ithin the ccntre were happy for their 
patients to be involved in the proposed study and that relevant management approval 
would be granted -mas also requested. 
Follo%%ing agrccment to participate in the study by the consultant rheumatologist, 
contact was made %%ith a scnior chartered physiotherapist within the same department 
Ilis was considcrcd bcncficial to proNide an accessible contact for all patient 
participantsý should such contact be requircd. 7"he physiotherapist would act as a 
source of hclp in cases of difficulty or %,. -here adNise was required. For the duration of 
the study cach physiothcrapist was contacted on a wcckly basis to identify any patient 
querics that rcquircd follow-up by the lead investigator (KLH) or to identify any 
problcms %%ith the study. 
4.7.3 Ethical approval 
Oncc the consultant thcumatologists had granted permission for access to their patient 
database, ethical approval was sought. Tbc research project took place %vithin six 
ccntrcs %ith diffcrcnt geographical boundaries and approval by the Multi-Ccntre 
Research Ethical Committcc (hIREC) was required. Following approval from the 
Northern and Yotkshirc NIREC in Dcccmbcr 1998 approval from Local Research 
Ethical Committccs (LREQ for cach participating ccntrc %vas sought. To reduce 
consultant burdc-n all LREC applications %%, crc complecd by the lead investigator 
(KLI 1) and signcd by the Icad thcumatologist. Ile postal survey commenced 
follo%ing LREC approval (Fcbruary to November 1999). 
Follo%ing NIREC approval the lead invcstigator (KLII) made a personal visit to the 
Icad thcumatologist and participating ph)-siothcrapist for cach ccntrc. The meeting 
providcd a forum %%ithin %%hich the rclationship bct%tcn participating ccntres and the 
Icad invcstigator could be dc%-clopcd. The aims, objectives and study requirements 
%%vrc discussed and the patient population for each ccntrc identified. 
4.7.4 Pilot study- postal sun-ey 
71w postal survcy scir-administercd questionnaire %%-as the same as the clinic survey 
uith the addition of the Body Chart and PGI-AS (table 4.1). Evidence and experience 
from the clinic survey (section 4.6) suggested a completion time of approximately 30- 
minutcs. 
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Six AS patients %%trc randomly selected from the SRC database (mean age 46.00 
years, SD 10.12; range 29-5 8 years). A patient information letter, consent form and 
self-completed questionnaire N%-js mailed to each patient. Patients were asked to 
complete the questionnaire and to return it in a reply-paid envelope to the SRC. Non- 
responders %%vm sent reminders after two and four weeks. A complete package of 
information %%-as sent on each occasion. Patients not wishing to participate were asked 
to return the prc-coded blank consent form. All patients responded (January 1999). 
I lo%%-cvcr, one patient was unable to participate due to family illness and a second due 
to work commitments. All four remaining patients completed the questionnaire 
correctly (mean age 43.75 years, SD 10.62; range 29-52 years) and a non-significant 
difference in age between responders and non-respondcrswas calculated (p= 0.50). 
The high response rate suggested an acceptable self-administered format and no 
changcs, w-crc made. 
4.7.5 Patient recruitment 
From a total of seven centrcs; approached, six expressed their wi1lingness to 
participate in the study (Appendix 7). For ccntreswith a large register (Glasgow, 
South Cleveland, Cambridge) a simple random swnple of patients was identified 
(table 4.9). ror the rcmaining ccntrcs (Bristol and Cannock) the total population were 
includcd in the study. Thosc patients from the SRC not previously selected for 
participation in carlicr stages of the study %%-crc included in the postal evaluation. 
Centre Tcgal AS pqmlabon (n)_ Rand(xn umple (n) Corrcctcd popqation (n) 
tulso 63 65 65 
CwnbWgt 140 110 110 
43 43 45 
Glasgow Igo 110 100 
Satals Cleveland 193 110 103 
Sk)kt 373 29 28 
Toal 99% 469 451 
Table 4.9 Patient population registcrod %ith postal survey thcumatology ccntres. 
Of the 469 randomly idcntiricd paticrits, a total of 15 questionnaires could not be 
dcli%-crcd by the post office (Glasgo%v n- 8, South Cleveland n- 7), and two patients 
from Glasgow and onc from Stokc had dicd but had not been removed from the 
databasc. The corrccled bascline total population is 451. 
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The initial approach to patients, %ý-as from the consultant rheumatologist acting as lead 
contact for each hospital. A letter and patient information sheet summarising the 
study requirements were sent to each patient to explain the purpose of the study and to 
request their participation (Appendix 8). The letter requested that should the patient 
be in agrccment to participate in the study, their name and address could be released 
to the lead investigator (KLH). 
All cn%-clopcs and patient names %, crc hand-%Titten. All baseline letters were signed 
by the respective consultant rheurnatologist. The initial approach to patients also 
included the sclkompletcd questionnaire (table 4.1) and a patient informed consent 
form (Appendix 8). Patients %%-crc asked to return the completed consent form and 
questionnaire to the SRC in the reply-paid envelope. The act of returning the 
completed items indicated that the patient %%-as willing to participate in the study 
further. Subsequent patient contact was addressed from the lead investigator, 
although rcrcrcncc to the respective rhcumatology team %%-as always made. Patients 
not %ishing to participate w-crc asked to return the pre-coded blank questionnaire and 
consent form in the rcply-paid envelope. Non-responders were sent reminders after 
two and again aflcr four %%-ccks. Evidence suggests that the low response rates 
associated %%ith single approaches to patients may invalidate the results of a postal 
survey (Bowling. 1997). 
Follow-up qucstionnaircs wcrc scnt to all participants at two wccks to asscss test- 
rctcst rcliability and at six months to assess responsiveness. Colourcoded 
questionnaires were sent to clarify the different assessments. Two-wcck and six 
month health transition questions rclating to general health and AS-rclated health 
u-cre included in the respective questionnaires (sections 4.6.5 and 4.6.4 respectively). 
At six months questionnaircs %%-crc scnt to all basclinc rcspondcrs (n= 348). 
4.7.6 Response rate- postal survey 
From a corrected baseline population or451,71 (15.7%) failed to respond and 31 
(6.9%) refused to take part. Thus, 349 patients agreed to take part in the study, giving 
a baseline response rate or 77.4% (table 4.10). 
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B"dine Diistol Cam btidge Can nock Glasgow Sotah 
Cleveland 
Stoke Total 
population 
a % Im % u % n% n % n% It % 
Total 65 Ito 45 100 103 28 451 
pymbtma 
Non- 
fe mw 
7 109 11 10.0 9 20.0 13 13.0 26 25.2 5 17.9 71 15.7 
q 
Refinal 4 6.2 5 4-5 0 0 10 10.0 6 5.8 6 21.4 34 6.9 
Pauem 54 33A 94 853 36 90.0 77 77.0 71 69.0 17 60.7 349 77.4 
takino ran 
Table 4.10 Postal survey baseline response rate 
At two %%rcks 303 patients agreed to take part in the survey (87.1%Xtable 4.11). The 
Post Officc returned a questionnaire from a patient from South Cleveland who had 
participated in the baseline evaluation but provided no forwarding address. The 
corrected population total at two %vccks is 348. 
2-%v& "Fugol Cam bndge ca mock Glusow South 
Clewland 
Stoke ToW 
population 
a% n % 0 % n% n% n% n% 
Total 54 94 m 77 70 17 348 
pqVIstion 
Now 
M low 
7 12-9 7 74 2 5.5 5 6.4 8 11.4 5 29.4 34 9.8 
-p 
Refusal 2 17 4 4.3 0 0 2 2. $ 3 4.3 00 11 3.2 
petwo 45 81,3 83 98.3 34 94.4 70 90.9 59 84.3 12 70.6 303 87.1 
ukn* PWI 
Table 4.11 Postal sunvy 2-week response rate 
All 348 basclinc rcspondcrs %vcrc sent follow-up questionnaires at six months. 45 
(13.2119) failcd to rcspond and 14 (4.00/, o) refused to take part, giving a response rate of 
289 paticrits (82.8"NOXtable 4.12). 
6-ftinth 
f"Oft" 
tk u" cambrulet Cannock Glasgow South 
Clc%vbtnd 
Stoke Total 
porKdation 
% a% n % n% n% n % n% 
Total 54 94 36 77 70 17 348 
IVIVIatmin 
NOW 
f"r"" 
8 141 13 138 3 12.0 3 6.5 13 19.7 3 17.6 45 13.2 
R*fwwl 3 56 4 4.2 0 0 4 3.1 2 2.8 1 5.9 14 4.0 
paimsdo 41 796 77 91,9 33 91,6 68 8R. 3 55 77.5 11 76.5 289 82.8 
taking red 
Table 4,12 Posial survey six-month response rate 
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The response rates for all postal centres at baseline, two-weeks and six-months is 
summarised in table 4.13. 
Tow populaLion Paticnis taLng part Non-response 
Reauiumd 0 n% n% 
Bzdine 454 349 76.9 105 23.1 
2-%, ccLs 348 303 87.1 45 13.0 
64nonLbs 348 289 92.8 59 171 
Table 4.13 Summary of postal survey response rates 
The ages of patients participating in the postal survey at baseline mnged from 18 to 75 
years (mean 46.09, SD 12.58). AS symptom duration ranged from I to 56 years 
(mean 19.8 years, SD 11.76), and duration of diagnosis from six months to 52 years 
(mean 13.63 years, SID 11.26Xn= 336Xtable 4.14). This suggests that the population 
covers a %%idc spectrum of disease duration. Ilic mean age of patients from 
Cambridge %%2s younger than all other ccntres (mean 42.07 years, SD 11.04), and the 
oldest population was Glasgow (mean 49.79 years, SD 11.6 1). A statistically 
significant difference between mean age %%-as observed between Bristol, Cambridge, 
Glasgow and South Cleveland (p- 0.002) at baseline. The response rate by gender 
supported a 3: 1 male to f=ale ratio (74.2% males) for all centrcs combined and 
closely resembles the reported gender ratio of between 2.5 to 4: 1 in the British 
population (Kennedy ct al. 1993). There was no statistically significant difference 
bct%%vcn ccntrcs in gender ratio. 
Thc combined age range and gender ratio did not differ significantly between 
responders at baseline, two weeks and six months (table 4.14). 
t)cwaqA&on D&wJuw (0- 149) 2-%vck (n- 303) 6-frmth (n- 289) 
(woluf (nute) 259(74.2%) 223 (73.60/*) 214 (74.0%) 
Apt ()van) 
M, -m NW) 46 09 (12.59) 46.37 (12.70) 46.87 (12.75) 
Mahan 470 46.0 47.0 
ftt*o 19-75 18-75 18-75 
Table 4.14 Descriptive data for postal responders 
To tcst for rcsponse bias at baseline, patients who failed to respond or refused to 
parlicipatc in ft postal survey %%-crc compared %kith respondents in age and gender 
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(table 4.15). Patients not taking part were significantly younger than responders (t- 
test p= 0.001), uith a non-signi fij cant difference in gender (Chi square p= 0.09). 
Rcspooders (n- 349) Non-responden (n7- 105) 
Gcndcr (malt) 259 (74.20/9) 84 (82.4%) 
Ape (years) 
mean (SM 46.09 (1239) 41.36 (12.66) 
median 47.0 40.0 
fww 19-75 18-71 
Table4.13 Responders and non-responders to postal survey at baseline. 
The youngest mean age for non-rcsponders %,., as reported for Cambridge and South 
Clcvcfand4 a similar pattern to that observed for responders (table 4.16). 
11"claw lk"101 CAunbndge Camxxk Glasgow South 
Cleveland 
Stoke Total 
NOW 7 11 9 11 25 6 71 
ftsponse 
Rcfusal 4 3 0 10 9 4 31 
Tout arm. 11 16 9 23 33 10 102 
MIPIVM 
Gcý to 12 9 16 27 10 84 
(n- fmlc) (901%) (75%) 0 (69-51/6) (1001/0) (82.4%) 
Ap () can) 
- Mean (SM 39.19017) 39,900.9) 45.7 (13-02) 45.3 (15.3) 38.9 (12.3) 43.5 (7.5) 41-36 (12.6) 
. fned&an 420 400 47,0 41.3 37.0 44.5 40.0 
- tv"Fe in ., %I IN . 64 20 - A4 20-71 18-66 32-33 18-71 
Table 4.16 Baseline non-responders to postal survey by postal ccntre. 
289 orthc 349 paticnts measured at baseline also completed the 6-month follow-up 
qucstionnairc. The mcan ne orrespondcrs to both baseline and 6-month surveys was 
46.8 ycars (SD 12.77), and a statistically significant difference to those who only 
complctcd the basclinc questionnaire was calculated (mean age 42.46 years, SD 
11.06, t. tcstp-0.013). Thcrc %%-as no signi ri cant di ffercnce in gender (Chi-square p= 
0.81). 
Response by occupation indicated that over 50% of the total population of 
respondents were in employment (54.3%Xtable 4.17) and is in keeping with reports 
from other authors (Ward, 1998). 1 lowcvcr, when ccntrcs were examined 
independently the majority of patients from Cambridge (76.6%) and Bristol (60.4%) 
%%vrc employed, whereas only a minority from Glasgow were in paid employment 
(35.1%). A large percentage of the population from Glasgow (23.4%) and Cannock 
(22.211110) reported being unable to %vork due to ill-health. For the total population this 
pacentage %%2s much lowcr (15.200; ). 
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Total 
Demographic data n% 
Marital status 
Married / co-habiting (n-- 306) 222 72.6 
Single 54 15.5 
Employment status 
- Employed / self-employed (n= 348) 189 54.3 
- Retired 73 21.0 
- Not working due to ill-health 53 15.2 
Educational status 
Continued education aftcr minimurn school leaving age (n=345) 176 51.0 
Degree or equivalent (n-- 34 1) 102 29.9 
Table 4.17 Demographic data for postal respondents. 
4.8 Discussion 
The most economic approach to completion of patient-based measures of outcome is 
postal self-administration within a patients home (Bowling, 1997). This represents a 
relatively inexpensive means of collecting data and the ability of an instrument to lend 
itself to such a format has been suggested as an important feature when intended for 
regular use in health evaluation (Ruta et al, 1994a). Although often a feature of 
research studies (Guyatt et al, 1987b; Abbott et al, 1994; Garratt et al, 2000), there is 
little evidence that postal self-administration is regularly accepted as part of the 
routine practice in AS. Self-completion or interview-administration of instruments 
with in a clinic environment may represent a more pragmatic reflection of normal 
practice within AS evaluation, and both postal and clinic-based completion has been 
addressed in this study. However, less than 50% of rheurnatologists incorporate 
patient-based instruments in routine clinic-based AS evaluation, the evaluation being 
dominated by anthropometric assessment (Bellamy et al, 1998,1999). 
This study describes the first AS-specific comparative evaluation of a systematically 
identified and evidence-based package of patient-based and anthropometric measures 
of outcome in both a postal and clinic environment. The size of both populations is 
comparable to many and larger than most other AS-specific studies with a specific 
intention to evaluate the quality and performance of outcome measures (Chapter 2). 
The response rate for the clinic-based surveys was satisfactory. A greater baseline 
response rate was observed for patients participating in the test-retest study (63.0%) 
than for participants in the longitudinal study (57.1%). The test-retest population was 
approached with the knowledge that patients regularly attended the SRC for self-help 
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exercise classes and the greater response rate may reflect the increased motivation of 
members of a self-help group (Barlow et al, 1993a) or the relative convenience of 
participating in a study. The two-week response for the test-retest study was also high 
(88.2%), and may further reflect the ease with which appointments could be arranged 
to coincide with usual attendance. 
High response rates were observed for the physiotherapy and doctor clinics (range 
61.9 - 66.7%) and may reflect the convenience of participating in a study run as part 
of a routine clinic. The lowest response rate was for the additional research clinic 
(52.0%), the majority of patients attending the clinic in their own time. However, a 
high follow-up response rate was observed for this group at six months which may 
reflect the limited impact of the study on the working day. Patients may also 
represent a particularly motivated group (McColl et al, 1998). Several patients 
indicated that they supported the research but were unable to find the time to attend 
the clinic. In light of this, the overall response rate is good and compares favourably 
with other studies (Fitzpatrick et al, 1993c; Lubrano et al, 1998). The six month 
response rate for the clinic survey was good (81.5%), although loss to follow-up may 
have been associated with difficulty in arranging follow-up research appointments to 
coincide with pre-arranged clinic appointments. No patients were lost due to change 
of address or pregnancy. 
Both groups of clinic patients experienced the same research assessment under similar 
circumstances, thus enabling baseline results to be combined. This provides a revised 
baseline population total of 159 patients (59.0% response rate). Both populations 
cover a similar age range and duration of symptom severity. However, a greater 
percentage of the test-retest survey population were male. This may be a reflection of 
the nature of the exercise classes, having a greater attraction to males with AS. - 
The response rate for the postal survey was very good at all stages of recruitment and 
follow-up, with some individual centres exceeding a 90% response rate. This result 
compares favourably to other studies (Bindman et al, 1990; Ruta et al, 1994b; 
Jenkinson et al,, 1994b). However, there was a statistically significant age difference 
between responders and non-responders at baseline for both the main clinic survey 
(49.62 versus 42.40 years respectively) and the postal survey (46.09 versus 41.36 
years respectively), with non-responders being younger. There was no significant 
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difference in gender. Other studies have reported a similar difference between 
responders and non-responders (Garratt et al, 1993). The peak incidence of disease 
onset is between 25-34 years of age (Carbone et al, 1992) and the bias of responders 
towards the older age group may reduce the generalisability of the result. For 
example, the results may have a greater relevance to patients with more severe 
disease. Limited resources prevented further contact with non-responders to 
investigate reasons for non-response. 
Completion and acceptability of questionnaires may be influenced by many factors. 
For example, time to complete, legibility and understanding of items, appearance and 
complexity of the questionnaire and the possibility of distress when completing 
sensitive items (Fitzpatrick et al, 1998b). Three questionnaires (2 from Glasgow, I 
from Stoke) were returned blank with covering notes written by carers to indicate that 
the patient was blind and unable to self-complete the questionnaire, and is an issue 
that should be considered as future exclusion criteria for studies of AS patients 
requiring questionnaire self-administration. 
The saliency of questionnaire content is an important factor influencing response rates 
in mailed surveys, and the level of importance attributed to the questionnaire by the 
respondent may have a greater influence over response than actual questionnaire 
length (McColl et al, 1998). These issues are of equal relevance to both surveys, and 
have been reflected in the response rates. The self-completed questionnaire mailed to 
patients, or alternatively completed in the clinic, was very long (14 pages) but 
contained specific items considered to be of importance to most patients with AS 
(Appendix 3). The introductory letter to patients indicated the importance of the 
information to be gained from completion of the questionnaire, helping to improve 
understanding of the effect of AS on people with the disease (Appendices 5 and 8). 
The excellent response rates to both surveys supports the fact that many patients were 
happy to share their experiences of the disease and to complete the questionnaire. 
However, several baseline postal questionnaires were returned blank with a covering 
note to indicate that the patient considered their AS to be 'too mild', or 'no longer 
caused them difficulty, and they therefore felt unable to add to the survey (n-- 5). 
This would suggest a perception of irrelevance associated with some items, perhaps 
addressing issues associated with more severe disease, and patients representing the 
less severe spectrum of disease may not be catered for by included items. Several 
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patients returned blank questionnaires at follow-up of the postal survey with a 
covering note to indicate that they'were the same as the last time', and did not provide 
information that could be used in the analysis. Likewise, some patients may have 
been lost to follow-up due to the burden of completing three long questionnaires, or 
the belief that they no-longer had relevant information to add to the study. 
Increasing the saliency of the questionnaire to respondents is an important factor 
influencing response rates (McColl et al, 1998), but there is no consensus on the best 
approach to encourage patients to complete questionnaires when they believe that 
their contribution may be of little value. However, the order of questionnaires within 
a self-completed package may influence completion. For example, patients 
experiencing minimal disease-related difficulties may find an enhanced affinity to 
items contained within generic instruments as opposed to those of disease-specific 
questions, thus facilitating questionnaire completion. Therefore, a revision of the 
order of instruments within the described package should be considered. Similar 
findings have been observed in other studies evaluating the performance of patient- 
based instruments (Grampian Health Outcomes Study (GHOST), Garratt AM. - 
personal communication, 2000). This is an important issue and warrants further 
investigation for measures of outcome intended for evaluative purposes. The 
following chapters consider the measurement properties and relative performance of 
the study instruments within the questionnaire. 
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Chapter 5 Reliability 
5.1 Introduction 
This chapter presents the reliability testing for all study instruments. A definition of 
reliability is given in section 5.2. Criteria that should be considered in the assessment 
of data quality and scaling assumptions at both item and scale level and in the overall 
assessment of reliability is presented. Section 5.3 considers the criteria for data 
quality, scaling assumptions and reliability for all study instruments. After the results 
are presented in section 5.4 the chapter closes with a discussion. 
It is recommended that both practical considerations and measurement properties are 
addressed in pursuit of evidence to support the acceptability of multi-item instruments 
and the standardisation of high quality data (Kosinski et al, 1999a). The development 
and testing of instruments should give consideration to whether data are of sufficient 
quality and scaling assumptions are being met (Gandek et al, 1998a; Ware and 
Gandek, 1998b). Data quality refers to the data completeness and end effects. 
Scaling assumptions refers to empirical evidence relating to the inclusion of items 
within hypothesised scales. These tests have implications for item reduction and 
should take place alongside the tests of internal consistency reliability. 
5.2 Reliability and measures of health outcome 
Reliability is associated with correctness, referring to the ability of a measure of 
outcome to produce consistent, reproducible and accurate results both at one point in 
time and over time when the underlying condition has not changed (Streiner and 
Norman, 1995). The expression of reliability reflects two components: a true score 
alternatively referred to as a'signal', and an underlying level of error ornoise, 
(Streiner and Norman, 1995). Reliability estimates the extent to which an instrument 
is free from error thus reflecting a true score (Fitzpatrick et al, 1998a). 
Two forms of reliability have been widely applied to patient-based instruments: 
internal consistency and test-retest reliability. Items within a multi-item instrument 
intended to address a specified domain of health should all relate to this domain and 
internal consistency reliability describes the level of item homogeneity (Nunnally and 
Bernstein, 1994). The test-retest reliability of an instrument refers to the temporal 
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stability of the resulting scores over time assuming that the underlying condition has 
not changed (McDowell and Newell, 1996). 
The analysis of data quality and scaling assumptions at both item and scale level 
provides evidence of item performance and supports instrument scale construction 
(Gandek et al, 1998a; Ware and Gandek, 1998b; Kosinski et al, 1999a). Interpretation 
of item performance plays an important role in establishing the quality of multi-item 
instruments before consideration is given to instrument internal reliability. For 
example, items with high levels of missing data are not acceptable to patients and 
limits analysis to a subset of patients, therefore introducing bias into the measurement 
Score distribution at both item and scale level shows the range of the defined domain 
covered. Items that have end effects, that is, a large percentage of patients are 
responding in the same way, are of limited value when discriminating between 
patients. Items within a scale designed to address aspects of the same domain should 
be related to each other and to the scale. Analysis of the relationship between items 
and the hypothesised scale can be assessed by principle component analysis and item- 
total correlation. These analyses of item performance support the inclusion of items 
within multi-item instruments and should be undertaken before more general 
measurement properties, including reliability, are assessed. Where appropriate these 
analyses have been adopted in the current study (table 5.1). 
-- ---------------------------------- Item performance Scale performance 
Data quality and scaling assumptions Data quality and scaling assumptions 
- item completion rates - scale completion rates 
distribution of item responses 
frequency of endorsement 
end effects (ceiling I floor) 
equivalence of item means and standard deviations 
Dimensionality 
principal component analysis 
content validity of dimensions 
Itern-total correlation 
- corrected item-total correlation 
distribution of scale scores 
frequency of endorsement 
end effects (ceiling / floor) 
Internal consistency reliability 
- Cronbachs alpha 
Test-retest reliability 
- 2-week test-retest (ICC) 
Inter-observer reliability 
between two or more observers (ICC) 
Table 5.1 Assessment of data quality, measurement performance and reliability of evaluative 
measures of health outcome. ICC = Intra-class coffelation. coefficient 
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The specific tests of data quality, scaling assumptions and reliability of the study 
instruments follow in sections 5.2.1 and 5.2.2. 
Instruments not based on classical test-construction are not amenable to tests of 
internal reliability. For example, instruments based on decision theory or economic 
theory, such as the EuroQol (EuroQol Group, 1991). The PGI-AS and 
anthropometric measures are not based on classical test-construction and are not 
assessed for internal consistency reliability. The reliability of these instruments is 
assessed by test-retest reliability. 
5.2.1 Data quality, scaling assumptions and internal consistency reliability. 
Data quality and scaling assumptions 
Data completeness shows the extent to which patients are both willing and able to 
respond to questionnaire items (Safmn et al, 1998). The frequency with which items 
are omitted or answered incorrectly gives an indication of items that should be 
considered for removal from the scale due to poor completion rates, or re-written due 
to poor comprehension, intolerance or ambiguity. The level of missing data has 
implications for the calculation of scale scores. Some instrument developers are 
explicit about the number of items that may be omitted whilst still allowing the 
calculation of a final score. For example, a final score may be calculated for the SF- 
36 if one-half or fewer items are missing (Ware, 1997). 
The aim of measuring an attribute is to assess the extent to which a defined 
characteristic or domain is present or, for example, the extent to which difficulties 
with specified activities are encountered (Streiner and Norman, 1995). In the 
evaluation of functional ability one may wish to estimate'how much difficulty'a 
patient experiences in'tying shoe laces' or'getting into and out of the batW. The 
process of measurement requires quantification or'scaling' and hence the numerical 
representation of an attribute in a manner that allows users of outcomes data to 
appoint both meaning and relevance to the result (Nunnally and Bernstein, 1994). 
Most features of HRQL should be considered on a continuum, and the level of 
measurement adopted in scaling will affect the quality and extent of information 
retrieved ftom its evaluation. Various scaling approaches have been described. For 
example, visual analogues scales (VAS), Likert scaling and adjectival scales (Streiner 
and Norman, 1995). The method of scaling items should provide sufficient 
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discrimination to demonstrate clinically meaningful change and to facilitate score 
interpretation (Kirshner and Guyatt, 1985). 
At item level categorical response options are chosen for many instruments. 
However, the final score is often assessed on a continuous scale (Nunnally and 
Bernstein, 1994). For example, the Revised Leeds Disability Questionnaire (RLDQ) 
(Abbott et al, 1994) employs a four-item categorical response scale with options 
scored between 0 and 3. The overall score is reported on a continuous scale between 
0 and 48. The transformation of data gathered at one level of measurement into a 
higher level of measurement is frequently observed for measures of behavioural 
attributes (Nunnally and Bernstein, 1994). The transformation of data into a 
continuous format facilitates the representation of score distribution characteristics as 
mean and standard deviation (SD) values at both item and scale level providing 
important information in relation to the variability of responses (Safran et al, 1998). 
Instruments based on classical test-construction theory produce a final score based on 
the summation of item scores (Nunnally and Bernstein, 1994). To assess whether 
standardisation or weighting of item scores is required before the addition of items 
two aspects of data quality should be assessed (Safran et al, 1998; Kosinski et al, 
1999a). First, the distribution and variability of item responses should be considered. 
An acceptable level of variability in item responses and final scores is necessary for 
instruments to provide meaningful information for the evaluation of a specified 
domain and change in this domain (Safmn et al, 1998). The distribution of responses 
at item level provides evidence in support of the discriminative ability of an item. 
Secondly, the equivalence of means and standard deviations across items indicates if 
standardisation of item variances is required before the addition of item scores. If 
items address similar attributes and responses are normally distributed, items 
contained within the same scale would in general be expected to produce similar 
mean and standard deviation values (Kosinski et al, 1999a). 
An exception to this result would be if items were specifically intended to define the 
ceiling or floor of the domain. Item performance would be reflected in a skewed 
distribution of responses and a mean and standard deviation value that departed from 
other items in the scale. Assuming a representative patient population, response 
distribution at item level would usually approximate normality. This would describe 
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the range of response options and the ability for most respondents to describe change 
(Nunnally and Bernstein, 1994). Skewed data at item level suggests that respondents 
score among the most or least favourable health states. End-effects, where the 
majority of item scores accrue at the ceiling or floor of the response scale should be 
identified (Streiner and Norman, 1995). A ceiling effect would be demonstrated 
where, for example, more than 80% of responders choose the response option 
reflecting the best possible health state (Jenkinson et al, 1996). This is of limited use 
for evaluative purposes due to the inability of a respondent to record any meaningful 
improvement in health. The opposite is true for an item demonstrating a floor effect 
(Fitzpatrick et al, 1998a). 
Items with a very large or very small level of endorsement for a particular response 
option add little to an instruments discriminative ability and should be removed 
(Streiner and Norman, 1995). If a large number of patients respond to an item in the 
same way, the item contributes little to the variation in the scale scores. In developing 
the Aberdeen Low Back Pain Scale, Ruta et al (1994b) considered items for rejection 
if more than 80% of patients gave the same response, suggesting that these items 
would inadequately discriminate between differing levels of severity. 
Dimensionality 
The dimensionality of multi-item instruments has been assessed with principal 
component analysis (PCA)(Joliffe, 1986). McHorney et al (1993) suggest that to 
further understanding of the impact of health or disease the multi-dimensional 
evaluation of health is necessary to provide a'synergistic and comprehensive 
assessment! . 
PCA can be used to describe the underlying structure of a multi-item 
instrument through the identification of components into which items may group 
(McDowell and Newell, 1996). PCA adds empirical weight to the hypothesised 
domains, thus informing further on the underlying concept and instrument internal 
structure (McHomey et al, 1993; McDowell and Newell, 1996). PCA may be used to 
confirm the presence of hypothesised domains described by instrument developers 
(Kosinski et al, 1999a). For example, in hypothesising the dimensionality of the SF- 
36 McHomey et al (1993) proposed that two domains, mental and physical, would 
underlie the structure of the eight scales and PCA supported this. An evaluation of 
the content validity of items captured within identified domains further supports the 
role of items in addressing the underlying conceptual base (Ruta et al, 1994b). 
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Item-total correlation 
Multi-item scales based on classical test construction must consist of homogeneous 
items that address an underlying domain of health. The inclusion of multiple items 
addressing the same clearly defined domain generates greater information relating to 
the construct. If these items relate closely to each other and to the specified domain, 
reliable information about the domain should be gained (Kosinski et al, 1999a). If 
items fail to relate closely to each other or inadequately represent the underlying 
domain error may be introduced into the measurement. Issues of acceptability and 
feasibility make it impossible to include all possible items in an instrument, and so 
items are sampled to represent different aspects of the domain, the combination of 
items fostering finer discrimination between patients. 
The relationship between items and the remainder of their scales should be assessed 
for all instruments based on classical test construction theory (Nunnally and 
Bernstein, 1994). Item-total correlation correlates an item and the total score for the 
scale. However, inclusion of the specific item in this calculation artificially inflates 
the score and its contribution is removed from the total scale score before calculating 
the 'corrected item-total correlation (Streiner and Norman, 1995). 
When an instrument or separate domains within an instrument consist of a small 
number of items a greater level of item-total correlation is required to achieve a 
satisfactory level of reliability. A score of 0.4 has been recommended as a minimal 
level to support the internal consistency of items (Ware, 1997; Kosinski et al, 1999a). 
Items with a high level of item-total correlation demonstrate more variance relating to 
the common domain between items and as such are more discriminating. These items 
add more to the estimated level of instrument reliability, as measured by Cronbachs 
alpha, than items with a lower item-total correlation (Nunnally and Bernstein, 1994). 
Items with low levels of item-total correlation usually demonstrate a poor relationship 
to the underlying construct and should be considered for rejection. ' These items may 
also be ambiguous, or attract very large or small levels of endorsement. 
If a rigorous approach to data completeness and item scaling is taken then this should 
produce satisfactory scale properties for the instrument as a whole. Once issues 
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relating to item performance have been addressed, and any necessary changes to 
instrument structure made, instrument properties at scale level should be assessed. 
Data quality and scaling assumptions at scale level 
Data quality and scaling assumptions include the distribution of total instrument 
scores and any end-effects. Assuming a representative population of interest, score 
distribution would usually approximate normality (Nunnally and Bernstein, 1994), 
and responses reflecting the full range of the domain described by the instrument 
should be recorded (Ware and Gandek, 1998b). If a skewed result is found the 
percentage scoring at the ceiling (best health) or floor (worst health) of the scale 
should be noted since this affects the ability of the instrument to measure change 
(Fitzpatrick et al, 1998a). Where more than 80% of responders score at the extreme 
of a scale the instrument may be of limited use in evaluation. If a scale score is 
skewed and does not cover the important range the performance of items and response 
options should be reviewed. However, if a patient population represents a specific 
spectrum of disease a skewed distribution may support instrument validity. Kosinski 
et al (1999a) reported a skewed distribution of responses towards less favourable 
health states for SF-36 scales representing disability and distress in patients 
experiencing an exacerbation of their arthritis. 
Internal consistency reliability 
The internal consistency reliability of a multi-item instrument is assessed by 
Cronbach's Alpha (Streiner and Norman, 1995). Alpha assesses the relationship 
between all items in a scale, reflecting both the total number of items and their 
average correlation (Nunnally and Bernstein, 1994). Alternatively, alpha may be 
described as representing the average expected correlation between an alternative 
scale consisting of the same number of items sampled from the same specific domain 
(Ware, 1997). 
Study instruments with published evidence of internal consistency reliability include 
the parent instrument of the RLDQ, the Leeds Disability Questionnaire 
(LDQ)(0.93)(Abbott et al, 1994) and the BASDAI (0.84)(Jones et al, 1996c; Calin et 
al, 1999a). 
176 
5.2.2 Test-retest Reliability 
Test-retest reliability addresses the accuracy of results over time assuming no 
underlying change in condition (Ware, 1997). Consistency of a result repeated on 
different occasions would be expected if contributing factors to the health state have 
not changed and there is an absence of random or systematic error. 
Test-retest reliability and internal consistency reliability are distinct concepts to the 
extent that high levels of test-retest reliability in multi-item instruments are not 
necessarily associated with high levels of internal reliability. Test-retest reliability 
may not provide a complete picture of the reliability of multi-item instruments based 
on classical test-construction theory because the result is only partly influenced by 
internal reliability (Nunnally and Bernstein, 1994). For example, an item may 
correlate weakly with other scale items but correlate highly with itself over a test- 
retest period. Thus, high temporal stability with low internal consistency may be 
demonstrated. However, internal consistency reliability may over-estimate true 
reliability due to the lack of consideration for different sources of variance (Streiner 
and Norman, 1995). Internal consistency reliability requires instrument completion 
on one occasion only and does not consider variation between repeated 
administrations. For example, variation between observations over time. Test-retest 
reliability requires consistency over two points in time and may provide a more 
rigorous measure for evaluative contexts (Kirshner and Guyatt, 1985). Evaluative 
instruments based on classical test-construction theory should be assessed for both 
internal consistency and test-retest reliability. The reliability of instruments not based 
on classical test-construction theory is dependent on establishing support for the 
temporal stability. 
Test-retest reliability generally involves patient self-completion of an instrument on 
two occasions separated by a suitable time period. Alternatively, an observer may 
complete the instrument on behalf of the patient on both occasions. For example, 
most anthropornetric measures require assessment by a trained observer. High levels 
of test-retest reliability, or alternatively intra-observer reliability, reflect low levels of 
within-person variance (Beurskens et al, 1995). 
Test-retest reliability is assessed for patients indicating no change in their condition 
(Deyo et al, 1991; Fitzpatrick et al, 1993b). Health transition questions to describe 
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the underlying stability have evidence of validity and ask patients if their health, in 
general or specific to a particular disease, has changed between administrations of the 
instrument (Fitzpatrick et al, 1993b; Peto et al, 1998). 
There is no agreed time period for test-retest studies. A shorter period may facilitate 
answer recall thus artificially inflating reliability (Nunnally and Bernstein, 1994; 
Streiner and Norman, 1995). Alternatively, the fluctuating nature of health could 
mean that too long an interval results in actual change and a reduced number of 
patients suitable for inclusion in the analysis. The time period is also influenced by 
the nature of the health state. For example, very acute disorders may achieve a state 
of full recovery by two weeks and a shorter retest period is necessary (Beurskens et a], 
1995). A window of between two days and two weeks has been recommended for 
most conditions (Streiner and Norman, 1995). 
Inter-observer reliability 
Inter-observer reliability assesses the level of agreement between results when 
different observers are responsible for the assessment. An instrument that produced 
differing results dependent on the observer would not be useful. Stability of results 
between observers supports instrument application by different observers, assuming 
the same format for administration is followed (McDowell and Newell, 1996). 
Statistical analysis 
The correlation coefficient is the most frequently used statistical method for 
calculating estimates of test-retest reliability. Pearson's correlation coefficient, r, is 
commonly used but fails to take account of systematic bias (Deyo et al, 1991; 
Beurskens et al, 1995; Streiner and Norman, 1995). Repeated observations may be 
systematically different but still demonstrate a linear relationship with the first set of 
observations. Therefore, Pearson's correlation may overestimate reliability. 
The Intra-class correlation coefficient (ICC) is based on Analysis of Variance and 
considers the variability between patients as a proportion of the total variability (the 
sum of between patient and within patient variability) (Jordan, 2000). Therefore, in a 
heterogeneous population reliability will be higher. The ICC takes account of 
systematic bias and is recommended in preference to Pearson's correlation coefficient 
(Streiner and Norman, 1995; Jordan, 2000). However, the main source of 
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measurement error is usually random and as a consequence the ICC and Pearsons 
correlation closely approximate each other (Streiner and Norman, 1995). Several 
forms of ICC have been described and an appropriate method for the assessment of 
measures of outcome considers observers as a random selection from a wider 
population of observers (random effects model; ICC(2, I)) (Shrout and Fleiss, 1979). 
Reliability ofthe study instruments 
Most of the study instruments have published evidence of test-retest reliability 
(Chapter 2)(table 5.2). There is no published evidence of the reliability for the 
ASQoL, PGI-AS or the RLDQ. 
Authors Instrument n Time between Correlation coefficient 
administrations 
Garrett et al (1994) BASDAI 46 24 hours 0.93 
Dziedzic (1997) Body Chart 14 1 hour p-0.34 
(Wilcoxon matched pairs) 
Abbott et al (1994) LDQ 9 5 days 0.98 
25 24 hours 0.92 
Hurst et al (1997) EuroQol - EQ-5D 93 3 month 0.73 
31 2 week 0.78 
Hurst et al (1997) EuroQol - thermometer 93 3 month 0.70 
31 2 week 0.85 
Hurst ct al (1998) SF-12 75 3 month MCS - 0.71 
PCS - 0.75 
Table 5.2 A selection of evidence of test-retest reliability of patient-based study instruments 
BASDAI - scored 0 -10; higher scares indicate greater disease activity. 
Body Chart - minimum score 0, no maximum score; higher scores greater perceived bodily pain. 
LDQ - scored 0-3; higher scores indicate worse functional ability. 
EuroQoI EQ-513 - scored -0.59 to 1.00; 1.00 the 'best possible health'. 
EuroQoI thermometer - scored 0-100; higher scores indicate better health status. 
SF-12 - uses norm based scoring from the general population. Scales are transformed to have a mean of 50 (sd 10), with a range 
0-100.1-figher scores indicate better health status. MCS-mental summary scale, PCS-physical summary scale. 
The selected generic instruments, EuroQoI and SF-12, have not previously been 
assessed for reliability in AS, but reliability has been described in patients with RA 
(n7-- 233) (Hurst et al, 1997,1998; Ruta et al, 1998). Test-retest reliability was 
assessed for patients indicating'no change'in RA on a transition question. The 
EuroQoI was assessed for both three-month (n-- 9 1) and two-week (n-- 3 1) test-retest 
reliability and satisfactory levels were reported (range 0.73 - 0.80) (Hurst et al, 1997). 
Three-month test-retest reliability of the SF-12 was satisfactory (>0.71)(n--- 75). 
5.2.3 Standards for estimates of reliability 
The reliability of an instrument has implications for whether it is suitable for 
application in group or individual evaluation. The levels of acceptable reliability have 
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increased over recent years as the complexity and conceptual base of measures of 
health outcome have advanced, supporting a reduction in measurement error as the 
ability to generate information has improved (Ware, 1997). For the evaluation of 
individuals high levels of reliability, above 0.90, have been recommended (Streiner 
and Norman, 1995; Ware, 1997). For group comparisons levels over 0.70 have been 
suggested (Nunnally and Bernstein, 1994; Streiner and Norman, 1995). 
5.3 Methods for assessing data quality, scaling assumptions and reliability of 
the study instruments 
When item performance of a multi-item instrument is addressed, requirements for 
item retention can be considered under three main headings (table 5.3). Following 
standards recommended by several authors (McHorney et at, 1994; Juniper et at, 
1997; Jenkinson et at, 1999a), items should be considered for rejection if they fail to 
fulfill any of the following criteria: 
Rejection of items 
Data quality and scaling assumptions 
-> 10% missing values 
- skewed distribution of responses at item level 
- 80% frequency endorsement for response option 
evidence of cnd-cffccts (> 80%) 
Dimensionality 
- items with low component loadings (item loading 
< 0.4) 
- poor content validity 
Itcm-total correlation 
itcm-total correlation < 0.4 
Table 5.3 Evidence to support item rejection from a multi-item instrument. 
Where appropriate the item and scale level performance of instruments completed 
during baseline evaluations was investigated (table 5.1). All instruments were 
assessed for missing data, the distribution and symmetry of item response scores and 
the endorsement frequency of response options. Items with high levels of missing 
data, the presence of end-effects or excessive or minimal levels of endorsement were 
considered for rejection. The data quality and distribution of scores was subsequently 
assessed at scale level. Where appropriate internal consistency reliability was 
assessed. A two-week test-retest reliability evaluation of all study instruments was 
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performed. The anthropometric measures were also assessed for inter-observer 
reliability. 
5.3.1 Data quality, scaling assumptions, internal consistency reliability and test- 
retest reliability of the study instruments 
PGI-AS 
A rating scale (Appendix 9) was completed by the therapist to assess the level of 
assistance and completion time required by patients during interview-administration. 
Completion was compared between baseline and six-month assessments. Anomalies 
in postal self-administration were identified. 
Data completeness for each step of the PGI-AS was considered. The number and 
frequency with which items were mentioned in step I and the data quality and scaling 
assumptions for the unweighted item responses in step 2 were assessed. At scale level 
the data quality and scaling assumptions for the final index score was assessed. 
Following the developers of the PGI (Ruta et al, 1994a) the final score and three steps 
in instrument completion were assessed for test-retest reliability. Constituent parts of 
the PGI-AS were assessed to identify any weaknesses in the instrument and to support 
any need for modification. Three follow-up formats (table 5.4) have been separately 
assessed for test-retest reliability. Evaluation of the different formats is required to 
ensure that patients, clinicians and researchers are able to make meaningful 
interpretations when completing the instrument (Jenkinson et al, 1998c). 
Follow-up completion Step 1: Identi4ing areas Step 2: Scoring each area Step 3: Spending points 
Blind Blind to baseline areas Blind to baseline score Blind to baseline points 
Closed Informed of baseline areas. Not Blind to baseline score Blind to baseline points 
allowed to change or add to list 
Informed and open Informed of baseline areas. Blind to baseline score Blind to baseline points 
Allowed to change or retain list 
as necessary 
Table 5.4 PGI-AS follow-up formats. 
The variation in follow-up format includes the provision or absence of the areas 
identified in step I at baseline. Patients are not informed of scores or points. The 
'blind' format asks the patient to complete the instrument without previous responses. 
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The 'closed' fonnat lists baseline areas, but the patient is not allowed to change or add 
to this list. The 'informed and open' format lists baseline areas and patients are 
allowed to retain or change these as necessary. 
Participants in the postal survey were randomly assigned to complete either the 'blind' 
or 'closed! formats at two-weeks. All clinic participants completed the'informed and 
opeW fonnat. 
An index of change was calculated for step I (identifying areas) for the Vind' and 
'informed and open'formats. The 'closed' format does not allow patients to change 
baseline areas and an index of change cannot be calculated. At baseline patients 
identify up to five areas of their life affected by AS. An area substituted at follow-up 
for a baseline area was given one point. An area added at follow-up in place of a 
blank at baseline was given half a point. An area omitted at follow-up resulting in a 
reduction in areas was also awarded half a point. The number of 'points' was then 
summed. The index of change is equal to (5-x) / 5, where x= the number of points 
(Ruta et al, 1994a). The final index of change ranges from 0 to 5 and three groups are 
described: first, those making 0-I area changes; secondly, those making 1.5 - 2.5 
area changes; and, finally those making 3-5 area changes. 
In step 2 of the PGI-AS ('scoring each area! ) the patient scores areas identified in step 
I between 0 (The worst you could imagine') and 10 (Exactly as you would like to 
be'). The summed scores for step 2 is the'unweighted! PGI-AS score. Two-week 
test-retest reliability was assessed. 
The test-retest reliability of the PGI-AS index score. was also assessed. Patients 
'spend points' in step 3 to reflect their priorities for improvement producing a 
'weighted! score (Ruta, et al, 1994a). The weighted and un-weighted reliability 
coefficients were compared. 
Fiqally, reliability coefficients for the unweighted and weighted PGI-AS were 
calculated for each group as defined by the 'index of change'. This analysis considers 
the influence of change in areas on the total score. In summary, test-retest reliability 
was calculated for several versions of the PGI-AS (table 5.5): 
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Completion format of PGI-AS 
PGI-AS Postal population Clinic population 
Blind format Closed format Total postal Informed and open 
population format 
PGI-AS Index Score VV 
- without index of change 
PGI-AS Index Score 
- with index of change 
Unweighted PGI-AS Score 
- without index of change 
Unweighted PGI-AS Score 
- with index of change 
Table 5.5 Summary of test-retest reliability analyses calculated for the PGI-AS. 
V Test-retest reliability estimated; X test-retest reliability not estimate& 
PGI-AS Format: 131ind' - blind to baseline areas. 'Closed' - informed of baseline areas, not allowed to change. Informed and 
open! - informed of baseline areas, allowed to change or retain areas as necessary. 
b) Disease-specific and c) Generic instruments 
The dimensionality of the ASQoL, BASDAI, and the RLDQ was assessed using 
principle component analysis (PCA). Criteria relating to the level of variation 
explained by components and the level of component loadings were based on 
previously published studies of measure of health outcome (Hyland et al, 199 1; 
McHorney et al, 1993; Juniper et al, 1997; Jenkinson et al, 1999a). PCA with 
varimax rotation (Jolliffe, 1986) was used to identify separate components of health 
within each instrument. Two approaches to PCA were considered. First, the 
dimensionality of instruments was assessed by evaluating eigenvalues (a statistical 
measure of the components ability to explain variation between patients) of more than 
1.0 (Hyland et al, 199 1; Jenkinson et al, 1999a). A further assessment sought the 
number of dimensions identified by instrument developers (McHorney et al, 1993). 
For example, if the ASQoL is to maintain the structure recommended by the 
developers then one dimension should be confirmed by the PCA. The content validity 
of components identified for all analyses was considered in light of the results of the 
PCA and the original work presented by the instrument developers. 
There is a lack of consensus between studies on the level of component loadings 
below which items should be considered not to be sufficiently related to the relevant 
component. Hyland et al (1991) rejected items if loadings were less than 0.3, Juniper 
et al (1997) removed items which loaded less than 0.4, and Jenkinson et al (1999a) 
consider loadings equal to or above 0.5 to be important. This lack of consensus meant 
that component loadings were interpreted with care but for both analyses component 
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loadings of more than 0.4 were sought (Junniper ct al, 1997; Garratt AM. - personal 
communication, 1999). Items with component loadings less than 0.4 were identified 
and considered for rejection. 
Item-total correlations were calculated at item level and CronbacWs alpha was 
calculated at scale level for the three instruments based on classical test theory: 
ASQoL, BASDAI and RLDQ. Levels of item-total correlation above 0.4 were sought 
(Ware, 1997), and items with low levels of correlation were considered for rejection. 
CronbacWs alpha greater than 0.7 were sought to support instrument internal 
consistency reliability (Streiner and Norman, 1995). 
Although the SF-12 consists of multi-items, the developers have indicated that the 
evaluation of internal consistency reliability underestimates the instruments reliability 
(Ware et al, 1995). This is because the SF-12 items, all selected from the parent 
instrument the SF-36, were chosen for their relative heterogeneity, having a'reliable 
variance of proven value in estimating physical or mental health' (Ware, 1995). 
Although the SF-36 is based on classic test construction theory, the SF-12 is not. The 
SF- 12 is based on multiple regression analysis of the SF-3 6 and is not suited to 
exploratory principle component analysis (Ware et al, 1994). Therefore, only test- 
retest reliability has been calculated for the SF- 12. 
All instruments were assessed for test-retest reliability for both clinic and postal 
modes of administration. A random sample of out-patients participated in the clinic 
based two-week test-retest survey (section 4.6.5), and patients participating in the 
postal survey were mailed a second questionnaire two-weeks after returning 
completing the first questionnaire. 
Two health transition questions were included in the two-week questionnaire (figure 
5.1). The first question related to AS-specific and the second to their general health. 
'Compared to two-wecks ago, how would you rate your Ankylosing 
Spondylitis / health in general nowT 
Much better than 2-weeks ago I 
Somewhat better than 2-week-s ago 2 
About the same as 2-weeks ago 3 
Somewhat worse than 2-weeks ago 4 
Much worse than 2-wecks ago 5 
Figure 5.1 AS-specific and general health transition questions. 
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The two transition formats were considered important to represent both disease- 
specific change represented primarily by disease-specific instruments and a broader 
appreciation of change in HRQL captured by the generic instruments. Test-retest 
reliability was calculated for those patients indicating that both their AS and general 
health had remained the same. The PGI-AS represents the impact of both AS-specific 
and general health and stability in both items is required for the assessment of test- 
retest reliability for this instrument. 
The intra-class correlation coefficient (2,1) (Shrout and Fleiss, 1979; Streiner and 
Norman, 1995) was used as a measure of agreement between repeated observations. 
5.3.2 Test-retest and inter-observer reliability of anthropometrie measures 
Following completion of the questionnaire five anthropornetric measures were 
assessed in all clinic patients. During the baseline assessment two observers (one 
experienced physiotherapist - KLH, and one 'trained non-physiotherapist - KJ) 
recorded all measurements in selected patients (section 4.6.5). The order of observers 
was randomised. One observer (KLH) repeated the measurements at two-weeks. 
A warm. -up period has been recommended when assessing the repeatability of lumbar 
anterior flexion (FFD) and cervical rotation (Roberts et al, 1988). Up to six 
repetitions may be required before stability is achieved (Roberts et al, 1988). 
However, this approach is not feasible in routine practice, and a standardised format 
was followed in an attempt to reduce performance error and to increase patient 
familiarity with the measurements. All movements were described to the patient by 
the first observer and each movement repeated once to ensure correct performance 
and to act as a'warm-up'. 
5.4 Results of reliability testing 
This section presents the results of the assessment of data quality and scaling 
assumption at both item and scale level and reliability testing in both surveys. 
5.4.1 Results of data quality, scaling assumptions, internal consistency 
reliability and teSt-retest reliability of the study instruments 
Analysis of instrument performance for the ASQoL, BASDAI, EuroQol, RLDQ and 
SF- 12 at both item and scale levels has been based on both clinic and postal surveys. 
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This maximises the sample sizes which is of particular importance for principle 
component analysis (PCA) and is justified because completion of the instruments in 
both surveys followed the same patient self-completed format. Completion of the 
Body Chart and the PGI-AS followed interview-administration during the clinic 
survey and self-administration during the postal and data will be assessed separately 
for each survey. Anthropometric measures were only assessed in the clinic survey. 
a) PGI-AS 
Completion of the PGI-AS was considered to be correct if all 3 steps were completed 
and allocation of points in step 3 was correct (Ruta et al, 1999). A possible total of 
seven areas may be scored and subsequently points may be spent. Area 7 ('All other 
non-health areas of your life') is the only'box'that must be scored, although points 
need not be spent in this area if priorities are described elsewhere. However, area 6 
('areas affected by health problems other than AS') must not be left blank. The patient 
must indicate 'none' in writing (as illustrated in the completed example) or score the 
item. 
Additional patient assistance during interview administration was described on a 
therapist completed rating scale (Appendix 9)(table 5.6) and compared for baseline 
and six-month assessments. A similar level of assistance was required for completion 
of all steps at baseline: the most for step 2 ('scoring each area! ) and the least for step I 
('identifying areas'). Overall, less assistance was required at six-months. 
However, at six-months more assistance was required to complete step I ('identifying 
areas') and many patients were more inquisitive about areas to identify. It is possible 
that the baseline completion had caused them to think at greater length about the 
impact of AS on their life and this was reflected in the increase in questions asked. 
Baseline completion time ranged from less than 5-minutes (28.6%) to approximately 
25-mintues (4.8%) with the majority of patients taking between 5 and 10 minutes 
(44.0%). 72.6% required less than I O-minutes. Follow-up completion was much 
quicker. At six-months 44.0% of patients required less than 5-minutes completion 
time and 83.3% less than 10-minutes. At baseline one patient required maximum 
assistance and more than 25-minutes to complete the instrument. This was influenced 
by the difficulty in maintaining a focus on instrument completion. The interview 
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provided an opportunity for issues to be addressed that the patient had felt previously 
unable to discuss. However, this patient required much less assistance and a reduced 
completion time at six-months. At six-months no patient required more than 15- 
minutes completion time. 
Rating Scale ' 
PGI-AS 
steps of completion 
None at all A little Moderate Significant Maximum 
assistance assistance assistance assistance 
Assessment n % n % n % n % n % 
Step I- Identifying areas Baseline 45 53.6 26 31.0 9 10.7 3 3.6 1 1.2 
6months 1 1.2 67 79.8 8 9.5 6 7.1 2 2.4 
Step 2- Scoring each area Baseline 52 61.9 16 19.0 12 14.3 3 3.6 1 1.2 
6months 1 1.2 71 84.5 6 7.1 4 4.8 2 2.4 
Step 3- Spending points Baseline 51 60.7 19 22.6 8 9.5 5 6.0 1 1.2 
6months 68 81.0 8 9.5 6 7.1 2 2.4 0 0.0 
Overall clinician reported Baseline 43 51.2 24 28.6 12 14.3 4 4.8 1 1.2 
level of assistance 6months 61 72.6 14 16.7 7 8.3 2 2.4 0 0.0 
5 mins 6-10 mins 11-15 mins 16-20 mins 21-25 mins 
Time taken to complete Baseline 24 28.6 37 44.0 13 15.5 6 7.1 3 3.6 
6months 37 44.0 33 39.3 14 16.7 0 0.0 0 0.0 
Table 5.6 Rating scale of assistance required to complete the interview-administered PGI-AS 
(n-- 84) (Pilot study excluded). 
'Rating scale: None at all = standard instructions only 
A little assistance = repetition of instructions 
Moderate assistance = repetition of instructions with increased reference to completed example 
Significant assistance increased reference to example. Possible re-wording of instructions 
Maximum assistance maximum reference to 'trigger list' and example. Examples read aloud to facilitate completion. 
Prolonged completion time. 
Various anomalies following postal self-administration were identified (table 5.7). 
Most difficulties involved 'spending points'in step 3 (n--24,6.8%). To allow for the 
calculation of an index score a total of 14 points must be spent in areas that have been 
scored in step 2. Occasionally patients spent 13 or 15 points suggesting a simple 
mistake in calculation, although some patients used an obscure number of points 
suggesting a level of confusion. 
Difficulties with step 2 of the PGI-AS most frequently involved score omission for 
items 6 and 7. Of the 303 patients for whom a baseline index score could be 
calculated a total of 23 patients (7.6%) failed to score box 6 ('areas affected by health 
problems other than AS'). However, 90 (29.7%) patients indicated no additional 
health problems by writing'none'in the box, and under this circumstance a score is 
not required. 14 patients (4.0%) failed to score box 7 ('all other non-health areas of 
your life') and 10 patients (2.8%) failed to score both boxes. 
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n% 
Completed PGI-AS correctly - index score calculable 303 $7.5 
(area 6/7 may or may not be scored) 
Completed PGI-AS correctly - index score calculable 276 79.8 
(area 6/7 completed correctly) 
Omitted to score box 6 13 3.7 
Omitted to score box 7 4 1.1 
Omitted to score boxes 6 and 7 10 2.9 
Incorrect points spent step 3 24 6.9 
Partially completed PGI-AS 6 1.7 
Evidence of misunderstanding in completion - index 6 1.7 
score not computable 
Left PGI-AS blank 7 2.0 
Questionnaire printing error 3 0.8 
Table 5.7 PGI-AS completion difficulties encountered in the baseline postal survey (n-- 346). 
Completion of PGI-AS considered to be incorrect if all 3 steps were not completed and allocation of points in step 3 incorrect 
Rather than scoring boxes 6 and 7 in step 2, eight patients (2.3%) indicated in writing 
'areas affected by other health problems' or 'other non-health areas of life' 
respectively. For example, writing'asthma! into box 6 or'marriage' into box 7. When 
this was not accompanied by a score completion was considered incorrect. If points 
were also spent in these areas in step 3a final score could not be computed. More 
frequently scores were simply not entered. 27 patients incorrectly completed areas 6 
and/or 7 and of these a final index score could not be calculated for 12 (3.5%). 
Four patients made a partial attempt at completing the PGI-AS. All patients entered 
areas in step 1, but did not complete steps 2 and 3. In a further six patients there was 
clear evidence of misunderstanding. For example, areas and scores were entered on 
the sample PGI or trigger list items circled. Seven patients left the PGI-AS blank. 
Two of these patients added notes to indicate that they did not experience any 
problems with their AS and so found completion difficult and one patient drew a line 
through the page. 
All patients attempting to complete the PGI-AS in the postal survey entered at least 
one area in step I (Identify areas')(n7- 336). Five areas were listed by 68.7% (n-- 233) 
of patients, 87.0% (n-- 295) completed four boxes, 94.4% (n--- 320) completed three 
boxes, and 96.4% (n= 327) completed two boxes. However, afinal score could only 
be calculated for 303 (90.2%) patients. 
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During interview-administration six patients (3.7%) were unable to complete step I 
because they felt so well. However, the remaining 153 patients listed at least one area 
(96.2%), 84.9% (n--135) identified two areas, 71.7% (n--I 14) listed three areas, 57.2% 
(n-- 91) patients listed four areas and 43.4% (n--69) listed a total of five areas. Those 
patients unable to list any areas were directed to score areas 6, if applicable, and area 
7 only, and to spend all 14 points between these two areas. When patients felt it 
unnecessary to complete step I it became apparent that the questionnaire was limited 
in guiding patients to completing boxes 6 and 7 only, and further guidance for self- 
completion is required. However, the results are an improvement on non-completion 
due to lack of problems reported by Ruta et al (1999). 
On the other hand, patients with severe disease or those capable of identifying many 
areas of life affected by their AS expressed difficulty in choosing the five most 
important. This did not prevent index completion but increased completion time. 
During the pilot study analysis of the postal PGI-AS one patient circled additional 
areas in the trigger list and indicated difficulty in limiting his selection to five. This 
problem has been reported by other investigators (Cotton et al, 1993). 
Each item in the PGI-AS is scored between 0 and 10, where lower scores indicate 
more difficulty with the identified item. Similar mean values at item level (between 
poor and faie) were found for both postal and clinic populations and for items one to 
four (table 5.8). Item response distribution approximated normality. The lowest item 
mean was found for item 5 ('poor, but not the worst you could imagine'). Responses 
to this item were slightly skewed towards the lower levels of disease-related quality of 
life. The largest floor effect was for item 5 in the clinic population (7.4%). Although 
patients were not requested to list the areas in any particular order the fifth item in 
step I produced the lowest score for both populations. 
Higher mean values were found for areas 6 and 7, suggesting that patients in general 
experienced'faie health in relation to other health problems and a'good' level of non- 
health related quality to their life respectively (table 5.8). Item responses were 
skewed slightly towards better levels of the underlying attribute. However, no item 
produced end-effects of greater than 80%. 
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Postal Survey 
Item / Scale data 
91! ality 
% 
Missing Mean (SD) 
% 
floor 
% 
ceiling 
Intra-class correlation 
coeffcient 
0/ 
-(2MLD- Postal Clinic Postal Clinic Post Chn. Post Clin. Postal Clinic 
PGI-AS 12.5 0.6 4.05 (1.65) 4.68 (2.25) 2.6 4.4 0.7 4.4 0.83 0.85 
(. 81-. 87) (. 69-. 93) 
Item 1 3.4 0.6 4.22 (2.05) 4.88 (2.69) 3.0 6.6 0.6 2.6 
Item 2 3.4 0.6 4.26(2.09) 4.72 (2.11) 2.4 2.2 0.9 0.7 
Item 3 3.7 0.6 4.28 (2.10) 4.33 (2.04) 2.8 3.5 1.6 0.9 
Item 4 3.4 0.6 4.16 (1.98) 4.22 (2.23) 1.4 4.4 1.4 1.1 - 
Item 5 4.3 0.6 3.81 (1.92) 3.76 (2.26) 2.6 7.4 0.9 2.9 - 
Item 6 7.6 0.6 5.65 (2.55) 5.53 (2.62) 2.2 1.0 6.7 3.8 - 
Item 7 4.6 0.6 6.92 (5.47) 6.90 (2.15) 0.3 1.3 4.7 6.6 - 
Table 5.8 Item and scale properties of the PGI-AS. Results from the postal (n-- 349) and clinic 
surveys (n-- 158). 
PGl-AS index score and single item are scored 0-10; higher scores indicate better diseas"elated cluality of life. 
Completion rates for the clinic survey were excellent (99.4%, n= 158). The 
completion rate for the postal survey was satisfactory (87.5%, n--- 303). Although not 
clearly indicated by the developers of the PG1 a final index score should not be 
calculated if step 2 for areas 6 and 7 is incorrectly completed or omitted (Garratt AM. 
- personal communication, 1999). When non-completion of areas 6 and 7 was 
considered a final score could be computed for 276 patients (79.8%). When a final 
score was calculated for the PGI-AS, with or without correct completion of areas 6 
and 7, completion rates were much higher than those reported by authors using earlier 
versions of the PG1 (table 5.9): 
Authors Patient population n Survey Version of PGI Correct completion of PGI 
AS 349 Postal PGI-AS 87.5 
Current study AS 349 Postal PGI-AS (corrected) 79.8 
AS 159 Clinic PGI-AS 99.4 
Ruta et al (I 994a) Low back pain 571 Postal Original PGI 63.0 
McArthur (1997) Rheumatoid arthritis 151 Postal Original PGI 77.0 
1 lerd et al (1997) Atopic dermatitis 56 Clinic Original PGI 100.0 
McDuff &Russell (1998) Limiting long term 71 Postal Revised PGI 62.0 
illness (corrected) 
Jenkinson et al (1998b) Obstructive sleep 89 Clinic Original PGI 100.0 
apnoea 
Ruta et al (1999) Low back pain 672 Postal Original PGI 51.0 
M, ermorrhagia 
Suspected peptic ulcer 
Varicose vein 
Table 5.9 Completion rates for different versions of the PGI. 
'Corrected! indicates that index score only calculated for patients completing items 6 and 7 correctly. 
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The PGI-AS index is scored between 0 and 10, where higher scores indicate better 
levels of the underlying attribute. The scores were wide ranging in both populations, 
and an approximately normal score distribution was observed. The mean values for 
both clinic and postal populations were similar (table 5.10), indicating that patients in 
both groups experienced similar levels of disease-related quality of life when assessed 
by the PGI-AS. 
PGI-AS 
Scale 
Frequency endorsement (0/6) 
Postal (n-- 303) Clinic (n-- 158) 
floor 
0-0.9 2.6 4.4 
1.0-1.9 7.0 5.7 
2.0-2.9 15.2 10.8 
3.0-3.9 26.4 16.2 
4.0-4.9 20.7 17.8 
5.0-5.9 14.9 17.7 
6.0-6.9 8.6 10.7 
7.0-7.9 2.9 5.7 
8.0-8.9 1.0 6.4 
9.0-10.0 0.7 4.4 
coiling 
% missing 12.5 0.6 
Mean (sd) 4.05 (1.7) 4.7 (2.3) 
Table 5.10 PGI-AS scale properties. Results from postal and clinic surveys. 
PGl-AS is scored 0-10; higher scores indicate better disease-related quality of life. 
A small percentage of postal respondents scored at the ceiling, indicating that their 
disease-related quality of life was'exactly as they would like it to be'(0.7%), 
compared to 4.4% of clinic patients (table 5.10). 
The test-retest reliability of the three follow-up formats of the PGI-AS were compared 
for un-weighted and weighted scores (table 5.11). Test-retest reliabili - ty greater than 
0.80 was found for the PGI-AS index for all formats and the highest levels were found 
for the 'closed' (0.87) and'informed and opeif (0.85) formats. Un-weighted reliability 
was lower than the weighted reliability on all occasions (range 0.70 - 0.81). The 
highest un-weighted reliability was also found for the 'closedý fonnat (0.8 1). 
The impact of step I area changes on PGI-AS reliability was assessed by calculating 
an index of change (tables 5.12 and 5.13). 
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PGI-AS Step 2- Un-weighted scare Step 3- Index score 
n ICC (95% CI) n ICC (95% CI) 
Postal survey 
Blind and Closed formats combined 143 0.76 (0.68 - 0.82) 144 0.83 (0.77 - 0.87) 
Blind 71 0.71 (0.57 -0.80) 75 0.82 (0.73 - 0.88) 
Closed 72 0.81 (0.72 - 0.88) 69 0.87 (0.81 - 0.92) 
Clinic survey 
Informed & open 25 0.84 (0.67 - 0.92) 25 0.85 (0.69 - 0.93) 
Table 5.11 Test-retest reliability of PGI-AS for index and un-weighted scores; postal and clinic 
surveys. 
Blind - blind to baseline areas; Closed - informed of baseline areas, not allowed to change; Informed and open - informed of 
baseline areas and allowed to change or to retain list. 
PGI-AS Step 2- Un-weighted score Step 3- Index score 
131ind! 
Index of change n ICC (95% Cl) n ICC (95%CT) 
0 to I area cbanges 24 0.84 (0.66 - 0.93) 25 0.91 (0.80 - 0.96) 
1.5 to 2.5 area changes 
3 to 5 area changes 
Total population 
22 0.75 (0.49 - 0.90) 
25 0.46 (0.10 - 0.72) 
71 0.71 (0.56 - 0.81) 
24 0.80 (0.57 - 0.91) 
26 0.56 (0.23 - 0.78) 
75 0.82 (0.72 - 0.88) 
Table 5.12 Postal survey PGI-AS test-retest reliability by area changes (blind). 
Following 'blind' completion high levels of reliability were found for patients not 
changing any areas or sconng up to I -point on the index of change (0.84 - 0.9 1). 
These patients may have substituted one area for another, omitted up to two areas, or 
added up to two additional areas. When 1.5 to 2.5 area changes were made reliability 
was also high (range 0.75 - 0.80). When more area changes were made reliability 
was low (0.46 - 0.56). On all occasions reliability was greater for the weighted index 
than for the un-weighted score. 
All clinic patients completing the'informed and open! format of the PGI-AS at two- 
weeks and indicating no change in health made between 0 and 1 area changes when 
assessed by the index of change (n7- 23), and test-retest reliability was high (> 0.84) 
for both the un-weighted and index score (table 5.13). Two patients completed the 
PGI-AS'blind'and have been excluded from the analysis. 
POT-AS Step 2- Un-weighted score Step 3- Index score 
Informed & open' 
Index of change n ICC (95% CI) n ICC (95% CI) 
0 to I area changes 23 0.84 (0.66 - 0.93) 23 0.85 (0.69 - 0.93) 
1.5 to 2.5 area changes 00 
3 to 5 area changes 00 
Table 5.13 Clinic survey PGI-AS test-retest reliability by area changes (informed & open). 
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b) Disease-specific 
ASQoL 
The item and scale properties for the ASQoL are shown in table 5.14. The most 
frequently omitted items were 9 ('1 have unbearable pain')(4.3%) and II ('I am unable 
to do jobs around the house)(4.1%). However, these items were not omitted with 
sufficient frequency to consider them suitable for rejection based purely on this 
criterion. 
Response options 
% No Yes Item-total Cronbach's ICC 
Scale / Item 
Mssing Mean (SD) % ceiling % floor coffelation 
Alpha 95% Cl 
(n-- 166) 
ASQol, 3.4 8.35 (5.6) 9.0 4.5 0.92 0.96 
(. 94-. 97) 
1. Limits places I can go 2.4 - 49.5 48.1 0.63 - 
2. Sometimes feel like 2.0 - 57.2 40.8 0.55 
crying 
3. Difficulty dressing 1.6 - 59.4 39.1 0.57 
4. Struggle -jobs around 1.8 - 43.2 55.0 0.72 
home 
5. Impossible to sleep 2.6 - 78.5 21.5 0.48 - 
6. Activities - friends 3.2 - 53.8 46.2 0.65 - 
family 
7. Tired all the time 2.8 - 49.5 50.5 0.55 - 
8. Stopping to rest 2.0 - 43.5 56.5 0.70 - 
9. Unbearable pain 4.3 - 79.4 20.6 0.50 - 
10. Time to get going - 3.0 - 47.0 53.0 0.63 - 
morning 
11. Unable to dojobs at 4.1 71.6 28.4 0.56 
home 
12. Tired easily 3.4 30.8 69.2 0.61 -- 
13. Often get fiustrated 2.4 38.4 61.6 0.64 -- 
14. Pain is always there 1.6 - 32.9 67.1 0.57 -- 
15. Mss out on a lot 2.6 - 54.3 45.7 0.72 -- 
16. Difficult to wash my 2.8 - 73.4 26.6 0.59 -- 
hair 
17. Condition gets me 2.4 - 41.4 58.6 0.68 -- 
down 
18. Worry - letting people 2.4 - 55.8 44.2 0.67 -- 
down 
Table 5.14 Item and scale properties of the ASQoI. Results fi7om the postal and clinic surveys 
combined (n-- 507). 
ASQoL scored 0-18; lower scores indicate better llRQL 
ICC = Intraclass correlation coefficient; 95% CI = 95% confidence interval 
During the clinic evaluation several patients asked for assistance. Most frequently 
patients were unable to make a clear distinction between'yes' and 'no' response 
options. Several patients responded by placing a'tick'between the two boxes, often 
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supplementing this with a comment such as 'sometimes' Wit depends'. This difficulty 
was encountered particularly with items relating to pain (item 9,1.3%) and the'time 
to get going in the moming(item 10,0.4%), and prevented item scoring. Several 
patients (0.8%) had read through the questionnaire andticked one box only, or one 
box on each page. 
The ASQoL employs a dichotomous response format. Both responses were covered 
for all items. Items 5 ('It's impossible to sleepý)( 78.5%), 9 ('1 have unbearable paid) 
( 79.4%) and 16 ('1 find it difficult to wash my hair')(73.4%) had high levels of 
endorsement for the Woresponse. Items 5 and item 9 were borderline for removal 
but neither item exceeded the proposed criteria (> 80%), and analysis of the ASQoL 
dimensionality by PCA maintained the number of items proposed by the developers. 
The first PCA of the ASQoL selected components with eigenvalues above 1.0, 
producing a three component solution to explain 55.8% of the variance (table 5.15). 
Postal and Clinic Surveys Combined (n-- 452) 
Eigenvalues > 1.0 One component 
I Typothesised. scale / item CI C2 C3 CI Item -total correlation 
ASQoL' 
I. Limits places I can go 0.77 0.69 0.63 
2. Sometimes feel like crying 0.62 0.60 0.55 
3. Difficulty dressing 0.63 0.63 0.57 
4. Struggle -jobs around home 0.71 0.77 0.72 
5. Impossible to sleep 0.77 0.54 0.48 
6. Activities - friends/family 0.70 0.70 0.65 
7. Tired all the time 0.74 0.61 0.55 
8. Stopping to rest 0.60 0.48 0.75 0.70 
9. Unbearable pain 0.70 0.55 0.50 
10. Time to get going -morning 0.40 0.48 0.68 0.63 
11. Unable to do jobs at home 0.55 0.62 0.56 
12. Tired easily 0.75 0.66 0.61 
13. Often get frustrated 0.63 0.69 0.64 
14. Pain is always there 0.51 0.57 0.52 
15. Nfiss out on a lot 0.65 0.72 0.67 
16. Difficult to wash my hair 0.56 0.43 0.59 0.54 
17. Condition gets me down 0.72 0.68 0.64 
18. Worry letting people down 0.55 0.67 0.62 
Table 5.15 Principle component analyses of ASQoL and item-total correlation. 
* inswunent scoring summarised in table S. 14. 
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With the exception of item 10 ('It takes a long time to get going in the momine) all 
items had component loadings above 0.5, and the majority were above 0.6. All other 
items load clearly onto one of the three components. Component I (C I) comprises 
items relating to the impact of disease on functional activities and social life. 
Component 2 (C2) is described by items relating to the emotional impact of disease. 
For example, feelings of tiredness, frustration and depression. Item 10 ('It takes a 
long time to get going in the morning) fails to load clearly between components one 
or two. It may be related to component I due to the impact of morning stiffness on 
the functional activity, or to component 2 due to influence of tiredness on the ability 
to'get going. Component 3 (0) contains two items only that may relate to extreme 
pain (item 5: 'It's impossible to sleep!; item 9: '1 have unbearable pain! ). 
A further PCA of the ASQoL assessed whether the instrument was uni-dimensional, 
the structure recommended by the developers (table 5.15). The single component 
explained 42. ý% of the variance. All items had component loadings above 0.50, with 
the majority above 0.60. The majority of items in the one component solution (11/18) 
have item loadings equal to or greater than the loadings in the three component 
solution demonstrating a strong relationship for all items within a single underlying 
domain. 
All items demonstrated acceptable levels of item-total correlation with the remainder 
of the hypothesised domain (table 5.15), and further supports the relationship of all 
items with the underlying construct. There is little evidence to suggest that any items 
should be rejected from the instrument when all aspects of item performance are 
considered. These results suggest that the ASQoL should be considered as a single 
domain measure of the impact of AS on HRQL. 
The completion rate for the ASQoL was excellent, and similar for both postal and 
clinic surveys (table 5.16), a pattern observed also in the completion of the EuroQoI 
thermometer and the RLDQ. A final score is calculable for the ASQoL if no more 
than 3 items are omitted. A total of 490 patients (96.6%) completed the ASQoL 
correctly. 
ASQoL scores for the total population covered the full range possible (0 - 18), a lower 
score representing better HRQL (table 5.14). The mean value was 8.35 ( SD 5.60) 
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and scores approximated normality. This indicates that the ASQoL is capable of 
detecting a full range of scores and that the majority of patients included in this 
analysis scored in the mid-range of values representing HRQL as measured by the 
ASQoL. The great majority of patients would therefore be able to record 
improvement or deterioration in score at a follow-up assessment. 
% Completion rate 
ASQoL BASDAI Body EuroQoI EuroQoI PGl-AS RLDQ SF-12 
Chart EQ-51) therm. 
Combined surveys 96.6 89.3 - 96.8 97.8 96.6 92.7 
(n--- 507) 
Postal (n-- 349) 97.1 91.0 88.8 97.4 98.3 86.8 98.0 94.8 
Clinic (n= 159) 95.0 88.0 99.4 94.8 96.3 99.4 96.2 87.4 
Table 5.16 Completion rates of instruments by survey. 
ASQoL internal consistency reliability as estimated by Cronbach! s Alpha was 0.92, 
and the test-retest reliability was 0.96 in the larger postal survey (n7- 166)(table 5.14). 
BASDAI 
The item and scale properties for the BASDAI are shown in table 5.17. The most 
frequently omitted item was item 6 (How long does your morning stiffness last from 
the time you wake up? ')(21.3%). Patients are requested to identify the duration of 
Imoming stiffness'on a VAS (anchored'O hours'to 12 or more hours'). Many patients 
failed to complete this item (n-- 22,4.4%) or completed it incorrectly (n-- 86,16.9%). 
For example, writing the duration of morning stiffness alongside the scale or placing 
obscure marks alongside the line, making it impossible to score. All other items were 
omitted with a similar high frequency of approximately 10%. 
The level of missing data influences the calculation of scale scores. However, the 
developers of the BASDAI make allowance for the omission of one item from items 1 
to 4, and the omission of either item 5 or 6 (Calin A. - personal communication, 
1999). The f inal score is the average of items I to 4 added to the average of items 5 
and 6. If one of items I to 4 is omitted the average of three completed items is 
calculated. If either item 5 or 6 is omitted the calculation is taken as the single scored 
item. Therefore, although many patients omitted item 6, item 5 was less frequently 
omitted and a final score could be calculated for the majority of patients. 
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%%% ItemAotal. Cronbach ICC 
Scale / Item Nfissing Mean (SD) ceiling floor correlation Alpha MCI 
(0-0.9) (9.0-10.0) (n- 150) 
BASDAI' 10.7 4.59 (2.31) 5.1 2.2 ---------- 0.87 0.87 
(. 83-. 90) 
1. Level of fatigueltiredness 10.6 6.00 (2.65) 6.2 8.6 0.66 - 
2. Level of AS neck, back or 10.8 5.60 (2.68) 6.0 10.6 0.77 - hip pain 
3. Level of pain / swelling - 10.6 3.45 (2.94) 26.5 5.1 0.60 - 
other than neck, back, hips 
4. Level of discomfort - 10.1 3.86 (3.07) 21.5 7.2 0.72 - 
tender to touch or pressure 
5. Severity of morning 10.2 4.75 0.05) 13.4 11.4 0.82 - 
stiffiess from waking 
6. Duration of morning 21.3 4.64 (3.37) 15.0 17.8 0.68 
stiffiess from waking 
Table 5.17 Item and scale properties of the BASDAL Results from the postal and clinic surveys 
combined (n= 507). 
'BASDAl scored 0-10; lower scores indicate a less active disease state. 
ICC = intraclass correlation coefficient; 95% CI = 95% confidence interval. 
The BASDAI employs six 10cm. horizontal VAS. When each VAS is divided into ten 
I cm segments, the responses to each item cover the full available range (table 5.18). 
Frequ ency Endorsement (0/, ) 
Scale Fatigue Pain Swelling Discomfort Morning Morning BASDAT' 
(0-10.0) Stifffiess Stiffness Total 
severity duration 
0-0.9 6.2 6.0 26.5 21.5 13.4 15.0 5.1 
1.0-1.9 6.4 6.4 15.4 13.6 10.3 11.3 9.9 
2.0-2.9 10.4 9.9 10.6 13.6 10.6 14.1 13.8 
3.0-3.9 6.8 8.2 7.3 6.3 9.9 8.0 15.4 
4.0-4.9 8.4 9.1 6.4 8.4 8.1 4.0 12.7 
5.0-5.9 10.4 12.8 11.7 8.7 10.1 13.5 11.5 
6.0-6.9 15.9 13.1 5.5 6.4 7.9 3.3 13.5 
7.0-7.9 19.2 14.8 6.9 8.3 9.9 8.2 10.8 
8.0-8.9 7.7 9.1 4.6 6.6 8.4 4.8 4.9 
9.0-10.00 8.6 10.6 5.1 7.2 11.4 17.8 2.2 
Mean 5.43 5.44 3.45 3.86 4.75 4.64 4.59 
SD 2.64 2.67 2.94 3.07 3.05 3.37 2.31 
n 453 452 453 456 455 399 453 
Mssing 54 55 54 51 52 108 54 
Table 5.18 BASDM - Frequency endorsement at item and scale level. Results from postal and 
clinic surveys combined (n-- 507). 
'instrument scoring surnmarised in table 5.17. SD -standard deviation. 
Item response did not approximate normality. Responses to items I ffatigue / 
Tiredness') and 2 (AS neck, back or hip pain) are skewed towards more severe levels 
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of the attribute, and responses to items 3 (Tain / swelling in joints other than neck, 
back or hips') and 4 (Discomfort from areas tender to touch or pressure') towards less 
severe levels. Responses to items 5 (Morning stiffness - severity') and 6 ('Morning 
stiffness - duration) both demonstrated a multi-modal distribution. The greatest 
levels of endorsement were for the lowest levels of 'swelling' (item 3,26.5%) and 
'discomfort' (item 4,21.5%). No item produced an end effect greater than 80%. 
There was little equivalence across item means and standard deviations for all items 
(table 5.18). However, there was similarity between item means and standard 
deviations for items I ('Fatigue') and 2 ('Pain'), for items 3 ('Swelling') and 4 
(Discomfort'), and for items 5 (Morning stiffness - severity) and 6 (Morning 
stiffness - duration). 
At item level all BASDAI items failed on the criterion of item completion, but were 
all retained so that measurement properties could be assessed in the group of patients 
completing the instrument. 
The PCA of the BASDAI selected components with eigenvalues above 1.0, producing 
a one component solution to describe 64.5% of the variance (table 5.19). All items 
had component loadings of more than 0.70 with three items above 0.80. Items 5 
(Morning stiffness - severity) demonstrated the highest component loading (0.88). 
The lowest loading was for item 3 (Tain / swelling in joints other than neck, back or 
hips'). The single dimension and high component loadings follow the developers 
findings that al I items relate to the same underlying domain. 
BASDAI Postal and clinic surveys combined (n-- 374) 
Item Eigenvalues > 1.0 Item-total 
Cl correlation 
1. Level of fatigue / tiredness experienced 0.76 0.66 
2. Level of AS neck, back or hip pain 0.85 0.77 
3. Level of pain/swelling in joints other than neck, back or hips 0.71 0.60 
4. Level of discomfort from any areas tender to touch or pressure 0.81 0.72 
5. Severity of morning stiffness from waking 0.88 0.82 
6. Duration of morning stiffness from waking 0.79 0.68 
Table 5.19 Principle component analysis of the BASDAI and item-total correlation. 
' inshwent scoring swnmarised in table 5.17. 
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All items demonstrated high levels of item-total correlation with the remainder of the 
hypothesised domain further supporting the relationship of all items with the single 
underlying domain. 
The completion rate of the BASDAI was reasonable. A total of 453 patients (89.3%) 
completed sufficient items in the BASDAI to produce a final score. For those 
instruments where data for both surveys could be combined the BASDAI completion 
rate was the lowest (table 5.16). The response rate was comparable to that of the 
Body Chart and the PGI-AS in the postal survey and the SF- 12 in the clinic survey. 
The BASDAI score is represented by a scale of 0- 10, where lower scores indicate a 
less active disease state. A wide range of scores was covered, but the lowest score of 
V ('no' disease activity) was not calculated. However, when the response scale was 
assessed in intervals of TO', 5.1 % of scores were at the ceiling (range 0-0.9)(table 
5.18). A lower endorsement for the highest possible scores (very severe') was 
observed with 2.2% of scores at the floor of the scale. 
The mean score was 4.59 (SD 2.3 1) and scale scores approximated normality. This 
suggests that the BASDAI is capable of recording a full range of scores, and that the 
majority of patients were described by the 'mid-range' of disease activity as measured 
by the BASDAL The majority of patients would therefore be able to record 
improvement or deterioration in score at a follow-up assessment. 
The internal consistency reliability of the BASDAI as estimated by Cronbach' s Alpha 
was 0.89, and test-retest reliability was 0.87 (n-- 150) in the larger po§tal survey. 
Body Chart 
The body chart asks patients to indicate areas of bodily pain on a body manikin and to 
score each area. The scoring range has a lower limit of 'zero'but no upper limit, with 
a higher score indicating a greater level of perceived body pain. The instrument does 
not consist of individual items and is considered at scale level only. 
A final score was computable for 99.4% of the clinic population, but a much lower 
completion rate of 89.9% was calculated following self-completion in the postal 
survey (table 5.16 and 5.20). 
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Body Chart % % % 
Scale / Item (response range) Nfissing Mean (SD) Median ceiling floor ICC (95% CI) 
Postal survey (n=3 10) 11.1 16.16 (16.20) 11.0 2.3 0.3 0.86 (81ý90) 
(0) (122) (n= 142) 
Clinic survey (n-- 158) 0.6 10.89 (11.19) 8.00 8.3 0.6 0.87 (. 73-. 94) 
(0) (56) (n= 25) 
Table 5.20 Item and scale properties of the Body Chart. 
Body Chart. minimum score 0, where 0 is no bodily pain (ceiling). No limit to maximum score. 
ICC = Intraclass correlation cA)efficient; 95% CI = 95% confidence interval. 
Features of incorrect completion in the postal survey (n-- 36,10.3%) included shading 
various parts of the body chart, with a subsequent failure to score areas. If more than 
two areas were not scored a final score could not be awarded (Dziedzic K. - personal 
communication, 1999). Several patients shaded the manikin with great precision but 
circled a single score, thus preventing scoring. Only 3 patients (0.8%) left the body 
chart blank. Such problems were not encountered during interview-administration. 
A much greater range of scores was observed in the postal population (range 0- 122) 
when compared to the clinic population (0 - 56). However, the distribution of scores 
was skewed towards the lower levels of pain for both populations with a greater 
percentage of the clinic population scoring at the ceiling of the range. 8.3% of the 
clinic population indicated that they were not experiencing body pain, whereas only 
2.3% of the postal population reported'no pain'(table 5.20). Mean values were 
greater for the postal population (mean 16.1.5, SD 16.20) than for the clinic population 
(mean 10.89, SD 11.19). 
Reporting the associated confidence intervals for the ICC as an estimation of test- 
retest reliability is based on the assumption that data is approximately normally 
distributed. Therefore, due to the positively skewed distribution of the Body Chart 
data, data was logarithmically transformed to yield a lognormal distribution (Altman, 
1996)(table 5.20). Similar levels of test-retest reliability of the Body Chart were 
estimated in both postal (0.86, n7-- 142) and clinic surveys (0.87, n-- 25). 
RLDQ 
The most frequently omitted item from the RLDQ was item 4a (Valking on your 
heels') omitted by 7.7% of patients (table 5.21). During self-completion of the RLDQ 
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in the clinic, several patients requested advise with this item and responded with 
comments such as: 
'I've never walked on my heels before -I don't know if I can do if 
and 
Valk on your heels - what does this meanT 
In addition, several patients were observed 'walking on their heels' along the clinic 
corridor, putting theirTunctional ability'to the test. Item 4b ('Cough or sneeze') was 
also frequently omitted (5.3%). 
Response options b 
Instrument %0123 1CC 95% 
Scale / Item Missing Mean (SD) %% ITC Alpha Cl 
ceding floor (n7--166) 
RLD(t 3.4 13.56 (9.9) 5.1 58.5 32.7 3.7 0.93 0.94 
(.. 92-. 96) 
1. Mobility - 
a. Into and out of the bath 3.7 0.74 (0.87) 48.7 33.7 12.1 5.5 0.76 - 
b. Into and out of the car 2.8 0.80 (0.75) 39.5 41.5 18.6 0.4 0.67 - 
c. Up/ out of bed-moming 4.1 0.71 (0.69) 42.1 44.8 12.9 0.2 0.61 
d. Rolling over in bed 3.3 0.78 (0.70) 36.0 51.3 10.8 1.8 0.63 - 
2. Bending Down -- 
a. Wiping yourself - toild 3.0 0.42 (0-64) 65.1 29.0 4.7 1.2 0.57 -- 
b. Put on / take off socks 3.1 0.85 (0.82) 37.8 44.3 13.2 4.7 0.73 -- 
c. Put on shoes & tic laces 4.7 0.89 (0.90) 38.6 41.1 12.6 7.6 0.74 -- 
d. Cut your toe nails 3. o 1.18 (1.11) 32.5 38.1 8.1 21.3 0.77 -- 
3. Neck Movements 
a. Opening high windows 3.3 0.92 (1.01) 42.2 36.5 8.4 13.0 0.77 - 
b. Look both ways before 3.1 0.73 (0.86) 48.4 35.0 11.6 5.1 0.72 - 
crossing the road 
c. Look at what you are 3.1 0.95 (1-05) 42.7 34.6 8.1 14.6 0.72 
reaching on a high shelf 
d. Drink frorn a srnall 3.5 0.56 (0.83) 61.8 24.7 9.4 4.1 0.62 
glass or can 
4. Posture 
a. Walk on your heels 7.7 0.55 (0.92) 65.4 23.2 2.1 9.2 0.61 
b. Coughing or sneezing 5.3 0.54 (0.60) 51.4 43.7 4.6 0.4 0.43 
c. Sleep on your back 3.1 1.08 (1-09) 35.6 41.1 3.5 19.9 0.47 
d. Sleep on your stornach 4.5 1.70 (1.21) 19.6 34.2 3.1 43.1 0.59 
Table 5.21 Item and scale properties of the RLDQ. Results from postal and clinic surveys 
combined (n=507). 
'RLDQ scored 048; lower scores indicate better functional ability. 
b Each item is scored 0-3. Response options: WAble to do without difficulty'. WAble to do with difficulty', 2='Only able to do 
using unusual movements or gadgets, 3=Unable to do. 
ITC - Item-total correlation; Alpha - Cronbach's Alpha; ICC = Intra-class correlation coefficient; 95% C1 = 95% confidence 
interval. 
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Although the full range of response options was found for all items, three items had 
very low levels of endorsement for the option Unable to do' (table 5.2 1). Lessthan 
0.5% of patients indicated an inability to perform activities described by items lb 
('Getting into and out of the car'), Ic (Getting up and out of the bed in the morning), 
and 4b ('Coughing or sneezing'). 
A large proportion of patients scored at the ceiling of the range for several items 
indicating that the activity could be performed'without difficulty': items 2a ('Wiping 
yourself after using the toilef)(65.1%), 3d ('Drinking from a small glass or 
can! )(61.8%) and item 4a ('Walk on your heels')(65.4%). However, no item produced 
an end-effect of greater than 80.0%. 
The skewed distribution of item responses suggests that most respondents experience 
no or only moderate limitation in functional activities described by the RLDQ. This 
is reflected in the low mean values for all items (item range 0- 3). Nine items have 
similar mean values (range 0.73 - 0.95; items la-d, 2 b-c, and 3 a-c). Four items have 
very low mean values (<0.55; items 2a, 3d and 4a-b). The remaining three items 
have marginally higher mean values (>1.00; items 2 d, and 4 c-d). 
Analysis of RLDQ dimensionality by PCA retained the number of items proposed by 
the developers. The first PCA selected components with eigenvalues above 1.0, 
producing a three component solution to describe 65.5% of the variance (table 5.22). 
All items had component loadings of more than 0.5, except for item 4a (Walk on your 
beels')(0.44), with the majority above 0.60. All components correspond to 
recognisable aspects of functional ability. Component I (C I) contains items 
representative of bending activities, consisting of all items from section 2 (Bending 
down') with the addition of items Ia ('Into and out of the bath') and items 4a (Walk on 
your heels'). The relationship between'walking on your heels'and items describing 
bending activities such as 'wiping yourself after using the toilef is not clear. 
Component 2 (C2) is described by activities that impose demands upon neck mobility, 
consisting of all items from section 3 (Neck movements'), with the addition of item 
4d ('Sleep on your stomach'). The relationship between these items has clinical 
validity. To lie prone requires an adequate range of neck rotation combined with 
extension. Component 3 (0) contains activities representative of general mobility 
and functional activities, containing three items from section I (b-d) and two items 
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from section 4 (b and c). The relationship between'coughing or sneezing' and items 
describing functional activities such as 'rolling over in bed' is not clear. 
Postal and Clinic Surveys Combined (n--- 490) 
Instrument 
Scale / Item Eigenvalues > i. 0 One component 
ZLW a R Cl C2 C3 C1 Itern -total correlation 
1. Mobility 
a. Into and out of the bath 0.61 0.46 0.81 0.76 
b. Into and out of the car 0.47 0.51 0.73 0.67 
c. Up/ out of bed-morning 0.41 0.68 0.67 0.61 
d. Rolling over in bed 0.68 0.69 0.63 
2. Bending Down 
a. Wiping yourself - toilet 0.64 0.63 0.57 
b. Put on I take off socks 0.85 0.78 0.73 
c. Put on shoes & tie laces 0.85 0.79 0.74 
d. Cut your toe nails 0.74 0.41 0.81 0.77 
3. Neck Movements 
a. Opming high windows 0.42 0.74 0.80 0.77 
b. Look both ways - cross road 0.80 0.76 0.72 
c. Look at what reaching-high 0.86 0.76 0.72 
shelf 
d. Drink from small glass/can 0.82 0.66 0.62 
4. Posture 
a. Walk on your heels 0.44 0.66 0.61 
b. Coughing or sneezing 0.72 0.49 0.43 
c. Sleep on your back 0.58 0.51 0.47 
d. Sleep on your stomach 0.57 0.40 0.63 0.59 
Table 5.22 Principle component analyses of RLDQ and item-total correlation 
' instrurnent scoring surnmarised in table 5.2 1. 
The RLDQ produces a single index score representing a single underlying domain of 
AS-specific functional disability (Abbott et al, 1994). Scores are not generated for 
individual sections. Therefore, a further PCA of the RLDQ assessed instrument uni- 
dimensionality (table 5.22). All items had component loadings above 0.50, except for 
item 4b ('Cough or sneeze')(0.48). The majority of items in the one component 
solution (14/16) have item loadings equal to or greater than 0.6 supporting the uni- 
dimensionality. 
All items demonstrated acceptable levels of item-total correlation with the remainder 
of the hypothesised domain of functional ability and further supports instrument 
unidimensionality. When all aspects of item performance are considered there is 
limited evidence to support the rejection of specific items from the RLDQ. 
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A final score was calculable for the RLDQ if no more than 2 items per section of the 
instrument were omitted. A total of 490 patients (96.4%) completed the RLDQ 
adequately to give a final score. A wide range of scores was observed, although the 
maximum score of 48 was not achieved (range 0- 41). The mean score for the total 
population was 13.56 (9.59) and scale score distribution was skewed towards the 
better levels of functional ability. 
5.1% of patients scored at the ceiling. No patients scored at the floor of the scale, but 
3.7% of scores were at the lower range of the scale (33 - 41 points) indicating great 
difficulty with the majority of activities. The most frequently endorsed levels of 
functional ability described mild (score range 1-16)(58.5%) to moderate (score range 
17 - 32)(32.7%) levels of difficulty with some or all functional activities. 
The internal consistency reliability of the RLDQ as estimated by Cronbach's Alpha 
was 0.93, and test-retest reliability was 0.94 in the larger postal survey (n-- 166). 
c) Generic 
EuroQoL 
The item properties of the EuroQoI EQ-513 are shown in table 5.23. The most 
frequently omitted were items 2 ('Self-care')(1.4%) and 4 (? ain / Discomforf)(1.4%). 
Response options 
EuroQol EQ-51) %% ceiling % floor 
Item level Missing Mean (SD) No problems (1) Some problems (2) Extreme problems (3) 
1. Mobility 0.6 1.58 (0.50) 42.5 57.1 0.4 
2. Self-care 1.4 
3. Usual activities 0.4 
4. Pain /Discomfort 1.4 
1.37 (0.51) 64.6 
1.78 (0.57) 29.7 
2.08 (0.53) 10.4 
34.2 1.2 
62.4 7.9 
71.0 18.6 
5. AnxietyMepression 1.2 1.60 (0.60) 45.5 48.5 6.0 
Table 5.23 Item properties of the EuroQol EQ-513. Results from combined postal and clinic 
surveys (n-- 507). 
The majority of patients responded using the first two response options. However, no 
item produced an end effect or level of endorsement of greater than 80%. 
The mean values (SD) for items I-3 and 5 were very similar. The mean value for 
item 4 (Tain / Discomfort') was slightly higher. 
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Completion of the EQ-51) was good and a final index score could be calculated for 
97.0% of patients. The full range of index scores was found (table 5.24). 
Score range 
EQ-513 %% ceiling % floor ICC (95% CI) 
Scale level Missing Mean (SD) (1.00) (0.59) (n7- 165) 
Index score 3.0 0.54 (0.33) 7.7 0.4 0.85 (. 80 -. 89) 
Table 5.24 Scale properties of the EuroQoI EQ-513. Results from combined postal and clinic 
surveys (n7- 507). 
EuroQoI EQ-5D is scored -0.59 - 1.0; -0.59 represents a state worse than death, and 1.0 the best possible health. 
ICC = intraclass correlation coefficient; 95% CI = 95% confidence interval. 
The distribution of index scores were slightly skewed towards a more positive health 
state. 38 patients (7.7%) scored at the ceiling of the scale range (best possible health 
state') and two patients scored at the floor (0.4%)('worst possible health state'). 
Test-retest reliability of the EQ-513 was 0.85 in the larger postal survey (n-- 165). 
Few problems with completion of the EuroQoI thermometer were experienced. The 
main problem concerned patients simply striking a line through the thermometer 
instead of 'drawing aline from the bo)e toward the thermometer. Completionrates 
were very good (97.6%)(table 5.25). 
Thermometer 
Scale / Itern (response range) 
% 
Missing 
% floor 
Mean (SD) (0-10) 
% ceiling 
(90-100) 
ICC (95% CT) 
(n= 166) 
Thermometer score 2.4 59.56 (21.36) 1.2 8.1 0.83 (. 78 -. 87) 
I 
Table 5.25 Scale properties of the EuroQol Thermometer. Results from combined postal and 
clinic surveys (n= 507). 
EuroQol Thermometer is scored 0-100; higher scores indicate better I]RQL. 
The wide range of scores (0 to 100) suggests that the thermometer was able to detect 
all health states from'worst imaginable'to 'best imaginable'in this population. The 
results were slightly skewed towards a more positive health state, with a mean value 
of 59.56 (21.36). When the scale was assessed in segments of'10-points', 1.2% of 
patients scored at the floor of the scale (between 0 and 10) and 8.1 % of patients 
scored at the ceiling (between 90 and 100). 
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The test-retest reliability of the thermometer was 0.83 in the larger postal survey (n-- 
166). 
SF-12 
The item and scale properties of the SF-12 are shown in table 5.26. The most 
frequently omitted items were items 7 ('Didn't do work or other activities as carefully 
as usual'- emotional)(3.5%) and item 5 (Were limited in the kind of work or other 
activities'- physical)(3.3%). Items 6 ('Accomplished less than you would like' - 
emotional)(2.0%) and item 4 CAccomplished less than you would like'- physical) 
(1.8%) were also frequently omitted. 
Response optims 
SF-12 %%% ICC (95% Cl) 
Item / Scale Missing Mean (SD) ceiling floor (n-- 156 ) 
Mental component scale 7.3 46.33 (10.43) 0.0 0.0 0.79 (. 73 -. 84) 
Physical component scale 7.3 36.95 (10.04) 0.0 0.0 0.90 (. 86 -. 92) 
1. General Health 1.2 2.80 (1.31) 4.4 11.0 
2. Moderate activities 1.2 2.42 (1.80) 24.3 27.7 
3. Climb flights of stairs 1.4 2.53 (2.04) 33.7 32.5 
4. Accomplished less- physical 1.8 1.86 (2.42) 37.3 62.7 
5. Limited in work/activities - 3.3 1.92 (2.44) 38.5 61.5 
physical health 
6. Accomplished less- emotional 2.0 2.92 (2.47) 58.4 41.6 
7. Work/activities as carefully - 3.5 0.76 (0.61) 60.8 39.2 
emotional 
8. Pain - normal work 1.0 2.59 (1.45) 8.5 11.5 
9. Cahn and peaceful 1.0 2.58 (1.37) 5.6 6.8 
10. Lot of energy 0.8 2.90 (1.46) 6.5 15.7 
11. Downhearted and blue 1.0 3.37 (1.23) 18.9 2.8 
12. Physical/Emotional health - 1.0 3.40 (1.49) 35.8 4.4 
social activities 
Table 5.26 Item and scale properties of the SF-12. Results from postal and clinic surveys 
combined (n=507). All items recoded (0-5). 
The SF-12 uses norm-based scoring from the general population, Scales are hwisformed. to have a mean of 50 (sd=10), with a 
=ge 0-100; higher scores indicate a better level of HRQL 
Items recoded 0-5, where 5 indicates a better level of HRQL 
To allow direct comparison of data quality and scaling assumptions between items, all 
response options were re-coded to equivalent scales (0-5). The response options for 
all items were covered and no item produced an end effect greater than 80%. 
There was equivalence of item means (SD) for seven items (items 1-3,6,8-9), with an 
approximately normal item response distribution. Item means were also similar for 
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items 4 (accomplished less than would like - physical) and 5 (limited in kind of work 
activities - physical), with a slightly skewed distribution of responses towards lower 
levels of HRQL. Items II (downhearted and blue) and 12 (physical / emotional 
health - social activities) had similar mean values with a slightly skewed distribution 
of responses towards better HRQL. Item 7 (work / activities as carefully as usual - 
emotional) had a very small mean value with no equivalence to other items and 
responses skewed towards better HRQL. 
A total of 470 (92.7%) patients completed all items in the SF-12. Mental (MCS) and 
physical component summary (PCS) scores were calculated for these patients. A 
wide range of scores were observed although the full possible range of either scale 
was not covered (MCS range 17.00 to 66.83; PCS range 12.04 to 63.34). The mean 
score for the MCS was 46.34 (SD 10.43), a value that was closer to the mean 
population score (50, SD 10) than the PCS mean value of 36.95 (SD 10.03). The 
scores for the MCS approximated normality. Scale sores for the PCS were slightly 
skewed towards the less physically abled scores. 
Levels of test-retest reliability were greater for the SF-12 PCS (0.90, n-- 156) than for 
the MCS (0.79). 
Summary oftest-retest reliahility 
Similar levels of test-retest reliability were found for both surveys (table 5.27). The 
lowest levels of reliability for both surveys was found for the SF-12 MCS (range 0.72 
- 0.79). All other instruments in the postal survey had levels of reliability above 0.80 
with three instruments producing estimates above 0.90 (ASQoL, RLDQ, SF-12 PCS). 
Three instruments in the clinic survey had estimated reliability levels greater than 
0.90 (RLDQ, Body Chart and EuroQol-therTnometer). Only the RLDQ consistently 
demonstrated this high level of reliability in both surveys. 
5.4.2 Results of data quality and test-retest reliability of anthropometric 
measures 
All patients participating in the clinic survey were assessed for their available range of 
movement by five different anthropornetric measurements. Scale properties are 
sbown in table 5.28. 
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Instrument / Score n 
Postal survey 
ICC (95% CI) n 
Clinic survey 
ICC (95% Cl) 
ASQoL 166 0.96 (. 94-. 97) 23 0.87 (. 73-. 94) 
BASDAI 150 0.87 (. 83-. 90) 21 0.89 (. 74-. 95) 
Body Chart (log) 142 0.86 (. 81-. 90) 25 0.87 (73-. 94) 
EuroQoI EQ-513 165 0.85 (. 80-. 89) 23 0.83 (. 63 to. 92) 
EuroQoI theTmometer 166 0.83 (. 78-. 87) 22 0.92 (. 82 to. 97) 
PGI-AS - 
blind and closed 144 0.83 (. 77-. 87) 
combined results 
PGI-AS - blind 75 0.81 (. 72 -. 90) 
PGI-AS - closed 69 0.87 (. 81 -. 92) 
PGl-AS -- 25 0.85 (. 69 to. 93) 
informed & open 
RLDQ 166 0.94 (92 -. 96) 23 0.93 (. 83 -. 97) 
SF-12 - MCS 156 0.79 (. 73 -. 84) 21 0.72 (. 75 -. 95) 
SF-12 - PCS 156 0.90 (86 -. 92) 21 0.89 (. 42 -. 87) 
Table 5.27 Test-retest reliability for study instruments (postal (n-- 173) and clinic surveys 
(n7=25)). 
ASQoL scored 0-18; lower scores indicate better HRQL. 
BASDAI scored 0-10; higher scores indicate greater disease activity. 
Body Chart scored from 0, with no maximum score. Hghcr scores indicate greater perceived body pain. 
EuroQol - EQ-51) scored -0.59 - 1.0; 1.0 is the best possible health. 
EuroQoI - thermometer scored 0-100; higher scores indicate better health states. 
PGI-AS scored 0-10; higher scores indicate better disease-related quality of life. Blind - blind to baseline areas; Closed - 
informed of baseline areas, but not allowed to change; Informed & open - informed of baseline areas, and allowed to change. 
RLDQ scored 048; higher scores indicate greater functional disability. 
SF-12 uses norm-based scoring from the general population. Scales are transformed to have a mean of 50 (sd 10), with a 
range 0-100; higher scores indicate better levels of HRQL. MCS - mental summary scale; PCS - physical summary scale. 
ICC = intra-class correlation coefficient. 95% Cl = 95% confidence interval 
The measurements of cervical rotation, fingertip to floor distance (FFD) and the 
Modified Scbober Index (15cm)(MSI) may all record minimum values of Ocm. This 
describes maximal limitation, or the'floor', of cervical rotation and the MSI, but the 
'ceiling' of FFD (maximal range equates to touching the floor). This score is not 
possible for lateral lumber flexion (LLF) or tragus to wall distance (TWD). It is not 
possible to describe a true end effect for these. measurements, there being no pre- 
defined maximal or minimal limit to the available range of movement. The number 
of patients scoring the maximum or minimum range of movement for the each 
measure is reported (table 5.28). 
Values for cervical rotation approximated normality, with equal range and similar 
mean values for both right and left rotation. Very few patients scored at the floor (0.0 
- 1. Ocm) (n= 1,0.6% left rotation; n-- 2,1.3% right rotation) or at the ceiling of the 
range (14.0-15. Ocm) (n-- 2,0.6% left rotation; n=4,1.9% right rotation). 
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Minimum score Maximum score 
Clinic Mean (SD) cm % cm % ICC 
Anthropometric measures (n-- 25) 
Cervical rotation 
- left 7.36 (3.74) 0.0 0.6 15.00 0.6 0.87 
0.0-1.0 4.3 14.0-15.0 1.2 
- right 7.28 (3.57) 0.0 0.6 15.50 2.4 0.95 
0.0-1.0 2.4 14.0-15.0 1.9 
Fingertip to floor distance 19.71 (15.73) 0.0 22.2 60.8 0.6 0.98 
Lateral lumbar flexion 
- left 53.10 (6.59) 25.8 0.6 68.4 0.6 0.95 
- right 52.21 (6.30) 21.3 0.6 65.0 0.6 0.98 
Modified Schober Index (I 5cm) 4.02 (2.30) 0.0 0.6 9.0 0.3 0.95 
0.0-1.0 10.8 8.0-9.0 3.3 
Tragus to wall Distance 17.94 (7.11) 9.1 0.6 44.5 0.6 0.98 
9.1-10.0 3.2 35.0-44.5 3.2 
Table 5.28 Scale properties of anthropornetric measures. Clinic survey (n-- 159) 
Cervical rotation - distance between tip of nose and acromioclavicular joint measured in neutral and maximum ipsilatcral 
rotation. Difference between two positions calculated, where a smaller difference indicates a more restricted range. 
Fingertip to floor distance - distance between tip of right middle finger and floor following maximum trunk flexion, where the 
smaller distance indicates greater movement. 
Lateral luinbar flexion - distance between tip of middle finger and floor measured following maximum ipsilateral lateral 
flexion, where the smaller distance indicates greater movement. 
Modified Schober index (15cm) (Macrae and Wright, 1969) - distance between two marks placed 15cm apart in standing (10cm 
proximal and Scm distal to posterior superior iliac spine). Distance after maximum trunk flexion, where a larger difference 
indicates greater lumbar movement 
Tragus to wall distance - Distance between right tragus and wall measured in standing, where a larger distance indicates worse 
spinal / upper cervical posture. 
A wide range. of results was observed for FFD (Ocrn to 60. Ocm). A large percentage 
of patients were capable of touching the floor, indicating very good trunk flexibility 
(n--35,22.2%). When these patients were taken into account, the results remained 
slightly skewed towards the smaller values, indicating better movement. When 
assessed in ranges of 10cm most patients were described by the range between 10- 
20cm FFD (27.2%). 11.4% of the population achieved measurements of more than 
40cm. FFD, with only one patient (0.6%) scoring at the floor of the recorded range 
(60.8cm). 
Lateral lumbar flexion was slightly skewed towards more limited movement A wide 
range of results was found, with most patients recording ranges between 50-59cm 
(55.1% left, 55.7% right). The distance was less than 40cm in very few patients (left 
2.5%, n-- 4; right 3.8%, n-- 5). 
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A wide range of values were found for the MSI (range 0-9.00cm). The measurement 
described a bi-modal distribution with a cluster of patients recording very limited 
movement (range 0-2.9cm), and a second cluster with greater range of movement 
(3.0-9. Ocm). One patient scored at the floor of the available range (O. Ocm) and two 
patients scored at the ceiling for this population (9. Ocm, 1.3%). When the movement 
is considered in lcm segments, 10.7% (n-- 17) of patients scored in the range 0-1. Ocm, 
and 3.3% (rr-- 7) patients scored between 8.0 - 9. Ocm. 
TWD provides an indication of the standing posture of the patient. Smaller values 
indicate a better posture. An increasingly stooped posture, often a hallmark of disease 
progression, increases TWD. A large range of values were found (range 9.1 to 
44.5cm), with results greatly skewed towards the lower values. However, 7.6% of the 
population recorded values in excess of 30. Ocm. 
High levels of test-retest reliability were found for all measurements (table 5.29), and 
levels greater than 0.90 were found for all measurements, except left cervical rotation. 
Test-retest reliability Inter-observer reliability 
(baseline values) 
Anthropometric measures n ICC (95% CI) n ICC (95%CI) 
Cervical rotation: starting position 
left - 51 0.65 (. 25 -. 82) 
right 0.68 (. 50 -. 80) 
Cervical rotation: difference 
- left 25 0.87 (. 94 -. 73) 51 0.94 (. 89-. 96) 
- right 0.95 (. 89-. 98) 0.90 (. 84-. 94) 
Fingertip to floor distance 25 0.98 (. 96-. 99) 51 0.96 (. 94-. 98) 
Lateral lumbar flexion 
left 25 0.95 (. 89-. 98) 51 0.96 (. 94-. 98) 
right 0.98 (. 95,99) 0.98 (. 97-. 99) 
Modified Schober Index (15cm) 25 0.95 (. 90-. 98) 51 0.90 (. 83-. 94) 
Tragus to wall distance 25 0.98 (. 96-. 99) 51 0.98 (. 97 -. 99) 
Table 5.29 Clinic survey test-retest reliability (AS and general health transition the same, n-- 25), 
and inter-observer reliability (2 observers) of anthropometric measures. 
aa description of each measurement can be found in table 5.28. 
ICC = intraclass correlation coefficient; 95% Cl = 95% confidence intervals. 
High inter-observer reliability was also found (table 5.29). The only exception was 
for the starting positions for cervical rotation (0.65 - 0.68). All other measurements 
achieved levels greater than 0.90. 
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5.5 Discussion 
Reliability may be defined as the extent to which an instrument produces consistent 
results when the underlying condition has not changed, and relates to consistency of 
results at one point in time or over time. For multi-item instruments based on 
classical test-construction theory internal consistency reliability describes the 
relationship between items measuring aspects of the same domain and is assessed at 
one point in time. Test-retest reliability assesses instrument temporal stability. 
Before instrument reliability is considered, performance both at item and scale level 
should be assessed through tests that relate to data quality and scaling assumptions. 
These tests have implications for item reduction and have been considered alongside 
the tests of internal consistency reliability. Where appropriate the study has 
demonstrated more extensive testing of the data quality and scaling assumptions, 
internal consistency reliability and test-retest reliability for all study instruments than 
previously reported. Also, a larger population of patients with AS than previously 
reported has been involved which increases the generalisability of the result. 
Two unresolved issues around the design of test-retest studies can be described: first, 
the most appropriate time period between repeat administrations; and secondly, how 
to account for patients who have actually changed. Published studies reporting the 
test-retest reliability of the study instruments have adopted various retest periods, 
varying from 1-hour to 3-months. Also, many fail to describe an external assessment 
of change. The current research has adopted a two-week retest period (Streiner and 
Norman, 1995) and may provide a more appropriate assessment of test-retest 
reliability than previously described for many study instruments. Researchers have 
attempted to describe change in health using clinical criteria, clinical opinion and 
health transition questions (Deyo et al, 1991; Fitzpatrick et al, 1993b). Health 
transition questions should address the underlying domain measured by the instrument 
and in the current study questions inquiring about change in both disease-specific and 
general health were adopted, with stability in both items being sought. The PGI-AS 
incorporates both disease-specific and generic issues in the final score and inclusion 
of both transition questions was particularly relevant. 
The data quality, scaling assumptions and reliability of individual instruments were 
assessed for both clinic and postal data individually. Results for both populations 
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were similar. Sample sizes for principal component analysis (PCA) were maximised 
by combining the two data-sets which produced components that were more readily 
interpretable. Results are discussed and recommendations for the modification and 
application of instruments made. 
a) PGI-AS 
This study has provided the first evidence for the data quality, scaling assumptions 
and test-retest reliability of the PGI-AS. Completion rates for the PGI-AS improve on 
levels reported by previous authors applying the original PGI (Ruta et al, 1999) which 
could be due to changes in the instrument structure. The PGI-AS trigger list is more 
extensive than those included in earlier versions of the PGI and closer affinity to items 
may have helped improve completion. During interview administration several 
patients remarked on the relevance of areas to their own life, gaining solace from the 
realisation that other patients with AS experienced similar problems. 
The test-retest reliability of the constituent parts of the PGI-AS and for three different 
formats was assessed. This deconstruction of the instrument promotes increased 
understanding of the contribution of each stage to overall reliability and any 
weaknesses can be identified. The three formats all had levels of reliability greater 
than 0.80 for the index score supporting their use in group evaluation (Ware, 1997). 
This is an improvement on all previous reliability estimates (Ruta et al, 1994a; 
MacDuff and Russel 1998; Ruta et al, 1999). 
High levels of reliability were found for patients not changing any areas in step 1, or 
scoring up to I -point on the index of change when completing the 'blind! (0.9 1) or 
'open and informed (0.85) formats. Although only a small sample size, this supports 
application of the 'blind' format in individual evaluation (>0.90). However, increased 
areas changes reduced reliability, and when more than three area changes were made 
reliability was not acceptable for group evaluation. When considered irrespective of 
the index of change 'blind' completion produced the lowest reliability (blind 0.8 1; 
informed and open 0.85; closed 0.87). 
Most patients completing the 'informed and oped format and indicating no change in 
health at two-weeks retained all baseline areas. Following the pattern observed for 
the Wind'format it may be hypothesised that reduced reliability would be associated 
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with an increase in area changes. Repetition of the study with a larger sample size 
may provide evidence to address this hypothesis. 
For all variants of the PGI-AS the un-weighted score reliability was lower than that 
estimated for the weighted index. The results satisfied levels recommended for group 
analysis (range 0.71 - 0.84) except where the index of change was high. This result 
suggests that the 'points' spent in step 3 are adding to instrument reliability. 
Evidence suggests that the most reliable versions of the PGI-AS are the'closed'and 
'informed and open! formats. In choosing the most appropriate follow-up format the 
trade-off between reliability and content validity should be considered. The 
assessment of disease-related quality of life in AS is a relative heterogeneous issue 
and the open nature of the PGI-AS baseline completion ensures the individuality of 
content to support the instrument conceptual base. The results suggest that during 
follow-up completion when informed of baseline areas and given the opportunity to 
change areas most patients reporting no change in their underlying condition choose 
not to make large changes to areas listed. Therefore, Wind' completion may introduce 
'noise'to follow-up completion of the PGI-AS leading to a reduction in reliability, and 
the 'informed and open! format may not be necessary. Therefore, keeping selected 
areas the same at follow-up completion may improve the clinical validity of the 
instrument for evaluative purposes, without threatening content validity. 
However, this result focuses only on patients indicating no change in condition at 
two-weeks and patients reporting change may not demonstrate the same stability of 
areas. The acceptability of providing patients with their baseline responses without 
providing the format whereby items can be changed or retained as necessary fails to 
support the potentially dynamic and reflective nature of the PGL This is an issue that 
will be returned to in the evaluation of instrument responsiveness (Chapter 7). 
Patients completing the PGI-AS in the clinic survey requested greatest assistance with 
step 2 (scoring areas). A reduction in the number of response options from 10 to, for 
example, 5 may reduce the complexity of this step thereby improving acceptability. It 
would also Teduce the variance associated with the score and may improve reliability. 
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The majority of scoring anomalies during self-completion of the PGI-AS involved the 
spending of points in step 3. Many instrument developers adjust for missing data and 
a'window of erroe could be calculated for the PGI-AS so that a score is not 
jeopardised by a possible miscalculation of points. For example, spending 13 to 15 
points. Several patients indicated that '14' points was an unusual number and found 
division difficult. A more rounded number such as'10'or 1100'was felt to be more 
acceptable. Other patients indicated that there werejust not enough points', finding 
prioritisation difficult. A revision of points instep 3 to '10' maybe more acceptable 
and may facilitate prioritisation of areas. 
b) Disease-specific 
Completion rates for the ASQoL and the RLDQ were very good and most items in 
both instruments had only minimal levels of missing data. No items were omitted by 
more than 10% of patients. Several patients (0.8%) had read through the ASQoL and 
'ticked' one box only which could be in response to the request 'tick the 'one' response 
that best applies', and further clarification may be beneficial. Also, several patients 
had difficulty with the dichotomous response. The most frequently omitted item from 
the RLDQ was item 4a (Valk on your heels')(7.7%). 
There were unacceptable levels of missing data for the BASDAI, in particular for item 
6 ('How long does your morning stiffness last from the time you wake upT). Strict 
application of the proposed criteria for item rejection would have resulted in removing 
the instrument from the study. However, the BASDAI was retained so that its 
measurement properties could be compared to the other instruments albeit for the 
subset of patients that completed the instrument adequately. 
The suggestion by the BASDAI developers that VAS offer highly sensitive response 
scales capable of detecting small degrees of change (Garrett et al, 1994) should be 
considered in light of the many completion inaccuracies encountered in this study. A 
revision of the response scale for the whole instrument is strongly recommended. For 
example, replacing the VAS with five or seven-point adjectival scales with discrete or 
continuous responses (Streiner and Norman, 1995). 
Completion rates for the Body Chart were greater for the clinic than for the postal 
survey (99.4% vs 88.8%). Improved completion in the clinic survey may be 
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explained by the ability of the therapist to further clarify instructions. Furthermore, 
the routine use of the instrument at the SRC may have helped to familiarise patients 
with the instrument. A larger score range was found in the postal population. 
Patients may have taken more time to consider their body pain and to complete the 
chart without feeling pressurised by the presence of the therapist. Alternatively, clinic 
patients often requested clarification about the time period over which to consider 
their pain and the therapist may have clarified the request for'current or present pain! 
only. A greater percentage of the clinic population scored at the ceiling. However, 
this may reflect the failure of the instrument to clearly indicate the procedure for self- 
completion ifno pain'is experienced. Body charts devoid of shading and scoring 
following self-completion may indicate non-completion due to lack of understanding 
or lack of pain. 
The expression of bodily pain on the body chart is limited by the approach adopted in 
shading the manikin. If the manikin is shaded as'one area! and a single score of 4 
awarded this low score would be in contrast to the patient shading the manikin as 
several areas and giving each area a score of 4. Although both patients describe pain 
traversing the whole body the final score does not describe the equality in pain 
distribution or severity. The low completion rate following self-completion indicates 
that modifications to enhance completion are required. For example, further 
clarification of the scoring procedure, both when minimal or extreme pain is present 
and when multiple areas of pain are identified. 
A check of the measurement properties is appropriate when an instrument is modified 
or applied in a new setting (13jorner et al, 1998), and this study provides the first 
evidence of the data quality, scaling assumptions and reliability of the revised RLDQ. 
Although all response options at item level were covered and end-effects did not 
exceed critical levels, the distribution of responses was skewed towards better levels 
of functional ability. The descriptors used in the ordinal response scale may fail to 
provide clear options for fine discrimination between levels of functional ability at 
item level with the majority of responders endorsing'Able to do'and'Able to do with 
difficulty'. Patients may find difficulty distinguishing between these options when, 
during the slow progress of the disease they learn to adapt to their environment. If 
response options and descriptors are limited a major change in functional ability is 
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required before a change in response is recorded, and if responses fail to cover the full 
range of limitations in AS the instrument may have limited validity. 
However, increasing the number of response options or changing the descriptors may 
not improve score distribution if the majority of patients score at the end of a scale. 
Therefore, there is also a case for using different items representing 'hardee functional 
activities that offer better discrimination between patients. Several items (2d, 4c-d) 
had a less skewed distribution of responses with higher mean values which would 
suggest that they addressed 'harder' functional activities. Two of these items (4c-d) 
also had lower levels of item-total correlation than all other items. Therefore, 
although appearing less efficient when assessed by item-internal consistency they may 
accomplish an objective of raising the scale ceiling and improving content validity 
(Ware and Gandek, 1998b). The final scale score of the RLDQ demonstrated a more 
normally distributed response although the full range of responses reflecting increased 
functional difficulty was not recorded. The need to include more arduous functional 
activities in the parent instrument, the LDQ, was described in Chapter 2. A similar 
problem with the revised RLDQ has been described by the current study. 
The assessment of dimensionality and item-total correlation supports the 
unidimensionality of the ASQoL, BASDAI and RLDQ proposed by the instrument 
developers. The results provide evidence in support of the data quality and scaling 
assumptions of the ASQoL at both item and scale level and of the BASDAI and 
RLDQ at scale level. 
Published evidence of the reliability of both the ASQoL and RLDQ is not available, 
and study estimates of both internal consistency reliability and test-retest reliability 
are very good supporting their use in individual evaluation. Greater levels of test- 
retest (0.97) reliability than internal consistency reliability (0.92) were calculated for 
the ASQoL. Internal consistency reliability (0.93) and test-retest reliability (0.94) for 
the RLDQ were similar, and were similar to levels reported for the parent instrument, 
the LDQ (Abbott et al, 1994). 
Test-retest reliability of the BASDAI was satisfactory and equivalent to the internal 
consistency reliability (0.87). The estimate of internal consistency reliability 
improved on published levels (Jones et al, 1996c; Calin et al, 1999a), although test- 
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retest reliability was lower (Garrett et al, 1994) and did not support application in 
individual evaluation. Satisfactory test-retest reliability was found for the Body Chart 
(>0.86). The BASDAI and Body Chart have levels of reliability acceptable for use in 
group evaluation. 
c) Generic 
This study has provided the first evidence for the reliability of the EuroQol and the 
SF-12 in AS. The EuroQol EQ-51) and thermometer had the lowest levels of missing 
data and hence the best completion rates for all study instruments. Completion rates 
of the SF-12 were also good. Items relating to limitation in work or usual activities 
due to emotional or physical health problems were most frequently omitted. Non- 
completion of these items in the SF-12 and in the parent instrument, the SF-36, has 
been previously reported in patients with RA (Hurst et al, 1998; Ruta et al, 1998). 
Although the omission of individual items was not high (range 0.8 to 3.5%), the 
omission of a single item prevents the calculation of a final score in the SF-12 (7.3%). 
The SF-36 allows patients to omit up to half of the items in the instrument without 
jeopardising a final score. It is suggested that final score calculation of the SF-12 
could be improved if the criterion for item completion was not so strict and the role of 
mean score computation could be assessed. The subsequent impact of this on 
measurement properties would need to be addressed. 
Test-retest reliability for both parts of the EuroQoI (EQ-5D 0.85; thermometer 0.83) 
and the SF-12 MCS (0.79) was good, supporting use in group evaluation. The result 
for the EuroQoI improves on those reported by authors applying the instrument in 
patients with RA (EQ-51) 0.78; thermometer 0.83) (Hurst et al, 1997). A high level of 
test-retest reliability was found for the SF-12 PCS (0.90), supporting application in 
individual evaluation. The two-week test retest reliability of the SF-12 has not been 
reported in a UK patient population with a similar status to AS. 
d) Anthropometric measures 
Both fingertip to floor distance following trunk anterior flexion (FFD) and lateral 
lumbar flexion (LLF) were measured purely as a reflection of the distance between 
the tip of the middle finger and the floor following the described movement. 
Measurement did not consider patient height or the starting distance in neutral. 
Therefore, a tall patient with large range of movement may record a similar fingertip 
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to floor distance as a patient of smaller stature with limited movement. In light of this 
anomaly the results for both measures are informative at the individual level only. 
Calculation of the score as a percentage of the starting position distance may provide 
a more standardised result suitable for group comparison. 
A wide range of values were recorded for the MSI (mean 4.02cm (SD 2.30); range 0- 
9.00cm). Moll et al (1971) investigated the available range of lumbar flexion in 
'normal' subjects when measured by the MSI and found an approximately normal 
distribution of results (n-- 237; mean 4.93cm (SD 0.90) to 7.23cm (SD 0.92) 
dependent on age and sex groupings; range 3.5-10. Ocm). The population described in 
the current study therefore covered a broad spectrum of lumbar mobility ranging from 
extreme limitation to levels comparable with the normal population. 
All anthropornetric measures had estimates of test-retest reliability greater than 0.90, 
achieving the more stringent levels of reliability for individual evaluation (Nunnally 
and Bernstein, 1994). 
Conclusion 
When data quality and scaling assumptions are assessed, all instruments, except for 
the BASDAI, demonstrate adequate properties at both item and scale level. The 
BASDAI demonstrates adequate properties at scale level in those patients completing 
the instrument adequately to receive a score but modification of the response format 
to improve item completion is strongly recommended. 
All measures of outcome are sufficiently reliable for group evaluation. The ASQoL, 
RLDQ, SF-12 PCS and all anthropometric measures have estimates of reliability that 
support application in individual evaluation (Nunnally and Bernstein, 1994). 
Modifications to the BASDAI, Body Chart, PGI-AS and RLDQ have been suggested 
that may lead to improved data quality, scaling assumptions and levels of reliability. 
Modifications to the scoring of FFD and LLF have been made that may support 
adoption in group evaluation. 
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Chapter 6 Validity 
6.1 Introduction 
This chapter presents the validity testing for the study instruments. Section 6.2 
describes the different types of validity used to assess measures of health outcome. 
Section 6.3 presents the methods of validity testing for the study instruments. After 
the results are presented in section 6.4 the chapter closes with a discussion. 
6.2 Validity and measures of health outcome 
Validity considers how well an instrument measures what it purports to measure in 
the settings in which the instrument may be applied (Nunnally and Bernstein, 1994). 
Evidence of the validity of applying an instrument in different situations, to evaluate 
underlying theories, to investigate different relationships and to further establish 
confirmatory information in support of the instruments purpose is an on-going 
process. The process of validity testing facilitates score interpretation and furthers 
appreciation of what change in scores actually mean (Ware, 1997). 
6.2.1 Methods of validity testing 
Three forms of validity are most frequently applied in the evaluation of measures of 
health outcome: content, criterion and construct validity (Ware, 1997). Evidence to 
support the extent to which an instrument is capable of expressing an underlying and 
defined domain is common to all forms of validity. Although methodologically the 
three forms vary, all may have the concept of construct validity as their base, 
construct validity representing the 'basic meaning of validity' (Streiner and Norman, 
1995). 
Content validity 
Content validity does not involve statistical analysis, but does require a more 
qualitative appreciation of instrument content. Judgement of domain coverage And 
the inclusion of representative items requires an accepted definition or theoretical 
description of instrument purpose. Appreciation of methods adopted in item selection 
may also be beneficial (Fitzpatrick et al, 1998a). However, instrument developers 
often omit to detail these important issues (McDowell and Newell, 1996; Chapter 2). 
If the purpose and conceptual base is not clarified or instrument content fails to cover 
the defined domain invalid inferences may be made. 
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Criterion validity 
The assessment of criterion validity requires the presence of external criteria for 
which known and independent evidence in support of the criteria is available and 
against which the results of the instrument may be compared (Ware, 1997). If 
criterion information is produced concurrently then it is concurrent validity. If it is 
produced in the future then it is predictive validity. 
Circumstances where evidence in support of concurrent validity may be observed in 
the evaluation of measures of health outcome are where refined versions of an 
instrument are assessed alongside the original. It would be hoped that the modified 
version would retain the important attributes of the original and a strong relationship 
would be predicted. In response to the need to produce a shorter patient-based 
measure of outcome the SF-12 was developed from the SF-36 (Ware et al, 1995). 
Multiple regression analysis was used to select twelve items from the eight scales of 
the parent measure that best represented the physical (PCS) and mental (MCS) 
component summary scales (Ware et al, 1994; Gandek et al, 1998b). The 
performance of the SF-12 is comparable to that of the SF-36 in several different 
patient populations (Ware et al, 1996; Hurst et al, 1998), whilst having the advantage 
of being shorter, quicker to complete and therefore potentially more acceptable to 
clinical practice and research. 
In the field of health outcomes it is unlikely that an instrument is available for which 
evidence of criterion validity or a'gold standard'is available. Ware (1997) suggests 
that most criteria are infact variables with a conceptual relationship to the domain of 
concern. They are not criteria in the sense of an independent 'gold standard! but they 
are capable of providing meaningful inforination for empirical tests evaluating 
instrument application. This requires that underlying relationships between different 
variables are considered. Most assessments of the validity of measures of health 
outcome will rely on establishing evidence in support of the hypothesised relationship 
between variables which is defined as construct validity. 
Construct validity 
Construct validity considers the relationship between a measure and a hypothetical 
construct. A construct may be defined as a non-observable variable which by 
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definition address a more general hypothesis than that supported by a specific 
behaviour (Nunnally and Bernstein, 1994). In the field of health outcomes variables 
relating to, for example, HRQL may be considered constructs due to the inability to 
relate such concepts to a concrete and observable theory. Theories to describe the 
hypothesised relationship between such variables, for example, between HRQL and 
functional disability, may be described as 'hypothetical constructs'. Instruments 
designed to measure health outcome attempt to address an aspect of this hypothetical 
construct (Streiner and Norman, 1995). 
The first step in establishing evidence to support the construct validity of an 
instrument is to clearly define the domain addressed. Once a domain and a construct 
have been defined the relationship between the instrument and different variables can 
be investigated to test underlying theories (Ware, 1997). The support for construct 
validity lies in the accumulation of evidence from various experiments to test a range 
of hypothesised relationships. 
Two forms of validity have been described which form the basis of construct validity. 
These are convergent and discriminant validity where the statistical relationship 
between variables is usually correlational (Ware, 1997). Convergent validity 
addresses the relationship between two different measures of the same construct. It 
would be hypothesised that these measures would produce similar results and 
demonstrate a strong correlation. Alternatively, discriminant validity estimates the 
relationship between two instruments measuring unrelated constructs. These 
instruments should not be related and small correlation would be expected. The 
adoption of the multitrait-multimethod matrix (MTMM)(Campbell and Fiske, 1959) 
allows a number of validity issues, in particular convergent and discriminant validity, 
to be addressed simultaneously. In circumstances where different methods of 
assessing the same domain have been included in the evaluation or where different 
domains have been measured with several instruments the convergent or discriminant 
nature of the relationships may be assessed. 
McDowell and Jenkinson (1996) stress the importance of predicting the strength of 
relationship to be expected between instruments apriori, and of describing both 
convergent and discriminant relationships 'to permit validity to be disproved'. 
Although it is difficult to predict relationships between constructs the level of 
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statistical correlation provides evidence in support of the hypothesised relationship. If 
it is hypothesised that a new instrument addresses a major part of the domain 
addressed by an established instrument a large correlation would be predicted 
(Streiner and Norman, 1995). Too high a correlation would suggest that the 
instruments were measuring very similar attributes and that the new instrument was 
offering little more than a different approach. If the new instrument addressed only 
one aspect of a multi-dimensional domain addressed by the established instrument 
then a small correlation would be expected. 
In assessing validity the level of instrument reliability and criteria to which it is being 
compared should be considered as this places an upper limit on the expected level of 
association (Streiner and Norman, 1995). McHorney et al (1993) provide guidance to 
interpretation of the level of correlation between variables: a correlation of more than 
0.70 would describe a large relationship, 0.50 a moderate relationship, and less than 
0.30 a small relationship. 
Construct validity can also be assessed by the use of 'extreme groups' which theorises 
that one group will possess more or less of the defined attribute to be measured by the 
instrument (Streiner and Norman, 1995). In support of the construct validity of the 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), scores of a 
population of AS in-patients and AS out-patients were compared (Garrett et al, 1994). 
The authors theorised that the in-patient population would have higher scores on the 
BASDAI than the out-patient population. This was the association which was 
evidence for the validity of the BASDAL 
Many instrument developers investigate the relationship between health and socio- 
deomographic characteristics as a basis for evidence in hypothesis testing for 
construct validity. Several authors have reported on the positive relationship between 
health and socioeconomic status (Garratt, 1997). 
Published evidence in support of the validity of all disease-specific study instruments 
(Chapter 2) is summarised in table 6.1. Most developers fail to provide apriori 
hypotheses. Rather, a list of correlation coefficients is provided which the authors 
indicate as evidence for instrument validity. 
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Author Instrument AS population 
(n) 
Method Correlation coefficient 
Garrett et al BASDAI 46 in-patients Comparison between scores for in-patient and Higher scores for in- 
(1994) 108 out-patients out-patients patients (p=0.005) 
46 in-patients Correlation between BASDAI and Bath Disease 0.75 
Activity Index (Bath DAI = original BASDAI) 
Jones et al BASDAI 200 out-patients Correlation between the BASDAI and the Bath 0.73 
(I 996a) AS Global scale (BAS-G) 
Dziedzic Body Chart 69 out-patients Correlation between Body Chart and: 
(1997) Patient perceived pain (VAS) 0.32 
Night pain (VAS) 0.55 
Stifliness (VAS) 0.54 
Enthesitis scores 0.50 to 0.53 
Pain disability questionnaire 0.50 
Cervical mobility (tape measure) -0.30 to -0.42 
Fingertip to Floor Distance 0.36 
Lumbar spine side flexion 0.30 to 0.39 
Modified Schober Index (flexion)(15cm) -0.30 
Tragus to Wall distance. 0.31 
Abbott et al LDQ 42 out-patients Two groups according to LDQ score -besf and Vorse functional 
(1994) 'worse' function. Comparison between groups group - older, longer for age, disease duration, ROM and posture. disease duration, 
limited ROM / posture. 
Correlation between sections of LDQ and: 
Cervical mobility (goniorneter) -0.27 to -0.73 
Chest expansion -0.33 to -0.54 
Fingertip to Floor Distance 0.35 to 0.62 
Lumbar spine extension -0.31 to -0.60 
Modified Schober Index (I 5cm) -0.38 to -0.62 
Tragus to Wall distance 0.30 to 0.57 
Table 6.1 Evidence of the validity of disease-specific study instruments. 
There is no published evidence in support of the ASQoL, RLDQ and PGI-AS in 
patients with AS. 
6.3 Methods for assessing the validity of the study instruments 
The measurement properties of the EuroQol and SF-12 have not previously been 
assessed in patients with AS. However, both have well documented evidence of 
development and validity testing, and have evidence supporting their validity as 
generic measures of HRQL in patients with chronic disorders similar to AS (table 6.2) 
(Ware et at, 1995; Hurst et at, 1997; Hurst et at, 1998). Evaluation in patients with 
RA supported the validity of the EuroQol as a measure of HRQL (Hurst et at, 1997), 
the SF-12 PCS as a measure of physical health and of the SF-12 MCS as a measure of 
mental health (Hurst et at, 1998). The SF-12 MCS was reportedly a better measure of 
mental health than the SF-36 MCS, the longer version demonstrating that in part it 
was measuring the impact of RA on physical status (Ruta et at, 1998). 
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Author Instrument Patient population Validation 
Hurst et al (1994) EuroQoI 55 RA out-patients Correlation between EQ-51) and EQ-thermometer with HAD; 
HAQ and clinical measures 
Hurst et al (1997) EuroQoI 233 RA out-patients Correlation between EQ-513 and MHAQ, HAD and socio- 
economic variables 
Ruta et al (1998 ) SF-36 233 RA out-patients SF-36 PCS and MCS scores and eight scales with SF-12 PCS 
and MCS scores, MHAQ, core disease activity measures, I LALD 
Hurst et al. (1998) SF-12 233 RA out-patients SF-12 PCS and MCS scores with SF-36 PCS and MCS scores, 
eight SF-36 subscales, IMAQ and the HAD 
Table 6.2 Studies assessing the validity of the EuroQol, SF-36 and SF-12 in patients with 
Rheumatoid Arthritis. 
Key: MI-IAQ - Modified Health Assessment Questionnaire; HAD - Hospital Anxiety and Depression questionnaire. 
Therefore, the EuroQol and SF-12 can contribute to the validation of other study 
instruments and both are expected to correlate more strongly with other measures of 
HRQL, disability and pain than with measures of impairment and disease process. 
6.3.1 Validity of the study instruments 
The content and conceptual base of a multi-item instrument provides a strategy by 
which the construct validity may be considered (Keller et al, 1999b). The content 
validity of all patient-based instruments has been summarised in Chapters 2 and 5, 
and now consideration is given to the expected relationships between all study 
instruments. Figure 6.1 surnmarises the tests of validity performed. 
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Figure 6.1 Tests of validity for the study instruments 
The PGI-AS is the most recent instrument to be applied in AS. Therefore, it is 
correlated with disease-specific, generic and anthropometric measures of outcome, 
and compared against sociodemographic variables. There are a number of disease- 
specific instruments within AS and those selected for inclusion in the study are 
correlated with each other to assess the convergent validity of related dimensions. 
They are also compared to the generic instruments, the anthropornetric measures and 
against sociodemographic variables. The generic instruments are used to test the 
construct validity of the PGI-AS and the disease-specific instruments, and are 
therefore assessed through comparison with anthropometric measures and against 
sociodemographic variables. The anthropometric measures are assessed for 
convergent validity through correlation with other anthropometric measures. 
To support the generation of theoretical relationships between patient-based 
instruments the underpinning purpose and item content of all instruments is 
considered (tables 6.3 and 6.4). Although the defined purpose is important in 
considering the relationship between instruments, item content and content overlap 
play the most important role in supporting hypothesis generation. The Body Chart is 
a disease-specific measure of current or present bodily pain, and does not contain 
individual items. 
Hypothesised theoretical relationships between all domains were considered a priori 
(table 6.5) and are detailed in the following section. Where possible, relationships 
tested previously by instrument developers were re-tested. 
a) PGI-AS 
The PGI-AS is a disease-specific measure of disease-related quality of life, 
represented as the gap between a patients expectations and reality (after Ruta et al, 
1994a). The PGI-AS reflects the extent to which a patients' experience of a disease 
may detract from fulfillment of life quality. 
Content validity 
The frequency with which trigger list and supplementary items are mentioned will be 
considered support for the adequacy to which issues akin to AS-related quality of life 
are measured by the PGI-AS, hence supporting the content validity of the trigger list. 
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Disease-specific instruments 
ASQoL - BASDAI - PGI-AS - trigger list RLDQ - 
HRQL disease activity disease-related quality of life finictional. disability 
Limits places Fatigue / tiredness Impact on work Life enjoyment Getting into and out 
Feel like crying, AS neck, back or hip Worry about future Worry-letting people of the 
bath 
Difficulty dressing pain Relationship with 
down Getting into and out 
Struggle with jobs at 
Pain / swelling - wife / husband Independence of 
the car 
home joints other than partner Difficulty dressing Getting up and out of 
Impossible to sleep 
neck, back, hips Unable to plan ahead washing 
bed - morning 
Unable to join in 
Discomfort - tender 
to touch / pressure 
Feelings of low self- Ability -jobs around 
Rolling over in bed 
activities with friends esteem 
the home Wiping yourself after 
/ family Morning stiffness 
(severity) 
Ability to play with Relationship with using the toilet 
Tired all of the time children 
friends Putting on / take off 
Have to keep stopping 
Morning stiffness 
(duration) 
Sex life Social life socks 
to rest Family life Embarrassment 
Put on shoes / tie 
laces 
Unbearable pain Pain Self body image Cut toe nails 
Time to get going - in Disturbed sleep Worry - future Open high window the morning Difficulty 'getting Fatigue 
Unable to do jobs goingý in morning Feeling tired 
Looking both ways - 
crossing road around the home Walking 
Tired easily 
Loss of motivation Look at what Teaching 
Difficulty sitting/ Depression - high shelf 
Often get frustrated standing / lying down 
Moody Drinking - small glass Pain always there Physical activity 
Hobbies Walk on heels 
Miss out on a lot Fear of falling 
Sporting activities Cough or sneeze Difficult-wash hair Increased time to do Sleep - back 
Condition gets me 
things Driving 
down Control over life Limited spinal 
Sleep - stomach 
Worry-letting people Ability to plan ahead mobility 
down Mental activity 
Table 6.3 Definition of purpose and item content of disease-specific instruments. 
Generic instruments 
EuroQoI 5-D EuroQoI Thermometer SF-12 MCS SF-12 PCS 
HRQL health status mental-component scale physical component scale 
Mobility Range: Accomplished less - role General health - (EVGFP 
No problems walking Worst imaginable health emotional rating) 
abour to 'confined to bed' state' to Not carefid - work Moderate activities - 
Self-care 'Best imaginable health activities - role emotional physical function 
No problems' to Unable to state' Calm and peaceful Climb several stairs 
wash or dress myself 
Usual activities (e. g., work, 
Energy Accomplished less - role 
study, housework, family or Downhearted and blue 
physical 
leisure activities) Social time - physical 
Limited in kind of work 
No problems' to Unable to health or emotional activities - role physical 
perform! problems Bodily pain interfere with 
Pain / discomfort normal work - includes 
No pain / discomfort'to work outside home and 
'extreme pain / discomfort' housework 
Anxiety /depression 
Not anxious or depressed 
to'extremely anxious or 
depressed 
Table 6.4 Definition of purpose and item content of generic instruments. 
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The item content of the PGI-AS will be compared to that of the only other AS- 
specific measure of HRQL, the ASQoL. It was hypothesised that a broader range of 
areas listed by patients completing the PGI-AS might confer greater validity as a 
measure of HRQL in AS above that of the ASQol (Herd et al, 1997). 
Construct validity 
In support of the conceptual base of the PGI Garratt (1997) suggests that'health is not 
usually valued for its own sake, but for the extent to which it influences our ability to 
enjoy life'. Rather than simply deriving a nominal score for health and non-health 
related issues determined important by a patient, the PGI-AS considers the 
relationship between these issues and the ability to fulfill ones expectations of life. 
Therefore, to the extent that health or disease influences life quality and the PGI-AS is 
a valid measure of disease-related quality of life, a moderate level of correlation 
would be hypothesised between the PGI-AS and other disease-specific and generic 
instruments (table 6-5). 
From a total of seven items that may be considered in completion of the PGI-AS five 
are disease-specific. Item 6 relates to general health status and the remaining item 
refers to non-health issues. It is therefore likely that the majority of PGI-AS content 
will be disease-specific and a larger (moderate) correlation with disease-specific 
instruments than seen with generic instruments is hypothesised. However, the 
inclusion of 'non-health! items is hypothesised to reduce the expected relationship of 
the PGI-AS with both disease-specific and generic instruments. 
The PGI-AS and ASQoL are disease-specific measures of HRQL with similar item 
content (table 6.3), but the generic and non-health components of the PGI-AS 
suggests that there will be a moderate, as opposed to a large level of correlation. Herd 
et al (1997) compared an original version of the PGI with a disease specific measure 
of HRQL (Dermatology Quality Life Index - DQI) and found a moderate correlation 
(-0.52). 
The main issues measured by the BASDAI (disease activity) and Body Chart (bodily 
pain) are within the PGI-AS trigger list (table 6.3). It is hypothesised that the 
BASDAI and Body Chart would have moderate levels of correlation with the PGI- 
AS. 
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Several issues measured by the RLDQ (functional ability) are within the PGI-AS 
trigger list (table 6.3). However, to the extent that additional items not included in the 
trigger list may be described by patients completing the PGI-AS a moderate 
correlation between these two instruments is expected. 
Previous research has demonstrated small to moderate levels of correlation between 
the original version of the PGI and scales of the SF-36 in patients with low back pain 
(Ruta et al, 1999). The largest correlations were between the PGI and the pain (0.47) 
and social functioning scales (0.38). Although the PGI-AS is disease-specific and the 
EuroQol and SF-12 generic measures of HRQL, several issues addressed by the 
generic instruments are within the PGI-AS trigger list (tables 6.3 and 6.4). Therefore, 
a small to moderate correlation is hypothesised between the PGI-AS and both generic 
instruments. 
Anthropornetric measures of impairment are not expected to have large correlations 
with patient-based instruments. Where movement limitation is potentially reversible 
such limitations are expected to influence ones ability to fulfill the demands and 
expectations of life, and a small to moderate correlation with the patient-based 
instruments are expected. Measures reflecting irreversible change in axial status and 
spinal mobility are associated with disease progression and changes occur over 
prolonged periods of time (van der Linden and van der Heijde, 1995; Calin et al, 
1999c). A patient may learn to compensate for movement limitation with a 
consequent change in expectation. A small relationship with measures of HRQL is 
expected. 
It is hypothesised that the PGI-AS would: 1) have moderate levels of correlation with 
the ASQoL, BASDAI, Body Chart, and the RLDQ; 2) have small to moderate levels 
of correlation with the EuroQoI and SF-12; 3) have small levels of correlation with 
cervical rotation and fingertip to floor distance (FFD); 4) have little or no correlation 
with other anthropornetric measures (table 6.5). 
b) Disease-spectric instruments 
The ASQoL (HRQL), BASDAI (disease activity), Body Chart (bodily pain) and the 
RLDQ (functional ability) all measure related aspects of HRQL. The main issues 
measured by the BASDAI and Body Chart, and several items measured by the RLDQ, 
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are within the item content of the ASQoL (table 6.3). Therefore, a large level of 
correlation is hypothesised between the ASQoL and the BASDAI, with moderate to 
large levels of correlation between the ASQoL and both the Body Chart and RLDQ 
(table 6.5). 
The BASDAI and Body Chart measure closely related aspects of health and have a 
similar item content (table 6.3), and a large correlation is hypothesised. There is 
minimal overlap of item content between the BASDAI or Body Chart and the RLDQ 
(table 6.3). However, all instruments measure related aspects of health and active 
disease and pain have an impact on normal function. Moderate levels of correlation 
between these three instruments are hypothesised. 
A similarity of item content exists between the ASQoL and the EuroQol EQ-51) and 
SF-12 PCS (tables 6.3 and 6.4). However, items in the ASQoL are not clearly 
anchored to AS and a moderate to large correlation is hypothesised with the EQ-51) 
and SF-12 PCS, and a moderate correlation with the EuroQol thermometer. If 
ASQoL items were more clearly anchored to the impact of AS a more moderate 
correlation would be hypothesised. Bodily pain is one aspect of HRQL measured by 
the SF-12 PCS and EQ-5D (table 6.4), and so a moderate correlation is hypothesised 
between the BASDAI and the Body Chart and these generic instruments, and small to 
moderate correlation with the EuroQoI thermometer. The EuroQol and SF-12 are 
generic instruments developed to measure multiple health domains related to HRQL 
and so a moderate correlation with instruments measuring varied disease-specific 
domains rather than a very large correlation with any single domain is hypothesised 
(table 6.5). 
Pain, tiredness and fatigue may be associated with adverse mental health (Jenkinson 
et al, 1999a). A similar item content between the ASQoL, BASDAI and SF-12 MCS 
exists (tables 6.3 and 6.4), and so a moderate correlation with the SF-12 MCS is 
hypothesised. A small to moderate correlation is hypothesised between the Body 
Chart and the SF-12 MCS. 
Both the RLDQ and SF- 12 PCS have similar item content (tables 6.3 and 6.4), but the 
disease-specific and generic nature suggests that there will only be a moderate level of 
correlation. Similarly, a moderate correlation is hypothesised between the RLDQ and 
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both sections of the EuroQol. The RLDQ and SF-12 MCS address different issues 
and therefore a small correlation is hypothesised. 
Limited mobility affects the ability to satisfy ones needs as reflected by items in the 
ASQoL and a small relationship with anthropometric measures which may reflect 
reversible change is hypothesised. Pain influences mobility and so a small correlation 
between the BASDAI, the Body Chart and these anthropometric measures is also 
hypothesised. However, anthropometric measures representative of irreversible 
change in mobility are not expected to have any relationship with measures of HRQL. 
The developers of the RLDQ reported moderate to large correlations between sections 
of the parent instrument, the LDQ, and a selection of anthropometric measures (table 
6.1) (Abbott et al, 1994). The largest correlation was between cervical rotation and 
section 3 (Neck mobility). However, the correlation between the LDQ index score 
and anthropometric measures was not reported. 
Activities measured by the RLDQ (table 6.3), are influenced by limited mobility and a 
moderate association with most anthropometric measures is hypothesised. Several 
items reflect cervical mobility and a moderate to large correlation with cervical 
rotation and tragus to wall distance (TWD) is hypothesised. A moderate correlation 
with FFD and the Modified Schober index (MSI) is expected due to the impact of 
reduced flexibility and limited spinal mobility on several activities measured. Lateral 
lumbar flexion (LLF) is not expected to influence many activities measured and a 
small correlation is hypothesised. 
As summarised in table 6.5, it is hypothesised that all disease-specific instruments 
would: 1) have a moderate to large level of correlation with other disease-specific 
instruments; 2) have a moderate (to large) level of correlation with the EuroQoI (EQ- 
5D and thermometer) and SF-12 PCS; 3) have a small to moderate correlation with 
the SF- 12 MCS; 4) have a small correlation with cervical rotation and FFD, and 6) 
have little or no correlation with remaining anthropometric measures. Only the 
RLDQ is expected to have a moderate to large correlation with cervical rotation, FFD, 
the MSI and TWD. 
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c) Generic instruments 
The EuroQoI and SF-12 have similar item content (table 6.4), and so a moderate 
correlation is hypothesised between the EuroQoI and the SF-12 PCS, and a small to 
moderate correlation with the SF-12 MCS (table 6-5). Evidence suggests that a small 
to moderate correlation is expected between the EQ-5D and thermometer (Hurst et al, 
1994), and a small correlation between the two components of the SF- 12 (Ware, 
1997). 
Specific spinal mobility has little association with the domains measured by the 
generic instruments (table 6.4), and little or no correlation is expected. However, a 
small correlation with measures reflecting reversible change is hypothesised. 
Evidence supporting the relationship between anthropometric measures and generic 
instruments of HRQL has not been identified. 
d) Anthropometric measures 
A large correlation between the MSI and LLF and progressive AS-specific 
radiographic change in the lumbar spine, and between TWD and change in the 
cervical spine has been reported (Kennedy et al, 1995; Dawes, 1999). A limited MSI 
and LLF are key features of AS and are included in the diagnostic criteria (van der 
Linden et al, 1984). Increased TWD is also a feature of progressive disease 
(Dziedzic, 1998). These findings support the inference that these measures are 
reflective of structural and irreversible change in AS. Changes in cervical rotation 
and FFD may, to a certain extent, be reversible (Roberts et al, 1988). 
it is hypothesised that cervical rotation will have a moderate correlation with FFD and 
TWD. Cervical rotation and FFD will have small levels of correlation with the other 
anthropometric measures. The MSI will have a moderate correlation with lateral 
lumbar flexion and TWD (table 6.5). 
e) Sociodemographic variables 
The validity of all patient-based instruments was further assessed in relation to 
socioeconomic status reflected by level of post-school education, occupational status, 
and housing tenure. T-tests were used to test for differences between these groups of 
patients. 
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Level of income and extent of education has a positive relationship with health (Hay, 
1988). Patients not continuing education beyond minimum school leaving age and 
those without a degree or equivalent qualification were hypothesised to have scores 
reflecting worse levels of health than their counterparts on all instruments. 
Patients reporting an inability to work due to ill-health were expected to have scores 
reflecting worse levels of health on all instruments than their counterparts who were 
in employment. Housing tenure was applied as a proxy for socioeconomic status with 
patients from a lower social class expected to report lower levels of health on all 
instruments (Hurst et al, 1998). 
6.4 Results of validity testing 
The results of validity testing are presented for the PGI-AS, disease-specific and 
generic instruments, anthropometric measures and finally all instruments compared to 
sociodemographic variables. 
6.4.1 Results of validity testing of the study instruments 
Analysis of the ASQoL, BASDAI, RLDQ, EuroQoI and the SF-12 has been based on 
the combined results of postal and clinic surveys to maximise the sample size (table 
6.6). This is justified because completion in both surveys followed the same self- 
completed format. The Body Chart and PGI-AS followed different completion 
formats and data is assessed separately for each survey (tables 6.7 and 6.8). 
Anthropornetric measures were only assessed in the clinic survey (table 6.8). 
ASQoL BASDAI EuroQol - EuroQol - RLDQ SF-12 MCS 
EQ - 5D therm 
BASDAI 0.75 
EQ-5D -0.75 -0.69 
EuroQol -therm -0.69 -0.59 0.61 
RLDQ 0.68 0.62 -0.59 -0.49 
SF-I 2- MCS -0.53 -0.40 0.49 0.39 -0.26 
SF-12 - PCS -0.70 -0.57 0.58 0.52 -0.64 0.20 
Table 6.6 Correlation between scores for patient-based measures of outcome. Combined postal 
and clinic survey (n-- 398). 
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ASQoL BASDAI Body EuroQol - EuroQol - RLDQ SF-12 SF-12 PCs 
Chart EQ 5D therm mcs 
Body Chart 0.67 0.72 -0.62 -0.56 0.55 0.38 0.60 
PGI-AS -0.53 -0.52 -0.46 0.50 0.57 -0.42 0.46 0.51 
Table 6.7 Correlation between the Body Chart and PGI-AS with other patient-based study 
instruments. Postal survey (n-- 224). 
a) PGI-AS 
Content validity 
Patients in the postal survey listed a total of 68 areas including all 37 trigger list items. 
The ftequency with which items were selected is shown in table 6.9. The most 
frequently mentioned area of importance affected by AS was 'worle, often described 
as'impact on ability to worle or'threat to worle. This was followed by the impact of 
AS on'sleep'. 
All but one of the items within the ASQoL are addressed by the PGI-AS trigger list 
(table 6.10). The item not within the list, item 13 (1 often get frustrated'), was 
identified as important by four (1.2%) patients in the postal survey. 
All correlations between the PGI-AS and other instruments were in the hypothesised 
directions and moderate correlations between the PGI-AS and all disease-specific and 
generic instruments were found. As hypothesised, a hierarchy of association with the 
largest correlations between the PGI-AS and disease-specific instruments followed by 
the generic instruinents and finally the anthropometric measures was found. Similar 
results were calculated for both postal and clinic data. 
The largest (moderate) correlation was with the ASQoL (453 postal, -0.70 clinic), 
and the smallest (moderate) correlation with a disease-specific instrument was with 
the RLDQ (-0.41 postal, -0.55 clinic). Moderate levels of correlation were found with 
the EQ-513 (0.50 postal, 0.54 clinic) and SF-12 MCS (0.46 postal, 0.57 clinic). 
Slightly larger correlations were found with the EuroQoI thermometer (0.57 postal, 
0.42 clinic) and SF-12 PCS (0.51 postal, 0.60 clinic). The small levels of correlation 
with cervical rotation and FFD and the weak correlations with the remaining 
anthropometric measures were hypothesised. 
234 
,9b 
tz 0 
rý 4 J-r 
n 
It 
t4 
Cl 
lp 00 
ei 
00 C4 
00 * 
C5 
0 C5 9 ci 
9 9 9 9 
C7, ul m 00 el wl v! 6 9 9 9 9 
f- 00 00 ON 00 00 n ýr cn " " " 9 C5 C5 6 9 1? 9 d 9 
0 rý 0 o r, Z; ýo CA 'q: in C4 C4 q . Cý 
Z; q 
9 6 Ci d 9 9 9 c; 9 
ID oN un 
In Zq ýq :; ;; C5 C? 9 9 C5 C: 5 c; 9 C; 
C7,0% 00 el -! 
%0 ýo C, ýo t- In el CA -! 
9C5 C5699969 
en f- C> f- 
C4 
00 C4 (4 r- 
cl cl el Cý 
0 0 a c) 9 
,4- -ýt r4 00 ;! M r- 4 
%0 '10: 'It C-4 eq -1 - 
699 cs ci 6 
00 
lo: 
C4 
w! o en 
W., W) 
C4 C4 
(7, 
-1 
6 9 9 C5 C5 C5 9 C5 
;b - 2 
Ow 
01 
Cw 
0 
0ý 
ýo 
Trigger list Frequency % Additional areas cited Frequency % 
Impact on / unable to Work 134 39.5 ------- Difficulty sitting 24 7.1 
Disturbed Sleep 101 29.8 Difficulty lying down 12 3.5 
Worry about the future 89 26.2 Gardening 11 3.2 
Sporting activities / exercise 76 22.4 Difficulty standing / standing 9 2.6 
for long periods 
Feeling tired 69 20.3 Ability to complete tasks / do 9 2.6 
simple tasks 
Difficulty with housework 58 17.1 Named body part (other than 9 2.6 
DIY / lifting back/Inees or hands) 
Walking 57 16.8 Travelling / travel distances 6 1.8 
Ability to remain physically 55 16.2 'Back' 6 1.8 
active /mobility in general 
Poor self body image / 50 14.7 Impact of medication / side 5 1.5 
posture / embarrassment effects / efficacy 
self-conscious 
Pain / discomfort 50 14.7 Shopping 5 1.5 
Feelings of depression 50 14.7 Morning stiffness / stiffness 5 1.5 
Fatigue / loss of energy 48 14.1 Vision / iritis 5 1.5 
lethargy / stamina 
social life / holidays 48 14.1 'Normal activities' 5 1.5 
relationship with ftiends 
Relationship with wife 45 13.3 General fitness (physical) 4 1.2 
husband / partner 
Driving / into and out of car 44 13.0 Ability to relax / relaxation 4 1.2 
Limitations tojoint / spinal 41 12.1 Frustration /anxiety 4 1.2 
movement-mobility specific 
Feelings of low self-esteem 41 12.1 Financial impact 3 0.9 
confidence 
Ability to play with / look 38 11.2 Difficulty with transfers - 2 0.6 
after childrai/ grandchildren crouch to standing / out of 
chairs / out of bath 
Pursuing chosen hobbies 32 9.4 Concern over weight gain 2 0.6 
past-times / leisure activities 
Sex life 31 9.1 Fear of being knocked or 2 0.6 
bumped/standing in crowds 
Getting going in the morning 28 8.2 Quality of life 2 0.6 
Family life /relationship with 27 7.9 74calth' 2 0.6 
fitmily and children 
Ability to plan ahead 25 7.4 Hands 2 0.6 
Level of independence 25 7.4 Knees 2 0.6 
dependency on others 
Loss of motivation 20 5.9 Breathing 2 0.6 
Feeling moody / miserable 15 4.4 Crossing the road 1 0.3 
irritable 
Difficulty sitting / standing 14 4.1 Reaching above head 1 0.3 
lying down 
Control over life / life in 11 3.2 Getting out of bed / turning 1 0.3 
general / daily living over in bed 
Fear of falling 10 3.0 Drinking 1 0.3 
Letting people down 8 2.3 Inability to defend oneself 1 0.3 
meeting commitments ones partner physically 
Enjoyment of life 8 2.3 Sneezing 1 0.3 
Dressing and bathing 8 2.3 Concern over childbirth 1 0.3 
personal hygiene future childbirth 
Slow to do things 7 2.1 Impact on choice of footwear 1 0.3 
Lack of spontaneous thought 7 2.1 
/ Mental concentration 
Table 6.9 Frequency endorsement of areas mentioned in step I of PGI-AS. Baseline postal 
survey (n= 339). 
236 
Trigger list of PGI-AS ASQoL - item content 
Impact on / unable to work 
Disturbed sleep Item 5: Ifs impossible to sleep 
Worry about the future 
Sporting activities / exercise 
Feeling tired Item 7: 1 am fired all the time 
Item 12: 1 get tired easily 
Difriculty with housework / DIY / lifting Item 4: 1 struggle to do jobs around the house 
Item 11: 1 am unable to do jobs around the house 
WaUdng 
Ability to remain physically active / mobility in general 
Poor self body imaget posturet embarrassmentt self-conscious 
Pain / discomfort 
Feelings of depression 
Fatigue / loss of energy / ledwgy / stamina 
Social life / holidays / relationship urith friends 
Relationship with wife /husband /partner 
Driving / getting into and out of car 
Limitations tojoint / spinal movement-mobility specific 
Feelings of low self-esteem / confidence 
Ability to play with / look after children/ grandchildren 
Pursuing chosen hobbies / post-times / leisure activities 
Sex life 
Getting going in the morning 
Family life / relationship with family and children 
Ability to plan ahead 
Level of independence / dependency on others 
Loss of motivation 
Feeling moody / miserable irritable 
Difficulty sitting / standing lying down 
Control over life / life in general / daily living 
Fear of falling 
Letting people down / meeting commitments 
Enjoyment of life 
Dressing and bathing / personal hygiene 
Slow to do things 
Lack of spontaneous thought / mental concentration 
Additional item cited by patients: 
Item 9: 1 have unbearable pain 
Item 14: The pain is always there 
Item 17: My condition gets me down 
Item 8: 1 have to keep stopping what I am doing to 
rest 
Item 15: 1 feel I miss out on a lot 
Item 10: It takes a long time to get going in the 
morning 
Item 6: 1 am unable to join in activities with my 
friends/ family 
Itern 2: 1 sometimes feel like crying 
Item 1: My condition limits the places I can go 
Item 18: 1 woffy about letting people down 
Itern 3: 1 have difficulty dressing 
Item 16: 1 find it difficult to wash my hair 
Frustration / anxiety Item 13: 1 often get frustrated 
Table 6.10 Comparison of items included in PGI-AS trigger list and ASQoL. 
b) Disease specific 
The results of the correlations between the disease-specific instruments, generic 
instruments and anthropometric measures are shown in tables 6.6 and 6.8. 
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All correlations between disease-specific instruments were in the predicted direction 
and the majority of correlations agreed with apriori hypotheses supporting the 
hypothesised convergent validity. The largest correlation was between the ASQoL 
and BASDAI (0.75). Moderate to large correlations were also found between the 
ASQoL and the RLDQ (0.68) and Body Chart (0.67 postal, 0.61 clinic). 
A large correlation between the BASDAI and Body Chart (0.72 postal, 0.62 clinic), 
and a moderate to large correlation between the BASDAI and RLDQ (0.62) was as 
hypothesised. A moderate correlation between the Body Chart and RLDQ was found 
for the larger postal survey (-0.55) although a small to moderate correlation was found 
for the clinic survey (-0.44). 
Correlation between the ASQoL and both generic instruments was slightly larger than 
hypothesised. A large correlation with the EQ-5D (-0.75) and moderate to large 
correlations with the SF-12 PCS (-0.70) and EuroQoI thermometer (-0.68) were 
found. A moderate correlation with the SF-12 MCS (-0.53) was found as 
hypothesised. 
As hypothesised, moderate to large correlations of the BASDAI, Body Chart and the 
RLDQ with the EQ-51), EuroQol- thermometer and SF-12 PCS, and a small to 
moderate correlation with the SF-12 MCS were found (tables 6.6 and 6.8). 
Small correlations of the ASQoL, BASDAI and Body Chart with the anthropometric 
measures of cervical rotation and FFD, and very small correlations with the remaining 
measures were found as hypothesised. 
Also hypothesised was the moderate to large correlation between the RLDQ and 
cervical rotation and moderate correlations with FFD, the MSI and TWD, and a very 
small correlation with lateral lumbar flexion (table 6.8). 
c) Generic instrunwnts 
The correlations between the generic instruments and anthropometric measures were 
in the predicted direction (tables 6.6 and 6.8). 
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The moderate to large correlation between the EQ-513 and thermometer (0.61) was 
larger than hypothesised. A moderate correlation between both sections of the 
EuroQol and the SF-12 PCS (EQ-51) 0.58, thermometer 0.52), and a small to 
moderate correlation with the SF-12 MCS (EQ-5D 0.49, thermometer 0.39) was 
found, as hypothesised, as was the very small correlation between the two sections of 
the SF-12 (0.20). 
All correlations between the generic instruments and anthropometric measures were 
in the hypothesised direction (table 6.8). A small to moderate correlation of the 
EuroQol and SF-12 PCS with cervical rotation (EQ-51) 0.34 to 0.36; thermometer 
0.33 to 0.46; SF-12 PCS 0.45 to 0.48), and a small correlation with FFD (EQ-51) - 
0.31; thermometer -0.36; SF-12 PCS -0.38) was found. Small correlations with the 
remaining anthoropometric measures and a small correlation between the SF- 12 MCS 
and all anthropometric measures (< 0.19) were hypothesised. 
d) Anthropometric measures 
The correlations between the anthropometric measures were in the predicted direction 
(table 6.8). 
As hypothesised, a small to moderate correlation between cervical rotation and TWD 
(range -0.53 to -0.49), and with FFD (range -0.3 1) was found. A larger than 
hypothesised relationship was found between FFD and lateral lumbar flexion (LLF) 
(range 0.46 to 0.47). Moderate correlations were found between the MSI and all 
anthropornetric measures (range 0.50 to 0.55), as hypothesised, except for the large 
correlation with TWD (-0.68) which was larger than expected. Small levels of 
correlation were found between LLF and both cervical rotation and TWD, as 
hypothesised. The largest correlations were between right and left cervical rotation, 
and right and left LLF (0.89). 
e) Sociodemographic Data 
The results of tests of validity relating to sociodernographic variables are shown in 
table 6.11. 
Compared to patients leaving school at the minimum leaving age their counterparts 
reporting a continuation of education rated their health as better for all instruments. 
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All results were in the direction hypothesised and the majority were significant (7/9). 
The most significant difference was calculated for the EuroQoI thermometer. There 
was no significant score difference for the PGI-AS or SF-12 MCS. 
Compared to those without a degree or equivalent qualification patients with a degree 
or equivalent have better scores on all instruments. All results were in the direction 
hypothesised although few were significant (4/9). Significant differences were found 
for the ASQoL, Body Chart and the EuroQol; the EuroQoI thermometer produced the 
most significant result. 
Compared to those unable to work due to ill-health patients in work have significantly 
better levels of health for all disease-specific and generic instruments (p< 0.01); the 
ASQoL produced the most significant score difference. The EQ-513 and SF-12 PCS 
demonstrated similar levels of significance, but the results were less significant than 
for three of the disease-specific instruments, the ASQoL, BASDAI, RLDQ. 
Compared to patients living in rented accommodation patients living in their own 
home reported better levels of health for the majority of instruments (7/9). The 
majority of results, apart from the SF-12 PCS, were in the direction hypothesised, but 
none were significant. 
6.5 Discussion 
Validity is the extent to which an instrument measures what it reports to measure, thus 
providing evidence in support of inferences and resulting scores (Fitzpatrick et al, 
1998a). Most measures of patient outcome describe phenomena that are not directly 
observable and as such rely on establishing evidence in support of their construct 
validity. McHomey et al (1993) indicate that validity'is not as simple as whether or 
not a health status scale is valid, rather, validity testing is a process of accumulating 
evidence that contributes to further understanding of inferences that may be made, 
and is essential for instruments that are new, modified or applied in a different context 
(Gaffatt, 1997; Bjomer et al, 1998). 
The construct validity of the study instruments was assessed by relating scores to 
other disease-specific instruments, to other more established instruments and to 
sociodemographic variables. The study has demonstrated more extensive testing of 
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instruments and involved a larger population of patients with AS than previously 
reported which increases the general isability of the results. No disease-specific 
instrument has previously been assessed against instruments with such well 
documented and established levels of validity as those for the EuroQol and SF-12. 
Previous attempts to provide evidence of construct validity for many study 
instruments has relied upon the correlation with other disease-specif ic or 
anthropometric instruments, often with little evidence to support the validity of these 
instruments. Further more, no study has constructed hypothetical relationships 
between instruments and set out to test these hypotheses. Rather, correlation was 
undertaken and a list of results provided as evidence of validity. None of the disease- 
specific study instruments have been previously compared against sociodemographic 
variables. 
a) PGI-AS 
The PGI-AS is a new instrument for the evaluation of disease-related quality of life in 
AS, adopting a modified version of the original PGI (Ruta et al, 1994a) (Chapter 3). 
This study has provided the first evidence for the validity of the PGI-AS and for the 
modified instrument. 
The majority of PGI-AS trigger list items were selected more frequently than 
supplementary items introduced by patients and supports the content validity of the 
list. The open nature of the PGI-AS addresses individuals'own concerns rather than 
imposing pre-determined items that may have less relevance, and the addition of 
supplementary items to the trigger list highlights the diversity and individuality of 
disease-related quality of life as a concept. 
The ASQoL includes many items frequently endorsed by patients completing the 
PGI-AS, but several issues considered important to the HRQL of patients with 
chronic disease, and included in the PGI-AS trigger list, are omitted by the ASQoL 
(Fitzpatrick, 1993a; Ware, 1998). In particular, the impact of AS on'work! is not 
measured. This was the most frequently endorsed item in the PGI-AS and is an 
important issue in AS (Guillemin et al, 1990; Ward, 1998). Multiple items measuring 
tiredness, jobs around the home and pain are included in the ASQoL and distinguish 
between the severity or frequency of a symptom. These items relate to three of the 
most frequently endorsed items in the PGI-AS. The inclusion of two items to address 
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one issue may enhance the precision of information provided (Gandek et al, 1998a, b). 
Alternatively, item repetition may reduce instrument content (Streiner and Norman, 
1995). The comparison of item content between the PGI-AS and ASQoL supports the 
hypothesis that the PGI-AS confers greater content validity as a measure of HRQL 
and justifies the individualised and open nature of the instrument. 
Evidence for the validity of the PGI-AS was gained from comparisons with widely 
used disease-specific and generic instruments, with anthropometric measures 
traditionally used in clinical practice, and with sociodemographic variables. All 
correlations were in the hypothesised direction. Moderate correlations with the 
disease-specific and generic instruments were found, which were generally larger for 
the former. Correlation with anthropometric measures reflecting reversible change 
was small. 
The more moderate levels of correlation with both disease-specific and generic 
instruments were hypothesised and may be a function of the alternative approach to 
measuring HRQL presented by the PGI-AS. In particular, due to the role of explicit 
weighting and the influence of items relating to'other health! and'non-healtw issues 
on the score. A similar low to moderate correlation between the original PGI and the 
SF-36 was reported by Garratt (1997). However, the level of correlation between the 
PGI-AS and generic measures of HRQL found in this study were greater than those 
reported by other authors comparing the original version of the PGI to the SF-36 
(Ruta et al, 1994a, 1999; Garratt, 1997). The improved correlation supports the 
improved validity of the modified version of the PGI in evaluating disease-related 
quality of life. Alternatively, the result could be due to AS having a greater impact on 
general health than the disorders assessed in earlier studies. That is, mennorhagia, 
varicose vein, peptic ulcer and low back pain. 
The correlation of the PGI-AS with the SF-12 was larger than that found between the 
uni-dimensional disease-specificiinstruments and the SF-12, and further supports the 
hypothesis that the PGI-AS measures a broader domain of HRQL. However, to 
further explore the ability of the PGI-AS to provide a multidimensional and 
comprehensive assessment of disease-related quality of life, the relationship with the 
eight dimension profile of HRQL derived from the SF-36 is suggested. Although the 
disease-specific and generic instruments included in the evaluation measure a wide 
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range of domains the SF-36 profile gives a broader picture of disability, role and 
social functioning. 
Finally, the PGI-AS behaved as hypothesised for the majority of socio-demographic 
variables, but the differences in scores were small and statistical significance was only 
found when discriminating between patients unable to work due to ill-health and those 
able to work. 
The results represent good evidence for the validity of the PGI-AS and suggests that it 
is sensitive to the effects of AS on aspects of HRQL measured by all disease-specific 
and generic instruments and by certain anthropometric measures and 
sociodemographic variables. 
b) Disease specific 
Evidence for the construct validity of the four additional disease-specific instruments, 
the ASQoL, BASDAI, Body Chart and RLDQ, was gained from comparisons 
between instruments, with generic instruments and anthropometric, measures and with 
sociodemographic variables. 
The majority of correlations between the disease-specific instruments were of a 
moderate to large size and were all in the hypothesised direction. The only 
correlation that was slightly less than hypothesised was between the Body Chart and 
the RLDQ in the clinic survey (0.44), but for the larger postal survey this correlation 
was moderate (0.55). The largest correlations were between the ASQoL and all other 
disease-specific instruments, and the largest was with the BASDAL 
The disease-specific instruments were all compared to the EuroQol and SF-12. All 
correlations were in the hypothesised direction and all disease-sPecific instruments 
were found to have moderate to large levels of correlation with the EuroQol and the 
SF-12 PCS, and a small to moderate correlation with the SF-12 MCS. The largest 
correlations were between the ASQoL and both generic instruments, and these 
correlations were larger than the correlations found between both generic instruments. 
All correlations with anthropometric measures were in the hypothesised direction. 
Small to moderate levels of correlation between anthropornetric measures reflecting 
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reversible change (cervical rotation and FFD) and most disease-specific instruments 
were found. A large correlation with cervical mobility and a moderate correlation 
with other measures, except for LLF, was found for the RLDQ. These results suggest 
that the RLDQ is more sensitive to the effects of AS on aspects of spinal mobility 
represented by anthropometric measures included in the study, than the other disease- 
specific instruments. 
Finally, all disease-specific instruments behaved as hypothesised for the ma ority of j 
socio-demographic variables. In particular the ASQoL was found to discriminate well 
for all sociodemographic variables, and results had greater statistical significance than 
found for both generic instruments. 
The results represent good evidence for the validity of the ASQoL as a disease- 
specific measure of HRQL and suggest that it is very sensitive to the effects of AS on 
aspects of HRQL measured by all disease-specif ic and generic instruments and certain 
anthropornetric measures. 
The results also provide good evidence for the validity of the BASDAI, Body Chart 
and RLDQ as AS-specific measures of disease activity, bodily pain and functional 
disability respectively. The results suggest that the instruments are sensitive to the 
effects of AS on aspects of HRQL measured by all disease-specif ic and generic 
instruments and certain anthropornetric measures. 
c) Generic 
Evidence for the validity of the EuroQoI and SF-12 was gained from comparison 
between both instruments, with anthropornetric measures and against 
sociodemographic variables. All correlations were in the hypothesised direction and a 
moderate to large correlation between both instruments and a small correlation with 
anthropometric measures measuring reversible change was found. A larger 
correlation than hypothesised was found between the EQ-5D and the thermometer 
(0.61) suggesting that they are both addressing similar aspects of HRQL. As 
hypothesised, a weak correlation between the SF- 12 PCS and MCS was found 
suggesting that the two components measure very different aspects of HRQL in 
patients with AS. 
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The EuroQoI thermometer was the generic instrument most capable of discriminating 
between patients on most sociodemographic variables (3/4), but the SF-12 PCS had 
the most significant difference in discriminating between patients able to work and 
those unable to work due to ill-health. 
Overall, results from the tests converged with study hypotheses and represent good 
evidence for the validity of the EuroQoI and SF-12 as generic measures of HRQL in 
AS. 
d) Anthropometric measures 
Evidence for the validity of the anthropometric measures was gained from 
comparison between all measures. All correlations were in the hypothesised 
direction. A moderate to large correlation between the MSI and all other 
anthropometric measures was found suggesting that the MSI is sensitive to aspects of 
mobility assessed by cervical rotation, FFD, LLF and TWD. As hypothesised, small 
to moderate correlations were also found between cervical rotation and both FFD and 
TWD. Further correlations between measures were very small. 
Conclusion 
The study has investigated a broad pattern of relationships between disease-specific 
and generic instruments and sociodemographic variables in a population of AS 
patients. Evidence of validity to further support inferences that may be made about 
the study instruments has been demonstrated. Evidence to support the application of 
the PGI-AS as a new individualised measure of AS-related quality of life has been 
provided. The best performing disease-specific instruments were the ASQoL and the 
PGI-AS, and the best anthropometric measures were the Modified Schober Index and 
cervical rotation. Additionally, the use of the EuroQoI and SF-12, two well- 
developed and tested generic measures of HRQL has not previously been reported in 
patients with AS. This study provides evidence to support their validity in this patient 
population. 
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Chapter 7 Responsiveness 
7.1 Introduction 
This chapter presents the tests of responsiveness for the study instruments. The 
evaluation of responsiveness in the field of outcome measurement is discussed in 
section 7.2. Section 7.3 discusses the methods adopted in the current study and the 
results of the responsiveness analysis are presented in section 7.4. The chapter closes 
with a discussion. 
7.2 Responsiveness and measures of health 
Responsiveness refers to the ability of an instrument to detect clinically important 
change over time, when change is present, and together with evidence of reliability 
and validity is an essential requirement of an evaluative instrument (Kirshner and 
Guyatt, 1985). However, despite this important role, it is a relatively neglected 
measurement property (Fitzpatrick et al, 1993c; Liang, 1995). This neglect was 
identified in qhapter 2, in the assessment of AS-specific meas&es of outcome. 
Interpretation of change in instrument score, and the ability to identify relevant or 
clinically important change is important in evaluation and may inform patient 
management and clinical decision making (Fortin et al, 1995; Redelmeier et al, 1996). 
However, the definition of change is problematic and no gold standard has been 
recommended. Real change in the underlying state is the'signal'that assessment of 
responsiveness aims to detect. The influence of an error variance that cannot be 
attributed to real change is referred to as 'noise' and represents the influence of 
random and systematic error. This may be due to non-specific influences such as 
natural variation in the underlying state, variation between patients, or variation from 
the effects of an intervention (Liang, 1995). Evaluation of responsiveness seeks to 
detect change that occurs above and beyond that due to random and systematic error 
(Deyo et al, 199 1). 
Variability in the level of responsiveness calculated for different instruments in the 
same group of patients with rheumatological disorders of a similar nature to AS has 
been reported (Kazis et al, 1989; Fitzpatrick et al, 1993a). This illustrates the concern 
that the use of multiple instruments may result in misleading, inconsistent and 
contradictory results (Ziebland, 1994). However, the use of a single instrument could 
be equally misleading. Knowledge of instrument responsiveness should aid selection 
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and assist prioritisation or reduction in the number selected for evaluative purposes. It 
may also assist in sample size estimation to enhance the statistical power of clinical 
trials (Deyo et al, 1991; Stucki et al, 1995). 
Responsiveness should be appraised in relation to the patient population and setting in 
which the evaluation was performed (Fitzpatrick et al, 1998a, b), and as for other 
measurement properties, should be viewed as a continual process of establishing 
evidence to support instrument application in different evaluative contexts. The 
conceptual base and item content will influence levels of responsiveness found in 
different circumstances. For example, an intervention to reduce disease activity is 
likely to result in greater responsiveness for a disease-specific measure of disease 
activity than would be found for a generic measure of HRQL, particularly if the 
intervention had little impact on HRQL. This highlights the importance of selecting 
instruments appropriate to the aims of the intervention and setting prior hypotheses of 
the expected behaviour of instruments under consideration (Garratt, 1997). 
7.2.1 Methods of responsiveness testing 
There is no clear consensus on the preferred method for assessing responsiveness and 
several methods have been proposed including responsiveness statistics, paired t-tests 
and correlation with other change scores (Deyo et al, 199 1; Fitzpatrick et al, 1998a). 
Garratt (1997) describes a two step approach: the first step involves the specification 
of external criteria by which change in health may be judged and the second step, the 
quantification of responsiveness. 
The choice of external criteria by which change in health or HRQL is estimated is 
important and will affect instrument relative responsiveness (Deyo et al, 199 1). 
Health transition questions, clinical variables or measures of disease process have 
been used to describe change. Patient or physician reported health transition 
questions which describe the magnitude and direction of change in health over a given 
time period provide a valid approach to measuring change and have been widely used 
as external criteria in the evaluation of instrument responsiveness (Fitzpatrick et al, 
1993b; Keller et al, 1999a, b). To the extent that a patient-based instrument is a valid 
measure of health and is capable of measuring change, a strong association with a 
patient reported health transition item would be expected (Garratt et al, 1996a), but 
will be dependent on the specific instrument domain and the form of transition 
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question. For example, a disease-specific transition question would be expected to 
have a stronger relationship with a disease-specific instrument than a generic 
instrument. 
Correlation of change scores between instruments and other well-established clinical 
variables or selected instruments provides evidence of whether an instrument 
demonstrates change in score over time that is consistent with change in other 
variables (Deyo et al, 1991; Fitzpatrick et al, 1998a; Kosinski et al, 1999b). This 
relationship has been described as longitudinal validity and requires that evaluative 
instruments demonstrate longitudinal within-patient score change that bears the 
expected relation to changes in external criteria (Kirshner and Guyatt, 1985). The 
measure of responsiveness is the relative strength of correlation between the change in 
instrument score and external criteria, and a correlation with other change scores of 
more than 0.40 has been described as a 'substantial' relationship (Stucki et al, 1995; 
Keller et al, 1999). It has been suggested that instruments demonstrating strong cross- 
sectional validity, should also be valid for measuring within-person change over time 
(Katz et al, 1992; Ware, 1997). However, the requirements for these two 
measurement properties are different and both should be assessed for evaluative 
instruments (Kirshner and Guyatt, 1985; Deyo et al, 1991). 
The responsiveness of the unweighted EuroQol EQ-5D in patients with Rheumatoid 
Arthritis (RA) was assessed by relating mean score change to categories of a health 
transition question ('Compared to three months ago is your arthritis better, the same or 
worse? ') (Hurst et al, 1997). Significant association between each category, except 
for the anxiety/depression item, supported the responsiveness of the EQ-5D profile in 
this population. 
An alternative ekternal criterion theorises that a treatment of known efficacy will 
result in a score improvement in instruments measuring domains targeted by the 
intervention. The study would aim to identify score change beyond that due to non- 
specific variance in patients otherwise described as stable. The responsiveness of the 
Leeds Disability Questionnaire (LDQ) was assessed in patients randomly assigned to 
receive one of three different physiotherapy treatment regimes with known efficacy 
(Abbott et al, 1994). Using a paired West, significant improvement in score for all 
patients supported instrument responsiveness. 
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Following the application of criteria to describe change, responsiveness may be 
quantified to enable judgement about instrument relative responsiveness. Threeeffect 
size statistics have been described (Fitzpatrick et al, 1998a)(table 7.1). 
Responsiveness statistic Method 
Effect size Change in instrument score divided by standard deviation of 
(Kazis et al, 1989) baseline score 
Standardised response mean (SRM) Change in instrument score divided by standard deviation of 
(Liang et al, 1990) change score 
Modified standardised response mean Change in instrument score divided by standard deviation of 
(MSRM) (Guyatt et al, 1987) change score for stable patients 
Table 7.1 Methods for calculating a responsiveness statistic (after Fitzpatrick et al, 
1998a). 
All calculations use the same numerator, but differ in the denominator adopted. 
The Effect size (ES) statistic divides the change in score by the standard deviation of 
baseline scores, therefore using the variation in baseline scores as a reference 
against which to assess change (Liang, 1995). The standardised response mean 
(SRM) uses the standard deviation of the change score to incorporate the response 
variance in change scores and is therefore more appropriate for comparisons of 
instrument responsiveness (Fitzpatrick et al, 1998a). However, both the ES and SRM 
may be influenced by natural variance in the underlying state and by measurement 
error (Liang, 1995; Hurst et al, 1997). The modified standardised response mean 
(MSRM) addresses the inherent natural variance that may occur in patients who 
otherwise report their health as unchanged and non-specific score change by using the 
standard deviation of change in patients who are defined as stable, and is therefore 
considered the preferred responsiveness statistic (Deyo et al, 1991). In demonstrating 
responsiveness to clinically important change, instruments should detect change 
above the non-specific change incorporated in the MSRM (Deyo et al, 199 1). 
Each effect size, or responsiveness statistic provides a quantitative and standardised 
unit of expression of the size and meaning of change to support instrument 
comparison (Fitzpatrick et al, 1998a). Guidance for data interpretation has been 
proposed: a score of more than 0.8 represents a large level of responsiveness, a score 
of 0.5 moderate, and a score of 0.2 a small level (Cohen, 1977; Fitzpatrick et al, 
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1998a). For example, a MSRM of more than 1.00 would indicate a change in score 
that is greater than the standard deviation of score change in stable patients. 
Most evidence suggests that disease-specific instiuments are more responsive than 
generic instruments (Guyatt et al, 1993), and evidence of comparative responsiveness 
is important when selecting evaluative instruments. Hurst et al (1997; 1998) and Ruta 
et al (1998) assessed the measurement properties of three generic instruments, the 
EuroQol, SF-36 and SF-12 and selected disease-specific instruments in patients with 
RA (table 7.2). 
Author Instrument RA population Methodology Result 
Hurst et at EuroQol 56 out-patients Self-reported improvement in RA (3months) 
(1997) EQ-513 Mean change +0.22 
SRM 0.70 
MSRM 1.00 
Hurst et at EuroQoI 56 out-patients Self-reported improvement in RA (3months) 
(1997) thermometer Mean change +12.2 
SRM 0.71 
MSRM 1.00 
Hurst et at SF-36 42 out-patients Self-reported improvement in RA (3months) 
(1998) Mean change PCs +4.30 MCS +3.50 
SRM PCs 0.61 MCS 0.35 
Ruta et at SF-36 233 out-patients Self-reported improvement in RA (3months) Mean change SRM 
(1998) Mean change, SRM PF +8.2 0.43 
SF +12.9 0.49 
RL-P +15.0 0.36 
RL-E +10.1 0.27 
MH +4.7 0.33 
BP +18.9 0.90 
Vit +10.6 0.50 
GH +5.8 0.36 
PCs +0.43 0.61 
MCS +0.35 0.35 
1 lurst et at SF-12 42 out-patients Self-reported improvement in RA (3months) 
(1998) Mean change PCS+4.10 MCS+2.60 
SRM PCs 0.52 MCS 0.31 
Table 7.2 Studies assessing the responsiveness of the EuroQol, SF-36 and SF-12 in patients 
with Rheumatoid Arthritis. 
Key: PF- Physical fimctioning; SF- Social functioning; RLP- Role limitations physical; RL-M- RL mental; MH- Mental health, 
BP-: Bodily pain; Vit- Energy and fatigue; G11- General health;, PCS- Physical component summary scale; MCS - Mental 
component summary scale. 
A statistically significant improvement in EuroQoI scores associated with patient- 
reported improvement in RA, but a non-statistically significant reduction in EQ-5D 
scores associated with deterioration in RA was found (Hurst et al, 1997). However, 
both sections of the EuroQol were more responsive than the Modified Health 
Assessment Questionnaire (MHAQ), a disease-specific measure of functional ability 
(Kirwan and Reeback, 1983). The authors conclude that the EuroQol is very 
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responsive to patient reported change in RA and is capable of reflecting clinically 
important change. 
The responsiveness of the SF-36 and the SF-12 was equivalent in the same patient 
population reporting improvement in RA (Hurst et al, 1998), and was greater than that 
found for the MHAQ. The size of change in both the SF-36 and disease-specific 
instrument was greater in patients reporting an improvement than in those reporting a 
deterioration, and the investigators suggest that this may reflect a larger 'biological 
change' in patients who perceive their arthritis as better, as opposed to being a 
reflection of instrument sensitivity (Ruta et al, 1998). 
For the AS-specific patient-based study instruments for which evidence of 
responsiveness is available (table 7.3), the study methodology adopted is lacking and 
restricted to the impact of physical therapy on change. 
Author Instrument AS population Methodology Result 
Garrett et al BASDAI 47 in-patients Known efficacy: 3-week BASDAL 
(1994) intensive physiotherapy. Mean change -0.85 (p- 0.009) 
Comparison of mean scores day 
16.4% score improvement 
'O'andday'18'. Bath DAL 
Mean change -1.22(p--0.002) 
22.8% score improvement 
Dziedzic (1997) Body Chart 41 out-patients Usual care. Statistically significant 
Assessed 3,6,9-months. Area relationship between Body 
under the curve - relationship 
Chart and all variables: pain, 
between variables (Spearmans) night pain, stiffness, enthesitis indices, disability questionnaire 
Abbott et al LDQ 42 out-patients Known efficacy: RCT -3 Significant improvement in 
(1994) physiodierapy regimes score for all patients at 6-weeks 
Assessments pre- 
(paired t-test t-- 2.79, p< 0.0 1). 
randomisation, post-treatment Interpretation of 6-month 
(6-weeks), 6-months. results difficult - poor response. 
Table 7.3 Evidence of the responsiveness of the patient-based study instruments. 
These findings may partly reflect the methodological difficulties in assessing 
responsiveness (Fitzpatrick et al, 1993c). There is no published evidence in support 
of the responsiveness of the ASQoL, RLDQ and PGI-AS. 
7.3 Methods for assessing the responsiveness of the study instruments 
Responsiveness was assessed using data collected from baseline and six-month 
administration of all instruments. The external criteria by which-responsiveness was 
judged was by self-reported health transition at six-months. 
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7.3.1 Assessing responsiveness using self-reported health transition 
Two separate health transition questions were included in the patient-completed 
questionnaire, relating to AS-specific or general health ('Compared to six-months ago, 
how would you rate your AS / general health now - much better, somewhat better, 
about the same, somewhat worse, much worse ? '). To maximise sample size 
responsiveness was assessed for patients indicating that they were 'bettee or 'worse'. 
For the purpose of assessing longitudinal validity instrument scores were compared to 
self-reported health transition. The level of concordance between change in 
instrument score and patient response to both transition items was calculated and 
assessed for a liner trend (Garratt, 1997). 
In addition, the responsiveness statistic, which is equal to the mean change in scores 
divided by the standard deviation of the score differences in stable patients 
(MSRM)(Fitzpatrick et al, 1998a; Garratt et al, 2000), was calculated for patients 
reporting an improvement or deterioration on specific transition questions. 
PGI-AS 
Two of the three follow-up formats of the PGI-AS were completed at six-months for 
both clinic and postal surveys: blind, and informed and open (table 7.4). These 
approaches are detailed in Chapter 3. 
Follow-up Step 1: Identifying areas Step 2: Scoring each area Step 3: Spending points 
completion 
Blind Blind to areas identified at baseline Blind to baseline score Blind to baseline points 
Informed and open Informed of areas identified at Blind to baseline score Blind to baseline points 
baseline. Allowed to change or 
retain list as necessary 
Table 7.4 PGI-AS completion formats at six months. 
The variation in format addresses the provision or absence of baseline areas in step 1. 
The lead investigator (KLH) was responsible for entering data into all follow-up 
questionnaires and the choice of format was made due to the limited study resources. 
The 'blind' format did not require the inclusion of baseline areas. The'informed and 
open! format was selected in preference to the 'closed' format due to the individualised 
and open nature reflected at all stages of instrument completion. This selection was 
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made prior to any data analysis. Patients were randomly assigned to receive either 
format at six-months. 
7.4 Results of responsiveness testing 
The results of the tests of longitudinal validity which compared change in instrument 
scores with self-reported change in AS and general health transition are shown in 
tables 7.5 to 7.10. 
The change scores of the ASQoL, BASDAI, RLDQ, EuroQoI and SF-12 have been 
based on the combined results of postal and clinic surveys to maximise sample size. 
Of the 254 patients who attempted the AS-specific transition and completed all 
instruments at baseline and six months, 56 (22.0%) perceived their AS-specific health 
as better, 125 (49.2%) stated that it was the same, and 73 (28.7%) indicated that their 
AS-specific health was worse than six months earlier (table 7.5). 
AS health transition 
Instrument Better About the same Worse F-test for 
(n-- 56) (n-- 125) (n-- 73) linearity 
ASQoL -1.00 (3.46) -0.03 (3.33) 1.21 (3.27) 7.16 
BASDAI -1.00 (1.44) 0.08 (1.63) 0.37 (2.11) 10.78 
RLDQ -2.01 (4.84) -0.12 (6.29) 1.87 (6.06) 6.86 
EuroQol EQ-5D 0.13 (0.25) -0.005 (0.25) -0.12 (0.34) 9.55 ** 
EuroQol - 23.44 (91.22) 2.13 (17.83) 4.56 (22.2) 12.4600 
dwmoineter 
SF-12 MCS 3.72 (10.18) -0.18 (9.21) -1.45 (10.52) 4.53 
SF-12 PCS 3.90 (7.40) 0.34 (7.70) -1.92 (6.85) 9.82** 
Table 7.5 Mean change (standard deviation) in instrument scores by 6-month AS health 
transition. Combined postal and clinic data (n-- 254). 
* significant at p< 0.05; ** significant at p< 0.01 
ASQoL. - scored 0-18, where lower scores indicate better HRQL. 
BASDAL scored 0-10, where higher scores indicate greater disease activity. 
RLDQ: scored 048, where higher scores indicate increased functional disabihty. 
EuroQoI EQ-51): scored -0.59-1.0, where -0.59 is the worst and 1.0 the best possible HRQL. 
EuroQoI thermometer: scored 0-100, where higher scores indicate better health states. 
SF-12: norm based scoring: mean of 50 (sd=10), range 0-100. MCS-mental component scale; PCS- physical component scale. 
Of the 248 patients completing the general health transition, 51 (20.6%) perceived 
their general health as better, 135 (54.4%) indicated that it was the same, and 62 
(25.0%) perceived their general health as worse than six months earlier (table 7.6). 
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General health transition 
Instnunent Better About the same Worse F-test for 
(n-- 5 1) (n7- 135) (n-- 62) linearity *0 
ASQoL -1.57 (2.53) 
BASDAI -1.13 (1.41) 
RLDQ -2.30 (4.93) 
EuroQol EQ-5D 0.16 (0.27) 
EuroQol - 27.00 (95.07) 
thermometer 
0.46 (2.88) 0.74 (4.21) 8.14 
-0.000 1 (1.66) 0.72 (2.08) 16.10 
-1.34 (6.20) 2.12 (6.15) 7.77 
-0.03 (0.26) -0.11 (0.35) 13.31 
-2.08 (16.33) -7.06 (23.57) 9.18 
SF-12 MCS 6.06 (10.41) -0.74 (9.11) -1.39 (10.35) 10.65 
SF-12 PCS 3.84 C7.82) 0.04 (6.71) -1.34 (8.64) 7.25 
Table 7.6 Mean changes (standard deviation) in instrument scores by 6-month general health 
transition. Combined postal and clinic data (n-- 248). 
** all significant at p< 0.01. 'instntment scoring summarised in table 7.5 
Analysis of the Body Chart and the PGI-AS was based on the results of the larger 
postal survey only (tables 7.7 and 7.8). Completion during the clinic survey followed 
an interview-administered format and could not be combined with the postal results. 
Also, once replies to the transition questions were taken into account the sample sizes 
for the clinic survey were too small to draw inferences from the data. 
AS health transition 
Instnment Better About the same Worse F-test for 
(n-- 36) (n-- 85) (n-- 44) linearity 
Body Chart (log) -0.46 (0.85) 0.13 (0.86) 0.44 (0.71) 11.980* 
PGI-AS 
(combined) 0.51 (1.80) 0.10 (1.58) -0.30 (1.43) 2.57 (p= 0.08) 
- blind 0.52 (1.62) 0.32 (1.58) -0.10 (1.49) 0.35 
(n= 16) (n 7-- 4 8) (n= 23) 
- informed/open 0.75 (1.63) -0.17 (1.56) -0.79 (1.24) 5.19 (p= 0.08) 
(n7- 20) (n --- 3 7) (n- 2 1) 
Table 7.7 Mean changes (standard deviation) in instrument scores by 6-month AS health 
transition. Postal data (n7- 165). 
** significant at p< 0.01 
Body Chart: scored from 0, with no maximum score limit. I-Iigher scores indicate greater levels of perceived body pain. 
PGI-AS: scored 0-10, where higher scores indicate better disease-related quality of life. Combined - combined results for both 
formats; Blind - not informed of baseline areas; Informed and open - informed of baseline areas and allowed to change. 
Of the 165 patients who attempted the AS-specific transition and completed all study 
instruments at baseline and six months, 36 (21.8%) perceived their AS-specific health 
as better, 85 (51.5%) stated that it was the same, and 44(26.6%) indicated that their 
AS-specific health was worse than six months earlier (table 7.7). Of the 162 patients 
completing the general health transition, 29 (17.9%) perceived their general health as 
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better, 95 (5 8.6%) indicated that it was the same, and 38 (23.4%) perceived their 
general health as worse than six months earlier (table 7.8). 
General health transition 
Instrument' Better About the same Worse F-test for 
(n-- 29) (n-- 95) (n7-- 3 8) linearity 
Body Chart (log) -0.33 (1.18) 0.10 (0.84) 0.32 (0.58) 4.71 
PGI-AS 
(combined) -0.86 (1.93) 0.13 (1.49) -0.61 (1.38) 7.440* 
blind 0.75 (1.47) 0.39 (1.56) -0.25 (1.56) 1.80 
(n-- 14) (n-- 52) (n= 20) 
informed/open 1.34 (1.87) -0.18 (1.34) -1.00 (1.13) 11.27*0 
(n-- 15) (n-- 43) (n-- 18) 
Table 7.8 Mean changes (standard deviation) in instrument scores by 6-month general health 
transition. Postal data (n= 162). 
-significant atp< 0.01. 'instnment scoring summarised in table 7.7 
The change scores for both formats of the PGI-AS reflect the categories of specific 
and generic health transition and is evidence for the longitudinal validity of the 
instrument (tables 7.7 and 7.8): those patients who indicate that their AS or general 
health is better over the six months have an average improvement in PGI-AS score; 
and those where AS or general health is worse have an average deterioration in score. 
The largest levels of change were found for the informed and open format of the PGI- 
AS on the general health transition: patients who say that their general health is better 
have an average improvement in their PGI-AS score of 1.34 (on a scale 0-10, where 
10 is the best disease-related quality of life); those whose general health is about the 
same have an average deterioration of -0.18; whilst those whose general health is 
worse have an average deterioration of -1.00. A strong relationship with AS health 
transition was also found for the informed and open format (table 7.7), although this 
did not quite reach statistical significance. Although reflecting the same trend, 
smaller levels of change and a non-significant relationship between the blind format 
of the PGI-AS and both transition questions was found. When both PGI-AS formats 
were considered together a reduced association with both transition questions, than 
seen for the informed and open format alone, was found. 
The informed and open format of the PGI-AS produced the largest F-statistic for 
linearity when compared to the blind format or combined PGI-AS results, and this 
format has the strongest relationship with both health transition formats. The strength 
of the relationship between the informed and open format of the PGI-AS and general 
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health transition (11.27) was comparable to the large levels of change and strength of 
the relationship between the Body Chart and AS transition (I 1.98)(table 7.7). These 
two instruments were assessed in a smaller data set and the results, although 
significant, are not directly comparable to the larger combined data set (tables 7.5 and 
7.6). 
The change scores for all disease-specific patient-based measures of outcome also 
reflect the categories of specific and generic health transition and is evidence for the 
longitudinal validity of the instruments (tables 7.5 to 7.8). The largest levels of 
change were found for the BASDAI on both AS and general health transition: patients 
who say that their AS is better have an average improvement in score of -1.00 (on a 
scale of 0-10, where 0 is the lowest level of disease activity), and where general 
health is better an average score improvement of - 1.13 is found; those whose AS is 
worse have an average deterioration in score of 0.37, and where general health is 
worse an average score deterioration of 0.72. 
The BASDAI also produced the largest F-statistic for linearity for both AS (10.78) 
and general health transition (16.10), demonstrating the strongest relationship with AS 
health transition when compared to other disease-specific instruments from the same 
data set, and the strongest relationship with general health transition when compared 
to disease-specific and generic instruments. 
Although significant, the smallest levels of change scores for disease-specific 
instruments were found for the ASQoL and RLDQ on both transition questions, the 
smallest levels of change seen in the RLDQ However, F-statistics for linearity were 
greater for both instruments than those found for the SF-12 MCS on AS transition and 
the SF-12 PC S on general transition, suggesting a stronger relationship with health 
transition. 
The change scores for all generic instruments reflect the categories of specific and 
generic health transition and is evidence for the longitudinal validity of the 
instruments (tables 7.5 to 7.6). The EuroQol and the SF-12 MCS have larger levels of 
change and a stronger linear relationship with responses to the generic transition than 
with the AS transition question: for example, patients who say that their general 
health is much better over the six months have an average improvement in EuroQol 
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thermometer score of 27.00 (on a scale 0-100, where 100 is the best possible health 
state), and an improvement of 23.44 when AS health is better; those whose general 
health is the same have an average reduction of -2.08 (general health) or and average 
increase of 2.13 (AS); and those whose general health is worse have an average 
deterioration of -7.06, and an average deterioration of -4.56 when AS is worse. 
However, the SF-12 PCS has similar levels of change and linear relationship with 
responses to both transition questions. The EuroQol thermometer produces the largest 
F-statistic for the relationship with AS health transition (12.46) than all other disease- 
specific and generic instruments, supporting the strongest relationship with AS health 
transition. Although significant, the SF-12 PCS has a weaker linear relationship with 
general health transition than all other instruments. The SF-12 MCS has a weak 
association with AS transition. 
Anthropometric measures were completed during the clinic survey only. The mean 
changes for anthropometric measures at six months in self-reported AS-specific and 
general health transition are shown in tables 7.9 and 7.10. 
AS health transition 
Instrument Better About the same Worse F-test for 
(n-- 7) (n-- 32) (n-- 15) linearity 
Cervical rotation 1.48 (2.17) 0.39 (1.65) 0.05 (2.22) 1.39 
- left 
Cervical rotation 0.45 (2.11) 0.06 (1.45) -13.57 (54.98) 1.22 
- right 
FFD . 5.87 (11.26) 2.52(6.85) 1.22 (6.20) 3.74 
LLF - left -0.31 (2.09) 1.87 (3.98) 1.08 (4.84) 0.86 
LLF - right -0.58 (3.16) 1.00 (3.28) 1.10 (4.11) 0.64 
msi 0.43 (0.66) -0.04 (0.75) 0.08 (0.85) 1.11 
TWD -0.63 (1.35) -0.33 (1.47) 0.25 (1.52) 1.13 
Table 7.9 Mean changes (standard deviation) in instrument scores by 6-month AS health 
transition. Clinic data (rr-- 54). 
* significant at p< 0.05 
Cervical rotation - distance between tip of nose and acromioclavicular joint measured in neutral and maximum ipsilateral 
rotation. Difference between two positions calculated, where a smaller difference indicates a more restricted range. 
FFD - Fingertip to floor distance - distance between tip of right middle finger and floor following maximum bw& flexion, where 
the smaller distance indicates greater movement. 0 is the maximum possible range (touching floor). 
LLF - Lateral lumbar flexion - distance between tip of middle finger and floor measured following maximum ipsilateral lateral 
flexion, where the smaller distance indicates greater movement 
MSI - Modified Schober Index (15cm) (Macrae and Wright, 1969) - distance between two marks placed 15cm apart in standing 
(10cm proximal and 5cm distal to posterior superior iliac spine). Distance after maximum trunk flexion, where a larger 
difference indicates greater lumbar movement. 
TWD - Tragus to wall distance - Distance between right tragus and wall measured in standing, where a larger distance indicates a 
worse spinal / upper cervical posture. 
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Of the 54 patients who attempted the AS-specific transition and completed all study 
instruments at baseline and six months during the clinic survey, 7 (12.9%) perceived 
their AS-specific health as better, 34 (62.9%) stated that it was the same, and 13 
(24.2%) indicated that their AS-specific health was worse than six months earlier 
(table 6.9). Of the 54 patients completing the general health transition, 7 (12.9%) 
perceived their general health as better, 37 (68.5%) indicated that it was the same, and 
10 (18.6%) perceived their general health was worse than six months earlier (table 
7.10). 
General health transition 
Instrument' Better About the same Worse F-test for 
(n-- 7) (n-7 32) (n7- 15) linearity 
Cervical rotation 0.94 (2.32) 0.27 (2.00) 0.74 (1.47) 0.45 
- left 
Cervical rotation 0.72 (2.43) -0.06 (2.00) -16.62 (61.56) 0.38 
- right 
FFD -8.22 (12.89) 2.49(6.77) 0.57 (5.51) 4.90* 
LLF - left 0.04 (2.45) 1.70 (3.81) 1.80 (4.06) 0.38 
LLF - right . 1.04 (3.73) 0.87 (3.13) 1.42 (4.43) 0.89 
MSI 0.42 (0.66) 0.08 (0.81) -0.22 (0.61) 1.40 
TWD -0.82 (1.55) -0.25 (1.38) 0.19 (1.74) 0.88 
Table 7.10 Mean changes (standard deviation) in instrument scores by 6-month general health 
transition. Clinic data (n7- 54). 
0 all significant at p< 0.05 
a insuwnent scoring summarised in table 7.9 
The change scores for four of the five anthropometric measures do not clearly reflect 
the categories of the specific or generic health transition questions (tables 7.9 and 
7.10). The only measure to produce a significant relationship with both transition 
questions is fingertip to floor distance following anterior trunk flexion (FFD): patients 
who say that they are better at six months have an average improvement in FFD of - 
5.87cm (AS) or -8.22cm. (general health)(on a scale where 0 is the best possible score; 
that is, fingers touch the floor); those whose AS health is worse have an average 
deterioration in score of 1.22cm, and where general health is worse an average score 
deterioration of 0.57cm. The F-statistic for linearity produced a significant result on 
both transition questions (AS health 3.74; general health 4.90). However, this was 
less than that found for most patient-based measures of outcome. 
The tests of responsiveness are shown in tables 7.11 to 7.13. 
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For patients reporting an improvement in AS-specific health the largest MSRM was 
found for the EuroQol thermometer (1.30), followed by the BASDAI (-0.60). 
Moderate MSRMs were found for the Body Chart (-0.53), EQ-5D (0.50), SF-12 (PCS 
0.51, MCS 0.41) and the PGI-AS (informed and open)(0.42). SmaIIMSRMswere 
found for the PGI-AS (blind)(0.33), the RLDQ(-0.32) and the ASQoL (-0.29). 
However, sample sizes for the Body Chart and PGI-AS, and particularly when the two 
versions of the PGI-AS were assessed, were smaller than the sample size for the 
analyses conducted for the other instruments and direct comparison of results is 
difficult. 
For patients reporting a deterioration in AS-specific health the largest MSRM was 
found for the Body Chart (0.5 1), followed by the PGI-AS (informed and open)(448). 
A moderate MSRM was also found for the EQ-5D (446), but for all other patient- 
based instruments a small MSRM was found. The lowest MSRMs were found for the 
ASQoL and RLDQ for patients reporting both improvement or deterioration in AS, 
suggesting that they show little responsiveness to AS-specific change in health. 
For patients reporting an improvement in general health the largest MSRM was found 
for the EuroQol thermometer (1.65), followed by the PGI-AS (informed and 
open)(0.74). Large MSRMs were also found for the SF-12 MCS (0.67), the BASDAI 
(0.67) and the EQ-5D (0.64). Moderate to large MSRMs were found for the SF-12 
PCS (0.57) and the ASQoL (0.55). All other MSRMs were small, the smallest was 
found for the Body Chart (0.13). 
For patients reporting a deterioration in general health the largest MSRM was 
calculated for the PGI-AS (informed and open)(-0.75) followed by the EQ-5D (-0.44), 
the EuroQol thermometer (-0.43) and the BASDAI (0.43). MSRMs for all other 
patient-based instruments were small. 
For patients reporting an improvement in AS (-0.86) or general health (-1.21) a large 
MSRM was produced for the anthropometric measurement of fingertip to floor 
distance (FFD) (table 7.13). However, this was associated with a very small MSRM 
in patients reporting a deterioration in health (AS 0.18; general health 0.08) 
suggesting that the measurement is not sensitive to deterioration in health. Anomalies 
in the cervical rotation results were found with very low and very high responsiveness 
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statistics calculated for right and left rotation. Sample sizes for the assessment of 
responsiveness for the anthropometric measures were very small, and interpretation of 
the results is therefore difficult. 
Although small to moderate MSRMs were found for lateral lumbar flexion (LLF) in 
patients reporting a deterioration in AS (0.33 to 0.45) or general health (0.45 to 0.47), 
and for the Modified Schober Index (MSI) and tragus to wall distance (TWD) in 
patients indicating an improvement in AS (MSI 0.57, TWD -0.43) or general health, 
the associated mean change in actual movement may not be of clinical significance 
(Moll et al, 1971)(table 7.13). 
7.5 Discussion 
Responsiveness describes the ability of an instrument to detect change in health over 
time and is an essential measurement property for evaluative instruments (Kirshner 
and Guyatt, 1985). Although several study instruments have satisfactory evidence in 
support of their reliability and validity, most have little published evidence of their 
responsiveness in patients with AS (Chapter 2). This study has demonstrated more 
extensive testing of instrument responsiveness than previously reported, and it has 
involved a larger sample of AS patients which improves generalisability. None of the 
disease-specific and anthropometric measures of outcome have previously been 
compared to change in patient-reported health transition as a reflection of longitudinal 
validity. The comparative responsiveness of instruments, particularly in relation to 
more established generic instruments such as the EuroQoL and the SF-12, has not 
previously been assessed. This provides important information to support the 
selection of evaluative instruments in a disease such as AS where the beneficial 
effects of management in routine care may not result in large changes in HRQL 
(Liang et al, 1985; Fitzpatrick et al, 1993c). 
In the current study most patients had established and well-controlled AS. All 
patients underwent usual care and although fluctuations in state would be anticipated 
(Fortin et al, 1995) large improvements or deterioration in HRQL were not expected- 
Under these circumstances, it may be difficult to distinguish between no real 
underlying change in condition and lack of instrument responsiveness (Ruta et al, 
1998; Peto et al, 1998), and narrowly focussed disease-specific instruments were 
expected to be more responsive to any change that occurred. However, both generic 
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and disease-specific patient-based measures of outcome demonstrated satisfactory 
evidence in support of their responsiveness. Although the majority of patients 
reported their health as on average the same as six months earlier, the strong 
relationship between both AS-specific and general health transition over the six 
month period and changes in health as measured by all patient-based instruments is 
evidence of the validity of both the disease-specific and generic instruments as 
measures of health outcome in AS. However, most anthropometric measures had a 
very poor relationship to both transition questions, suggesting poor validity as 
evaluative measures of outcome in AS when assessed against the described external 
criteria over a six month period. 
A stronger relationship between the generic instruments and the general health 
transition was expected but only found for the EuroQol. The PGI-AS (informed and 
open) and the BASDAI had a strong relationship with both transition questions, but 
had the strongest relationship with general health transition when compared to all 
other instruments. Likewise a stronger relationship between the specific transition 
and the disease-specific instruments was expected, but again a stronger relationship 
with the EuroQol thermometer was found in comparison to all other instruments. A 
similar result was reported by investigators assessing the responsiveness of the 
EuroQoI in patients with RA (Hurst et al, 1997) and in patients with angina (Garratt et 
a], 2000). 
The EuroQoI thermometer was found to be more responsive to improvement in both 
AS and general health than all other study instruments when the responsiveness 
statistic was calculated. Although not as responsive to deterioration in health, 
moderate MSRMs comparable to most disease-specific instruments were found for 
the EQ-5D for deterioration in AS-specific health, and for both sections of the 
EuroQol to deterioration in general health. The Body Chart and the PGI-AS 
(informed and open) produced large responsiveness statistics for deterioration in 
health on AS transition. The PGI-AS (informed and open) also produced a large 
responsiveness statistic for detecting both improvement and deterioration in general 
health. 
The small sample size for the anthropometric measures made data interpretation 
difficult. However, FFD appeared to be the most responsive measure to improvement 
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in AS or general health, but was unable to reflect deterioration in health, and cervical 
rotation appears worthy of further investigation. However, most other measures 
appear not to be responsive to change in health over six months. 
Apart from the performance of the EuroQoI thermometer, there is no clear trend that 
disease-specific or generic instruments are more responsive to patient-reported change 
in health, but the anthropometric measures would appear not to be as responsive as 
patient-based instruments to change in health over the limited study period. 
Item content and overlap between generic and disease-specific instruments, for 
example, pain and functional activity, and the influence of both specific and general 
health on these items may explain why all patient-based instruments demonstrated a 
strong relationship with both transition questions. Alternatively, the instruments 
demonstrating greater responsiveness may reflect the goals of usual care (Guyatt et al, 
1999). Pain is a dominant feature of AS, and pain management is often an important 
objective in routine practice (Dziedzic, 1998). The strong influence of pain on a 
patients perception of short term change in RA has been described (Fitzpatrick et al, 
1993b). Therefore, instruments with a focus on pain may be expected to demonstrate 
a stronger relationship with patient reported health transition following routine 
management over a six month period. Pain is a dominant feature of both the BASDAI 
and the Body Chart, it may be nominated by patients completing the PGI-AS and is 
included in the EuroQol. These instruments all demonstrated strong levels of 
correlation with health transition, supporting the importance of including the 
evaluation of pain in the short term assessment of change in AS. 
a) PGI-AS 
Evidence for the responsiveness of the PGI-AS (informed and open) in patients with 
AS is satisfactory. The blind format was not responsive to change and did not 
correlate strongly, or significantly with AS or general health transition. The closed 
format was not assessed for responsiveness in the current study. The stronger 
relationship between the PGI-AS and general health transition than observed with the 
specific transition may indicate a narrowness of context addressed by the AS health 
transition when compared to the scope of the PGI-AS. Patients may relate change in 
disease symptomology more clearly to AS-specific transition, whereas the PGI-AS 
addresses a broader concept that is more clearly reflected in the general transition. 
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Alternatively, the relationship may indicate that the areas picked by patients have 
wide implications for general health. Validity testing of the PGI-AS found a stronger 
relationship with both generic instruments than found for most other disease-specific 
instruments, supporting the hypothesis that the PGI-AS measures a broad domain of 
HRQL (Chapter 6). This may also indicate that AS has a large impact on general 
health. 
Further information of the role of the different formats in patients indicating change in 
health is required. An index of change for areas mentioned in step I of the PGI-AS 
(identifying areas), as calculated for test-retest reliability (Chapter 5), may inform on 
the nature of change in areas over the six month period in patients indicating 
improvement or deterioration in health, and the relative responsiveness of the PGI-AS 
associated with this change. Following completion in the clinic survey, blind to areas 
mentioned at baseline, a patient listed identical areas despite indicating that he was 
much better than six months earlier. All areas had better scores. When shown his 
baseline areas he commented: 
'These are always the most important elements of my life affected by AS, whether the 
disease is active or in remission - an underlying feeling of tiredness is always present 
which affects everything else' 
However, the blind completion format may introduce 'noise' when patients do not list 
the same areas, thus reducing reliability, and may be a factor in the reduced 
responsiveness calculated for the blind format. When patients remaining the same at 
two-weeks were given the opportunity to change areas, all patients retained the 
original list. The impact of change in health on this decision requires further 
assessment. 
Sample sizes for the evaluation of all measurement properties of the PGI-AS, in 
particular the responsiveness and reliability testing for the different formats, were 
small and reduces confidence in the results. Further work to assess the measurement 
properties, acceptability and feasibility of the PGI-AS should be performed with a 
larger sample size for all three formats to improve confidence in the results and to 
support the recommendation of one format for evaluative purposes. 
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b) Disease-specific 
Items within the ASQoL are not directly anchored to the impact of AS on HRQL, and 
the stronger association with change in general health than with change in AS-specific 
health, and the stronger than predicted relationship with the generic instruments in the 
assessment of validity (Chapter 6), suggests that the ASQoL more effectively 
evaluates change in general HRQL than change in AS-specific HRQL. Specific 
anchoring of items towards the impact of AS may improve AS-specificity. However, 
evidence of responsiveness was poor and does not support its adoption in the routine 
evaluation of AS patients. Large changes in HRQL are required before a change in 
the dichotomous response format can be expected, and the ASQoL may therefore be 
insensitive to small, but important changes in HRQL. A revision of the response scale 
to include more response options may improve responsiveness (Streiner and Norman, 
1995). 
In patients for whom a final score could be calculated, high levels of responsiveness 
were found for the BASDAL Although items within the BASDAI are symptom 
based, the stronger relationship with general health transition than with AS-specific 
transition may indicate that the items have a greater implication for general health. 
Validity testing of the BASDAI generally found stronger levels of correlation with the 
generic instruments than hypothesised (moderate to high)(Chapter 6), and further 
supports the hypothesis that AS has a wide impact on general health. 
As predicted, the Body Chart has a strong relationship with AS transition, but a weak 
relationship with general transition, supporting the importance of specific pain 
evaluation in AS. A satisfactory level of responsiveness was found in the postal 
survey for patients reporting an improvement or deterioration in health. The sample 
size for the clinic survey was too small to draw inferences from the data, and this 
evaluation should be repeated with a larger sample size. 
Responses to the RLDQ generally corroborate a patients perception of change on 
both transition questions. However, the ceiling effect described in Chapter 5 suggests 
that the instrument may underestimate improvement in function, which is supported 
by the poor responsiveness found in the current study. Documentation of 
improvement in patients with excellent health may be less of a concern than 
documenting deterioration in all patients, but especially in those already experiencing 
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poor health (Bindman et al, 1990). However, the responsiveness of the RLDQ to 
deterioration in health also appears to be limited. The four response options of the 
RLDQ present a compressed response range and revision to the response fonnat is 
recommended, in addition to a revision of items (Chapter 5). 
c) Genetic 
The EuroQoI (EQ-51) and thermometer) was found to be more responsive than all 
other disease-specific and generic instruments, and combined it is able to detect 
improvement or deterioration of AS-specific or general health. The SF-12 was also 
responsive to change in both general and AS-specific health, with results that were 
comparable to most disease-specific instruments. However, the SF-12 was less able 
to detect deterioration in health. 
These results challenge the recommendation to include disease-specific instruments in 
evaluation for their greater responsiveness when compared to generic instruments. 
The study does not provide sufficient information to determine why the EuroQol was 
more responsive than disease-specific instruments, but several hypotheses can be 
proposed. The item content of the EuroQol is biased towards the measurement of 
functional disability and so has a close affinity to the problems experienced by 
patients with AS (Bakker et al, 1995). In conditions with a similar impact on function 
such as RA (Hurst et al, 1997) and angina (Garratt et al, 2000), the EuroQol has also 
demonstrated greater levels of responsiveness than disease-specific instruments. 
However, in conditions with a lesser impact on functioning, such as obstructive sleep 
apnoea, the EuroQol has not demonstrated such satisfactory responsiveness 
(Jenkinson et al, 1998b). Alternatively, certain disease-specific study instruments 
may have inadequate measurement properties, a suggestion supported by the results of 
further evaluations conducted in this study. The suitability of the health transition 
questions included as external criteria in the evaluation of responsiveness should also 
be considered. However, both generic and disease-specific transition items were 
assessed separately and the EuroQol demonstrated a stronger relationship with both 
items than most other instruments. Finally, the role of external valuations in 
calculating the index score for the EuroQol, as opposed to item summation, may also 
support the high level of responsiveness found in patients with AS. 
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d) Anthropometric 
Most anthropometric measures were not responsive to change over six months. 
Fingertip to floor distance (FFD) was the only measure to demonstrate a significant 
relationship with transition questions and a moderate level of responsiveness 
associated with improvement in health. However, FFD methodology does not 
account for the starting position or patient height and should not be recommended for 
group comparison (Chapter 5,6). Interpretation of the responsiveness of cervical 
rotation was difficult. A strong correlation with radiographic change in the lumbar 
spine (Kennedy et al, 1995) supports the role of the Modified Schober Index (MSI), 
lateral lumbar flexion (LLF) and tragus to wall distance (TWD) in reflecting long 
term, irreversible change in spinal status, but these measures do not reflect clinically 
important change in range of movement over six-months. 
Assessment of validity suggests that most anthropornetric measures bear little relation 
to patient-based measures of HRQL, indicating that they measure a different concept 
of disease impact. This result therefore challenges the appropriateness of the health 
transition questions included in the assessment of the anthropometric measures. 
Change in disease-specific or general health may have little impact on change in 
range of movement and more appropriate external critieria may be radiographic 
change or change in alternative clinical criteria. 
The domains addressed by many study instruments may not be expected to change 
over the relatively short period of the study in patients with stable AS. However, the 
six month period reflects normal practice in the routine evaluation of AS in many 
rheurnatology centres (Dziedzic, 1998; Lubrano et al, 1998). The level of 
responsiveness found in several patient-based instruments, particularly the EuroQol, 
PGI-AS (informed and open) and the BASDAI may make them suitable for routine 
monitoring of health outcome in the longitudinal evaluation of AS, where routine 
management may result in subtle change in HRQL. However, levels of reliability 
(Chapter 5) suggest that these instruments are only suitable for group assessment. 
Instruments with the highest reliability, the ASQoL, RLDQ and the SF-12 (PCS), 
where individual assessment was supported, demonstrated poor responsiveness. 
The choice of patients and external criteria may influence responsiveness and the use 
of health transition questions may overestimate responsiveness when compared to 
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trials of known efficacy because the latter will also include patients who have not 
improved (Deyo et al, 1991). Therefore, further evaluation of instrument 
responsiveness following a trial of known efficacy in AS is recommended. Limited 
evidence of the responsiveness of disease-specific study instruments has been 
generated following trials of physical therapy only and responsiveness statistics have 
not been calculated. Evidence of the impact of drug therapy should also be 
considered in future evaluations. It is suggested that comparison of instruments in 
randomised controlled trials may provide the strongest evidence of the differential 
measurement properties of evaluative instruments (Guyatt et al, 1999). 
The patient population represents a wide range of disease presentation, with similar 
features to those reported in other hospital based studies (Garrett et al, 1994; Lubrano 
et al, 1998). However, patients with newly diagnosed disease were not widely 
represented. This may be a suitable subset of patients in which to assess the impact of 
diagnosis and early stages of management on HRQL. Evaluation of measurement 
properties in a variety of patient groups improves confidence in instrument 
performance and the generalisability of application (Bindman et al, 1990). 
Conclusion 
Although the results from the evaluation of the PGI-AS are based on a smaller sample 
size, evidence suggests that the PGI-AS (informed and open) and the BASDAI are the 
most responsive disease-specific instruments in the current study. 
The generic instruments were not markedly less sensitive to change over time when 
compared to disease-specific instruments, and the EuroQoI was generally the most 
responsive instrument on both methods of assessment, and when both improvement or 
deterioration in health was considered. These results challenge the assumption that 
disease-specific instruments are more responsive than generic instruments and 
hypotheses to explain these findings have been proposed. 
Based on the available evidence no anthropometric measure can be clearly 
recommended for evaluation of AS. The measurement of cervical rotation and FFD 
require further exploration as measures capable of reflecting short term and reversible 
change. The MSI may reflect structural and irreversible change in the long term 
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evaluation of outcome in AS (Kennedy et al, 1995; Dawes, 1999). Further empirical 
evidence of the role of anthropometric measurement in AS is required. 
The expectation of including patient-based and anthropornetric measures of outcome 
in the evaluation of AS, the relevance of change in score to clinicians and patients, 
and the minimal clinically important difference that may influence clinical decision 
making must be addressed. 
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Chapter 8 Summary and Discussion 
8.1 Introduction 
This chapter provides a summary of the current state of research into the measurement 
of health outcome, and the contribution of the described study to this body of 
knowledge. The limitations of this research are discussed and an agenda for future 
research is presented both within the context of AS health outcome measurement and 
for the measurement of health outcome in general. Section 8.2 summarises the 
current state of research into the measurement of health outcome, and specifically 
within AS, and Section 8.3 discusses the main findings of the preceding Chapters. 
Section 8.4 addresses the general implications and main conclusions from the study. 
Study limitations and suggestions by which deficiencies in the study might be 
addressed in future research are discussed in Section 8.5. The chapter concludes with 
Section 8.6. 
8.2 The measurement of health outcome 
Accurate measurement of outcome across the wide spectrum of health and disease has 
become an important medical and social issue (Ware, 1998). Whereas traditional 
methods of measurement focussed on the presence or absence of disease or the 
measurement of impairment, the changing prevalence of disease dictated a change in 
emphasis in management and the methods of evaluation (McDowell and Newell, 
1996). The role of the patient is increasingly seen as central to this process and is 
reflected in the increasing availability of patient-based measures of outcome and the 
emergence of individualised measures, for example, the PGI-AS. 
A wide range of evaluative instruments can be described (McDowell and Newell, 
1996; Bowling, 1997). However, there is little standardisation. in measurement 
practice and instruments often have inadequate evidence describing their 
development, testing and practical features which makes instrument selection for 
routine practice or clinical research very difficult (McDowell and Newell, 1996). 
Selection has often been guided by historical precedence (Jenkinson et al, 1994a) or 
more recently by expert opinion (van der Heijde et al, 1999a, b, c), and the need to 
improve the quality of patient evaluation by the adoption of instruments with clear 
evidence to support the development, measurement properties, acceptability to 
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patients and feasibility for the required application is an important requirement for all 
fields of health care (Kirshner and Guyatt, 1993; Fitzpatrick et al, 1998a). 
Within several areas of rheumatology recommendations for domains to include in 
patient evaluation and instruments to fulfil these domains have been made (Calin et al, 
1999b). However, many instruments were developed for research application 
(Bellamy et al, 1998) and recommendations often appear to have little relevance to 
routine practice. Not surprisingly the application of patient-based measures of 
outcome has been greatest in clinical and health services research and the role, 
integration and acceptance of these instruments in routine practice now demands 
greater attention. Clinicians demand that instruments are quick, simple and easy to 
score whilst requiring information about the benefits of including patient-based 
instruments alongside traditional methods of evaluation in routine practice and 
medical audit (Bellamy et al, 1998). For example, the benefit to clinical decision- 
making, individual patient outcome and quality of care, resource allocation, 
purchasing decisions and health policy. Although the importance of these qualities is 
widely recognised (Ware, 1997), the feasibility of using this information to inform on 
these attributes is poorly understood (Garratt, 1997; Greenhalgh and Meadows, 1999). 
83 Health outcomes in AS: summary of findings 
The current research consists of three main stages: first, a systematic review and 
evaluation of patient-based and anthropometric measures of outcome applied in 
evaluative studies ofAS (1990-2000). Second, the development of the first AS- 
specific individualised measure of disease-related quality of life, the PGI-AS. And 
third, an empirical comparison of generic and disease-specific patient-based and 
anthropometric measures of outcome in patients with AS. 
The systematic review of the entire range of patient-based and anthropometric 
measures of outcome applied in published studies of AS, and the evaluation of all 
disease-specific and anthropoinetric measures represents the first detailed and explicit 
synthesis of evidence relating to the development, measurement properties, 
acceptability and feasibility of outcome measures applied in current practice in AS. 
Data evaluation supported the adoption of two disease-specific patient-based and five 
anthropometric measures in the third stage of the study. Selected instruments 
reflected domains considered important in the evaluation of AS (van der Hcijde et: al, 
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1997; RAG - expert opinion, 1998), and patient-based measures were acceptable for 
self-completion in a postal survey. 
Although domain-specific instruments capable of evaluating a wide range of issues 
related to HRQL were identified, disease-specific measures of pain or of HRQL were 
not identified by the original review. The first AS-specific, individualised measure of 
disease-related quality of life, the PGI-AS, was therefore developed. The PGI was 
identified as a basis for the new instrument due to the individualised approach to 
evaluation described (Ruta et al, 1994a). Before the PGI-AS can be recommended for 
the evaluation of patients with AS in the United Kingdom (UK), it must demonstrate 
acceptable levels of acceptability, feasibility and measurement properties. The third 
stage of the study has provided initial evidence for these properties. Communication 
with measurement experts in rheumatology subsequently identified the AS Quality of 
Life questionnaire (ASQoL), an unpublished AS-specific measure of HRQL, (Doward 
L. - personal communication, 1998), and the Body Chart, an AS-specific measure of 
global bodily pain. Both instruments were included in the comparative study. 
Several generic measures of HRQL were identified in the review but these were long 
and not suitable for application in self-completed format. Therefore, a further 
literature search identified two additional generic instruments, the EuroQoI and the 
SF- 12, which had good evidence of measurement properties in patients with similar 
disorders to AS and were brief and suitable for self-completion (Hurst et al, 1997, 
1998; Coons et al, 2000). 
The third stage of the study describes the first comparative evaluation of the 
measurement and practical properties of a broad ranging and evidence-based package 
of instruments in the same population of AS patients. The instruments have also been 
assessed for data quality and scaling assumptions, the results of which have 
previously not been reported for the disease-specific instruments. In addition, the 
ASQoL, BASDAI and RLDQ were assessed for dimensionality, a property not 
previously reported. 
The comparative study involved a longitudinal evaluation of instruments in both a 
clinic based and postal survey. The baseline response rate to the clinic survey was 
acceptable (n = 159,59.0%) and comparable to other studies (Lubrano et al, 1998). 
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Postal evaluation involved completion of all patient-based instruments in a self- 
completed questionnaire using a multi-centre study design with participants from the 
North, Nfidlands and South of the UK. The baseline response rate (n-- 349,77.4%) 
was satisfactory. The study represents the largest clinic-based and one of the largest 
multi-centre postal evaluations of outcome measures in UK-based AS patients. The 
study also describes the most rigorous process of instrument testing previously 
reported in AS. This enhances confidence in the results, which are more generalisable 
to the evaluation of the wider AS population. 
When data quality and scaling assumptions were assessed all instruments, except for 
the BASDAI and RLDQ, demonstrated adequate properties at both item and scale 
level. Items in the BASDAI had high levels of missing data and modification of the 
response format is strongly recommended. Although all response options were 
covered, and end-effects did not exceed recommended levels, responses to items of 
the RLDQ were skewed towards better levels of functional ability. Increasing the 
number of response options, changing descriptors to improve discrimination between 
options, or adding further items that represent more difficult functional activities are 
suggested as ways to improve the data quality of the RLDQ. The BASDAI 
demonstrated adequate properties at scale level for those patients for whom a score 
could be calculated, and the distribution of responses to the RLDQ at scale level were 
approximately normally distributed, although still failing to cover the extreme range 
of disability described by the instrument. Assessment of the dimensionality and item- 
total correlation of the ASQoL, BASDAI and RLDQ supports the uni-dimensional 
structure proposed by the developers. 
Although completion of the PGI-AS following interview-administration was 
excellent, acceptability of the self-completed format may be improved by simplifying 
the spending of points in step 3 (spending points), and allowing for minor errors in 
summation of these points. Also, more explicit guidance for completion by patients 
not experiencing AS-specific problems is required. 
All instruments were assessed for test-retest reliability in patients indicating no 
change in both AS and general health at two-weeks, and all instruments exceeded 
levels recommended for group evaluation (Nunnally and Bernstein, 1994). The 
ASQoL, RLDQ, SF-12 PCS and all anthropometric measures achieved levels that 
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support their use in individual evaluation (Streiner and Norman, 1995). Where 
appropriate, tests of internal consistency reliability also exceeded levels recommended 
for group analysis (BASDAI), and for the ASQoL and RLDQ exceeded levels for 
individual evaluation. 
An index of change for step I (identifying areas) of the PGI-AS was calculated to 
assess the impact of area changes on test-retest reliability. In patients completing the 
instrument blind to baseline areas, when few areas were changed reliability supported 
its use in individual evaluation (0.9 1). However, when more than three areas were 
changed reliability levels suggested that the format was not suitable for use in group 
evaluation (0.56). All patients completing the informed and open format retained 
their original list and reliability supported its use in group evaluation (0.85). When 
considered irrespective of the index of change, the highest level of reliability was 
calculated for the closed format (0.87), and the lowest for the blind format (0.81). It 
is suggested that the blind format may introduce noise into the assessment of 
reliability, and the open and informed format may not be necessary. Therefore, 
keeping the selected areas the same at follow-up completion (closed format) may 
improve the reliability and clinical validity of the instrument, without a threat to the 
content validity. However, this result only applies to patients indicating no change to 
health at two weeks, and does not consider the role of the PGI-AS in patients 
indicating change. Recommendations to reduce the number of response options in 
stage 2 of the PGI-AS (scoring areas) may also help to improve reliability. 
Construct validity was assessed by relating instrument scores to other more 
established instruments, to other disease-specific instruments and to 
sociodemographic variables. No disease-specific instrument has previously been 
assessed against instruments with such well-established and documented levels of 
validity as observed in the EuroQoI and SF-12. In addition, no study evaluating 
measures of outcome in AS has constructed hypothetical relationships between 
instruments and set out to test these hypotheses. All correlations between instruments 
were in the hypothesised directions. The results represent good evidence for the 
validity of the PGI-AS as a measure of disease-related quality of life and support the 
validity of all disease-specific patient-based measures of outcome. The ASQoL and 
the PGI-AS were the best performing disease-specific measures. However, the 
ASQoL had a stronger than predicted relationship with the generic measures of 
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HRQL, which may suggest inadequate anchoring of items to the specific impact of 
AS. Evidence further supported the validity of both the EuroQoI and the SF-12 as 
generic measures of HRQL in AS. The EuroQol was the generic instrument and the 
ASQoL the disease-specific instrument most capable of discriminating between 
patients on most sociodemographic variables. As hypothesised, very weak 
associations between all anthropometric; measures and patient-based measures were 
found supporting a minimal association between limitation in specific spinal mobility 
and the impact of AS on various aspects of HRQL. The strongest, but weak, 
associations were observed between cervical rotation and fingertip to floor distance 
(FFD) and all patient-based measures. 
All instruments were assessed and compared for responsiveness to change at six 
months by two criteria: first, the linear relationship between change in instrument 
score and patient reported change on health transition; and secondly, a responsiveness 
statistic was calculated. Although most patients indicated that on average their AS- 
specific and general health was the same, all patient-based instruments demonstrated 
strong and significant linear relationships with both AS and general health transition 
questions, which supported instrument longitudinal validity. The strongest 
relationships were found for the EuroQol, the PGI-AS (informed and open) and the 
BASDAI on both AS-specific and general health transition. The changes in scores for 
four of the five anthropometric measures did not reflect the categories of AS or 
general health transition. A significant relationship between fingertip to floor distance 
(FFD) and both transition questions was found, and although the results apply to a 
smaller sample size, this was a smaller relationship than observed for all patient-based 
instruments. 
Instrument responsiveness was compared for all patients reporting an improvement or 
deterioration on health transition using the Modified Standardised Response Mean 
(MSRM)(Fitzpatrick et al, 1998a). The EuroQol was generally the most responsive 
instrument, with both sections of the instrument able to detect improvement or 
deterioration in AS-specific or general health. The thermometer and the EQ-51) were 
the most responsive to improvements and deterioration in health respectively. The 
PGI-AS (informed and open) also performed well in measuring improvement or 
deterioration in AS-specific or general health. The lowest levels of responsiveness 
were found for the ASQoL, the RLDQ and PGI-AS (blind) for change in AS-specific 
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health and for the Body Chart, the RIDQ and PGI-AS (blind) for change in general 
health. Although the sample size was greater than most identified studies evaluating 
the measurement properties of anthropometric measures in AS, sample sizes were too 
small to allow clear inferences to be drawn from the data. However, FFD and 
cervical rotation demonstrate small levels of responsiveness. The results suggest that 
the PGI-AS (informed and open) and the BASDAI are the most responsive disease- 
specific instruments. The EuroQoI (EQ-5D and thermometer) is the most responsive 
generic instrument, and in the majority of comparisons was more responsive than the 
disease-specific instruments. 
Two formats of the PGI-AS were completed at six months; the informed and open 
format was the most responsive. It is suggested that the noise that influences the 
reliability of the blind format may also influence responsiveness. The closed format 
was not assessed for responsiveness. 
8.4 General implications and conclusions 
The systematic review highlighted the wide diversity of outcome measures applied in 
the evaluation of AS. It also described the lack of standardisation, the limited 
evidence describing the measurement properties or comparative performance, 
acceptability and feasibility of the majority of patient-based and anthropometric 
measures of outcome adopted in AS, and the focus towards measures of impairment 
and disability. The review supported the need to recommend a standardised and 
evidence-based package of patient-based and anthropometric measures of outcome 
that would be suitable for application in routine practice and clinical research, and to 
extend measurement practice to consider the role of both disease-specific and generic 
measures of HRQL in AS. 
The subsequent empirical evaluation has provided the first comparative evidence for 
the measurement properties, acceptability and feasibility of the PGI-AS, an evidence- 
based selection of disease-specific patient-based and anthropornetric measures, and 
two widely applied generic measures of HRQL in a large population of AS out- 
patients. Combined with the systematic review and data evaluation, this provides 
important information against which the relationship between instruments can be 
judged in terms of necessary measurement properties (McHorney and Tarlov, 1995; 
Beaton et a], 1997). 
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Most patients with AS present with multiple, coexisting problems and in order to 
develop a thorough understanding of the impact of AS, a multi-dimensional approach 
to evaluation is required. However, in making recommendations consideration must 
be given to what the clinician or investigator wishes to measure, and what is 
important to the patient. It is therefore convenient to describe measures of outcome in 
terms of the domains considered important in the evaluation of AS. 
Recommendations for instruments to ftdfill these domains, based upon the available 
empirical evidence of measurement properties, acceptability and feasibility are made, 
together with a recommendation for application in routine practice or research. 
Individualised disease related quality of life 
Available evidence suggests that the PGI-AS (informed and open) may be used in the 
evaluation of groups of patients with AS in routine practice or clinical research 
following an interview-administered format. Although interview-administration will 
reduce acceptance in clinical research, minimal interviewer training is required and 
after the initial average completion time of 10-minutes, most patients complete 
subsequent formats in approximately 5-minutes. Although completion rates for the 
modified version of the PGI reported here are a great improvement on those 
previously reported, further recommendations are made to reduce missing data, which 
may improve acceptance as a self-completed instrument in clinical research or routine 
practice. Evidence suggests that the informed and open format is both more reliable 
and more responsive to change at six months than the blind format, but evidence of 
the responsiveness of the more reliable closed format is required before 
recommendations for a particular format for purposes of evaluation can be made. 
The PGI-AS offers a unique approach to the evaluation of disease-related quality of 
life by allowing patients to nominate individualised areas of life affected by AS. The 
moderate correlation with other patient-based and generic measures of HRQL suggest 
that it is measuring different aspects of HRQL, not covered by the more conventional 
patient-based instruments included in the study. When applied in combination with 
patient-based and anthropometric measures of outcome the PGI-AS has the potential 
to provide more individualised information relating to health outcome, but further 
refinement of the instrument is recommended to improve levels of reliability and to 
enhance its role in individual evaluation. Evidence also supports the hypothesis that 
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the individually tailored evaluation of disease-related quality of life described by the 
PGI-AS provides a more responsive patient-specific evaluation than found for most 
other conventional disease-specific instruments included in the study. The original 
versions of the PGI were also found to be generally more responsive to change than 
disease-specific and generic instruments in several different patient populations (Ruta 
et al, 1994; Garratt, 1997; Ruta et al, 1999). 
AS-specific HRQL 
Although the ASQoL has good completion rates, satisfactory data quality and scaling 
assumptions, and a very high level of reliability, it is not recommended for the routine 
evaluation of AS patients due to its poor level of responsiveness. Anchoring of items 
to the impact of AS may improve the validity of the instrument as an AS-specif ic 
measure of HRQL, and revision of the dichotomous response scale may improve 
discrimination and responsiveness to change. 
Disease Activity 
High levels of missing data following self-completion of the BASDAI prohibits the 
recommendation for use as a self-completed instrument in clinical practice or 
research. Although interview-administration may reduce these levels, this is a time 
consuming process and reduces instrument acceptance in clinical trials (Fitzpatrick, 
1999). However, satisfactory measurement properties in the current study for those 
patients completing the instrument adequately to receive a score, support a 
recommendation for its use in the evaluation of groups, and strongly indicate that a 
revision of the response scale is necessary before recommendation for self-completion 
in clinical practice or research can be made. 
BodyPain 
The Body Chart was the only disease-specific instrument to demonstrate a much 
stronger association with change in AS-specific health than general health over the six 
months, being responsive to both improvement and deterioration in AS. The 
instrument also had satisfactory levels of reliability and validity and can be 
recommended for the evaluation of groups following interview administration in 
routine practice or research. Although not originally designed for self-completion, 
further clarification of the self-completed format is required which may improve 
instrument acceptance in clinical research. Improved instrument reliability may be 
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achieved by a more standardised approach to shading the body manikin and the 
awarding of points. 
Functional Disability 
Although the RLDQ has good completion rates and a very high level of reliability, it 
is not recommended for evaluative purposes in AS due to its poor data quality at item 
level, the inadequacy of the instrument to provide a broad reflection of functional 
disability in AS, and the low level of responsiveness. Recommendations to revise the 
response format and item content have been made which may improve data quality, 
the coverage of functional disability and responsiveness. 
Generic HRQL - Utility measure 
Both sections of the EuroQol had high completion rates and levels of reliability that 
support application of the instrument in group evaluation. Evidence supports the 
validity of the instrument as a measure of generic HRQL in AS, and both sections of 
the instrument, when applied together provide a generic instrument that is both 
responsive to improvement or deterioration in AS-specific and general health over six 
months. Where an index of generic HRQL is acceptable the EuroQol is 
recommended for the evaluation of groups in both routine practice and clinical 
research in AS. 
Generic HRQL - Health profile 
Completion rates of the SF- 12 were satisfactory although lower than the EuroQol, and 
modification of the treatment of missing values has been recommended to allow for 
item omission without jeopardising a final score. Reliability of the SF-12 PCS 
supports application in individual evaluation, but the MCS should only be used in the 
evaluation of groups. Evidence of validity supports its role as a generic measure of 
HRQL in AS. The levels of responsiveness were small to moderate, were less than 
those observed for the EuroQol, and the instrument was less able to detect 
deterioration in general or AS-specific health. Where a limited health profile is 
acceptable and respondent burden is a factor, the SF-12 may be acceptable for 
individual evaluation in routine practice or research. However, the measurement error 
associated with the MCS and the limited ability to detect deterioration in health may 
limit this role. 
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All patient-based instruments are readily available and most are easy to score without 
the use of a computer-based programme. However, due to the external weighting of 
the EuroQol and the scoring algorithms of the SF-12 computer-based scoring of these 
instruments is recommended. 
Anthropometric measures 
The results suggest that the choice of anthropometric measures could be reduced to 
the measurement of cervical rotation, as a short term reflection of reversible change in 
-spinal mobility and the MSI as a long term reflection of irreversible change in spinal 
status (Kennedy et al, 1995; Dawes, 1999). Both measurements can be completed in 
less than 5 minutes, and the only instrumentation required is a relatively inexpensive 
plastic tape measure. Routine use of the approaches in clinical practice would suggest 
that they already have a level of clinical acceptance (Bellamy et al, 1998,1999; 
Lubrano et al. 1998). However, a further evaluation of the responsiveness of both 
cervical rotation and a revised methodology of FFD over the short term, and of the 
MSI over the long term (that is, more than two-years (Calin et al, 1999c)), with 
revised external criteria, is required in a larger patient population. 
in conclusion, no study instrument fulfilled the required measurement properties for 
the evaluation of individual patients. That is, instruments with adequate levels of 
reliability (> 0.90)(ASQoL, RLDQ, SF-12 PCS, all anthropometric measures) were 
not sufficiently responsive to change, and instruments that were responsive over the 
six month period did not have sufficiently high levels of reliability for individual 
assessment (BASDAT, Body Chart, PGI-AS, EuroQoI). Although instrument 
selection should be made following consideration of all measurement and practical 
properties (Fitzpatrick et al, 1998a), reliability may be the most important issue when 
identifying an instrument for individual evaluation (McHorney and Tarlov, 1995). 
However, some clinicians may be willing to accept lower levels of reliability, and the 
associated increase in measurement error, if the adoption of a patient-based measure 
includes areas of HRQL not covered by traditional methods of evaluation (McHorney 
and Tarlov, 1995). For example, the identification of mental health problems or 
functional difficulties. In many cases the usefulness of an instrument at the individual 
level has been constrained by the requirements for higher levels of reliability (Garratt, 
1997). 
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Recommendations have been made to make modifications to all disease-specific study 
instruments, and to the measurement of FFD, and for further empirical evaluations of 
instrument properties once changes have been made. Therefore, recommendations 
may change in light of the proposed modifications and further evaluation of 
measurement properties. 
8.5 Limitations and criticisms 
The first evidence-based selection of instruments fulfilling domains considered 
important in the evaluation of AS were described following the systematic review, 
communication with experts, an additional literature overview, and the development 
of the first individualised measure of AS-related quality of life (PGI-AS). However, 
further appraisal in the first comparative study of its type in AS indicated that no 
instrument adequately fulfilled the required measurement properties and practical 
criteria considered necessary for use in individual evaluation (McHorney and Tarlov, 
1995). Several instruments can be recommended for use in group analysis and in 
clinical trials, but because the ASQoL and RLDQ cannot be recommended, all 
relevant domains are not described, that is, disease-specific HRQL and functional 
disability. Also, the acceptability of the BASDAI is limited without modification to 
the response format. The measurement of spinal mobility requires further evidence to 
support the responsiveness of cervical mobility and the MSI before any 
recommendation can be affirmed. 
A second disease-specif ic measure of HRQL has recently been published: the AS- 
Arthritis Impact Measurement Scale 2 (AS-AIMS2)(Guillemin et al, 1999). Although 
developed in French, early evidence suggests satisfactory measurement properties, 
acceptability and feasibility (Guillemin et al, 1999). Following English translation 
direct comparison with the ASQoL and with generic measures of HRQL, for example, 
the EuroQol and SF-36, is recommended to assess the measurement properties of the 
instrument. 
Two additional AS-specific measures of functional disability have been recommended 
by the ASAS group (van der Heijde et al, 1999ab): the Dougadas Functional Index 
(DFI)(Dougadas et al, 1988; Spoorenberg et al, 1999a) and the Bath AS Functional 
Index (BASFI)(Calin et a], 1994). Following suggested modifications to the RLDQ, 
direct instrument comparison is recommended to support the selection of a single AS- 
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specific measure of functional disability. Alternatively, the modified RLDQ may so 
closely resemble the revised DFI, that the more widely used DFI is accepted as the 
most appropriate instrument. The response scales of the BASE are identical to the 
BASDAI and completion in a patient population unfamiliar with the instrument, as 
described in the current research, may provide important information relating to the 
acceptability of the response scales. 
in recommending a single format of the PGI-AS for evaluative purposes in AS a full 
appreciation of the measurement properties and practical considerations for all 
versions is required and was not provided by the current study. The closed format 
was not assessed for responsiveness and sample sizes were very small when the 
different formats were considered. It is recommended that the study is repeated with 
a larger sample size. 
Although the PGI-AS was readily incorporated into the routine 20-minute clinic 
assessment, the views of the clinical physiotherapist following administration to 26 
baseline patients were not obtained. This was due to the unavailability of the 
physiotherapist (JW), who was subsequently unable to participate in the six-month 
follow-up. However, the clinical relevance to health care professionals and feasibility 
of adopting the instrument in routine practice or in research should be addressed. 
Also, due to the individualised nature of the PGI-AS, consideration of the format with 
the greatest relevance to patients may further assist in recommending a particular 
format. For example, different versions could be used in a clinic setting followed by 
focus group interviews where patients and clinicians are asked which version they 
prefer. it is suggested that the closed format may be more acceptable to research 
where the investigator wishes to evaluate change in disease-related quality of life in 
relation to areas listed at baseline. 
An additional follow-up format of the PGI has been adopted in patients with Multiple 
Sclerosis (MS)(Pimm J. - personal communication, 1999). Following completion 
blind to baseline areas patients are shown a copy of their original areas and are asked 
to score these if they differ from the new list. Although published evidence of the 
measurement properties of this format are not available the approach may have 
enhanced clinical relevance, whereby a clinician is willing to accept the incumbent 
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time implications. This format was not suitable for self-completion and was not 
included in the current research. 
Although not addressed in the current research, anecdotal reports suggest that the PGI 
may have an important role to play in directing patient management (Ruta et al, 
1999). Theoretically, the incorporation of patients needs and expectations into the 
management of incurable and chronic disease such as AS could be of great benefit. 
However, modifications to reduce the measurement error associated with the present 
format of the PGI-AS are required before it can be recommended for individual 
evaluation. 
Direct comparison of the PGI-AS with an alternative individualised approach, for 
example, the SEIQoL-DW (Hickey et al, 1996) would allow the measurement 
properties of instruments with a similar conceptual base to be compared. This may 
provide more relevant information than an assessment of validity against instruments 
following a more traditional approach to the evaluation of HRQL, and may lend 
further support to the validity of the PGI-AS as a broad measure of disease-related 
quality of life. 
A recent concept proposed as an important consideration for patient-based measures 
of outcome is that of response shift (RS), defined as a change in the meaning of an 
individuals self-evaluation of a target construct (Schwarz and Sprangers, 1999). This 
may be a result of three interrelated concepts: scale recalibration, concept redefinition 
or a change in the patients' internal values. Although all study instruments are 
susceptible to RS, it is of particular relevance to the PGI-AS where patents nominate 
areas for inclusion in the evaluation. RS may influence the PGI-AS format adopted 
for follow-up evaluation and the setting in which the instrument is completed. For 
example, due to the influence of social comparison. Patients completing the PGI-AS 
in the clinic often required more assistance at six months than at baseline, with several 
patients indicating that since the original completion they had thought at greater 
length about the impact of AS on their life. Therefore, although the impact of AS at 
six months may not have changed, scale recalibration by which the patient evaluated 
disease impact, or a redefinition and reconceptualisation of disease impact may have 
resulted in a RS. it is possible that such a RS could partially account for the improved 
responsiveness of the PGI-AS at six months when compared to other disease-specific 
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instruments, as opposed to reflecting a real change. It may also partially describe the 
poor responsiveness of the blind format. 
There is no empirical evidence to support the existence of RS in individualised 
instruments. However, recent evidence has described the role of RS in administering 
the Health Assessment Questionnaire (HAQ), an arthritis-specific measure of 
functional ability, to patients with osteo-arthritis (OA)(Daltroy et al, 1999). Patients 
with a recent onset of health problems may have an inflated perception of functional 
difficulties due to a shift in their internal standards of measurement. Physical 
performance of an activity before instrument completion influenced self-reported 
function, possibly due to a redefinition of the concept. In the current research 
anthropometric assessment followed completion of patient-based instruments and 
should not have unduly influenced the results. 
RS may be a useful construct to investigate in future research to further address the 
most suitable format of the PGI-AS to adopt. Change in patients perceptions, values 
and priorities over time are important considerations to the conceptual base of the PGI 
(that is, the interaction between expectation and reality), and are concepts that relate 
strongly to that of a response shift where patients may'rethink and reframe'the impact 
of disease on HRQL (Wilson, 1999). 
Few studies have compared the relationship between the EuroQol and the SF- 12 
(Johnson and Coons, 1999). Although both measure generic HRQL the moderate 
correlation between instruments in the current study suggests that they measure 
different aspects of HRQL. The SF-12 produces a limited profile of HRQL 
describing only mental and physical component summary scores, and selection of the 
EuroQol (EQ-5D and thermometer) is supported by the results of the current study. 
Although the relationship between both instruments and other disease-specific 
instruments is similar the EuroQol has greater discriminatory power when 
sociodemographic variables are assessed. The EuroQol also demonstrates a greater 
responsiveness to change in AS or general health over six months than the SF-12, and 
the inability of the SF-12 to detect deterioration in health is an important 
consideration if the instrument is used to assess AS relative to other disorders within 
health care. However, the SF-12 PCS had a level of reliability that supported its use 
in individual evaluation. The SF-12 was identified for the current study in preference 
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to the parent instrument, the SF-36, due to the reduced respondent burden. However, 
the SF-36 describes both component summary scores and a profile across eight 
domains of health. Further studies should. consider the advantages of the additional 
information provided by the SF-36 against instrument acceptability and feasibility. 
The measurement properties of the SF-36 have not been rigorously tested in AS and it 
should be compared to the EuroQoI to provide a further assessment of the role and 
usefulness of generic profile and utility measures in AS. 
Anthropornetric assessment is one component (impairment) of a multidimensional 
group of outcome measures considered relevant in the evaluation of patients with AS. 
The results of the current study present a view that challenges the role and usefulness 
of anthropometric assessment described by clinical investigators (Lubrano et at, 1997; 
Dziedzic, 1997; Lubrano and Helliwell, 1999). However, the widespread adoption of 
anthropometric assessment in both routine practice (Bellamy et at, 1998,1999) and in 
clinical research (Chapter 2) demands that both viewpoints should be considered in 
recommending anthropometric assessment in AS evaluation. 
When empirical evidence of the acceptability, feasibility and measurement properties 
of selected anthropometric measures is appraised in light of the systematic review and 
comparative study, this suggests that although reliable and suitable for use in 
individual evaluation, most measures are not responsive to change in general or 
disease-specific health over a six-month period. In addition, most measures have little 
relationship with measures of HRQL and patient perception of disease impact. 
However, certain measures have a strong relation to disease-specific radiographic 
change of the spine (Kennedy et al, 1995; Dawes, 1999). Therefore, based on this 
empirical evidence most anthropometric measures appear to have a limited role in the 
evaluation of short-term change in patients with AS. However, clinical experience 
and further empirical evidence of validity suggests that they may have a different role 
in AS evaluation to patient-based measures of outcome. 
The clinical viewpoint suggests that anthropometric assessment is essential to 
ascertain clinical outcome in AS, to provide an insight into the natural history and 
serial progression of disease and to identify sub-groups of patients (Lubrano and 
Helliwell, 1999; Dawes, 1999; van der Heijde and Spoorenberg, 1999). An important 
consideration in the role of anthropometric assessment is the ability of a measure to 
287 
reflect the irreversible or reversible nature of AS, and in selecting a measure 
consideration should be paid to what the clinician or investigator expects from the 
assessment. 
Structural damage is considered an important outcome in the evaluation of AS, and 
one that is often measured by radiographic assessment (van der Heijde and 
Spoorenberg, 1999). The strong relationship between AS-specific radiographic 
change and certain anthropometric measures, for example, the MSI, LLF and TYM 
(Kennedy et al, 1995), supports the ability of these measures to reflect the structural 
change and the irreversible nature of AS, whilst reducing the need for radiographic 
exposure in the serial evaluation of disease progression. However, radiographic 
assessment is unable to detect structural change over periods of less than two-years 
(Calin et al, 1999c; van der Heijde and Spoorenberg, 1999), and therefore, as 
demonstrated, these anthropometric measures would not be expected to be responsive 
to change over the six-month period of the current study. Although this result could 
reflect the insensitivity of the measures, it is more likely to represent the 
inappropriateness of the six-month follow-up period and the slow rate of AS disease 
progression in patients with stable disease. Therefore, significant change in these 
measures over the short term plays an important role in clinical decision making, and 
would act as a trigger for further investigations (Dawes P. and Dziedzic K. -personal 
communication, 2000). Over longer periods of time (six to 14 years), a gradual 
deterioration in range of movement has been reported in AS patients, irrespective of 
initial disease severity or level of exercise (Stuffock et al, 1973; Lubrano and 
Helliwell, 1999), and may describe more suitable periods of time over which to assess 
the responsiveness of anthropometric assessments reflective of irreversible change in 
AS. 
Certain anthropornetric measures have a lower correlation with radiographic change 
and may be more reflective of reversible change in AS (Roberts et al, 1988). For 
example, cervical rotation and FFD. Results from the current study suggest that these 
measures may be responsive to change in range of movement over six-months and 
may be acceptable in evaluative practice to capture the short-term effects of 
management. However, evidence is limited and requires further evaluation of 
measurement properties in larger populations of patients with AS, particularly in 
relation to responsiveness to change. 
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Clinicians may be willing to reduce the number of anthropometric measures included 
in an evaluation in light of empirical evidence, but may not be willing to forgo 
anthropornetric assessment completely in favour of patient-based assessment. 
Additional information intuitively gained from the recording of such measures in 
routine practice, for example, the quality of patient movement (hesitant movement), 
the state ofjoints and skin quality Ooint swelling, muscle wasting, psoriasis), the 
ability of the patient to dress independently (functional disability), is often purely 
qualitative. However, the clinical interpretation of this information associated with a 
theoretical appreciation of disease process is often used to assist in clinical decision 
making and to direct patient management. These combined issues reflect the reality 
of evaluation in routine practice, a reality that may not be quite so apparent in clinical 
trials and one that places different demands on instruments recommended for 
evaluative purposes. 
The relevance of anthropometnc assessment to patients should also be considered. 
Although anecdotally clinicians suggest that patients consider change in range of 
movement an important indicator of progression, this may be due to a lack of viable 
alternative that considers a patients' viewpoint of change. For example, the PGI-AS 
or other patient-based instrument. Several patients interviewed during the pre-pilot 
evaluation of the PGI-AS (Chapter 3) indicated that they were empowered by the 
opportunity to identify important areas of life impacted by AS, as opposed to the 
'mechanical' nature of anthropometric measurement: 
To be told that my measurements are the same as last time, when I already know this 
- the quality of my life is far more important - it is very real'. 
However, patients also indicated that the relevance of such instruments would be 
enhanced if they lead to the development of a plan of action, and did not just result in 
a #paper exercise'. 
The selection of anthropometric measures recommended as a result of the review and 
empirical study differ from those recommended by the ASAS group (table 2.65). 
Clear guidance in the selection of measures is required to support standardisation and 
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to ensure that anthropometric measures with inadequate measurement properties are 
not included in routine evaluative practice. 
Dynamic movement has recently been assessed in AS using the Fastrack (FK). 
Evidence suggests that the FK more accurately describes shoulder and cervical 
movement than goniometer or tape measure assessment and was able to distinguish 
between sub-groups of disease severity (Jordan K. -personal communication, 2000). 
The computer generated imaging allows the visual comparison of movement against 
normal values and against previous assessments. However, the feasibility of 
including the FK in routine practice or research requires further evaluation. 
Alternatively, there is little evidence to support the effectiveness of including patient- 
based measures of outcome in routine practice (Greenhalgh and Meadows, 1999). 
Clinicians may view the information as difficult to interpret and possibly as irrelevant 
(Bellamy et al, 1998,1999; Chesson, 1998). However, when used alongside 
traditional measures score comparison may serve to enhance data interpretation of the 
patient-based instruments by a form of 'calibration! (Deyo and Carter, 1992; 
McHomey and Tarlov, 1995). Eventually, an intuitive feel for these instruments may 
develop. Comparison of patient-based instruments against anthropometric measures 
in the current research described a very small correlation providing minimal support 
for data interpretation. Further comparison of the patient-based instruments against 
other traditional measures, for example, laboratory based measures and radiographic 
assessment may provide further support for data interpretation. 
The current research did not include laboratory based and radiographic assessment in 
the evaluation and identification of instruments for additional domains identified by 
ASAS was not possible (table 2.1) (van der Heijde et al, 1997). Further research 
should address the role of these forms of evaluation in AS and their association with 
patient-based instruments. The ASAS group have recently appraised the evidence for 
two laboratory based measures (ESR and CRP) but no consensus was reached on their 
role in AS (Ruof and Stucki, 1999b; Spoorenberg et al, 1999b). Several instruments 
for radiographic evaluation, including the Stoke AS Spine Score (SASSS)(Avems et 
al, 1996a; Dawes, 1999) and the Bath AS Radiographic Index (BASRI)(MacKay et al, 
1998) have also been assessed and suggest good reliability, but evidence for 
responsiveness is limited (Spoorenberg et al, 1999c). 
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Associated with data interpretation and instrument application is the ability of an 
instrument to describe the full range of a domain (Fitzpatrick et al, 1998a). In the 
current research an inconsistency between items in the RLDQ and the wide impact of 
AS on functional disability was observed. That is, most items were easily performed 
by most patients, and very few items were considered difficult. Therefore, a score at 
the ceiling of the RLDQ may be interpreted as perfect function, when the instrument 
is more suited to measuring severe functional dysfunction and is unable to capture 
more subtle levels of dysfunction (McHomey and Tarlov, 1995). 
Item contribution can be further investigated by Item Response Theory (IRT) 
including Rasch models analysis (Nunnally and Bernstein, 1994). Rasch models 
assume that items within a uni-dimensional instrument are equally discriminative, and 
evaluates items in terms of their level of difficulty and interval location within a 
structured hierarchy (Raczek et al, 1998; Fitzpatrick et al, 1998a). This analysis 
identifies gaps in the domain described by the instrument, placing greater emphasis on 
the ability to describe a range of difficulties so as to maximise information as opposed 
to maximising internal consistency reliability (Nunnally and Bernstein, 1994; Raczek 
et al, 1998). Rasch models analysis may therefore improve instrument performance 
whilst producing a linear, interval-level score which is easier to interpret and more 
precise than the ordinal level of measurement produced by traditional summated 
rating scales (Raczek et al, 1998). It may also more accurately estimate scores when 
data is missing by utilising expected response information for each item, as opposed 
to substituting a person-specific estimate (Raczek et al, 1998). However, this analysis 
is only suitable for multi-item instruments decribing the range of a single domain. 
For example, the ASQoL and the RLDQ. It is not clear that the BASDAI contains 
items covering the range of AS-specific symptomlogy. The Body Chart, PGI-AS and 
EuroQol would not be suitable because they incorporate explicit weiglitings and 
certain domains of the SF-12 are described by a single item. However, separate scales 
of the SF-36 have been assessed by Rasch analysis supporting the unidimensional and 
hierarchical nature of the physical functioning scale (Fitzpatrick et al, 1998a; Raczek 
et al, 1998). The RLDQ is currently being assessed by Rasch models analysis to 
evaluate the extent to which items cover the range of AS functional disability 
(Helliwell P. - personal communications, 2000). 
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Data interpretation may be further enhanced by describing a score range against 
which real change may be assessed. Calculating the 95% limits of agreement as an 
estimation of test-retest reliability describes a range of values that is expected to 
describe the agreement between two observations for most patients indicating no 
change in health (Bland and Altman, 1986; Altman, 1996). The range acknowledges 
that few repeat observations will be identical due to random error. However, there 
has not been a wide spread adoption of this methodology and few authors describe 
what they consider to be a minimally important change in instrument score. 
Therefore, interpretation of the limits described is difficult. 
The elderly (over 75 years) and children (less than 18 years) were excluded from the 
current study for reasons related to difficulty in instrument comprehension and self- 
completion, and due to the impact of co-morbidity (elderly) or the juvenile expression 
of AS (children) on the data. However, AS does not markedly reduce life expectancy 
and with the ageing population many patients in routine practice will be older than 75 
years. To obtain valid information from this important section of the population the 
acceptance of questionnaires by these patients must be addressed. Likewise, the 
ability to clearly record the impact of disease in children is important. In 
circumstances where self-completed patient-based instruments are not acceptable the 
use of proxy respondents in the form of carers or health care professionals has been 
described (Guyatt et al, 1993; Garratt, 1997). In the current research several patients 
were unable to complete the questionnaire due to blindness caused through persistent 
iritis, a severe complication of AS (Dziedzic, 1998). These patients may represent a 
section of the population with a high risk for poor outcome and the role of proxy 
respondents requires further investigation. 
10 
Patients unable to comprehend the written English language were also excluded from 
the study and may reduce the generalisability of the result. The ability to apply 
patient-based instruments cross-nationally supports meta-analysis of data from multi- 
national studies dnd supports comparison of results across countries and patient- 
groups (Anderson et al, 1995; Ware and Gandek, 1998b, c). Several disease-specific 
instruments have evidence of formal translation into a non-English format, and 
initiatives to support the translation and cross-cultural adaptation of generic measures 
of HRQL have been identified: the International Quality of Life Assessment (IQoLA: 
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SF-36; Ware and Gandek, 1998a); World Health Organisation Quality of Life 
(WHOQoL)(Anderson et al, 1995). 
The non-response bias of the current research towards the younger age group, a 
feature described by other investigators (Garratt et al, 1993), and the return of several 
questionnaires by patients describing a perception that their AS was too mild to be of 
benefit to the study, suggests that the generalisability of the result may be reduced and 
focussed towards older patients with more severe disease. The impact of this form of 
bias on the evaluation of instrument measurement properties is not clear, but may not 
be as important as non-response bias when information from outcomes is used to 
evaluate the effectiveness of competing interventions, and ultimately to direct 
resource allocation within the health care system (Garratt, 1997). It was not possible 
to contact a random sample of non-responders, for example, by telephone, due to the 
limited study resources. However, this may have provided beneficial information 
relating to AS and general health and further supported interpretation of the non- 
responder bias. Providing patients the opportunity to indicate that they experience 
minimal symptoms, and directing these patients to complete the generic instruments 
or a summary of items may enhance data retrieval from patients otherwise lost to the 
study. 
8.6 Conclusion 
The thesis makes three important contributions to the evidence base for outcome 
measurement in AS. First, the study was in a unique position to describe the first 
evidence-based and systematic selection of patient-based and anthropometric 
measures to fulfil a defined selection of domains considered important in the 
evaluation of AS. Secondly, the development of the first AS-specific individualised 
measure of disease-related quality of life, the PGI-AS, is described. Thirdly, the first 
comparative evaluation of the PGI-AS and an evidence-based selection of disease- 
specific, anthropornetric and generic measures of outcome in patients with AS was 
performed. 
The methodology adopted for the systematic review and evaluation may provide a 
format whereby the wide range of outcome measures available in other diseases can 
be identified and explicitly appraised to support instrument recommendation. For 
example, in neurology, respiratory care or oncology. Alternatively, the results may 
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highlight gaps in the availability of evaluative instruments for specific domains of 
health, or the need for finiher research to evaluate the measurement properties of 
widely used instruments, as described in the current research. 
Systematic reviews of RCTs consider the quality of measures of outcome when 
assessing the quality of trials included in the review (Jadad et al, 1998). However, no 
previous attempt to systematically and explicitly assess the quality of measures of 
outcome has been described. This study describes the first attempt to describe 
instrument quality within a specific disease, and should be considered an important 
addition to systematic reviews of RCTs in AS. The methodology described may 
support the development of guidelines for future reviews of patient-based and 
anthropometric measures of outcome. 
The first comparative evaluation of a wide ranging selection of outcome measures in 
AS supports appreciation of instrument measurement properties, acceptability and 
feasibility, and the recommendation of instruments to include, and not to include in 
the evaluation of groups in routine practice or clinical research. Unfortunately, no 
instrument had sufficient measurement properties to support recommendation for use 
in individual evaluation and no clear recommendation for the disease-specific 
evaluation of HRQL, disease activity, functional disability or spinal mobility could be 
made. 
Following suggested modifications, the next step for the current research is to address 
the feasibility of including the identified package of instruments in routine practice or 
clinical research, and a re-evaluation of measurement properties and practical criteria 
following these applications. It is not proposed that all instruments should be 
included in clinical pmctice. or research due to the burden of completion and 
administration. The list is not intended to be prescriptive, but to provide an evidence- 
based and standardised approach to evaluation in AS. The selected instruments 
describe different although often complimentary domains of health, and instrument 
selection for use in routine practice or research will be influenced by several factors: 
the multi-dimensional nature of AS; the objectives of the clinician, investigator or 
possibly the patient; the objectives of the intervention or management; the patient 
population; and available resources for administration, scoring and data interpretation 
(Read, 1987). Application of the package of instruments in a clinical trial will 
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provide ftirther information on the performance of instruments and support data 
interpretation on a range of scores between different arms of a trial. 
Although instrument administration in the clinic-based survey aimed to reflect the 
demands and requirements of routine clinical practice (Dziedzic, 1998; Lubrano et a], 
1998), the role of patient self-completion of instruments prior to a consultation and 
the feasibility of scoring, interpretation and inclusion of these results within the 
consultation period requires further appraisal. The role of postal self-completion of 
instruments in routine practice may also be worthy of further investigation, but the 
costs and benefits of such an exercise would also require careful evaluation. 
However, the question remains 'WhyT at the start of the 21 st Century in patients with 
chronic and incurable disease such as AS for which the HRQL and psychosocial 
impact of disease have been described as major considerations (Barlow et al, 
1993a, b), does evaluation in clinical practice appear to remain focused towards 
recording impairment? Whereas, evaluation in clinical trials has for the last decade 
included patieht-based evaluation addressing wider issues of HRQL (after Brooks and 
Kamberg, 1987). 
This chapterhas identified several issues that may support the reasons for poor 
acceptance of patient-based instruments in routine practice. Despite the increasing 
evidence to support the measurement properties of patient-based instruments and the 
increasing importance of including patient-based assessment in evaluation, clinicians 
often cite a lack of intuitive feeling for the interpretation of the data (Fitzpatrick et al, 
1992) and a perceived lack of relevance of these instruments to patient management 
and intervention (Chesson, 1998). 
Improving the awareness of health care professionals to patient-based measures of 
outcome and facilitating the incorporation into routine practice is an important 
requirement if these instruments are to gain acceptance. Through the combined input 
of several chartered physiotherapists with a specialist interest in outcome 
measurement, including the lead investigator of the current research (KLH), the 
Chartered Society of Physiotherapy (CSP), the professional body of physiotherapists 
in the UK, has produced a database of outcome measures for access by the 
membership. The database is housed at the National Institute for Clinical Excellence 
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(NICE) and can be accessed by the Internet (http: //www. nice. org. uk), by post or by 
telephone. The main objective of the site was to provide a facility where up to date 
information relating to available patient-based instruments, their measurement 
properties, acceptability, feasibility and cost of administration could be accessed by 
clinicians interested in incorporating these instruments into routine practice. To have 
an increased relevance to physiotherapists in routine practice, as opposed to research, 
the database has focussed on measures of disability, handicap and HRQL. Feedback 
to the CSP indicated that further information relating to instrument selection, 
incorporation into routine practice and score interpretation was required, and several 
workshops have been proposed to support the acquisition of this knowledge. 
Further work to evaluate the most effective approach supporting the integration of 
patient-based instruments into routine practice and to support standardisation in 
routine practice and research is required. From a starting point of a package of 
evidence-based evaluative instruments which describe domains of health considered 
important in the evaluation of HRQL focus group interviews with clinicians and 
patients may provide additional information to support this process. However, 
evidence of the benefit to clinical decision making, resource allocation and health 
policy that may be gained by the inclusion of these instruments in routine practice is 
also required (Greenhalgh and Meadows, 1999). Following initial evidence of 
satisfactory measurement properties, the role of individualised measures such as the 
PGI-AS in routine practice and research, in clinical decision making and directing 
patient-centred management also demands further investigation. 
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Appendix 1 Data extraction sheet 
Publication details Re% lew number. 
Author (s) 
Article title 
Source 6ournal or conference), year. volume, part, pages 
Country of origin 
institutional affiliation (first author) and contact address 
outcome measure 
Stage of development described by article 
Name of measure 
Definition of purpose 
Conceptual base 
General description and scale structure General description 
Number of items 
Length 
Response possibilities (ordinal t interval / nominal / yes - no VAS) 
Method of administration and scoring (time and training required) 
Item development 
Sub-scales 
Capacity / performance based 
Application (clinical / research / survey / screening) 
Time specificity 
Comments 
Study design 
Type of study Study design 
Aims clarified 
Sample size; do numbers add up at end of study period? 
Study duration - follow-up and adequacy of - were relevant outcome 
measures ignored? 
Population investigated Patient population 
Setting and methods for recruitment 
Inclusion and exclusion criteria 
Diagnosis and co-morbidity 
Disease duration (symptoms and diagnosis) and severity 
Patients broken down by age (range, mean, SD), sex, other variables 
Reliability testing 
Internal consistency reliability (multi-item scales) Item total correlation 
Overall correlation between items - Cronbachs alpha 
Result 
Test-retest reliability Test-retest; intra-observer; inter-observer 
Nurnber of patients - who; how selected 
Number of observers - who; how selected, experience / training 
Number of repetitions 
Retest period 
Blinding of observers /patients 
Time of day 
VVhich measurement recorded? - meaw, last attempt 
Statistical tests; description of method 
Result 
Validity testing 
Construct validity Use of 'extreme groups' Hypothesis stated a priori (or implicit) 
Correlation of measurements: physical tests / signs, pain measures, 
psychosocial findings, disability assessments, other. 
Quality of measures correlated against 
Statistical tests applied 
Result 
Responsiveness testing 
Longitudinal validity Use of Health Transition Questions 
Used in trial of known efficacy Effect size statistic 
Correlation of scale change with changes in other measures 
Acceptability / Practicality 
Application - research; clinical practice; other (time, convenience, 
confidence, training, cost, etc. ) 
Acceptability to clinician / patient 
Use in published articles Original developers 
Others 
Commentary 
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Appendix 2 The Patient-Generated Index for AS (PGI-AS) 
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Appendix 3 Patient-based Measures of Outcome 
Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) 
On the following pages you will find some statements which have been made by people who 
have Ankylosing Spondylifis. 
Please read each statement carefully. We would like you to tick 'Yes' if you feel that 
statement applies to you and tick 'No' if it does not. 
Please choose the response that best applies to you AT THE MOMENT 
Please read each item carefully and tick the one response that applies best to you at the 
moment 
Yes 
F-1 
1. My condition limits thi places I can go. 
No 
17 
Yes 
2.1 sometimes feel like crying. 
No 
Yes F-I 3.1 have difficulty dressing. 
No F1 
ý Yes F-I 
4.1 struggle to do jobs around the house. 
No F-I 
Yes F-1 5. It's impossible to sleep. 
No F-1 
Yes 
6.1 am unable to join in activities with my friends / family. 
No 
Yes F-I 
7.1 ain tircd all the time. 
No F-I 
Yes 
17 
8.1 have to keep stopping what I arn doing to rest. 
No F-I 
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Please read each item carefully and tick the one response that applies best to you 
at the moment. 
Yes 
9.1 have unbearable pain. 
No 
Yes 
10. It takes a long time to get going in the morning. 
No 
Yes 
11.1 am unable to do jobs around the house. 
No 
12.1 get tired easily. 
13.1 oficn gct frustratcd. 
14. The pain is always there. 
15.1 feel I miss out on a lot. 
16.1 find it difficult to wash my hair. 
17. My condition gets me down. 
18.1 wony about letting people down. 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
No 
Fl 
Fý 
Fý 
71 
Fý 
71 
F-1 
Fý 
F-1 
F7 
F-I 
F-I 
F-I 
F7 
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Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
PLEASE PLACE A MARK ON EACH LINE BELOW TO INDICATE YOUR ANSWER 
TO EACH QUESTION, RELATING TO THE PAST WEEK 
1. How would you describe the overall level of fatigue / tiredness you have experienced? 
NONE VERY SEVERE 
2. How would you describe the overall level of AS necký back or hip pain you have had? 
NONE VERY SEVERE 
3. How would you describe the overall level of pain/ swelling in joints other than neck, 
back or hips you have had? 
NONE VERY SEVERE 
4. How would you describe the overall level of discomfort you have had from any areas 
tender to touch or pressure? 
NONE VERYSEVERE 
5. How would you describe the overall level of morning stiffness you have had from the 
time you wake up? 
NONE VERY SEVERE 
6. How long does your morning sfiffness lastfirom the time you wake up? 
1/2 1 /2 2 or more 
hrs hrs 
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The Body Chart 
Ile following two line drawings represent a 'body chart'. The pictures illustrate the front and 
the back of a person. Please look at these line drawings. 
Using a pen please shade in the body chart to show the area or areas where you are 
experiencing pain. 
This refers to vour current or present pain. 
Now score these areas of pain as: I= mild pain 
2= moderate pain 
3= severe pain 
4= very severe pain 
Please make sure that each individual area or areas of pain are scored. 
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Revised Leeds Disability Questionnaire 
PLEASE TICK THE ONE RESPONSE WHICH BEST DESCRIBES YOUR ABILITIES 
OVER THE PAST WEEK 
PLEASE PAY CAREFUL ATTENTION TO COLUMN 3 (USING UNUSUAL MOVEMENTS). For 
example, if you only get out of a car by pulling yourself up with your hand on the roof, then tick this 
column in response to question 1b. 
1. Mobility 
a. Getting into and out of the 
bath 
b. Getting into and out of the 
car 
c. Getting up and out of bed in 
the morning 
d. Rolling over in bed 
2. Bendins! Down 
a. Wiping yourself after using 
the toilet 
b. Putting on and taking off 
yoursocks 
c. Putting on your shoes and 
tying your laces 
d. Cutting your toe nails 
3. Neck Movements 
a. Opening high windows 
b. Looking both ways before 
crossing the road (e. g. do you 
have to move your feet) 
c. Looking at what you are 
reaching on a high shelf 
d. Drinking from a small glass 
or can (e. g Do you have to 
bend your knees? ) 
4. Posture 
a. Walk on your heels 
b. Coughing or sneezing 
c. Sleep on your back 
d. Sleep on your stomach 
Able to do 
without 
difficulty 
Able to do 
with 
difficulty 
Only able to do 
using unusual 
movements or 
gadgets 
Unable 
to do 
Total score 
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The EuroQoL -, EQ-5D 
By placing a tick (' P) in one box in each group below, please indicate which 
statement best describes your own health state today. 
Do not tick more than one box per question. 
1. Mobility: 
I have no problems in walking about 
I have some problems in walking about 
I am confined to bed 
2. Self-Care: 
I have no problems with self-care 
I have some problems washing or dressing myself 
I am unable to wash or dress myself 
0 
0 
0 
0 
3. Usual Activities. (e. g. work, study, housework, family or leisure activities): 
I have no problems with performing my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities 
4. Pain /Discomfort: 
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
5. Anxiety / Depression: 
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
0 
0 
Compared with my general level of health over the vast 6-months, my health state 
today is: 
Please tick one box: 
Better 
Much the same 
Worse 
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The EuroQoI - Thermometer 
Your own health state today 
To help people say how good or 
bad a health state is, we have drawn a 
scale (rather like a thermometer) on 
which the best state you can 
imagine is marked by 100 and the 
worst state you can imagine is 
marked by 0. 
We would like you to indicate on this 
scale hoW good or bad is your own 
health toda in your opinion. 
Please do this by drawing a line from 
thejLox beloly, to whichever point o 
the scale indicates how good or bad 
your current health state is toda 
Best 
imaginable 
health stato 
100 
900 
goo 
740 
600 
Your own health 
state TODAY 
51 00 
44 PO 
300 
20 
1400 
Please do not write in this box: 
IIIi 
0 
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Short-Form 12-Item Health Survey Questionnaire (SF-12) 
The fmal twelve questions ask for your views about your health. This infonnation. will help 
keep track of how well you are able to do your usual activities. 
Please answer every question by marking one box. If you are unsure about how to answer, 
please give the best answer you can. 
1. In general, would you say your health is: 
00000 
Excellent Very Good Good Fair Poor 
The following items are about activities you might do during a typical day. Does your health 
now limit yo in these activities? If so, bow much? 
Yes, Yes, No, Not 
Limited Limited Limited 
A Lot A Little At All 
2. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling or playing golf El 
3. Climbing several flights of stairs F1 
During the past 4-weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health? 
YES NO 
4. Accomplished less than you would like 
5. Were limited in the kind of work or other activities 
During the past 4-weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of gny emotional problems such as feeling depressed or 
anxious) ? 
YES NO 
6. Accomplished less than you would like 11 
7. Didn't do work or other activities as carefully as usual 13 
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8. During the Rast 4-weeks, how much did pgdn interfere with your normal work (including 
both work outside the home and housework) ? 
00000 
Not at all A little bit Moderately Quite a bit Extremely 
These questions are about how you feel and how things have been with you during the 1 2ast 4- 
weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling. 
How much of the time during the past 4-week - 
All Most A Good Some A Little None 
of the of the Bit of the of the of the of the 
Time Time Time Time Time Time 
9. Have you felt calm and 
peaceffil? 
10. Did you have a lot of F1 F-I 
energy? 
1. Have you fclt downhearted 
and blue? 
0 0 0 0 
0 0 0 0 
12. During the past 4-week , 
how much of the time has your physical health or emotional 
problern interfered with your social activities (like visiting with ftiends, relatives, etc. ) ? 
EJ 11 El El 0 
All of the Most of the Some of the 
time time time 
A little of the None of the 
time time 
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Appendix 4 Ethical Approval 
North Staffordshim Health Authority 
Heron House 
Gmal Fenton Business Park 
Grove Road 
Stoke-on. Tmnt 
Notib Staffordsbire 
A, 
Staffordsbire ST4 4LX 
Tel: 01782 298000 
Heafth Fax: 01782 298298 Mialcom Tel: 01782 29803S 
PLEASE REPLY TO: RESEARCH ETHICS COMMITTEE, HUMAN RESOURCES DIRECTORATE, ROYAL 
INFIRMARY, HARYSHILL, STOKE-ON-TRENT, ST47PS 
Ext. 4530 (Direct Dial 01782 5545M) 
VGH/IEC 
ist June 1998 
PRIVATE AND CONFIDENTIAL 
Ms. K. L. Haywood 
12 Haig Road 
Catterick Garrison 
Richmond 
North Yorkshire 
DL93AH 
i Dear 
Ms. Haywood 
Project 884 
Vne-c-7aiua-tion of health outcome in Ankylosing Spondylitis 
I am pleased to inform you that the above project was approved at the meeting of the Research Ethics Committee 
on the 27th May 1998. 
Yours sincerely 
Dr. N. G. Hug es 
Chairman 
Local Research Ethics Committee 
40 
Chairman: Mrs Julia Jessel Chief Executive: Richard Priestley 73 PRNT 1247 
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Appendix 5 Clinic Survey - Patient information and consent form 
All Letters printed on appropriately headed paper. 
Dr Peter Dawes, Consultant Rheumatologist. 
Date: 
Dear ..................................... 
How does Ankylosing Spondylitis Affect You? 
We are interested in finding out how peoples day-to-day lives are affected by AS. 
The Staffordshire Rhcumatology Centre and the University of York are carrying out an 
important study of people with Ankylosing Spondylitis (AS). The research will involve a 
research physiotherapist (Kirstie Haywood), Jackie Waterfield (Senior Physiotherapist) and 
myself (Dr. Peter Dawes, Consultant Rheumatologist). 
We are writing to you to ask if you would please consider taking part in this study. Your 
participation will help to improve our understanding of the way in which people with AS are 
affected by the disease, and how this can be measured. 
The research physiotherapist would like to meet with you when you attend for your pre- 
arranged clinic appointment with the doctor at the Haywood Hospital out-patients 
theurnatology clinic. Your routine appointment with the doctor will not be affected should you 
be happy to take part in the research study. 
Should you be happy to take part in the research study we would like you to attend the clinic 
30-minutes before your pre-arranged clinic appointment time. During this time we would like 
you to complete a questionnaire. The questionnaire will ask you about your AS, the areas of 
your life affected by the disease, and the importance of these areas to you. In addition, the 
physiotherapist would like to take several measurements of your back and neck movement. 
These will be similar to the measurements taken when you attend for a normal clinic 
appointment with the physiotherapist. A gown will be provided for your comfoM or you may 
wish to bring a pair of shorts with you. These measurements may be taken following your 
assessment with the doctor and will take about 10-minutes. All information will be completely 
confidential and will only be used for research purposes. The research will not alter any part of 
your usual care and does not require you to come into hospital for any additional appointments. 
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If you are able to take part in the study you will be invited to attend for a follow-up assessment 
when you attend for your next 'routine' clinic assessment in six-months time. This assessment 
will follow the same format as the initial research assessment. If you choose to withdraw from 
the study you may do so freely at any time without having to give your reasons. 
If you feel able to take part in the study please complete the enclosed 'consent form' to indicate 
your willingness to meet with the physiotherapist for the research assessment. Once completed, 
the form should be returned to the physiotherapist in the reply-paid envelope. Please keep this 
letter for your future reference and make a note of your appointment time. 
Please be assured that you are under no obligation to take part in the study. If you choose not 
to take part in the study please still attend the clinic for your pre-arranged clinic appointment. If 
you choose not to take part in the study, your usual management will not be affected. Even if 
you are unable to assist in this study we would be grateful if you would return the 'consent 
form' in the reply-paid envelope to indicate you would not like to take part in the research 
assessment. 
We hope that you will feel able to help us with this important study and look forward to your 
response. If you would like to know more about this study please do contact the research 
physiotherapist (Kirstie Haywood) on the following number: xxxxxxx (daytime, evening and 
weekends). 
Yours sincerely, 
Dr. Peter Dawes. 
Consultant Rheumatologist, Staffordshire Rheumatology Centre. 
Roufine Clinic Appointment: Wednesday ........................... 1999: Time: ............ 
Research Assessment: Please arrive 30-minutes before your clinic appointment: 
Time: 
Should you decide to take part in the study, please indicate to the receptionist when you 
arrive at the clinic that you are taking part in the 'AS Study' with 
Kirstie Haywood (Research Physiotherapist). 
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Clinic Study: Informed Consent Form 
Name: ................................... Date of Birth: .............................. 
Address: ........................................................... 
........................ q .................................. 
Post Code: .................................... Telephone Number: ........................ 
Are you able to take part in the research study when you attend for your next routine 
clinic appointment? 
Please place a ', (' in the chosen box: 
Routine Clinic Appointment Wednesday ................... 1999: Time: ............ 
Research Assessment: Please arrive 30-minutes before your clinic appointment: 
Time: .............. 
Yes -I am happy to take part in the study 
El 
No -I do not wish to take part in the study 
El 
If 'NO': 
Many thanksforyour time and consideration. 
Please return this page in the reply-paid envelope. 
Please still attend the clinkforyour 'routine'clinic appointment. 
If 'YES': 
Please sign below to confirm your willingness to participate in the study before returning 
the completed form. 
I .......................................... of the above address 
hereby fully and freely consent 
to participate in the study: 'How does Ankylosing Spondylitis Affect You? '. 
I understand and acknowledge that the study is designed to improve medical understanding 
of the way in which people with AS are affected by the disease, and how this can be 
measured. 
*I note that I may withdraw my consent to take part at any stage in the study. 
I have received a written explanation of the study and understand the requirements of my 
participation. 
Signed: ...................................................... 
Date: ................................. 
Many thanksforyour assistance. 
The information thatyou provide will be very helpful to us. 
Please return th is page in th e pre-paid en velope. 
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Clinic - Patient Information Leaflet 
How Does Ankylosina Spondylitis Affect You? 
We are interested in finding out how peoples day-to-day lives are affected by AS. 
We are seeking people with AS to take part in this study. Before deciding whether you would 
like to take part, please read this information leaflet carefully. It tells you about the study and 
what you would be expected to do. 
What is the studv for? 
Your participation in the study will help to improve our understanding of the way in which 
people with AS are affected by the disease, and how this can be measured. 
What will T be reguired to do if I take part in the study? 
If you are happy to take part in the study you will be invited to attend the Haywood Hospital 
rheumatology clinic on two separate occasions to participate in a research assessment. The 
research assessment will follow a similar format to the assessment when you attend for a 
normal clinic appointment. The assessment will take approximately 45-minutes. During this 
time we would like you to complete a questionnaire. The questionnaire will ask you about your 
AS, the areas of your life affected by the disease, and the importance of these areas to you. In 
addition, the physiotherapist would like to take several measurements of your back and neck 
movement. These will be similar to the measurements taken when you attend for a normal 
clinic appointment. A gown will be provided for your comfort, or you may wish to bring a pair 
of shorts with you. 
If you are able to take part in the study you will be invited to attend for a follow-up assessment 
in six-months time. This assessment will follow the same format as the initial research 
assessment. 
Who will be takina part in the studv? 
We are writing to over 120 people with diagnosed AS to ask about the disease and how it 
affects their day-to-day life. The study would not be suitable for pregnant women. If you are 
pregnant you should not take part in the study, but please do return the consent form to prevent 
further letters being sent to you. 
What are the riskstbenefits to me from taking part in the studv? 
There are no known risks or side effects from participating in the research study. Tie study 
will not alter your usual care in any way. 
What about confidentiality? 
All information will be deemed to be confidential and your identity will not be made known to 
other individuals. In all instances your confidentiality will be respected and maintained. 
Can I withdraw from this studv? 
Yes. You may withdraw from the study freely at any time without having to give your reasons. 
Further information 
The research will involve the research physiotherapist (Kirstie Haywood) and (Dr. Peter 
Dawes). If you choose to take part in the study further contact will be made with you by 
Kirstie Haywood (Research Physiotherapist). Should you have any questions or problems 
about this study, please do contact: Kirstie Haywood, Research Physiotherapist on xxmcxrxx 
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Appendix 6 Postal Survey - Database Questionnaire (Consultant completion) 
The Evaluation of Health Outcome in Ankylosing Spondylitis - 
Postal Survey 
I would be very grateful if you would complete and return the following questionnaire. A 
stamped-and-self-addressed-envelope has been included for your reply. 
Ile information is intended to determine the accessibility of a random sample of patients with 
diagnosed AS under your care. 
Name: Consultant Rheumatologist. Hospital: Department ofRheumatology. 
Would you be willing for a random sample of subjects with AS under your care to be 
approached in a mail-base survey? 
Yes 11 No 0 
If 'no', please do not continue. Many thanksforyour time. 
If 'yes', please answer the following questions. 
ii). Is there access to a database of subjects with AS within your department? 
Yes 11 No 
If 'no', please do not continue. Many thanksforyour time. 
If 'Yes': 
a). How oflen is this database updated? 
Frequency (in weeks or monihs): Unsure 11 
b). In what format does this database exist? 
c). Is the database easily accessible? 
Yes ID No 
iii). Is there a clear indication of individual patient diagnosis within the database? 
Yes 0 No 11 
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iv). Is it possible to identify the number of individuals with diagnosed AS (Modified New 
York Criteria - van der Linden et al, 1984) on the database? 
Yes El No El 
V). How many patients with diagnosed AS (Modified New York Criteria) are there on the 
database? 
Number: Unsure 11 
vi). Would it be possible to take a 'random sample' from the patients identified with 
diagnosed AS on the database? 
Yes Fl No 0 
vii). Would you be willing for me to identify a random sample from the identified 
database? 
Yes 11 No El 
viii). Is it possible to identify the 'disease specmm' of AS covered by the database? 
Yes 0 No 0 
ix). Is it possible to readily distinguish between 'newly diagnosed' and 'established' 
disease on the database? 
Yes 0 No El 
X). Is it possible to readily distinguish between males and females on the database? 
Yes 11 No 0 
xi). Could you please indicate the process for obtaining ethical approval for the proposed 
postal evaluation. 
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Appendix 7 Rheumatology centres, and contacts for postal survey 
Rheumatology centre Consultant contact Physiotherapist contact 
Addenbrooke's Hospital, Professor JSH Gaston Mrs J Isaacson 
Cambridge 
Cannock Chase Hospital, Dr T Price Mrs C David 
Stafford Mrs L Preston 
Glasgow Royal Infirmary, Professor R Sturrock Ms F Gough 
University Hospital Trust 
South Tees Acute Hospitals Professor I Haslock Mrs K West 
NES Trust, South Dr M Plant 
Cleveland 
Southmead Hospital, Bristol Dr P Creamer Mrs R Lewis 
Staffordshire Rheurnatology Dr PT Dawes KLH 
Centre (SRC), Stoke-on- 
Trent 
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Appendix 8 Postal Survey - Patient information and consent form 
All Letters printed on appropriately headed paper. 
Name of Consultant Rheumatologist. 
Date: 
Dear ..................................... 
How does Ankylosing Spondylitis Affect You? 
We are interested in finding out how peoples day-to-day lives are affected by AS. The 
Department ofRheumatology, = Hospital and the Staffordshire Rheurnatology Centre are 
carrying out an important study of people with Ankylosing Spondylitis (AS). The research 
will involve a research physiotherapist (Kirstie Haywood), local Physiotherapist contact and 
myself (Consultant Rheumatologist). 
I mn writing to you to ask if you would please consider taking part in this study. Your 
participation will help to improve our understanding of the way in which people with AS are 
affected by the disease, and how this can be measured. We are writing to over 400 people 
with AS to ask if they will take part. 
If you are able to help in this study please complete the enclosed questionnaire. The 
questions ask you about your AS, the areas of your life affected by the disease, and the 
importance of these aspects to you. 
once completed, the questionnaire should be returned to the research physiotherapist (Kirstie 
Haywood) at the Staffordshire Rheurnatology Centre in the reply-paid envelope. All 
information will be completely confidential and will only be used for research purposes. The 
research will not alter any part of your usual care. 'Me return of the completed questionnaire 
will indicate that you are happy for your name and address to be given to the physiotherapist 
for the purpose of the study. 
If you are happy to take part in the study you will be invited to complete a second 
questionnaire 2-weeks after the return of the first questionnaire, with a final questionnaire 
being sent to you in 6-months time. Each questionnaire will be completed at home, which will 
take about 30-minutes, and then returned in the reply-paid envelopes provided. You will not 
be required to come into hospital for any additional appointments. If you choose to withdraw 
from the study you may do so freely at any time without having to give your reasons. If you 
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feel able to take part in the study please complete the attached 'consent form' and return it 
with the completed questionnaire. Please keep this letter for your future reference. 
Please be assured that you are under no obligation to take part in the study. If you choose not 
to take part in the study, your usual care will not be affected. Even if you are unable to assist 
in this study I would be grateffil if you would return the blank questionnaire and consent fonn 
in the reply-paid envelope to indicate that you would not like to take part. 
If you would like to know more about this study please read the enclosed Tatient Infon-nation 
Leaflet' or contact the physiotherapist on the telephone number indicated. 
I hope that you will feet able to help with this important study and look forward to your 
response. 
Yours sincerely, 
Consultant Rheumatologist 
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Postal Evaluation - Informed Consent Form 
How Does Ankylosing Spondylitis Affect You? 
Are you able to help with the study by completing the enclosed 
questionnaire? 
Please place a V' in the chosen box: 
Yes -I am happy to take part in the study El 
No -I do not wish to take part in the study 
11 
If 'NO': 
Many thanksforyour time and consideration. 
Please return this page and the 'blank'questionnaire in the reply-paid envelope. You do 
not need to write your name and address on this letter. 
If 'YES': 
Please sign below to confirm your willingness to participate in the study, and complete 
your name and address, before returning this form with the completed questionnaire. 
I .......................................... of the 
below address fully and freely consent to 
participate in the postal study entitled: 'How does Ankylosing Spondylitis Affect You? '. 
I understand and acknowledge that the study is designed to improve medical 
understanding of the way in which people with AS are affected by the disease, and how 
this can be measured. 
01 note that I may withdraw my consent to take part at any stage in the study. 
I have received a written explanation of the study and understand the requirements of my 
participation. 
Signed: ...................................................... Date: ........................... 
Name: ................................... Date of Birth: .............................. 
Address: ........................................................... 
se.. Goooo*** .................. * *0 ................... 
Post Code: .................................... Telephone Number: ........................ 
Many thanksfor your assistance. The information that you provide will be very helpful to 
us. 
Please return this page in the pre-paid envelope with the completed questionnaire 
You will receive a second questionnaire in 2-weeks time. 
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Postal - Patient Information Leaflet 
How Does Ankylosin Spondylitis Affect You? 
We are interested in finding out how peoples day-to-day lives are affected by AS. 
We are seeldng people with AS to take part in this study. Before deciding whether you would 
Re to take part, please read this information leaflet carefully. It tells you about the study and 
what you would be expected to do. 
What is the study for? 
Your participation in the study will help to improve our understanding of the way in which 
people with AS are affected by the disease, and how this can be measured. 
What wfll I be reauired to do if I take part in the studv? 
If you are happy to take part in the study you will be invited to complete a questionnaire on 
three separate occasions. The first questionnaire is included with this letter. A second 
questionnaire will be sent to you 2-weeks after the return of the first questionnaire, with a 
final questionnaire being sent to you in 6-months time. Each questionnaire will be completed 
at home, which will take about 30-minutes, and then returned in reply-paid envelopes. You 
will not be required to come into hospital for any additional appointments. 
Who will be taking part in the study? 
We are writing to over 400 people with diagnosed AS to ask about the disease and how it 
affects their day-to-day life. Ile study would not be suitable for pregnant women. If you are 
pregnant you should not take part in the study, but please do return the blank questionnaire to 
prevent further questionnaires being sent to you. 
What are the risksibenefits to me from takin2 part in the studv? 
Tlere are no known risks or side effects from completing the questionnaires. The study will 
not alter your usual care in any way. 
What about confidentialitv? 
All information we receive will be deemed to be confidential and your identity will not be 
made known to other individuals. In all instances your confidentiality will be respected and 
maintained. Ile return of a completed questionnaire and consent form will indicate that you 
are happy for your name and address to be released to the research physiotherapist for the 
purpose of the study. 
Can I withdraw from this study? 
Yes. You may withdraw from the study freely at any time without having to give your 
reasons. 
Further infonnation 
The research will involve ourselves (Physiotherapist and Consultant Rheumatologist) and a 
research physiotherapist (Kirstie Haywood, Research Physiotherapist, Staffordshire 
Rheurnatology Centre). If you choose to take part in the study further contact will be made 
with you by Kirstie Haywood. Should you have any questions, or problems about this study, 
please do contact: Physiotherapist, on: xxxxxxxxx 
321 
Appendix 9 PGI-AS Rating Scale 
Step 1 'Identify Areas' 
0 0 0 
None A little Moderate 
at all assistance assistance 
00 
Significant Maximum 
assistance assistance 
Coding: 
None At all Standard instructions read out only. No rcpefition of 
instructions. 
A little assistance Repetition of elements of standard instructions required. For 
example, repeat reference made to the 'trigger list' (but no 
examples read out). 
Moderate assistance Increased repetition of standard instructions with increased 
reference to usefulness of 'trigger list' and the completed 
form. 
Significant assistance Increased reference to 'trigger list' and completed form. 
Possible minimal re-wording of standard instructions to 
improve understanding. 
Maximum assistance Maximum reference to 'trigger list' and completed form. 
Random examples from the trigger list and completed form 
read out aloud to patient to facilitate identification of 'most 
important areas of life'. Interviewer may add that the areas 
chosen by the patient may 'be quite personal and only have 
meaning to you, or it may be quite a big thing'. Re-wording 
of standard instructions to improve understanding. 
Prolonged period of time to identify areas. 
Step 2 'Score Areas'. 
El EJ F] EJ R 
None A little Moderate Significant Maximum 
at all assistance assistance assistance assistance 
Coding: 
None At all Standard instructions read out only. No repetition of 
instructions. 
A little assistance Repetition of elements of standard instructions required. For 
example, repeat reference made to the scale (no repetition of 
standard example). 
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Moderate assistance Increased repetition of standard instructions with increased 
reference to the use of the scale and the completed form. 
Moderate assistance is considered to have been offered if 
attention needs to be drawn to the scoring of the 'last two 
boxes', beyond that provided in the standard instructions. 
Significant assistance Increased reference to use of the scale and the example of the 
completed form. Possible minimal re-wording of standard 
instructions to improve understanding. 
Maximum assistance Maximurn reference to the format of the scale and the 
possible assistance from the completed example. Random 
examples from the trigger list and completed form read out 
aloud to the patient to facilitate identification of 'most 
important areas of life' and scoring of these areas. Re- 
wording of standard instructions to improve understanding. 
Prolonged period of time to identify areas. 
Step 3 'Spend Points'. 
0 0 0 
None A little Moderate 
at all assistance assistance 
00 
Significant Maximum 
assistance assistance 
Coding: 
None at all Standard instructions read out only. No repetition of 
instructions. 
A little assistance Repetition of elements of standard instructions required. For 
example, repeat reference made to the number of points to be 
spent. 
Moderate assistance Increased repetition of standard instructions with increased 
reference to the method and purpose of spending points, with 
reference to the completed example. 
Significant assistance Increased reference to method and purpose of spending 
points, the number of points to be spent, and the example of 
the completed form. Possible minimal re-wording of 
standard instructions to improve understanding. 
Maximum assistance Mwdmum reference to the reason for spending points, the 
number of points to be spent and the possible assistance from 
the completed form. Examples of how the points may be 
spent in relation to the areas identified by the subject will be 
made. Re-wording of standard instructions to affect 
understanding. Prolonged period of time to spend points. 
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Step 4 Overall: Clinician-reported level of assistance required to complete PGI-AS. 
0 0 0 0 0 
None A little Moderate Significant Maximum 
at all assistance assistance assistance assistance 
Step 5 Time taken to complete PGI-AS: 
1-1 F] Fý El 
5 mins 6-10 mins 11-15 mins 16-20 mins 21-25 mins 
Step 6 Additional Patient Comments 
(in relation to PGI-AS or other instruments) 
0 
>25 mins 
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PGI-AS Rating Scale (Clinic) 
Date of PGI-AS Completion: 
Number of Times PGI-AS completed 
Step 1 'Identify Areas' 
0 0 0 0 11 
None A little Moderate Significant Maximum 
at all assistance assistance assistance assistance 
Step 2 'Score Areas'. 
11 11 F] El 
None A little Moderate Significant Maximum 
at all assistance assistance assistance assistance 
Step 3 'Spend Points. 
0 0 0 0 0 
None A little Moderate Significant Maximum 
at all assistance assistance assistance assistance 
Step 4 Overal l: Clinician-reported level of assistance required to complete PGI-AS 
EJ EJ 1: 1 Fý El 
None A little Moderate Significant Maximum 
at all assistance assistance assistance assistance 
Step 5 Time tAen to complete PGI-AS 
FI El El R F] El 
5 mins 6-10 mins 11-15 mins 16-20 mins 21-25 mins > 25 mins 
Step 6 Additional patient comments (in relation to PGI-AS or other questions) 
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Glossary 
List of Abbreviations 
Acromioclavicular Joint ACJ 
American Academy of Orthopaedic Surgeons AAOS 
American Rheurnatology Association ARA 
Andrew Garratt AG 
Ankylosing Spondylitis AS 
Ankylosing Spondylifis Quality of Life Questionnaire ASQol, 
Arthritis Impact Measurement Scale AIMS 
Assessment in Ankylosing Spondylitis group ASAS 
Assessment in Ankylosing Spondylitis Questionnaire ASAQ 
Bath Ankylosing Spondylifis Disease Activity Index BASDAI 
Bath Ankylosing Spondylifis Functional Index BASFI 
Bath Ankylosing Spondylifis Global Index BAS-G 
Bath Ankylosing Spondylifis Metrology Index BASMI 
Bath Ankylosing Spondylitis Radiological Index BASRI 
Bath Disease Activity Index Bath - DAI 
Cervical rotation C. rot 
Cervical spine - 7th spinous process C7 
Chest expansion C. exp 
Computerised Tomographic Scan CT 
Correlation of Variation (*/o) CV (0/0) 
C-reactive protein CRP 
Dougadas Functional Index DFI 
Effect Size ES 
Erythrocyte Sedimentation Rate ESR 
Fingertip to floor distance (anterior flexion) FFD 
Forced Vital Capacity FVC 
Health Assessment Questionnaire - Spondyloarthropathies HAQ-S 
Health Related Quality of Life HRQL 
Human Leucocyte Antigen - B27 HLA-B27 
Intraclass Correlation Coefficient ICC 
Jackie Watcrfield (physiotherapist) JW 
Kirstie Louise Haywood (lead investigator) KLH 
Lateral Lumbar Flexion LLF 
Leeds Disability Questionnaire LDQ 
Lumbar Flexion Index LFI 
MacMastcr and Toronto Questionnaire for AS / Patient Elicitation MACTAS PET 
Technique 
Mental component summary scale (SF-36; SF-12) MCS 
Modirted Schober Index (15cm) MS1 
Modified Standardised Response Mean MSRM 
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Newcastle Enthesitis Index NEI 
Non-steroidal anti-inflammatory drug NSAID 
Occiput to wall distance OWD 
Outcome Measures in Rheumatology and Clinical Trials OMERACT 
Patient Generated Index PGI 
Physical component summary scale (SF-36; SF-12) PCs 
Portable Spinal Mobility Scale PSMS 
Quality of Life QoL 
Radiograph XR 
Randomised Controlled Trial RCT 
Research Advisory Group RAG 
Response Shift RS 
Revised Leeds Disability Questionnaire RLDQ 
Rheumatoid Arthritis RA 
Schedule for the Evaluation of Individual Quality of Life SEIQoL - DW 
(direct weighting) 
Short Form 36-itern Health Survey Questionnaire SF-36 
Short Form 12-item Health Survey Questionnaire SF-12 
Smythe technique (S); upper / middle / lower S: U/M/L 
Staffordshire Rheumatology Centre SRC 
Standard deviation SD 
Standardised Response Mean SRM 
Stoke Ankylosing Spondylitis Spinal Score SASSS 
Sickness Impact Profile SIP 
Stoke Enthesitis Index SEI 
Temperomandibular Joint TMJ 
Thoracolumbar flexion TLF / TLflex 
Toronto Activities of Daily Life Questionnaire TADLQ 
Tragus to Wall distance TWD 
Visual Analogue Scale VAS 
World I lealth Organisation WHO 
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